

Heterocycle derivatives for treating TRPM3 mediated disorders**FIELD OF THE INVENTION**

[0001] The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

BACKGROUND OF THE INVENTION

[0002] The TRP superfamily consists of proteins with six transmembrane domains (6TM) that assemble as homo- or heterotetramers to form cation-permeable ion channels. The name TRP originates from the *Drosophila* trp (transient receptor potential) mutant, which is characterized by a transient receptor potential in the fly photoreceptors in the response to sustained light. In the last 15 years, trp-related channels have been identified in yeast, worms, insects, fish and mammals, including 27 TRPs in humans. Based on sequence homology, TRP channels can be divided into seven subfamilies: TRPC, TRPV, TRPM, TRPA, TRPP, TRPML and TRPN.

[0003] Members of the TRP superfamily are expressed in probably all mammalian organs and cell types, and in recent years great progress has been made in the understanding of their physiological role. The tailored selectivity of certain TRP channels enables them to play key roles in the cellular uptake and/or transepithelial transport of Ca^{2+} , Mg^{2+} and trace metal ions. Moreover, the sensitivity of TRP channels to a broad array of chemical and physical stimuli, allows them to function as dedicated biological sensors involved in processes ranging from vision to taste, and tactile sensation. In particular, several members of the TRP superfamily exhibit a very high sensitivity to temperature. These so-called thermoTRPs are highly expressed in sensory neurons and/or skin keratinocytes, where they act as primary thermosensors for the detection of innocuous and noxious (painful) temperatures.

[0004] It is becoming increasingly clear that TRP channel dysfunction is directly involved in the etiology of various inherited and acquired diseases. Indeed, both loss-of-function and gain-of-function mutations in the TRP channel genes have been identified as the direct cause of inherited diseases, including brachyolmia, hypomagnesemia with secondary hypocalcemia, polycystic kidney disease, mucopolipidosis type IV and familial focal segmental glomerulosclerosis. Moreover, TRP channel function/dysfunction has been directly linked to a wide range of pathological conditions, including chronic pain, hypertension, cancer and neurodegenerative disorders.

[0005] TRPM3 (Transient receptor potential melastatin 3) represents a promising pharmacological target. TRPM3 is expressed in a large subset of small-diameter sensory neurons from dorsal root and trigeminal ganglia, and is involved in heat sensing. The neurosteroid pregnenolone sulfate is a potent known activator of TRPM3 (Wagner et al., 2008). The neurosteroid pregnenolone sulfate evoked pain in wild type mice but not in knock-out TRPM3 mice. It was also recently shown that CFA induced inflammation and inflammatory pain are eliminated in TRPM3 knock-out mice. Therefore, TRPM3 antagonists could be used as analgesic drugs to counteract pain, such as inflammatory pain (Vriens J. et al. Neuron, May 2011).

[0006] A few TRPM3 antagonists are known, but none of them points towards the compounds of the current invention (Straub I et al. Mol Pharmacol, November 2013). For instance, Liquiritigenin, a postulated TRPM3 blocker has been described to decrease mechanical and cold hyperalgesia in a rat pain model (Chen L et al. Scientific reports, July 2014). There is still a great medical need for novel, alternative and/or better therapeutics for the prevention or treatment of TRPM3 mediated disorders, more in particular for pain such as inflammatory pain. Therapeutics with good potency on a certain type of pain, low level or no side-effects (such as no possibilities

for addiction as with opioates, no toxicity) and/or good or better pharmacokinetic or -dynamic properties are highly needed.

[0007] The invention provides a class of novel compounds which are antagonists of TRPM3 and can be used as modulators of TRPM3 mediated disorders.

5 SUMMARY OF THE INVENTION

[0008] The invention provides benzofuran derivatives and pharmaceutical compositions comprising such benzofuran derivatives. The invention also provides benzofuran derivatives for use as a medicament, more in particular for use in the prevention and/or treatment of TRPM3 mediated disorders, especially for use in the prevention and/or treatment of pain and/or inflammatory hypersensitivity; and/or for counteracting pain and/or

10 inflammatory hypersensitivity.

[0009] The invention also provides the use of benzofuran derivatives for the manufacture of pharmaceutical compositions or medicaments for the prevention and/or treatment of TRPM3 mediated disorders, especially for the prevention and/or treatment of pain and/or inflammatory hypersensitivity; and/or for counteracting pain and/or inflammatory hypersensitivity.

15 [0010] The invention also provides a method for the prevention or treatment of a TRPM3 mediated disorder by administering the benzofuran derivatives according to the invention to a subject in need thereof. More in particular, the invention relates to such method for the prevention and/or treatment of pain and/or inflammatory hypersensitivity; and/or for counteracting pain and/or inflammatory hypersensitivity.


[0011] The invention further provides a method for the preparation of the benzofuran derivatives of the invention, comprising the steps of:

- reacting a benzoquinone with a suitable β -ketoester or an enamine derivative to obtain 5-hydroxybenzofuran-3-carboxylate ester derivatives,
- substituting previously obtained 5-hydroxybenzofuran-3-carboxylate ester derivatives with suitable derivatives bearing a leaving group or alcohol derivatives under Mitsunobu conditions to obtain 5-O-substituted-benzofuran-3-carboxylate ester derivatives
- 25 - converting the previously obtained 5-O-substituted-benzofuran-3-carboxylate ester derivatives in carboxylic acid to obtain the desired benzofuran derivatives of the invention, and
- coupling the previously obtained 5-O-substituted-benzofuran-3-carboxylic acid derivatives with a suitable amine to obtain the desired amide derivatives of the invention.

30 DETAILED DESCRIPTION OF THE INVENTION

[0012] The invention will be further described and in some instances with respect to particular embodiments, but the invention is not limited thereto.

[0013] The first aspect of the invention is the provision of a compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof



(I)

preferably for use in the treatment of pain;

wherein

- 5 **R¹** represents -F, -Cl, -Br, -I, -CN, -**R^W**, -**OR^W**, -OC(=O)**R^W**, -**NR^WR^X**, -**NR^WC(=O)R^X**, -**SR^W**, -S(=O)**R^W**, -S(=O)₂**R^W**, -C(=O)**R^W**, -C(=O)**OR^W**, or -C(=O)**NR^WR^X**;

Q represents -**OR²** or -**NR³R⁴**;

R² represents -**R^Y**;

R³ represents -OH or -**R^Y**;

- 10 **R⁴** represents -**R^Y** or -S(=O)₂**R^Y**;

or **R³** and **R⁴** together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

T represents -O- and **U** represents -**CR⁵R^{5*}**-; or **T** represents -**CR⁵R^{5*}**- and **U** represents -O-;

R⁵ and **R^{5*}** independently of one another represent -**R^Y**;

- 15 **R⁶**, **R⁷** and **R⁸** independently of one another represent -F, -Cl, -Br, -I, -CN, -NO₂, -SF₅, -**R^W**, -**OR^W**, -OC(=O)**R^W**, -**NR^WR^X**, -**NR^WC(=O)R^X**, -**SR^W**, -S(=O)**R^W**, -S(=O)₂**R^W**, -C(=O)**R^W**, -C(=O)**OR^W**, or -C(=O)**NR^WR^X**;

V represents 3-14-membered heterocycloalkyl, saturated or unsaturated; or 5-14-membered heteroaryl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -**OR^Y**, -OC(=O)**R^Y**, -**NR^YR^Z**, -**NR^YC(=O)R^Z**, -**SR^Y**, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)**OR^Y**, or -C(=O)**NR^YR^Z**;

- 20

wherein

R^W and **R^X** independently of one another in each case independently represent

-H;

-C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

- 25 -C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said

- 30 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;


R^Y and **R^Z** independently of one another in each case independently represent


- H;
- C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
- 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- or **R^Y** and **R^Z** together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;
- and wherein "mono- or polysubstituted" in each case independently means substituted with one or more, e.g. 1, 2, 3, 4, or more substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -C₁₋₆-alkyl, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-O-CF₃, -C₁₋₆-alkylene-O-CF₂H, -C₁₋₆-alkylene-O-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C₁₋₆-alkylene-C(=O)-OH, -C(=O)-OC₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-OC₁₋₆-alkyl, -C(=O)-O-C₁₋₆-alkylene-CF₃, -C(=O)-NH₂, -C₁₋₆-alkylene-C(=O)-NH₂, -C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-C(=O)-NH(C₁₋₆-alkyl), -C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-C(=O)-N(C₁₋₆-alkyl)₂, -C(=O)-NH(OH), -C₁₋₆-alkylene-C(=O)-NH(OH), -OH, -C₁₋₆-alkylene-OH, =O, -OCF₃, -OCF₂H, -OCFH₂, -OCF₂Cl, -OCFCl₂, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -O-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-C₁₋₆-alkyl, -O-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-O-C₁₋₆-alkyl, -O-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-C(=O)-NH(C₁₋₆-alkyl), -O-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-C(=O)-N(C₁₋₆-alkyl)₂, -O-S(=O)₂-NH₂, -C₁₋₆-alkylene-O-S(=O)₂-NH₂, -O-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-S(=O)₂-NH(C₁₋₆-alkyl), -O-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-S(=O)₂-N(C₁₋₆-alkyl)₂, -NH₂, -NO, -NO₂, -C₁₋₆-alkylene-NH₂, -NH(C₁₋₆-alkyl), -N(3-14-membered cycloalkyl)(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C₁₋₆-alkylene-OH, -N(H)-C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -NH-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-C₁₋₆-alkyl, -NH-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-O-C₁₋₆-alkyl, -NH-C(=O)-NH₂, -C₁₋₆-alkylene-NH-C(=O)-NH₂, -NH-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-NH-C(=O)-NH(C₁₋₆-alkyl), -NH-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C(=O)-N(C₁₋₆-alkyl)₂, -N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH₂, -N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -NH-S(=O)₂OH, -C₁₋₆-alkylene-NH-

$\text{S(=O)}_2\text{OH}$, $-\text{NH-S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-NH-S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{NH-S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-NH-S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{NH-S(=O)}_2\text{-NH}_2$, $-\text{C}_{1-6}\text{-alkylene-NH-S(=O)}_2\text{-NH}_2$, $-\text{NH-S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{C}_{1-6}\text{-alkylene-NH-S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{NH-S(=O)}_2\text{N(C}_{1-6}\text{-alkyl)}_2$, $-\text{C}_{1-6}\text{-alkylene-NH-S(=O)}_2\text{N(C}_{1-6}\text{-alkyl)}_2$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-OH}$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-OH}$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-NH}_2$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-NH}_2$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-N(C}_{1-6}\text{-alkyl)}_2$, $-\text{C}_{1-6}\text{-alkylene-N(C}_{1-6}\text{-alkyl)-S(=O)}_2\text{-N(C}_{1-6}\text{-alkyl)}_2$, $-\text{SH}$, $=\text{S}$, $-\text{SF}_5$, $-\text{SCF}_3$, $-\text{SCF}_2\text{H}$, $-\text{SCFH}_2$, $-\text{S-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-S-C}_{1-6}\text{-alkyl}$, $-\text{S(=O)-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-S(=O)-C}_{1-6}\text{-alkyl}$, $-\text{S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-C}_{1-6}\text{-alkyl}$, $-\text{S(=O)}_2\text{-OH}$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-OH}$, $-\text{S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-O-C}_{1-6}\text{-alkyl}$, $-\text{S(=O)}_2\text{-NH}_2$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-NH}_2$, $-\text{S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-NH(C}_{1-6}\text{-alkyl)}$, $-\text{S(=O)}_2\text{-N(C}_{1-6}\text{-alkyl)}_2$, $-\text{C}_{1-6}\text{-alkylene-S(=O)}_2\text{-N(C}_{1-6}\text{-alkyl)}_2$, 3-14-membered cycloalkyl, $-\text{C}_{1-6}\text{-alkylene-(3-14-membered cycloalkyl)}$, 3 to 14-membered heterocycloalkyl, $-\text{C}_{1-6}\text{-alkylene-(3 to 14-membered heterocycloalkyl)}$, -phenyl, $-\text{C}_{1-6}\text{-alkylene-phenyl}$, 5 to 14-membered heteroaryl, $-\text{C}_{1-6}\text{-alkylene-(5 to 14-membered heteroaryl)}$, $-\text{O-(3-14-membered cycloalkyl)}$, $-\text{O-(3 to 14-membered heterocycloalkyl)}$, $-\text{O-phenyl}$, $-\text{O-(5 to 14-membered heteroaryl)}$, $-\text{C(=O)-(3-14-membered cycloalkyl)}$, $-\text{C(=O)-(3 to 14-membered heterocycloalkyl)}$, $-\text{C(=O)-phenyl}$, $-\text{C(=O)-(5 to 14-membered heteroaryl)}$, $-\text{S(=O)}_2\text{-(3-14-membered cycloalkyl)}$, $-\text{S(=O)}_2\text{-(3 to 14-membered heterocycloalkyl)}$, $-\text{S(=O)}_2\text{-phenyl}$, $-\text{S(=O)}_2\text{-(5 to 14-membered heteroaryl)}$.

[0014] In preferred embodiments of the benzofuran derivative according to the invention


- (a-1) **Q** represents $-\text{OR}^2$; and **R¹** represents $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, or $-\text{CF}_3$; and/or
 (a-2) **Q** represents $-\text{OR}^2$; and at least one of **R⁵** and **R^{5'}** does not represent -H; and/or
 (a-3) **Q** represents $-\text{OR}^2$; and **R⁶** does not represent -H; and/or
 (a-4) **Q** represents $-\text{OR}^2$; and **R⁸** does not represent -H;
- or
- (b-1) **Q** represents $-\text{NR}^3\text{R}^4$; with the proviso that the following compounds and their salts are excluded





; and/or

- (b-2) Q represents $-NR^3R^4$; and R^1 represents $-CH_2F$, $-CHF_2$, $-CF_3$, $-CN$, $-propyl$ or $-cyclopropyl$; and/or
- (b-3) Q represents $-NR^3R^4$; and at least one of R^5 and $R^{5'}$ does not represent $-H$; and/or
- (b-4) Q represents $-NR^3R^4$; and R^3 represents $-H$.
- 5 [0015] In a preferred embodiment of the benzofuran derivative according to the invention T represents $-O-$ and U represents $-CR^5R^{5'}$. According to this embodiment, the benzofuran derivative according to the invention is a compound of formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof



(II).

10

- [0016] In another preferred embodiment of the benzofuran derivative according to the invention T represents $-CR^5R^{5'}$ and U represents $-O-$.
- [0017] In a preferred embodiment of the benzofuran derivative according to the invention Q represents $-NR^3R^4$.
- [0018] In another preferred embodiment of the benzofuran derivative according to the invention Q represents $-OR^2$.
- 15 [0019] In a preferred embodiment of the benzofuran derivative according to the invention V represents 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-NO$, $-NO_2$, $=O$, $=S$, $-SF_5$, $-R^Y$, $-OR^Y$, $-OC(=O)R^Y$, $-NR^YR^Z$, $-NR^YC(=O)R^Z$, $-SR^Y$, $-S(=O)R^Y$, $-S(=O)_2R^Y$, $-C(=O)R^Y$, $-C(=O)OR^Y$, or $-C(=O)NR^YR^Z$.
- 20 [0020] Preferably, the 5-14-membered heteroaryl within the definition of V is not benzofuran, unsubstituted, mono- or polysubstituted.
- [0021] Preferably, the 5-14-membered heteroaryl within the definition of V is selected from benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine,
- 25 isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole,

phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0022] Preferably, the 5-14-membered heteroaryl within the definition of **V** is selected from the group consisting of furane, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole, pyridine, isoquinoline, benzothiazole, pyridazine, pyrimidine, imidazopyridine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0023] Preferably, the 5-14-membered heteroaryl within the definition of **V** is selected from the group consisting of furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, pyrazol-5-yl, oxazol-5-yl, isoxazol-4-yl, thiazol-2-yl, thiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, isoquinolin-1-yl, isoquinolin-5-yl, benzo[d]thiazol-2-yl, pyridazin-3-yl, pyrimidin-5-yl, and imidazo[1,2-a]pyridin-6-yl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0024] In another preferred embodiment of the benzofuran derivative according to the invention **V** represents 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0025] Preferably, the 3-14-membered heterocycloalkyl within the definition of **V** is selected from azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0026] Preferably, the 3-14-membered heterocycloalkyl within the definition of **V** is tetrahydropyran or pyrrolidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

[0027] Preferably, the 3-14-membered heterocycloalkyl within the definition of **V** is tetrahydropyran-4-yl or pyrrolidin-3-yl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.

- [0028] In a preferred embodiment of the benzofuran derivative according to the invention **V** is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from
- F, -Cl, -Br, -I, -CN, -C(=O)OH, -NH₂, -NO₂, -OH, =O, -SF₅;
 - C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - 5 -C(=O)O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - S(=O)₂-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - 10 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
 - 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in
 - 15 each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
- [0029] Preferably, **V** is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from
- OH, -F, -Cl, -Br, -I, -SH, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -CN, -NO₂, -C(=O)OH, -NH₂, or -N(CH₃)₂;
 - 20 -C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
 - C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents
 - 25 independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
 - OC₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃,
 - 30 -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
 - O(C=O)C₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
 - C(=O)OC₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another,
 - 35 selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
 - 3-14-membered cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -
 - 40

C(=O)NH₂;

- 3-14-membered heterocycloalkyl selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂.

- [0030] Preferably, **V** is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -CN, -OH, =O, -C₁₋₆-alkyl, -CHF₂, -CF₃, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NHC(=O)-O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -OC₁₋₆-alkyl, -OCF₃, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -S(=O)₂-C₁₋₆-alkyl, -azetidine, -C₁₋₆-alkylene-O-tetrahydropyran, or -piperazine substituted with -C₁₋₆-alkyl.


[0031] In a preferred embodiments of the benzofuran derivative according to the invention **V** is

- (i) unsubstituted;
- (ii) monosubstituted;
- (iii) disubstituted;
- (iv) trisubstituted; or
- (v) tetrasubstituted.

[0032] In a preferred embodiments of the benzofuran derivative according to the invention **V** is

- (i) unsubstituted;
- (ii) monosubstituted; or
- (iii) disubstituted.


- [0033] In preferred embodiments, **V** represents a 3-14-membered heterocycloalkyl (preferably 5-membered heterocycloalkyl), saturated or unsaturated; or 5-14-membered heteroaryl (preferably 5-membered heteroaryl); in each case unsubstituted, mono- or polysubstituted; preferably a residue selected from the group consisting of:



[0034] In a preferred embodiment, **V** represents -oxetanyl, unsubstituted, mono- or polysubstituted; preferably



[0035] In preferred embodiments, **V** represents a residue according to general formula (E)



5

(E)

wherein

Y^{E1} represents -N=, -NR^{E2}-, S, O, or -CR^{E3}=; **Y^{E2}** represents -N=, -NR^{E3}-, S, O, or -CR^{E4}=; and **Y^{E3}** represent -N=, -NR^{E4}-, S, O, or -CR^{E5}=; with the proviso that at least one of **Y^{E1}**, **Y^{E2}**, and **Y^{E3}** is not -CR^{E3}=, -CR^{E4}=, and -CR^{E5}=, respectively. In another preferred embodiment, **V** represents a residue according to general formula (E)


10 wherein **YE1** represents -N=, -NRE2-, S, or -CRE3=; **YE2** represents -N=, -NRE3-, S, or -CRE4=; and **YE3** represent -N=, -NRE4-, S, or -CRE5=; with the proviso that at least one of **YE1**, **YE2**, and **YE3** is not -CRE3=, -CRE4=, and -CRE5=, respectively.

R^{E1}, **R^{E2}**, **R^{E3}**, and **R^{E4}** independently of one another represent -H, -CH₃-, -CH₂-cyclopropyl, -CH₂CF₃-, -CH₂CHF₂ or -CF₃; more in particular **R^{E1}**, **R^{E2}**, **R^{E3}**, and **R^{E4}** independently of one another represent -H, -CH₃, or -CF₃;


15 preferably with the proviso that only one of **R^{E1}**, **R^{E2}**, **R^{E3}**, and **R^{E4}** represents a residue that is not -H.

[0036] In preferred embodiments, **V** represents 2-pyridine, unsubstituted, mono- or polysubstituted. In preferred embodiments, **V** represents a residue selected from the group consisting of:


--	--	--	--	--	--



[0037] In preferred embodiments, **V** represents 3-pyridine, unsubstituted, mono- or polysubstituted. In preferred embodiments, **V** represents a residue selected from the group consisting of:




[0038] In preferred embodiments, **V** represents 4-pyridine, unsubstituted, mono- or polysubstituted. In preferred embodiments, **V** represents a residue selected from the group consisting of:




5


[0039] In preferred embodiments, **V** represents a residue selected from the group consisting of:



[0040] In preferred embodiments, **V** represents a bicyclic heteroaryl, unsubstituted, mono- or polysubstituted, preferably selected from the group consisting of:



[0041] In preferred embodiments, **V** represents a residue according to general formula (F')



(F')


10

wherein

Y^{F1} represents -N= or $-CR^{F4}=$; and Y^{F2} represents -N= or $-CR^{F5}=$; and Y^{F3} represents -N= or $-CR^{F3}=$; with the proviso that at least one of Y^{F1} and Y^{F2} is not $-CR^{F4}=$ and $-CR^{F5}=$, respectively;

R^{F1} , R^{F2} , R^{F3} , R^{F4} , and R^{F5} independently of one another represent -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, or -azetidiny; preferably with the proviso that only one of R^{F1} , R^{F2} , R^{F3} , R^{F4} , and R^{F5} represents a residue that is not -H.

In another preferred embodiment, V represents a residue according to general formula (F)




(F)

wherein


Y^{F1} represents -N= or $-CR^{F4}=$; and Y^{F2} represents -N= or $-CR^{F5}=$; with the proviso that at least one of Y^{F1} and Y^{F2} is not $-CR^{F4}=$ and $-CR^{F5}=$, respectively;

R^{F1} , R^{F2} , R^{F3} , R^{F4} , and R^{F5} independently of one another represent -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, or -azetidiny; preferably with the proviso that only one of R^{F1} , R^{F2} , R^{F3} , R^{F4} , and R^{F5} represents a residue that is not -H.

[0042] In preferred embodiments, V represents a residue according to general formula (G) or (H)




(G)




(H)

wherein R^{G1} and R^{H1} are selected from the group consisting of -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, azetidiny, -cyclopropyl, -O-cyclopropyl, and -CHF₂; or wherein R^{G1} and R^{H1} are selected from the group consisting of -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, and azetidiny.

In other preferred embodiments, V represents a residue according to general formula (G') or (H')



(G')



(H')

wherein R^{G1} and R^{H1} are selected from the group consisting of -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, azetidiny, -cyclopropyl, -O-cyclopropyl, and -CHF₂; or wherein R^{G1} and R^{H1} are selected from the group consisting of -H, -CH₃, -CF₃, -OH, -OCH₃, -OCH₂CH₃, -Cl, and azetidiny.

- [0043] In a preferred embodiment of the benzofuran derivative according to the invention **R**¹ represents
-H, -F, -Cl, -Br, -I, -CN;
-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -O-C₁₋₆-alkyl, saturated or
5 unsaturated, unsubstituted, mono- or polysubstituted;
-C(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C(=O)OC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C(=O)NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C(=O)N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
10 -S(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-S(=O)₂-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-
membered cycloalkyl is optionally connected through -C₁₋₆-alkylene- or -C₁₋₆-heteroalkylene-, in each case
15 saturated or unsaturated, unsubstituted, mono- or polysubstituted.
- [0044] Preferably, **R**¹ represents -H, -F, -Cl, -Br, -I, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-
alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃,
-C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-
alkylene-CF₃, -C(=O)C₁₋₆-alkyl, -C(=O)OC₁₋₆-alkyl, -C(=O)NH₂, -C(=O)NHC₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -
20 S(=O)-C₁₋₆-alkyl, -S(=O)₂-C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -cyclopropyl unsubstituted, cyclobutyl unsubstituted,
cyclopentyl unsubstituted or cyclohexyl unsubstituted.
- [0045] Preferably, **R**¹ represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -CH₂F, -CHF₂, -CF₃, -cyclopentyl,
unsubstituted, or -cyclopropyl. Preferably, **R**¹ represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -CH₂F, -
CHF₂, -CF₃, -cyclopentyl, or unsubstituted. Preferably, **R**¹ represents -CH₃.
- 25 [0046] Preferably, **R**¹ represents -CH₂F, -CHF₂, -CH₃, or -cyclopropyl. Preferably, **R**¹ represents -CH₂F, -CHF₂,
or -CH₃. Preferably, **R**¹ represents -C(=O)NH₂, or -CHF₂.
- [0047] Preferably, **R**¹ represents -H, -C₁₋₃-alkyl, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₃-alkylene-CF₃, -C₁₋₃-
alkylene-CF₂H, -C₁₋₃-alkylene-CFH₂, or -cyclopropyl; preferably, **R**¹ represents -H, -C₁₋₃-alkyl, -CF₃, -CF₂H, -
CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₃-alkylene-CF₃, -C₁₋₃-alkylene-CF₂H, or -C₁₋₃-alkylene-CFH₂; more preferably -CH₃.
- 30 [0048] In a preferred embodiment of the benzofuran derivative according to the invention **R**² represents
-H;
-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-
35 membered cycloalkyl is optionally connected through -C₁₋₆-alkylene- or -C₁₋₆-heteroalkylene-, in each case
saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said
3-14-membered heterocycloalkyl is optionally connected through -C₁₋₆-alkylene- or -C₁₋₆-heteroalkylene-, in
each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
- 40 [0049] Preferably, **R**² represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋

6 -alkylene- $N(C_{1-6}\text{-alkyl})_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, $-CF_2Cl$, $-CFCl_2$, $-C_{1-6}\text{-alkylene-}CF_3$, $-C_{1-6}\text{-alkylene-}CF_2H$, $-C_{1-6}\text{-alkylene-}CFH_2$, $-C_{1-6}\text{-alkylene-NH-}C_{1-6}\text{-alkylene-}CF_3$, or $-C_{1-6}\text{-alkylene-N}(C_{1-6}\text{-alkyl})\text{-}C_{1-6}\text{-alkylene-}CF_3$.

[0050] Preferably, R^2 represents $-H$ or $-C_{1-6}\text{-alkyl}$.

[0051] In a preferred embodiment of the benzofuran derivative according to the invention R^3 represents

5 $-H$;

$-OH$;

$-C_1\text{-}C_6\text{-alkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

$-C_1\text{-}C_6\text{-heteroalkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0052] Preferably, R^3 represents $-H$, $-OH$, $-C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-OH}$, $-C_{1-6}\text{-alkylene-O-}C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-NH}_2$, $-C_{1-6}\text{-alkylene-NH}(C_{1-6}\text{-alkyl})$, $-C_{1-6}\text{-alkylene-N}(C_{1-6}\text{-alkyl})_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, $-CF_2Cl$, $-CFCl_2$, $-C_{1-6}\text{-alkylene-}CF_3$, $-C_{1-6}\text{-alkylene-}CF_2H$, $-C_{1-6}\text{-alkylene-}CFH_2$, $-C_{1-6}\text{-alkylene-NH-}C_{1-6}\text{-alkylene-}CF_3$, or $-C_{1-6}\text{-alkylene-N}(C_{1-6}\text{-alkyl})\text{-}C_{1-6}\text{-alkylene-}CF_3$.

[0053] Preferably, R^3 represents $-H$, $-OH$, or $-C_{1-6}\text{-alkyl}$, saturated, unsubstituted or monosubstituted with $-OH$. Preferably, R^3 represents $-H$.

15 [0054] Preferably, R^3 represents $-H$ and R^4 represents a residue other than $-H$.

[0055] In a preferred embodiment of the benzofuran derivative according to the invention R^4 represents

$-H$;

$-S(=O)C_{1-6}\text{-alkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

$-S(=O)_2C_{1-6}\text{-alkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

20 $-C_1\text{-}C_6\text{-alkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

$-C_1\text{-}C_6\text{-heteroalkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through $-C_1\text{-}C_6\text{-alkylene-}$ or $-C_1\text{-}C_6\text{-heteroalkylene-}$, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

25 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through $-C_1\text{-}C_6\text{-alkylene-}$ or $-C_1\text{-}C_6\text{-heteroalkylene-}$, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through $-C_1\text{-}C_6\text{-alkylene-}$ or $-C_1\text{-}C_6\text{-heteroalkylene-}$, in each case saturated or unsaturated,

30 unsubstituted, mono- or polysubstituted; or

5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through $-C_1\text{-}C_6\text{-alkylene-}$ or $-C_1\text{-}C_6\text{-heteroalkylene-}$, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0056] Preferably, R^4 represents

35 $-S(=O)_2C_{1-6}\text{-alkyl}$, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of $-F$, $-Cl$, $-C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-}CF_3$, $-OH$, $=O$, $-OC_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-OH}$, $-C_{1-6}\text{-alkylene-O-}C_{1-6}\text{-alkyl}$, $-NH_2$, $-NHC_{1-6}\text{-alkyl}$, $-N(C_{1-6}\text{-alkyl})_2$, $-NHC(=O)O\text{-}C_{1-6}\text{-alkyl}$, $-N(C_{1-6}\text{-alkyl})C(=O)O\text{-}C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-NHC(=O)O-}C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-NH}_2$, $-C_{1-6}\text{-alkylene-NH-}C_{1-6}\text{-alkyl}$, $-C_{1-6}\text{-alkylene-N}(C_{1-6}\text{-alkyl})_2$, $-C_{1-6}\text{-alkylene-NH-}C_{1-6}\text{-alkylene-}CF_3$, $-C(=O)\text{-}C_{1-6}\text{-alkyl}$, $-C(=O)OH$, $-C(=O)O\text{-}C_{1-6}\text{-alkyl}$, $-C(=O)O\text{-}C_{1-6}\text{-alkylene-}CF_3$, $-C(=O)NH_2$, $-C(=O)NH(C_{1-6}\text{-alkyl})$, $-$

- C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;
- S(=O)₂(3-14-membered cycloalkyl), wherein said 3-14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;
- C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;
- 3-14-membered cycloalkyl or -C₁₋₆-alkylene-(3-14-membered cycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;
- 3-14-membered heterocycloalkyl or -C₁₋₆-alkylene-(3-14-membered heterocycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin; in each case

unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂,
 5 -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;


-phenyl unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;

5-14-membered heteroaryl or -C₁₋₆-alkylene-(5-14-membered heteroaryl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted.

[0057] Preferably, R⁴ represents


-H;
 -S(=O)₂C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or polysubstituted with -F;
 35 -S(=O)₂(3-14-membered cycloalkyl), saturated, unsubstituted;
 -C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -OH, =O, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C(=O)NH₂, -C(=O)-NH-C₁₋₃-alkyl, -C(=O)-N(C₁₋₃-alkyl)₂, -phenyl unsubstituted;
 40 3-14-membered cycloalkyl or -C₁₋₆-alkylene-(3-14-membered cycloalkyl), wherein -C₁₋₆-alkylene- is

- unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -OH, -OC₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl;
- 5 3-14-membered heterocycloalkyl or -C₁₋₆-alkylene-(3-14-membered heterocycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydro-
- 10 pyrrolo[1,2-a]pyrazin, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolizine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxothiacyclohexane, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -OH, =O, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -S(=O)₂C₁₋₆-alkyl, oxetanyl,
- 15 pyrimidinyl, -C₁₋₆-alkylene-phenyl; -phenyl unsubstituted;
- 5-14-membered heteroaryl or -C₁₋₆-alkylene-(5-14-membered heteroaryl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine, in
- 20 each case unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -OH.
- [0058] In a preferred embodiment of the benzofuran derivative according to the invention **R**³ and **R**⁴ together form a 5- or 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted.
- 25 [0059] Preferably, **R**³ and **R**⁴ together form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -C₁₋₆-alkyl, -NH₂, -NHCH₃, -N(CH₃)₂, -C(=O)NH-C₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -C(=O)O-C₁₋₆-alkyl, -NHC(=O)O-C₁₋₆-alkyl, -pyridyl unsubstituted, and 1,2,4-oxadiazole unsubstituted or monosubstituted with -C₁₋₆-alkyl. In a preferred embodiment, **R**³ and **R**⁴
- 30 together do not form morpholine unsubstituted, mono- or polysubstituted.
- [0060] Preferably, **R**³ and **R**⁴ together form a pyrrolidine ring, unsubstituted or monosubstituted with -N(CH₃)₂;
- piperidine ring, unsubstituted or monosubstituted with a substituent selected from the group consisting of -C₁₋₆-alkyl, -NH₂, -N(CH₃)₂, -C(=O)NH-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkyl, -NHC(=O)O-C₁₋₆-alkyl, and 1,2,4-oxadiazole
- 35 unsubstituted or monosubstituted with -C₁₋₆-alkyl;
- morpholine ring, unsubstituted; or
- piperazine ring, unsubstituted or N-substituted with a substituent selected from the group consisting of -C₁₋₆-alkyl and -pyridyl unsubstituted.
- [0061] In a preferred embodiment, **R**³ and **R**⁴ both do not represent -H. In preferred embodiments, **R**³ and **R**⁴
- 40 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of:



[0062] In other preferred embodiments, R^3 represents -H and R^4 does not represent -H.

[0063] In preferred embodiments, R^3 represents -H and R^4 represents -C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:



- 5 [0064] In preferred embodiments, R^3 represents -H and R^4 represents a residue -CR' R'' -(CH₂)_m-OH, wherein **m** is an integer of from 1 to 6, preferably from 1 to 3; and wherein R' and R'' independently of one another represent -H, -C₁₋₃-alkyl, -CF₃, -CF₂H, -CFH₂, -C₁₋₃-alkylene-CF₃, -C₁₋₃-alkylene-CF₂H, -C₁₋₃-alkylene-CFH₂, -C₁₋₃-alkylene-O-C₁₋₃-alkyl, -C₁₋₃-alkylene-OH, -C(=O)-NH₂, or C(=O)-NH-C₁₋₃-alkyl; preferably -H, -CH₃, -C₁₋₃-alkylene-OH, -C(=O)-NH₂, or C(=O)-NH-C₁₋₃-alkyl. In a preferred embodiment, at least R' or R'' does not represent -H. In a preferred embodiment, neither R' nor R'' represents -H.


[0065] In other preferred embodiments, R^3 represents -H and R^4 represents a 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

- 15 [0066] In preferred embodiments, R^3 represents -H and R^4 represents a 3-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:



- [0067] In preferred embodiments, R^3 represents -H and R^4 represents a 3-14-membered cycloalkyl (preferably a 4-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (preferably a 4-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:

[0068] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (A),



(A)

wherein

5 m^A is 0 or 1;

Y^A is selected from -O-, $-NR^{A6}$ - and $-CR^{A7}R^{A8}$ -; and

R^{A1} , R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A6} , R^{A7} , and R^{A8} independently of one another represent -H, F, $-C_{1-3}$ -alkyl, $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene-NH₂, $-C_{1-3}$ -alkylene-NH(C_{1-3} -alkyl), $-C_{1-3}$ -alkylene-N(C_{1-3} -alkyl)₂, $-C_{1-3}$ -alkylene-NH(C_{1-3} -alkylene- CF_3), $-C_{1-3}$ -alkylene-C(=O)NH₂, $-C_{1-3}$ -alkylene-NH-C(=O)OC₁₋₄-alkyl, $-C(=O)NH_2$, $-C(=O)$ -NH- C_{1-3} -alkyl, $-C(=O)$ -N(C_{1-3} -alkyl)₂, -3 -oxetanyl, or $-CHF_2$; preferably, R^{A1} , R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A6} , R^{A7} , and R^{A8} independently of one another represent -H, F, $-C_{1-3}$ -alkyl, $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene-NH₂, $-C_{1-3}$ -alkylene-NH(C_{1-3} -alkyl), $-C_{1-3}$ -alkylene-N(C_{1-3} -alkyl)₂, $-C_{1-3}$ -alkylene-NH(C_{1-3} -alkylene- CF_3), $-C_{1-3}$ -alkylene-C(=O)NH₂, $-C_{1-3}$ -alkylene-NH-C(=O)OC₁₋₄-alkyl, $-C(=O)NH_2$, $-C(=O)$ -NH- C_{1-3} -alkyl, $-C(=O)$ -N(C_{1-3} -alkyl)₂, or -3 -oxetanyl; or R^{A7} and R^{A8} together with the carbon atom to which they are attached form a ring and represent $-CH_2OCH_2-$, $-CH_2OCH_2CH_2-$ or $-CH_2CH_2OCH_2CH_2-$, $-CH_2NHCH_2-$, $-CH_2NHCH_2CH_2-$ or $-CH_2CH_2NHCH_2CH_2-$.

[0069] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (A) as defined above, wherein

m^A is 0 or 1;

Y^A is selected from -O- and $-CR^{A7}R^{A8}$ -; and

20 R^{A1} , R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A7} , and R^{A8} independently of one another represent -H, $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene-N(C_{1-3} -alkyl)₂, $-C(=O)NH_2$, or $-CHF_2$; preferably R^{A1} , R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A7} , and R^{A8} independently of one another represent -H, $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene-N(C_{1-3} -alkyl)₂, or $-C(=O)NH_2$; preferably with the proviso that only one of R^{A1} , R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A7} , and R^{A8} represents a residue that is not -H.

[0070] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (A)

25 as defined above, wherein


m^A is 0 or 1;

Y^A is selected from -O- and $-CR^{A7}R^{A8}-$; and


R^{A1} represents $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene- $N(C_{1-3}$ -alkyl) $_2$, $-C(=O)NH_2$, or $-CHF_2$; preferably R^{A1} represents $-C_{1-3}$ -alkylene-OH, $-C_{1-3}$ -alkylene- $N(C_{1-3}$ -alkyl) $_2$, or $-C(=O)NH_2$; and

5 R^{A2} , R^{A3} , R^{A4} , R^{A5} , R^{A7} , and R^{A8} represent -H.

[0071] In preferred embodiments, R^3 represents -H and R^4 represents a 3-14-membered cycloalkyl (preferably a 5-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (preferably a 5-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl (preferably a 5-membered heteroaryl), unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:



[0072] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (B),



(B)

wherein

Y^B is selected from -O-, -NR^{B8}- and -CR^{B9}R^{B10}-; and

- R^{B1}**, **R^{B2}**, **R^{B3}**, **R^{B4}**, **R^{B5}**, **R^{B6}**, **R^{B7}**, **R^{B8}**, **R^{B9}** and **R^{B10}** independently of one another represent -H, -F, -OH, -C₁₋₃-alkyl, -C₁₋₃-alkylene-OH, -C₁₋₃-alkylene-O-C₁₋₃-alkyl, -C₁₋₃-alkylene-CF₃, -C₁₋₃-alkylene-CO₂H, -C₁₋₃-alkylene-C(=O)O-C₁₋₃-alkyl, -C(=O)NH₂, -C(=O)NH-C₁₋₃-alkyl, or -C(=O)N(C₁₋₃-alkyl)₂; or **R^{B2}** and **R^{B3}** together represent =O; or **R^{B4}** and **R^{B5}** together represent =O.

[0073] In preferred embodiments, **R³** represents -H and **R⁴** represents a residue according to general formula (B)


- 10 as defined above, wherein

$\mathbf{Y}^{\mathbf{B}}$ is selected from -O- and -NR^{B8}-; and


R^{B1}, **R^{B2}**, **R^{B3}**, **R^{B4}**, **R^{B5}**, **R^{B6}**, **R^{B7}**, **R^{B8}** independently of one another represent -H, -F, -C₁₋₃-alkyl, -C₁₋₃-alkylene-OH, -C₁₋₃-alkylene-CF₃ or -C(=O)NH₂; or **R^{B2}** and **R^{B3}** together represent =O; or **R^{B4}** and **R^{B5}** together represent =O; preferably with the proviso that only 1, 2 or 3 of **R^{A1}**, **R^{A2}**, **R^{A3}**, **R^{A4}**, **R^{A5}**, **R^{A7}**, and **R^{A8}** represent a residue that is not -H; preferably with the proviso that at least one of **R^{A1}**, **R^{A2}**, **R^{A3}**, **R^{A4}**, **R^{A5}**, **R^{A7}**, and **R^{A8}** represent a residue that is not -H.

- [0074] In preferred embodiments, **R³** represents -H and **R⁴** represents a 3-14-membered cycloalkyl (preferably a 6-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (preferably a 6-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 6-14-membered aryl (preferably a 6-membered aryl), unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl (preferably a 6-membered heteroaryl), unsubstituted, mono- or polysubstituted. In preferred embodiments, **R³** represents -H and **R⁴** represents a residue selected from the group consisting of:



[0075] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (C),



wherein

- 5 Y^{C1} is selected from -O-, $-S(=O)_2-$, $-NR^{C8}-$ and $-CR^{C9}R^{C10}-$ and Y^{C2} represents $-CR^{C11}R^{C12}-$; or Y^{C1} represents $-CR^{C9}R^{C10}-$ and Y^{C2} is selected from -O-, $-S(=O)_2-$, and $-NR^{C8}-$;
- R^{C1} , R^{C2} , R^{C3} , R^{C4} , R^{C5} , R^{C6} , R^{C7} , R^{C8} , R^{C9} , R^{C10} , R^{C11} and R^{C12} independently of one another represent -H, -F, -OH, $-C(=O)OC_{1-3}\text{-alkyl}$, $-NH_2$, $-NH(C_{1-3}\text{-alkyl})$, $-N(C_{1-3}\text{-alkyl})_2$, $-C_{1-3}\text{-alkyl}$, $-C_{1-3}\text{-alkylene-OH}$, $-C_{1-3}\text{-alkylene-}$, $-C(=O)NH_2$, $-C(=O)NH-C_{1-3}\text{-alkyl}$, or $-C(=O)N(C_{1-3}\text{-alkyl})_2$; or R^{C2} and R^{C3} together represent =O; or
- 10 R^{C4} and R^{C5} together represent =O; or R^{C9} and R^{C10} together represent =O; or R^{C11} and R^{C12} together represent =O.

[0076] In preferred embodiments, R^3 represents -H and R^4 represents a residue according to general formula (C) as defined above, wherein

- Y^{C1} is selected from -O- or $-NR^{C8}-$ and Y^{C2} represents $-CR^{C11}R^{C12}-$; or Y^{C1} represents $-CR^{C9}R^{C10}-$ and Y^{C2} is selected from -O-, and $-NR^{C8}-$;
- 15 R^{C1} , R^{C2} , R^{C3} , R^{C4} , R^{C5} , R^{C6} , R^{C7} , R^{C8} , R^{C9} , R^{C10} , R^{C11} and R^{C12} independently of one another represent -H, -F, $-C_{1-3}\text{-alkyl}$, $-C_{1-3}\text{-alkylene-OH}$, or $-C(=O)NH_2$; preferably with the proviso that only 1, 2 or 3 of R^{C1} , R^{C2} , R^{C3} ,

R^{C4} , R^{C5} , R^{C6} , R^{C7} , R^{C8} , R^{C9} , R^{C10} , R^{C11} and R^{C12} represent a residue that is not -H; preferably with the proviso that at least one of R^{C1} , R^{C2} , R^{C3} , R^{C4} , R^{C5} , R^{C6} , R^{C7} , R^{C8} , R^{C9} , R^{C10} , R^{C11} and R^{C12} represent a residue that is not -H.


[0077] In preferred embodiments, R^3 represents -H and R^4 represents a 7-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 7-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue:



[0078] In preferred embodiments, R^3 represents -H and R^4 represents a 3-14-membered cycloalkyl (preferably a 4, 5 or 6-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (preferably a 4, 5 or 6-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 6-14-membered aryl (preferably a 6-membered aryl), unsubstituted, mono- or polysubstituted; wherein said 36-14-membered aryl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl (preferably a 5 or 6-membered heteroaryl), unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:


[0079] In preferred embodiments, R^3 represents -H and R^4 represents a 5-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 5-membered heterocycloalkyl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-membered heteroaryl is connected through -C₁-C₆-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0080] In preferred embodiments, R^3 represents -H and R^4 represents a residue selected from the group consisting of:



[0081] In preferred embodiments, R^3 represents -H and R^4 represents

- (i) a residue $-CR'R''-(CH_2)_m-OH$, wherein m is an integer of from 1 to 6, preferably from 1 to 3; and wherein R' and R'' independently of one another represent -H, $-C_{1-3}$ -alkyl, $-CF_3$, $-CF_2H$, $-CFH_2$, $-C_{1-3}$ -alkylene- CF_3 , $-C_{1-3}$ -alkylene- CF_2H , $-C_{1-3}$ -alkylene- CFH_2 , $-C_{1-3}$ -alkylene- $O-C_{1-3}$ -alkyl, or $-C_{1-3}$ -alkylene-OH; preferably -H, $-CH_3$, or $-C_{1-3}$ -alkylene-OH. In a preferred embodiment, at least R' or R'' does not represent -H. In a preferred embodiment, neither R' nor R'' represents -H; or
- (ii) a residue according to general formula (D),



(D)

wherein

- m^D and n^D independently of one another are 0, 1, 2, or 3; preferably with the proviso that $m^D + n^D \leq 3$;
 Y^{D1} is selected from $-O-$, $-S(=O)_2-$, $-S(=O)(=NH)-$, $-NR^{D8}-$ and $-CR^{D9}R^{D10}-$ and Y^{D2} represents $-CR^{D11}R^{D12}-$;
 or Y^{D1} is selected from $-O-$, $-S(=O)_2-$, $-NR^{D8}-$ and $-CR^{D9}R^{D10}-$ and Y^{D2} represents $-CR^{D11}R^{D12}-$; or Y^{D1} represents $-CR^{D9}R^{D10}-$ and Y^{D2} is selected from $-O-$, $-S(=O)_2-$, and $-NR^{D8}-$;
 R^{D1} , R^{D2} , R^{D3} , R^{D4} , R^{D5} , R^{D6} , R^{D7} , R^{D8} , R^{D9} , R^{D10} , R^{D11} and R^{D12} independently of one another represent -H, -F, -OH, $-C_{1-3}$ -alkylene-OH, $-C(=O)NH_2$, $-C_{1-3}$ -alkylene- $C(=O)NH_2$, $-C(=O)O-C_{1-3}$ -alkyl, $-NH_2$, $-C_{1-3}$ -alkylene- NH_2 , $-NH(C_{1-3}$ -alkyl), $-N(C_{1-3}$ -alkyl) $_2$, $-NH(C_{1-3}$ -alkylene- CF_3), $-C_{1-3}$ -alkylene- OCH_3 , $-C_{1-3}$ -alkyl, $-C_{1-3}$ -alkylene- CF_3 ; or R^{D2} and R^{D3} together represent $=O$; or R^{D4} and R^{D5} together represent $=O$; or R^{D9} and R^{D10} together represent $=O$; or R^{D11} and R^{D12} together represent $=O$;

preferably wherein

- m^D and n^D independently of one another are 0, 1, 2 or 3; preferably with the proviso that $m^D + n^D \leq 3$;
 Y^{D1} is selected from $-O-$, $-NR^{D8}-$ and $-CR^{D9}R^{D10}-$ and Y^{D2} represents $-CR^{D11}R^{D12}-$; or Y^{D1} represents $-CR^{D9}R^{D10}-$ and Y^{D2} is selected from $-O-$ and $-NR^{D8}-$;
 R^{D1} , R^{D2} , R^{D3} , R^{D4} , R^{D5} , R^{D6} , R^{D7} , R^{D8} , R^{D9} , R^{D10} , R^{D11} and R^{D12} independently of one another represent -H, -F, -OH, $-C_{1-3}$ -alkylene-OH, $-C(=O)NH_2$, $-CH_2NH_2$, $-CH_2N(CH_3)_2$, $-NHCH_2CF_3$, $-CH_3$, or $-CH_2CF_3$; or R^{D2} and R^{D3} together represent $=O$; or R^{D4} and R^{D5} together represent $=O$; or R^{D9} and R^{D10} together represent $=O$; or R^{D11} and R^{D12} together represent $=O$; preferably with the proviso that only 1, 2 or 3 of R^{D1} , R^{D2} , R^{D3} , R^{D4} , R^{D5} , R^{D6} , R^{D7} , R^{D8} , R^{D9} , R^{D10} , R^{D11} and R^{D12} represent a residue that is not -H; preferably with the proviso that at least one of R^{D1} , R^{D2} , R^{D3} , R^{D4} , R^{D5} , R^{D6} , R^{D7} , R^{D8} , R^{D9} , R^{D10} , R^{D11} and R^{D12} represent a residue that is not -H.

[0082] In a preferred embodiment of the benzofuran derivative according to the invention R^5 and R^5'

independently of one another represent

-H;

-C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

- 5 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.


[0083] Preferably, **R**⁵ and **R**^{5'} independently of one another represent -H, -C₁-C₆-alkyl, or -C₁-C₆-alkylene-N(C₁-C₆-alkyl)₂.

- 10 [0084] In a preferred embodiment of the benzofuran derivative according to the invention, at least one of **R**⁵ and **R**^{5'} is not -H.


[0085] In a preferred embodiment of the benzofuran derivative according to the invention, **R**⁵ and **R**^{5'} are both -H.

[0086] In preferred embodiments, **T** represents -O- and **U** represents -CR⁵R^{5'}- and the resultant moiety -O-

- 15 CR⁵R^{5'}- represents a residue selected from the group consisting of:



[0087] In preferred embodiments, **T** represents -CR⁵R^{5'}- and **U** represents -O- and the resultant moiety -CR⁵R^{5'}-O- represents a residue:



- [0088] In preferred embodiments, **R**⁵ represents -H and **R**^{5'} represents a residue selected from the group consisting of -H, -C₁₋₃-alkyl, -CF₃, -CF₂H, -CFH₂, -C₁₋₃-alkylene-CF₃, -C₁₋₃-alkylene-CF₂H, -C₁₋₃-alkylene-CFH₂, and -C₁₋₃-alkylene-OH; preferably -H or C₁₋₃-alkyl.

[0089] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁶, **R**⁷ and **R**⁸ independently of one another represent

-H;

- 25 -F, -Cl, -Br, -I, -OH, -SH, -SF₅, -CN, -NO₂, -C(=O)OH, -NH₂;

-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


- 30 -C(=O)OC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-OC(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0090] Preferably, **R**⁶, **R**⁷ and **R**⁸ independently of one another represent

- H, -F, -Cl, -Br, -I, -OH, -SH, -SF₅, -CN, -NO₂, -C(=O)OH, -NH₂,
 -C₁₋₆-alkyl, -CF₃, -CHF₂, -CH₂F,
 -O-C₁₋₆-alkyl, -OCF₃, -OCHF₂, -OCH₂F,
 -NHC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another selected
 5 from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -
 C(=O)OH, -NH₂, and -C(=O)NH₂;
 -N(C₁₋₆-alkyl)₂ unsubstituted or substituted with one or more substituents independently of one another selected
 from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -
 C(=O)OH, -NH₂, and -C(=O)NH₂;
 10 -C(=O)OC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -
 C(=O)OH, -NH₂, and -C(=O)NH₂;
 -OC(=O)C₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂,
 15 -C(=O)OH, -NH₂, and -C(=O)NH₂; or
 -C₁₋₆-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another selected
 from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -
 C(=O)OH, -NH₂, and -C(=O)NH₂.
 [0091] In preferred embodiments, **R**⁶, **R**⁷ and **R**⁸ independently of one another represents a residue selected from
 20 the group consisting of -H, -F, -Cl, -Br, -I, -CN, C₁₋₃-alkyl, -CF₃, -CF₂H, and -CFH₂; preferably -H or -F.
 [0092] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁶ represents -H, -F,
 -Cl, -CN, or -C₁-C₆-alkyl.
 [0093] In a preferred embodiment of the benzofuran derivative according to the invention, **R**⁶ does not represent
 -H.
 25 [0094] In preferred embodiments, **R**⁶ represents a residue selected from the group consisting of -H, -F, -Cl, -CN
 or -CH₃; preferably -H, -F, -CN or -CH₃.
 [0095] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁷ represents -H, -F,
 -Cl, -CN, or -C₁-C₆-alkyl.
 [0096] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁷ does not represent
 30 -H.
 [0097] In preferred embodiments, especially when Q represents -NR³R⁴, **R**⁷ represents a residue selected from
 the group consisting of -H, -F, -Cl, -CN or CH₃; preferably -H, -F, -Cl or -CH₃.
 [0098] In preferred embodiments, especially when Q represents -OR², **R**⁷ represents a residue selected from the
 group consisting of -H or



- 35 [0099] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁸ represents -H, -F,
 -Cl, -CN, or -C₁-C₆-alkyl.
 [0100] In a preferred embodiment of the benzofuran derivative according to the invention **R**⁸ does not represent

-H.


[0101] In preferred embodiments, **R**⁸ represents a residue selected from the group consisting of -H, -F, -Cl, -CN or CH₃; preferably -F.

[0102] In a preferred embodiments of the benzofuran derivative according to the invention

- 5 (i) **R**⁶, **R**⁷ and **R**⁸ each represent -H; or
 (ii) two of **R**⁶, **R**⁷ and **R**⁸ represent -H and the other of **R**⁶, **R**⁷ and **R**⁸ represents -F, -Cl, -CN, or -CH₃; or
 (iii) one of **R**⁶, **R**⁷ and **R**⁸ represents -H and the other of **R**⁶, **R**⁷ and **R**⁸ independently of one another represent -F, -Cl, -CN, or -CH₃.

[0103] In a particularly preferred embodiment, the compound is according to general formula (I), wherein

- 10 - **R**¹ represents -CH₃; and/or
 - **R**⁶, **R**⁷ and **R**⁸ each represent -H; and/or
 - **T** represents -O-; and/or
 - **U** represents -CH₂-; and/or
 - **V** represents thiazolyl, pyridyl, or pyrazolyl; wherein said thiazolyl, pyridyl, and pyrazolyl each independently
 15 from one another can be unsubstituted, monosubstituted or disubstituted with a substituent selected from the group consisting of -CH₃; -F; -CH₂CHF₂; and -CF₃; and/or
 - **Q** represents NR³R⁴; and/or
 - **R**³ represents H; and/or



[0104] In preferred embodiments of the invention, the benzofuran derivative is selected from the group consisting of:

- | | |
|------------|--|
| cpd 001 | 5-(furan-3-ylmethoxy)-2-methylbenzofuran-3-carboxylic acid |
| cpd 002 | 2-methyl-5-(oxazol-5-ylmethoxy)benzofuran-3-carboxylic acid |
| 25 cpd 003 | 2-methyl-5-(pyrrolidin-3-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 004 | 2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 005 | 2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 006 | 2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 007 | 2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxylic acid |
| 30 cpd 008 | 2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxylic acid |
| cpd 009 | 2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxylic acid |
| cpd 010 | 2-methyl-5-((1-methyl-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid |
| cpd 011 | 2-methyl-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 012 | 2-methyl-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxylic acid |
| 35 cpd 013 | 2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxylic acid |
| cpd 014 | 2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxylic acid |

	cpd 015	2-methyl-5-((tetrahydro-2H-pyran-4-yl)methoxy)benzofuran-3-carboxylic acid
	cpd 016	5-((3,5-dimethylisoxazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	cpd 017	5-(benzo[d]thiazol-2-ylmethoxy)-2-methylbenzofuran-3-carboxylic acid
	cpd 018	2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylic acid
5	cpd 019	5-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	cpd 020	(S)-2-methyl-5-(oxazol-5-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 021	(S)-2-methyl-5-(pyridin-4-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 022	(S)-2-methyl-5-(pyridin-3-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 023	(S)-2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carbox-
10		amide
	cpd 024	(S)-2-methyl-N-(pyrrolidin-3-yl)-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
	cpd 025	(S)-2-methyl-N-(pyrrolidin-3-yl)-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 026	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 027	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
15	cpd 028	(S)-2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 029	(S)-2-methyl-5-((6-methylpyridin-2-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 030	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	cpd 031	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 032	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyrimidin-5-ylmethoxy)benzofuran-3-carboxamide
20	cpd 033	2-methyl-5-((6-methylpyridin-3-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
	cpd 034	2-methyl-5-((4-methylpyridin-3-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
	cpd 035	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxamide
	cpd 036	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 037	2-methyl-5-((4-methylpyridin-3-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
25	cpd 038	2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 039	2-methyl-N-(1-methylpiperidin-4-yl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 040	5-((4-methoxypyridin-3-yl)methoxy)-2-methyl-N-(tetrahydrofuran-3-yl)benzofuran-3-carbox-
		amide
	cpd 041	2-methyl-N-(1-methylpiperidin-4-yl)-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxamide
30	cpd 042	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 043	2-methyl-5-((4-methylthiazol-2-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 044	5-((2,6-dimethylpyridin-3-yl)methoxy)-2-methyl-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carbox-
		amide
	cpd 045	2-methyl-N-(1-methylpiperidin-4-yl)-5-(1-(pyridin-4-yl)ethoxy)benzofuran-3-carboxamide
35	cpd 046	5-((2-methoxypyridin-3-yl)methoxy)-2-methyl-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carbox-
		amide
	cpd 047	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-
		carboxamide
	cpd 048	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide

	cpd 049	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 050	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
5	cpd 051	5-((2-methoxypyridin-3-yl)methoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
	cpd 052	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylpyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 053	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamide
10	cpd 054	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
	cpd 055	(S)-2-methyl-N-(pyrrolidin-3-yl)-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 056	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	cpd 057	2-methyl-N-(tetrahydrofuran-3-yl)-5-((4-(trifluoromethyl)thiazol-2-yl)methoxy)benzofuran-3-carboxamide
	cpd 058	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	cpd 059	5-(isoquinolin-1-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
	cpd 060	5-(isoquinolin-5-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
	cpd 061	5-(isoquinolin-6-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
	cpd 062	N-(3,3-difluoropiperidin-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	cpd 063	N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	cpd 064	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 065	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((6-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamide
30	cpd 066	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 067	5-((2-chloropyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
35	cpd 068	5-((4-chloropyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
	cpd 069	2-methyl-N-(1-methylpiperidin-4-yl)-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxamide
40	cpd 070	N-(3,3-difluoropiperidin-4-yl)-5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamide

	cpd 071	N-(3,3-difluoropiperidin-4-yl)-5-((6-(dimethylamino)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	cpd 072	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
5	cpd 073	tert-butyl (S)-3-(2-methyl-5-((5-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 074	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 075	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
10	cpd 076	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamide
	cpd 077	tert-butyl (S)-3-(2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
15	cpd 078	tert-butyl 4-(5-((6-(dimethylamino)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate
	cpd 079	tert-butyl 3-(((3-(ethoxycarbonyl)-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidine-1-carboxylate
	cpd 080	tert-butyl (R)-3-(2-methyl-5-(oxazol-5-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
20	cpd 081	tert-butyl (R)-3-(2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 082	tert-butyl (R)-3-(2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 083	tert-butyl (R)-3-(2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxamido)-pyrrolidine-1-carboxylate
25	cpd 084	tert-butyl (R)-3-(2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 085	tert-butyl (R)-3-(2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
30	cpd 086	tert-butyl (R)-3-(2-methyl-5-((6-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamido)-pyrrolidine-1-carboxylate
	cpd 087	tert-butyl 3,3-difluoro-4-(2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 088	tert-butyl 3,3-difluoro-4-(2-methyl-5-((3-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
35	cpd 089	tert-butyl 3,3-difluoro-4-(5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 090	tert-butyl 3,3-difluoro-4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate

	cpd 091	tert-butyl 3,3-difluoro-4-(5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carbox-amido)piperidine-1-carboxylate
	cpd 092	tert-butyl 4-(5-((2-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoro-piperidine-1-carboxylate
5	cpd 093	tert-butyl 4-(5-((4-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoro-piperidine-1-carboxylate
	cpd 094	tert-butyl 3,3-difluoro-4-(5-(imidazo[1,2-a]pyridin-6-yl)methoxy)-2-methylbenzofuran-3-carbox-amido)piperidine-1-carboxylate
	cpd 095	tert-butyl 3,3-difluoro-4-(2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
10	cpd 096	tert-butyl 3,3-difluoro-4-(2-methyl-5-((3-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 097	tert-butyl 3,3-difluoro-4-(2-methyl-5-(pyridin-2-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
15	cpd 098	tert-butyl 3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 099	2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	cpd 100	5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	cpd 101	2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
20	cpd 102	2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	cpd 103	N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 104	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	cpd 105	N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzo-furan-3-carboxamide
	cpd 106	N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 107	N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	cpd 108	N-(1-((dimethylamino)methyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzo-furan-3-carboxamide
	cpd 109	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzo-furan-3-carboxamide
35	cpd 110	N-(3,3-difluoro-1-methylpiperidin-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 111	N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
40	cpd 112	N-(3,3-difluoropiperidin-4-yl)-4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide

	cpd 113	N-(3,3-difluoropiperidin-4-yl)-6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 114	N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	cpd 115	N-(5,5-difluoropiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 116	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 117	N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
10	cpd 118	N-(4,4-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 119	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	cpd 120	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 121	N-(3-(2-hydroxyethyl)tetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 122	7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	cpd 123	N-(4,4-difluoro-1-methylpyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 124	N-(4,4-difluoro-1-methylpyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
25	cpd 125	N-(5,5-difluoropiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 126	N-(3-(2-hydroxyethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 127	N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
30	cpd 128	N-(3-(2-hydroxyethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 129	N-(3-(2-hydroxyethyl)oxetan-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
35	cpd 130	N-(3,3-difluoro-1-methylpiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 131	N-(4,4-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 132	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40		

	cpd 133	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 134	N-(4,4-difluoro-1-(2-hydroxyethyl)pyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
5	cpd 135	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
	cpd 136	N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 137	N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbox-
10	cpd 138	amide 2-methyl-N-(1H-pyrazol-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carbox-
	cpd 139	amide N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-
	cpd 140	carboxamide N-(1-((dimethylamino)methyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-
15	cpd 141	benzofuran-3-carboxamide N-(5,5-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-
	cpd 142	benzofuran-3-carboxamide N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-
20	cpd 143	carboxamide 2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-
	cpd 144	3-carboxamide 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1H-pyrazol-3-yl)benzofuran-3-carboxamide
	cpd 145	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(((2,2,2-trifluoroethyl)amino)methyl)cyclo-
25	cpd 146	butyl)benzofuran-3-carboxamide 2-methyl-N-(1-methyl-1H-pyrazol-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-
	cpd 147	3-carboxamide N-(4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-
	cpd 148	benzofuran-3-carboxamide 2-methyl-N-(tetrahydrofuran-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-
30	cpd 149	carboxamide 2-methyl-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)-
	cpd 150	methoxy)benzofuran-3-carboxamide 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1H-pyrazol-4-yl)benzofuran-3-carboxamide
35	cpd 151	N-(4,4-difluoro-1-(2-hydroxyethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-
	cpd 152	benzofuran-3-carboxamide 2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbox-
	cpd 153	amide 2-methyl-N-(1-(((2,2,2-trifluoroethyl)amino)methyl)cyclobutyl)-5-((2-(trifluoromethyl)pyridin-3-
40		yl)methoxy)benzofuran-3-carboxamide

	cpd 154	2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 155	N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	cpd 156	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxaspiro[3.3]heptan-6-yl)benzofuran-3-carboxamide
	cpd 157	N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 158	2-methyl-N-(1H-pyrazol-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
10	cpd 159	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
	cpd 160	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 161	2-methyl-N-(1-methyl-1H-pyrazol-3-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	cpd 162	N-(4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 163	N-(5,5-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	cpd 164	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 165	6-chloro-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 166	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzofuran-3-carboxamide
25	cpd 167	2-methyl-N-(2-oxaspiro[3.3]heptan-6-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 168	2-methyl-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
30	cpd 169	N-(1-(2-methoxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 170	(3-aminotetrahydrofuran-3-yl)methyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate
	cpd 171	2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	cpd 172	2,2,2-trifluoroethyl 3,3-difluoro-4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 173	2-methyl-N-(2-azaspiro[3.3]heptan-6-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide

	cpd 174	6-chloro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 175	2,2,2-trifluoroethyl (R)-3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
5	cpd 176	N-(3,3-difluoropiperidin-4-yl)-7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 177	4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 178	(3-amino-1H-pyrazol-1-yl)(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-yl)methanone
10	cpd 179	N-(3,3-difluoropiperidin-4-yl)-2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 180	N-(1-(2-hydroxyethyl)-5-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	cpd 181	(4-amino-1H-pyrazol-1-yl)(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-yl)methanone
	cpd 182	6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 183	N-(3,3-difluoropiperidin-4-yl)-2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
20	cpd 184	7-chloro-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 185	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
25	cpd 186	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
	cpd 187	7-chloro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 188	7-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
30	cpd 189	N-((3-aminooxetan-3-yl)methyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 190	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-azaspiro[3.3]heptan-6-yl)benzofuran-3-carboxamide
35	cpd 191	4-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 192	(3-amino-1H-pyrazol-1-yl)(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-yl)-methanone
	cpd 193	4-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
40		

	cpd 194	6-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 195	6-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
5	cpd 196	7-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 197	2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 198	2-(difluoromethyl)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
10	cpd 199	2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 200	N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
15	cpd 201	N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 202	N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 203	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	cpd 204	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)-methoxy)benzofuran-3-carboxamide
	cpd 205	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
25	cpd 206	5-((2-ethoxypyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	cpd 207	N-(3,3-difluoropiperidin-4-yl)-5-((2-ethoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 208	2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
30	Cpd 209	2-methyl-5-((2-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 210	2-methyl-5-((2-methyl-4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 211	2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 212	2-methyl-5-((2-methylthiazol-4-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 213	2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid
35	Cpd 214	2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 215	2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 216	2-methyl-5-((5-methylthiazol-4-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 217	2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 218	2-methyl-5-(oxetan-3-ylmethoxy)benzofuran-3-carboxylic acid
40	Cpd 219	2-methyl-5-(pyrimidin-4-ylmethoxy)benzofuran-3-carboxylic acid

Cpd 220	5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 221	5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 222	5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 223	5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
5 Cpd 224	5-((2,5-dimethylthiazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 225	5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 226	5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 227	5-((6-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 228	5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
10 Cpd 229	2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 230	2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 231	2-cyclopropyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 232	2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
Cpd 233	4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
15 Cpd 234	4-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 235	5-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 236	5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 237	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 238	5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
20 Cpd 239	5-((2-ethoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 240	5-((3-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 241	5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 242	5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 243	6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
25 Cpd 244	6-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 245	7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 246	7-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
Cpd 247	2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 248	2-methyl-5-(1-(2-(trifluoromethyl)thiazol-5-yl)ethoxy)benzofuran-3-carboxylic acid
30 Cpd 249	2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 250	2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 251	2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 252	2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylic acid
Cpd 253	2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylic acid
35 Cpd 254	2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 255	2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 256	2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 257	2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxylic acid
Cpd 258	2-methyl-5-((3-methylloxetan-3-yl)methoxy)benzofuran-3-carboxylic acid
40 Cpd 259	2-methyl-5-((4-methylloxazol-2-yl)methoxy)benzofuran-3-carboxylic acid

	Cpd 260	2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 261	2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 262	2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 263	2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxylic acid
5	Cpd 264	2-methyl-5-(pyrimidin-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 265	2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 266	5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 267	5-(imidazo[1,2-a]pyridin-6-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 268	2-methyl-5-(1-(4-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxylic acid
10	Cpd 269	5-((2-methoxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 270	(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbonyl)serine
	Cpd 271	(R)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 272	(R)-N-(1-amino-3-(methylsulfonyl)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 273	(R)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 274	(R)-N-(1-hydroxy-3-(methylsulfonyl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 275	(R)-N-(1-hydroxy-3-(methylsulfonyl)propan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 276	(R)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 277	(S)-N-(1-(3,3-difluoropyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 278	(S)-N-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 279	(S)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 280	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 281	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 282	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methyl-4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 283	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methyloxazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 284	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 285	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-4-

		yl)methoxy)benzofuran-3-carboxamide
	Cpd 286	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 287	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 288	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 289	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 290	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylthiazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 291	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 292	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(oxetan-3-ylmethoxy)benzofuran-3-carboxamide
15	Cpd 293	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 294	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrimidin-4-ylmethoxy)benzofuran-3-carboxamide
20	Cpd 295	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 296	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 297	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 298	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 299	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,5-dimethylthiazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 300	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 301	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 302	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
35	Cpd 303	(S)-N-(1-amino-3-methoxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 304	(S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 305	(S)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-

		yl)methoxy)benzofuran-3-carboxamide
	Cpd 306	(S)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 307	(S)-N-(3-hydroxy-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5		
	Cpd 308	2-(difluoromethyl)-N-(1-(hydroxymethyl)cyclopropyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 309	2-(difluoromethyl)-N-(3-(hydroxymethyl)oxetan-3-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 310	2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 311	2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 312	2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxamide
15		
	Cpd 313	2-cyclopropyl-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 314	2-cyclopropyl-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 315	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(oxazol-2-yl)ethyl)benzofuran-3-carboxamide
	Cpd 316	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1,1,1-trifluoro-3-hydroxypropan-2-yl)benzofuran-3-carboxamide
	Cpd 317	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(5-oxo-1,4-oxazepan-6-yl)benzofuran-3-carboxamide
25	Cpd 318	2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 319	2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 320	2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
30	Cpd 321	2-methyl-N-(2-(methylamino)-2-oxoethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 322	2-methyl-N-(2-(methylsulfonamido)ethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 323	2-methyl-N-(2-(methylsulfonyl)ethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35		
	Cpd 324	2-methyl-N-(3-(methylcarbamoyl)oxetan-3-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 325	3-(((3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)methyl)picolinamide
40	Cpd 326	4-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-

		yl)methoxy)benzofuran-3-carboxamide
	Cpd 327	4-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 328	4-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5		
	Cpd 329	4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 330	4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
10	Cpd 331	5-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 332	5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 333	5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
15		
	Cpd 334	5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 335	5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
20	Cpd 336	5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 337	5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 338	5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
25		
	Cpd 339	5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 340	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
30	Cpd 341	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 342	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 343	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
35		
	Cpd 344	5-((2-(dimethylamino)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 345	5-((2,4-dimethylthiazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
40	Cpd 346	5-((2-aminopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-

		methylbenzofuran-3-carboxamide
	Cpd 347	5-((2-cyanopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 348	5-((2-ethoxypyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
5		
	Cpd 349	5-((2-hydroxypyridin-3-yl)methoxy)-N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 350	5-((2-hydroxypyridin-3-yl)methoxy)-N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methylbenzofuran-3-carboxamide
10		
	Cpd 351	5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 352	5-((3-fluoropyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 355	5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide
15		
	Cpd 356	5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 357	5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
20		
	Cpd 358	5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 359	5-((5-fluoropyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
	Cpd 360	6-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25		
	Cpd 361	6-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 362	6-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30		
	Cpd 363	6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 364	6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 365	7-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35		
	Cpd 366	7-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 367	7-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40		
	Cpd 368	7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-

		methylbenzofuran-3-carboxamide
	Cpd 369	7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 370	N-((1-cyanocyclopropyl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 371	N-((1-cyanocyclopropyl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 372	N-((1-fluorocyclopropyl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 373	N-((1-fluorocyclopropyl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 374	N-((1H-pyrazol-3-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 375	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 376	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 377	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 378	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 379	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 380	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 381	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 382	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 383	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 384	N-((3-fluorooxetan-3-yl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 385	N-((3-fluorooxetan-3-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 386	N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 387	N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
40	Cpd 388	N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-

		3-carboxamide
	Cpd 389	N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
5	Cpd 390	N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 391	N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 392	N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 393	N-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 394	N-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 395	N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(1-(2-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxamide
15	Cpd 396	N-(1-((2-hydroxyethyl)(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 397	N-(1-((2-hydroxyethyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 398	N-(1-((2-hydroxyethyl)amino)-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 399	N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 400	N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 401	N-(1-(1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 402	N-(1-(2-(2-hydroxyethoxy)ethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 403	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 404	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 405	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 406	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 407	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
40	Cpd 408	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-

		methylbenzofuran-3-carboxamide
	Cpd 409	N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 410	N-(1-(2-hydroxyethyl)-3-methyl-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 411	N-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 412	N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 413	N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 414	N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 415	N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
15	Cpd 416	N-(1-(hydroxymethyl)cyclobutyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 417	N-(1-(hydroxymethyl)cyclobutyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 418	N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 419	N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 420	N-(1-(hydroxymethyl)cyclopropyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 421	N-(1-(hydroxymethyl)cyclopropyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 422	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 423	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 424	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 425	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 426	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 427	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 428	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
40	Cpd 429	N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyrimidin-4-ylmethoxy)benzofuran-3-

		carboxamide
	Cpd 430	N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 431	N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 432	N-(1-amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 433	N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 434	N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 435	N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 436	N-(1-amino-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 437	N-(1-amino-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 438	N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 439	N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 440	N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 441	N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
25	Cpd 442	N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 443	N-(1-amino-2-methyl-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 444	N-(1-amino-2-methyl-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 445	N-(1-amino-3-(cyclopropyl(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 446	N-(1-amino-3-(cyclopropyl(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 447	N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 448	N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 449	N-(1-amino-3-(dimethylamino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40		

	Cpd 450	N-(1-amino-3-(dimethylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 451	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 452	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 453	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 454	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 455	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 456	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 457	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 458	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 459	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 460	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 461	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 462	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 463	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 464	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 465	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 466	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
35	Cpd 467	N-(1-amino-3-methoxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 468	N-(1-amino-3-methoxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 469	N-(1-amino-4-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide

	Cpd 470	N-(1-carbamoyl-3,3-difluorocyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 471	N-(1-carbamoylcyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 472	N-(1-carbamoylcyclobutyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 473	N-(1-carbamoylcyclobutyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 474	N-(1-carbamoylcyclobutyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
10	Cpd 475	N-(1-carbamoylcyclopropyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 476	N-(1-carbamoylcyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 477	N-(1-carbamoylcyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 478	N-(1-carbamoylcyclopropyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 479	N-(1-carbamoylcyclopropyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 480	N-(1-carbamoylcyclopropyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 481	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 482	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 483	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 484	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 485	N-(1-hydroxy-2-methylpropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 486	N-(1-hydroxy-2-methylpropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 487	N-(1-hydroxy-3-morpholinopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 488	N-(1-hydroxy-3-morpholinopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 489	N-(1-hydroxypropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 490	N-(1-hydroxypropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 491	N-(1-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 492	(S)-N-(1-hydroxypropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide

	Cpd 493	(R)-N-(1-hydroxypropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 494	(S)-N-(1-hydroxypropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 495	(R)-N-(1-hydroxypropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 496	(S)-N-(1-hydroxypropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 497	(R)-N-(1-hydroxypropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
10	Cpd 498	N-(2,2-difluoroethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 499	N-(2,2-difluoropropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 500	N-(2,2-difluoropropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 501	N-(2-acetamidoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 502	N-(2-amino-1-cyano-2-oxoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 503	N-(2-amino-2-oxoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 504	N-(2-fluoro-2-methylpropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 505	N-(2-fluoro-2-methylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 506	N-(2-hydroxy-2-methylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 507	N-(3-(aminomethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 508	N-(3-(dimethylamino)oxetane-3-carbonyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 509	N-(3-(dimethylcarbamoyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 510	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 511	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 512	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 513	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 514	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 515	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
40		

	Cpd 516	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 517	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 518	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 519	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 520	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-
10		carboxamide
	Cpd 521	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 522	N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 523	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 524	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 525	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-
20		carboxamide
	Cpd 526	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 527	N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 528	N-(3-(hydroxymethyl)oxetan-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 529	N-(3-(hydroxymethyl)oxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 530	N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 531	N-(3-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
30		
	Cpd 532	N-(3-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 533	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 534	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 535	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 536	N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-
40		methylbenzofuran-3-carboxamide

	Cpd 537	N-(3,3-difluoro-1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 538	N-(3,3-difluoropiperidin-4-yl)-2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 539	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxamide
	Cpd 540	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 541	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 542	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 543	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 544	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 545	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 546	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 547	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 548	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 549	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 550	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-methyloxetan-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 551	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methyloxazol-2-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 552	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 553	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 554	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 555	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 556	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxamide

	Cpd 557	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 558	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 559	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 560	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
5	Cpd 561	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
	Cpd 562	N-(3,3-difluoropiperidin-4-yl)-4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 563	N-(3,3-difluoropiperidin-4-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
10	Cpd 564	N-(3,3-difluoropiperidin-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 565	N-(3,3-difluoropiperidin-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 566	N-(3,3-difluoropiperidin-4-yl)-5-((3-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 567	N-(3,3-difluoropiperidin-4-yl)-5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 568	N-(3,3-difluoropiperidin-4-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 569	N-(3,3-difluoropiperidin-4-yl)-5-((6-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 570	N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 571	N-(3,3-difluoropiperidin-4-yl)-5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 572	N-(3,3-difluoropiperidin-4-yl)-6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 573	N-(3,3-difluoropiperidin-4-yl)-7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 574	N-(3,3-difluoropropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 575	N-(3-amino-2-(dimethylamino)-3-oxopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 576	N-(3-amino-2,2-dimethyl-3-oxopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 577	N-(3-carbamoyloxetan-3-yl)-2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 578	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 579	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
40		

	Cpd 580	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 581	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 582	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
5	Cpd 583	N-(3-carbamoyloxetan-3-yl)-4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 584	N-(3-carbamoyloxetan-3-yl)-5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 585	N-(3-carbamoyloxetan-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
10	Cpd 586	N-(3-carbamoyloxetan-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 587	N-(3-carbamoyloxetan-3-yl)-6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 588	N-(3-carbamoyloxetan-3-yl)-7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 589	N-(3-carbamoyloxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 590	N-(3-carbamoyltetrahydro-2H-pyran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 591	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 592	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 593	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 594	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 595	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
30	Cpd 596	N-(3-carbamoyltetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 597	N-(3-carbamoyltetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
35	Cpd 598	N-(3-carbamoyltetrahydrofuran-3-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 599	N-(3-cyanooxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 600	N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide

	Cpd 601	N-(3-hydroxy-1-(methy lamino)-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 602	N-(3-hydroxy-2,2-dimethylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 603	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,4-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 604	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 605	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 606	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 607	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 608	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 609	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 610	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 611	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 612	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 613	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 614	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 615	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 616	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methyloxazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 617	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 618	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 619	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 620	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
40		

	Cpd 621	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 622	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 623	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(1-(4-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxamide
	Cpd 624	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 625	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
10	Cpd 626	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 627	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
15	Cpd 628	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 629	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 630	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 631	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 632	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 633	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 634	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 635	N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 636	N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 637	N-(4,4-difluoropiperidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
35	Cpd 638	N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 639	N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 640	N-(4,4-difluoropyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide

	Cpd 641	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 642	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 643	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 646	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 647	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
10	Cpd 648	N-(4,4-difluorotetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 649	N-(4-amino-2-methyl-4-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 650	N-(4-carbamoyltetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 651	N-(4-hydroxy-2-methylbutan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 652	N-(4-hydroxy-2-methylbutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 653	N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 654	N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 655	N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 656	N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 657	N3-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-2,3-dicarboxamide
30	Cpd 658	N3-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-2,3-dicarboxamide
	Cpd 659	N-cyclobutyl-N-(2-hydroxyethyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 660	N-cyclobutyl-N-(2-hydroxyethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 661	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxoazepan-3-yl)benzofuran-3-carboxamide
	Cpd 662	N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 663	N-(4,4-difluoropyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
40		

	Cpd 664	N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 665	N-(4,4-difluorotetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 666	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2,2,2-trifluoroethyl)benzofuran-3-carboxamide
	Cpd 667	5-((1,4-Dimethyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 668	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((1,4-dimethyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 669	5-((4-Chloro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
10	Cpd 670	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-chloro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 671	5-((4-chloro-1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 672	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-chloro-1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 673	2-Methyl-5-((3-methylisoxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 674	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((3-methylisoxazol-5-yl)methyl)benzofuran-3-carboxamide
	Cpd 675	5-((1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 676	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 677	5-((2,4-Dimethylloxazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 678	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethylloxazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 679	2-Methyl-5-((4-methylloxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
25	Cpd 680	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 681	5-((2-Isopropylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 682	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-isopropylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 683	N-(1-(Difluoromethyl)cyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 684	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 685	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 686	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 687	2-Methyl-5-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 688	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
40		

	Cpd 689	5-((1-(Cyclopropylmethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 690	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 691	2-Methyl-5-((1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid
5		
	Cpd 692	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 693	2-Methyl-5-((4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 694	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxamide
10		
	Cpd 695	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 696	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15		
	Cpd 697	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
	Cpd 698	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 699	2-Methyl-5-((5-methylpyridin-2-yl)methoxy)benzofuran-3-carboxylic acid
20		
	Cpd 700	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamide
	Cpd 701	5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 702	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25		
	Cpd 703	5-((3-Cyclopropylpyridin-2-yl) methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 704	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((3-cyclopropylpyridin-2-yl) methoxy)-2-methylbenzofuran-3-carboxamide;
	Cpd 705	5-((3-cyclopropylpyridin-2-yl) methoxy)-N-(4-(hydroxymethyl) tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
30		
	Cpd 706	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(azetidin-1-yl) pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 707	2-Methyl-5-((2-methylpyrimidin-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 708	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyrimidin-5-yl)methoxy)benzofuran-3-carboxamide
35		
	Cpd 709	5-((2-Cyclopropoxypyridin-3-yl) methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 710	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-cyclopropoxypyridin-3-yl) methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 711	5-((2-cyclopropoxypyridin-3-yl) methoxy)-N-(4-(hydroxymethyl) tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
40		
	Cpd 712	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-

		carboxamide
	Cpd 713	2-Methyl-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxylic acid
	Cpd 714	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxamide
5	Cpd 715	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 716	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxamide
	Cpd 717	5-((3-(Difluoromethyl)pyridin-2-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
10	Cpd 718	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 719	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
15	Cpd 720	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 721	N-(1-(Difluoromethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 722	N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 723	N-(3,3-difluorotetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 724	N-(3,3-Difluorotetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 725	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 726	N-(1-Amino-3-(methylsulfonyl)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 727	N-(1-Imino-1-oxidotetrahydro-1H-116-thiophen-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 728	N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 729	N-(1-Amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 730	N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 731	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
	Cpd 732	N-(3-(Hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
40		


- Cpd 733 N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 734 N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
- 5 Cpd 735 5-((5-Fluoropyridin-2-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 736 5-((2-(Difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 737 5-((2-(Difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide
- 10 Cpd 738 N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 739 N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 740 N-(3-carbamoyltetrahydrofuran-3-yl)-5-((1-(2, 2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 741 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 742 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 743 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 744 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 25 Cpd 745 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 746 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 747 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 30 Cpd 748 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 749 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 750 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 751 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide

and the physiologically acceptable salts thereof.

- 40 [0105] The benzofuran derivative according to the invention is for use in the treatment of pain which is preferably

selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain.

[0106] Another aspect of the invention relates to a compound of formula (I),



5

(I)

a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof, as defined above; preferably wherein

(a-1) Q represents $-OR^2$; and R^1 represents $-CH_2F$, $-CHF_2$, or $-CF_3$; and/or


(a-2) Q represents $-OR^2$; and at least one of R^5 and $R^{5'}$ does not represent $-H$; and/or

10 (a-3) Q represents $-OR^2$; and R^6 does not represent $-H$; and/or


(a-3) Q represents $-OR^2$; and R^8 does not represent $-H$;

or

(b-1) Q represents $-NR^3R^4$; with the proviso that the following compounds and their salts are excluded



15



; and/or

- (b-2) Q represents $-NR^3R^4$; and R^1 represents $-CH_2F$, $-CHF_2$, $-CF_3$, or $-cyclopropyl$; and/or
 (b-3) Q represents $-NR^3R^4$; and R^1 represents $-CH_2F$, $-CHF_2$, or $-CF_3$; and/or
 (b-4) Q represents $-NR^3R^4$; and at least one of R^5 and $R^{5'}$ does not represent $-H$; and/or
 5 (b-5) Q represents $-NR^3R^4$; and R^3 represents $-H$.

[0107] In preferred embodiments of the benzofuran derivatives according to the invention (a-1), (a-2), (a-3), (b-1), (b-2), (b-3), and (b-4) T represents $-O-$ and U represents $-CR^5R^{5'}$ - (i.e., the benzofuran derivatives is of formula (II)).

- [0108] All definitions, preferred embodiments and preferred meanings of Q, T, U, V, R^1 , R^2 , R^3 , R^4 , R^5 , $R^{5'}$,
 10 R^6 , R^7 , and R^8 including the preferred substituents also analogously apply the benzofuran derivatives according to the invention, including but not limited to (a-1), (a-2), (a-3), (b-1), (b-2), (b-3), and (b-4), which are not necessarily restricted for use in the treatment of pain. Thus, this aspect of the invention relates to the benzofuran derivatives as such, compositions comprising the benzofuran derivatives, medicaments comprising the benzofuran derivatives, and the benzofuran derivatives for use in the prevention and/or treatment of TRPM3 mediated
 15 disorders such as pain and/or inflammatory hypersensitivity; and/or for counteracting pain and/or inflammatory hypersensitivity. Preferably, the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain.

[0109] In preferred embodiments of the invention, the benzofuran derivative is selected from the group consisting of cpd 001 to cpd 207 as mentioned above and the physiologically acceptable salts thereof.

- 20 [0110] Another aspect of the invention relates to a pharmaceutical composition or a medicament comprising a compound according to the invention as described above.

- [0111] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in
 25 various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments. Also, embodiments described for an aspect of the invention may be used for another aspect of the invention and can be combined. Where an indefinite or definite article is used when referring to a singular noun e.g., "a" or "an", "the",
 30 this includes a plural of that noun unless something else is specifically stated.

[0112] Similarly, it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects.

[0113] In each of the following definitions, the number of carbon atoms represents the maximum number of carbon atoms generally optimally present in the substituent or linker; it is understood that where otherwise indicated in the present application, the number of carbon atoms represents the optimal maximum number of carbon atoms for that particular substituent or linker.

5 [0114] The term “leaving group” or “LG” as used herein means a chemical group which is susceptible to be displaced by a nucleophile or cleaved off or hydrolyzed in basic or acidic conditions. In a particular embodiment, a leaving group is selected from a halogen atom (e.g., Cl, Br, I) or a sulfonate (e.g., mesylate, tosylate, triflate).

[0115] The term “protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructure of a protecting group
10 varies widely. One function of a protecting group is to serve as intermediates in the synthesis of the parental drug substance. Chemical protecting groups and strategies for protection/deprotection are well known in the art. See: “Protective Groups in Organic Chemistry”, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion.
15 Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.

[0116] Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in
20 vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency in vivo than the parental drug. Protecting groups are removed either
25 in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g., alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

[0117] The term “heteroatom(s)” as used herein means an atom selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone.

30 [0118] The term “alkyl, saturated or unsaturated” as used herein encompasses saturated alkyl as well as unsaturated alkyl such as alkenyl, alkynyl, and the like. The term “alkyl” as used herein means normal, secondary, or tertiary, linear or branched hydrocarbon with no site of unsaturation. Examples are methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iPr), 1-butyl, 2-methyl-1-propyl (i-Bu), 2-butyl (s-Bu), 2-dimethyl-2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-
35 hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl. The term “alkenyl” as used herein means normal, secondary or tertiary, linear or branched hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp² double bond. Examples include, but are not limited to: ethylene or vinyl ($-\text{CH}=\text{CH}_2$), allyl ($-\text{CH}_2\text{CH}=\text{CH}_2$), and 5-hexenyl ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}=\text{CH}_2$). The double bond may be in the cis or trans
40 configuration. The term “alkynyl” as used herein means normal, secondary, tertiary, linear or branched

hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. Examples include, but are not limited to: ethynyl ($-\text{C}\equiv\text{CH}$), and 1-propynyl (propargyl, $-\text{CH}_2\text{C}\equiv\text{CH}$).

[0119] The term "alkylene, saturated or unsaturated" as used herein encompasses saturated alkylene as well as unsaturated alkylene such as alkenylene, alkynylene, alkenynylene and the like. The term "alkylene" as used herein means saturated, linear or branched chain hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene ($-\text{CH}_2-$), 1,2-ethyl ($-\text{CH}_2\text{CH}_2-$), 1,3-propyl ($-\text{CH}_2\text{CH}_2\text{CH}_2-$), 1,4-butyl ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$), and the like. The term "alkenylene" as used herein means linear or branched chain hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp² double bond, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. The term "alkynylene" as used herein means linear or branched chain hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.

[0120] The term "heteroalkyl, saturated or unsaturated" as used herein encompasses saturated heteroalkyl as well as unsaturated heteroalkyl such as heteroalkenyl, heteroalkynyl, heteroalkenynyl and the like. The term "heteroalkyl" as used herein means linear or branched chain alkyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by a heteroatom, i.e., an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. This means that one or more $-\text{CH}_3$ of said alkyl can be replaced by $-\text{NH}_2$ and/or that one or more $-\text{CH}_2-$ of said alkyl can be replaced by $-\text{NH}-$, $-\text{O}-$ or $-\text{S}-$. The S atoms in said chains may be optionally oxidized with one or two oxygen atoms, to afford sulfoxides and sulfones, respectively. Furthermore, the heteroalkyl groups in the benzofuran derivatives of the invention can contain an oxo or thio group at any carbon or heteroatom that will result in a stable compound. Exemplary heteroalkyl groups include, but are not limited to, alcohols, alkyl ethers (such as for example -methoxy, -ethoxy, -butoxy...), primary, secondary, and tertiary alkyl amines, amides, ketones, esters, alkyl sulfides, and alkyl sulfones. The term "heteroalkenyl" means linear or branched chain alkenyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term heteroalkenyl thus comprises imines, $-\text{O}-\text{alkenyl}$, $-\text{NH}-\text{alkenyl}$, $-\text{N}(\text{alkenyl})_2$, $-\text{N}(\text{alkyl})(\text{alkenyl})$, and $-\text{S}-\text{alkenyl}$. The term "heteroalkynyl" as used herein means linear or branched chain alkynyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term heteroalkynyl thus comprises -cyano, $-\text{O}-\text{alkynyl}$, $-\text{NH}-\text{alkynyl}$, $-\text{N}(\text{alkynyl})_2$, $-\text{N}(\text{alkyl})(\text{alkynyl})$, $-\text{N}(\text{alkenyl})(\text{alkynyl})$, and $-\text{S}-\text{alkynyl}$.

[0121] The term "heteroalkylene, saturated or unsaturated" as used herein encompasses saturated heteroalkylene as well as unsaturated heteroalkylene such as heteroalkenylene, heteroalkynylene, heteroalkenynylene and the like. The term "heteroalkylene" as used herein means linear or branched chain alkylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by a heteroatom, i.e., an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term "heteroalkenylene" as used herein means linear or branched chain alkenylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O

atoms or two adjacent S atoms. The term "heteroalkynylene" as used herein means linear or branched chain alkynylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms.

[0122] The term "cycloalkyl, saturated or unsaturated" as used herein encompasses saturated cycloalkyl as well as unsaturated cycloalkyl such as cycloalkenyl, cycloalkynyl and the like. The term "cycloalkyl" as used herein and unless otherwise stated means a saturated cyclic hydrocarbon radical, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, fenchyl, decalyl, adamantyl and the like. The term "cycloalkenyl" as used herein means a non-aromatic cyclic hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp² double bond. Examples include, but are not limited to cyclopentenyl and cyclohexenyl. The double bond may be in the cis or trans configuration. The term "cycloalkynyl" as used herein means a non-aromatic cyclic hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple. An example is cyclohept-1-yne. Fused systems of a cycloalkyl ring with a heterocycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkyl ring with an aryl ring are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0123] The term "heterocycloalkyl, saturated or unsaturated" as used herein encompasses saturated heterocycloalkyl as well as unsaturated non-aromatic heterocycloalkyl including at least one heteroatom, i.e., an N, O, or S as ring member. The term "heterocycloalkyl" as used herein and unless otherwise stated means "cycloalkyl" wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term "heterocycloalkenyl" as used herein and unless otherwise stated means "cycloalkenyl" wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term "heterocycloalkynyl" as used herein and unless otherwise stated means "cycloalkynyl" wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. Examples of saturated and unsaturated heterocycloalkyl include but are not limited to azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin. Further heterocycloalkyls in the meaning of the invention are described in Paquette, Leo A. "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, C.W. and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566. When the heterocycloalkyl contains no nitrogen as ring member, it is typically bonded through carbon. When the heterocycloalkyl contains nitrogen as ring member, it may be bonded

through nitrogen or carbon. Fused systems of heterocycloalkyl ring with a cycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. Fused systems of a heterocycloalkyl ring with an aryl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. Fused systems of a heterocycloalkyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0124] The term "aryl" as used herein means an aromatic hydrocarbon. Typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like. Fused systems of an aryl ring with a cycloalkyl ring are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of an aryl ring with a heterocycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. Thus, indoline, dihydrobenzofuran, dihydrobenzothiophene and the like are considered as heterocycloalkyl according to the invention. Fused systems of an aryl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0125] The term "heteroaryl" as used herein means an aromatic ring system including at least one heteroatom, i.e., N, O, or S as ring member of the aromatic ring system. Examples of heteroaryl include but are not limited to benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine.

[0126] By further way of example, carbon bonded heterocyclic rings are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.

[0127] Preferred carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl. By way of example, nitrogen bonded heterocyclic rings are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β -carboline. Preferred nitrogen bonded heterocycles include 1-aziridyl, 1-azetetyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl. Further heteroaryls in the meaning of the invention are described in Paquette, Leo A. "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, C.W. and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566.

[0128] As used herein with respect to a substituting group, and unless otherwise stated, the terms "monosubstituted", "disubstituted", "trisubstituted", "polysubstituted" and the like means chemical structures defined herein, wherein the respective moiety is substituted with one or more substituents, meaning that one or more hydrogen atoms of said moiety are each independently replaced with a substituent. For example, -C₁₋₆-alkyl that may be polysubstituted with -F covers -CH₂F, -CHF₂, -CF₃, -CH₂CF₃, CF₂CF₃, and the like. Likewise, -C₁₋₆-alkyl that may be polysubstituted with substituents independently of one another selected from -F and -Cl covers -CH₂F, -CHF₂, -CF₃, -CH₂CF₃, CF₂CF₃, -CH₂Cl, -CHCl₂, -CCl₃, -CH₂CCl₃, CCl₂CCl₃, -CHClF, -CClF₂, -CCl₂CF₃, -CF₂CCl₃, -CClFCCl₂F, and the like. Any substituent designation that is found in more than one site in a compound of this invention shall be independently selected.

[0129] As used herein and unless otherwise stated, the term "solvate" includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g., hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.

[0130] The term "subject" as used herein, refers to an animal including humans, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

[0131] The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease or disorder being treated.

[0132] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

[0133] The term "antagonist" or "inhibitor" as used herein refers to a compound capable of producing, depending on the circumstance, a functional antagonism of the TRPM3 ion channel, including competitive antagonists, non-competitive antagonists, desensitizing agonists, and partial agonists.

[0134] For purposes of the invention, the term "TRPM3-modulated" is used to refer to the condition of being affected by the modulation of the TRPM3 ion channel, including the state of being mediated by the TRPM3 ion channel.

[0135] The term "TRPM3 mediated disorder" as used herein refers to disorders or diseases for which the use of an antagonist of TRPM3 would prevent, treat, (partially) alleviate or improve the symptoms and consist of pain and inflammatory hypersensitivity condition. According to the International Association for the Study of Pain and for the purpose of the invention, pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Preferably, the TRPM3 mediated disorder is pain which is preferably selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain. For the purpose of the invention, the term "inflammatory hypersensitivity" is used to refer to a condition that is characterized by one or more hallmarks of inflammation, including edema, erythema, hyperthermia and pain, and/or by an exaggerated physiologic or pathophysiologic response to one or more than one type of stimulation, including thermal, mechanical and/or chemical stimulation.

[0136] The benzofuran derivatives of the invention have been shown to be antagonists of TRPM3 and the invention therefore provides the compounds as such, the compounds for use as a medicine, more specifically for use as a medicine in the prevention or treatment of TRPM3 mediated disorders in a subject with a therapeutically

effective amount of a benzofuran derivative of the invention.

[0137] In a preferred embodiment of the invention, the benzofuran derivative of the invention is the sole pharmacologically active compound to be administered for therapy. In another preferred embodiment of the invention, the benzofuran derivative of the invention may be employed in combination with other therapeutic agents for the treatment or prophylaxis of TRPM3 mediated disorders. The invention therefore also relates to the use of a composition comprising:

- one or more compounds of the formulae and embodiments herein, and
- one or more further therapeutic or preventive agents that are used for the prevention or treatment of TRPM3 mediated disorders as biologically active agents in the form of a combined preparation for simultaneous, separate or sequential use.

[0138] The pharmaceutical composition or combined preparation according to this invention may contain benzofuran derivatives of the invention over a broad content range depending on the contemplated use and the expected effect of the preparation. Generally, the content of the benzofuran derivatives of the invention of the combined preparation is within the range of 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from 5 to 95% by weight.

[0139] In view of the fact that, when several active ingredients are used in combination, they do not necessarily bring out their joint therapeutic effect directly at the same time in the mammal to be treated, the corresponding composition may also be in the form of a medical kit or package containing the two ingredients in separate but adjacent repositories or compartments. In the latter context, each active ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g., one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.

[0140] Those of skill in the art will also recognize that the benzofuran derivatives of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state - any and all protonated forms of the compounds are intended to fall within the scope of the invention.

[0141] The term "pharmaceutically acceptable salts" as used herein means the therapeutically active non-toxic salt forms which the compounds of formulae herein are able to form. Therefore, the compounds of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example, Na^+ , Li^+ , K^+ , Ca^{2+} and Mg^{2+} . Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. The benzofuran derivatives of the invention may bear multiple positive or negative charges. The net charge of the benzofuran derivatives of the invention may be either positive or negative. Any associated counter ions are typically dictated by the synthesis and/or isolation methods by which the compounds are obtained. Typical counter ions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion. Moreover, as the compounds can exist in a variety of different forms,

the invention is intended to encompass not only forms of the compounds that are in association with counter ions (e.g., dry salts), but also forms that are not in association with counter ions (e.g., aqueous or organic solutions). Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this way are salts containing Li^+ , Na^+ , and K^+ . A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound. In addition, salts may be formed from acid addition of certain organic and inorganic acids to basic centers, typically amines, or to acidic groups. Examples of such appropriate acids include, for instance, inorganic acids such as hydrohalogen acids, e.g. hydrochloric or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic (i.e. 2-hydroxybenzoic), p-aminosalicylic and the like. Furthermore, this term also includes the solvates which the compounds of formulae herein as well as their salts are able to form, such as for example hydrates, alcoholates and the like. Finally, it is to be understood that the compositions herein comprise benzofuran derivatives of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

[0142] Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids, especially the naturally-occurring amino acids found as protein components. The amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

[0143] The benzofuran derivatives of the invention also include physiologically acceptable salts thereof. Examples of physiologically acceptable salts of the benzofuran derivatives of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX_4^+ (wherein X is $-\text{C}_{1-6}$ -alkyl). Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound containing a hydroxy group include the anion of said compound in combination with a suitable cation such as Na^+ and NX_4^+ (wherein X typically is independently selected from $-\text{H}$ or a $-\text{C}_{1-4}$ -alkyl group). However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the invention.

[0144] As used herein and unless otherwise stated, the term "enantiomer" means each individual optically active form of a benzofuran derivative of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.

[0145] The term "isomers" as used herein means all possible isomeric forms, including tautomeric and stereochemical forms, which the compounds of formulae herein may possess, but not including position isomers. Typically, the structures shown herein exemplify only one tautomeric or resonance form of the compounds, but

the corresponding alternative configurations are contemplated as well. Unless otherwise stated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers (since the compounds of formulae herein may have at least one chiral center) of the basic molecular structure, as well as the stereochemically pure or enriched compounds. More particularly, stereogenic centers may have either the R- or S-configuration, and multiple bonds may have either cis- or trans-configuration.

[0146] Pure isomeric forms of the said compounds are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure. In particular, the term "stereoisomerically pure" or "chirally pure" relates to compounds having a stereoisomeric excess of at least about 80% (i.e., at least 90% of one isomer and at most 10% of the other possible isomers), preferably at least 90%, more preferably at least 94% and most preferably at least 97%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, having regard to the enantiomeric excess, respectively the diastereomeric excess, of the mixture in question.

[0147] Separation of stereoisomers is accomplished by standard methods known to those in the art. One enantiomer of a benzofuran derivative of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents ("Stereochemistry of Carbon Compounds," (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3) 283-302). Separation of isomers in a mixture can be accomplished by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure enantiomers, or (3) enantiomers can be separated directly under chiral conditions. Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, α -methyl- β -phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched compound. A method of determining optical purity involves making chiral esters, such as a menthyl ester or Mosher ester, α -methoxy- α -(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). Under method (3), a racemic mixture of two asymmetric enantiomers is separated by chromatography using a chiral stationary phase. Suitable chiral stationary phases are, for example, polysaccharides, in particular cellulose or amylose derivatives. Commercially available polysaccharide based chiral stationary phases are ChiralCel® CA, OA, OB5, OC5, OD, OF, OG, OJ and OK, and

Chiralpak® AD, AS, OP(+) and OT(+). Appropriate eluents or mobile phases for use in combination with said polysaccharide chiral stationary phases are hexane and the like, modified with an alcohol such as ethanol, isopropanol and the like. ("Chiral Liquid Chromatography" (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) "Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", J. of Chromatogr. 513:375-378).

[0148] The terms cis and trans are used herein in accordance with Chemical Abstracts nomenclature and include reference to the position of the substituents on a ring moiety. The absolute stereochemical configuration of the compounds of the formulae described herein may easily be determined by those skilled in the art while using well-known methods such as, for example, X-ray diffraction.

[0149] When a compound is crystallized from a solution or slurry, it can be crystallized in a different arrangement lattice of spaces (this property is called "polymorphism") to form crystals with different crystalline forms, each of which is known as "polymorphs". The term "Polymorph" as used herein, therefore, refers to a crystal form of a compound of Formula (I), where the molecules are localized in the three-dimensional lattice sites. Different polymorphs of the compound of Formula (I) may be different from each other in one or more physical properties, such as solubility and dissolution rate, true specific gravity, crystal form, accumulation mode, flowability and/or solid state stability. etc.

[0150] Benzofuran derivatives of the invention and their physiologically acceptable salts (hereafter collectively referred to as the active ingredients) may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intranasal, intravenous, intraarterial, intradermal, intrathecal and epidural). The preferred route of administration may vary with for example the condition of the recipient.

[0151] The therapeutically effective amount of the preparation of the compound(s), especially for the treatment of TRPM3 mediated disorders in humans and other mammals or in animals, preferably is a TRPM3 ion channel inhibiting amount of the compounds as defined herein and corresponds to an amount which ensures a plasma level of between 1 µg/ml and 100 mg/ml, optionally of 10 mg/ml.

[0152] Suitable dosages of the compounds or compositions of the invention should be used to treat or prevent the TRPM3 mediated disorders in a subject. Depending upon the pathologic condition to be treated and the patient's condition, the said effective amount may be divided into several sub-units per day or may be administered at more than one day intervals.

[0153] The invention further provides (pharmaceutical) compositions comprising one or more benzofuran derivatives of the invention, more in particular of all the Formula (I) and other formulas and embodiments described herein and the more particular aspects or embodiments thereof. Furthermore, the invention provides the compounds or (pharmaceutical) compositions of the invention, more in particular of all the Formula (I) and other formulas and embodiments described herein and the more particular aspects or embodiments thereof, for use as a medicine, more in particular for use in the treatment of pain. The TRPM3 mediated disorders are selected from pain and an inflammatory hypersensitivity condition.

[0154] The benzofuran derivatives of the invention may be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral

administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the "Handbook of Pharmaceutical Excipients" (1986).

5 [0155] Subsequently, the term "pharmaceutically acceptable carrier" as used herein means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e., the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders.

10 [0156] Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, surface-active agents, solvents, coatings, antibacterial and antifungal agents, isotonic agents and the like, provided the same are consistent with pharmaceutical practice, i.e., carriers and additives which do not create permanent
15 damage to mammals. The pharmaceutical compositions of the invention may be prepared in any known manner, for instance by homogeneously mixing, coating and/or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 μ m, namely for the manufacture of microcapsules for controlled or
20 sustained release of the active ingredients.

[0157] While it is possible for the benzofuran derivatives to be administered alone it is preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above described, together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) optimally are "acceptable" in the
25 sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the
30 active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0158] Formulations of the invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or
35 granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

[0159] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing
40 form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface

active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. For infections of the eye or other external tissues e.g., mouth and skin, the formulations are optionally applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.

[0160] The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Optionally, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

[0161] The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should optionally be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

[0162] Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is optionally present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0163] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle

sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.), which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents.

[0164] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0165] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0166] Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

[0167] It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0168] Benzofuran derivatives of the invention can be used to provide controlled release pharmaceutical formulations containing as active ingredient one or more benzofuran derivatives of the invention ("controlled release formulations") in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given invention compound. Controlled release formulations adapted for oral administration in which discrete units comprising one or more benzofuran derivatives of the invention can be prepared according to conventional methods.

[0169] Another embodiment of this invention relates to various precursor or "prodrug" forms of the benzofuran derivatives of the invention. It may be desirable to formulate the benzofuran derivatives of the invention in the form of a chemical species which itself is not significantly biologically-active, but which when delivered to the animal, mammal or human will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein. The term "prodrug" thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.

[0170] The prodrugs of the benzofuran derivatives of the invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and

the like, may be used. The counterpart of the active pharmaceutical ingredient in the pro-drug can have different structures such as an amino acid or peptide structure, alkyl chains, sugar moieties and others as known in the art.


[0171] For the purpose of the invention the term “therapeutically suitable pro-drug” is defined herein as “a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of the animal, mammal or human to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome”.

[0172] More specifically the term “prodrug”, as used herein, relates to an inactive or significantly less active derivative of a compound such as represented by the structural formulae herein described, which undergoes spontaneous or enzymatic transformation within the body in order to release the pharmacologically active form of the compound. For a comprehensive review, reference is made to Rautio J. et al. (“Prodrugs: design and clinical applications” Nature Reviews Drug Discovery, 2008, doi: 10.1038/nrd2468).

[0173] Representative benzofuran derivatives of the invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reaction and specific conditions described in the schemes and examples. The various starting material used in the schemes are commercially available or may be prepared by methods well within the skill persons versed in the art. The variables are as defined herein and within the skill of persons verses in the art.

[0174] Preferred embodiments of the invention are summarized as Clauses 1 to 51 hereinafter:

1. A compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof



(I)

preferably, the compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof, for use in the treatment of pain;

wherein

R¹ represents -F, -Cl, -Br, -I, -CN, -**R^W**, -**OR^W**, -**OC(=O)R^W**, -**NR^WR^X**, -**NR^WC(=O)R^X**, -**SR^W**, -**S(=O)R^W**, -**S(=O)₂R^W**, -**C(=O)R^W**, -**C(=O)OR^W**, or -**C(=O)NR^WR^X**;

Q represents -**OR²** or -**NR³R⁴**;

R² represents -**R^Y**;

R³ represents -OH or -**R^Y**;

R⁴ represents -**R^Y** or -**S(=O)₂R^Y**;

or R^3 and R^4 together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

T represents -O- and **U** represents $-CR^5R^{5*}-$; or **T** represents $-CR^5R^{5*}-$ and **U** represents -O-;

R^5 and R^{5*} independently of one another represent $-R^Y$;

5 R^6 , R^7 and R^8 independently of one another represent -F, -Cl, -Br, -I, -CN, -NO₂, -SF₅, $-R^W$, $-OR^W$, $-OC(=O)R^W$, $-NR^WR^X$, $-NR^WC(=O)R^X$, $-SR^W$, $-S(=O)R^W$, $-S(=O)_2R^W$, $-C(=O)R^W$, $-C(=O)OR^W$, or $-C(=O)NR^WR^X$;

V represents 3-14-membered heterocycloalkyl, saturated or unsaturated; or 5-14-membered heteroaryl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, $-R^Y$, $-OR^Y$, $-OC(=O)R^Y$, $-NR^YR^Z$, $-NR^YC(=O)R^Z$, $-SR^Y$, $-S(=O)R^Y$, $-S(=O)_2R^Y$, $-C(=O)R^Y$, $-C(=O)OR^Y$, or $-C(=O)NR^YR^Z$;

wherein

R^W and R^X independently of one another in each case independently represent

-H;

15 $-C_1-C_6$ -alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

$-C_1-C_6$ -heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

20 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

R^Y and R^Z independently of one another in each case independently represent

-H;

25 $-C_1-C_6$ -alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

$-C_1-C_6$ -heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

30 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

35 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through $-C_1-C_6$ -alkylene- or $-C_1-C_6$ -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

or R^Y and R^Z together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

40

and wherein "mono- or polysubstituted" in each case independently means substituted with one or more substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -C₁₋₆-alkyl, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-O-CF₃, -C₁₋₆-alkylene-O-CF₂H, -C₁₋₆-alkylene-O-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C₁₋₆-alkylene-C(=O)-OH, -C(=O)-OC₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-OC₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)-NH₂, -C₁₋₆-alkylene-C(=O)-NH₂, -C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-C(=O)-NH(C₁₋₆-alkyl), -C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-C(=O)-N(C₁₋₆-alkyl)₂, -C(=O)-NH(OH), -C₁₋₆-alkylene-C(=O)-NH(OH), -OH, -C₁₋₆-alkylene-OH, =O, -OCF₃, -OCF₂H, -OCFH₂, -OCF₂Cl, -OCFCl₂, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-NH₂, -O-C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -O-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-C₁₋₆-alkyl, -O-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-O-C₁₋₆-alkyl, -O-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-C(=O)-NH(C₁₋₆-alkyl), -O-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-C(=O)-N(C₁₋₆-alkyl)₂, -O-S(=O)₂-NH₂, -C₁₋₆-alkylene-O-S(=O)₂-NH₂, -O-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-S(=O)₂-NH(C₁₋₆-alkyl), -O-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-S(=O)₂-N(C₁₋₆-alkyl)₂, -NH₂, -NO, -NO₂, -C₁₋₆-alkylene-NH₂, -NH(C₁₋₆-alkyl), -N(3-14-membered cycloalkyl)(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C₁₋₆-alkylene-OH, -N(H)-C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -NH-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-C₁₋₆-alkyl, -NH-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-O-C₁₋₆-alkyl, -NH-C(=O)-NH₂, -C₁₋₆-alkylene-NH-C(=O)-NH₂, -NH-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-NH-C(=O)-NH(C₁₋₆-alkyl), -NH-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C(=O)-N(C₁₋₆-alkyl)₂, -N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH₂, -N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -NH-S(=O)₂OH, -C₁₋₆-alkylene-NH-S(=O)₂OH, -NH-S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-S(=O)₂-C₁₋₆-alkyl, -NH-S(=O)₂-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-S(=O)₂-O-C₁₋₆-alkyl, -NH-S(=O)₂-NH₂, -C₁₋₆-alkylene-NH-S(=O)₂-NH₂, -NH-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-NH-S(=O)₂-NH(C₁₋₆-alkyl), -NH-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-S(=O)₂-N(C₁₋₆-alkyl)₂, -N(C₁₋₆-alkyl)-S(=O)₂-OH, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-OH, -N(C₁₋₆-alkyl)-S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-S(=O)₂-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-NH₂, -N(C₁₋₆-alkyl)-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-N(C₁₋₆-alkyl)₂, -SH, =S, -SF₃, -SCF₃, -SCF₂H, -SCFH₂, -S-C₁₋₆-alkyl, -C₁₋₆-alkylene-S-C₁₋₆-alkyl, -S(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)-C₁₋₆-alkyl, -S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)₂-C₁₋₆-alkyl, -S(=O)₂-OH, -C₁₋₆-alkylene-S(=O)₂-OH, -S(=O)₂-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)₂-O-C₁₋₆-alkyl, -S(=O)₂-NH₂, -C₁₋₆-alkylene-S(=O)₂-NH₂, -S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-S(=O)₂-NH(C₁₋₆-alkyl), -S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-S(=O)₂-N(C₁₋₆-alkyl)₂, 3-14-membered cycloalkyl, -C₁₋₆-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -C₁₋₆-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -C₁₋₆-alkylene-phenyl, 5 to 14-membered heteroaryl, -C₁₋₆-alkylene-(5 to 14-membered heteroaryl), -O-(3-14-membered cycloalkyl), -O-(3 to 14-

- membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3-14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)₂-(3-14-membered cycloalkyl), -S(=O)₂-(3 to 14-membered heterocycloalkyl), -S(=O)₂-phenyl, -S(=O)₂-(5 to 14-membered heteroaryl).
- 5 2. The compound per se, or for use according to Clause 1, wherein **T** represents -O- and **U** represents -CR⁵R^{5'}-.
 3. The compound per se, or for use according to Clause 1, wherein **T** represents -CR⁵R^{5'}- and **U** represents -O-.
 4. The compound per se, or for use according to any one of Clauses 1 to 3, wherein **Q** represents -NR³R⁴.
 - 10 5. The compound per se, or for use according to any one of Clauses 1 to 3, wherein **Q** represents -OR².
 6. The compound per se, or for use according to any one of Clauses 1 to 5, wherein **V** represents 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.
 - 15 7. The compound per se, or for use according to Clause 6, wherein the 5-14-membered heteroaryl is not benzofuran.
 8. The compound per se, or for use according to Clause 6 or 7, wherein the 5-14-membered heteroaryl is selected from benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, 20 imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, 25 -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.
 9. The compound per se, or for use according to any one of Clauses 6 to 8, wherein the 5-14-membered heteroaryl is selected from the group consisting of furane, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole, pyridine, isoquinoline, benzothiazole, pyridazine, pyrimidine, 30 imidazopyridine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.
 10. The compound per se, or for use according to any one of Clauses 6 to 9, wherein the 5-14-membered heteroaryl is selected from the group consisting of furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, 35 pyrazol-5-yl, oxazol-5-yl, isoxazol-4-yl, thiazol-2-yl, thiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, isoquinolin-1-yl, isoquinolin-5-yl, benzo[d]thiazol-2-yl, pyridazin-3-yl, pyrimidin-5-yl, and imidazo[1,2-a]pyridin-6-yl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -R^Y, -OR^Y, -OC(=O)R^Y, -NR^YR^Z, -NR^YC(=O)R^Z, -SR^Y, -S(=O)R^Y, -S(=O)₂R^Y, -C(=O)R^Y, -C(=O)OR^Y, or -C(=O)NR^YR^Z.
 - 40 C(=O)OR^Y, or -C(=O)NR^YR^Z.

11. The compound per se, or for use according to any one of Clauses 1 to 5, wherein **V** represents 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -OR^Y, -OC(=O)**R^Y**, -NR^Y**R^Z**, -NR^YC(=O)**R^Z**, -SR^Y, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)OR^Y, or -C(=O)NR^Y**R^Z**.
12. The compound per se, or for use according to Clause 11, wherein the 3-14-membered heterocycloalkyl is selected from azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -OR^Y, -OC(=O)**R^Y**, -NR^Y**R^Z**, -NR^YC(=O)**R^Z**, -SR^Y, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)OR^Y, or -C(=O)NR^Y**R^Z**.
13. The compound per se, or for use according to Clause 11 or 12, wherein the 3-14-membered heterocycloalkyl is tetrahydropyran or pyrrolidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -OR^Y, -OC(=O)**R^Y**, -NR^Y**R^Z**, -NR^YC(=O)**R^Z**, -SR^Y, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)OR^Y, or -C(=O)NR^Y**R^Z**.
14. The compound per se, or for use according to any one of Clauses 11 to 13, wherein the 3-14-membered heterocycloalkyl is tetrahydropyran-4-yl or pyrrolidin-3-yl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -OR^Y, -OC(=O)**R^Y**, -NR^Y**R^Z**, -NR^YC(=O)**R^Z**, -SR^Y, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)OR^Y, or -C(=O)NR^Y**R^Z**.
15. The compound per se, or for use according to any one of the preceding Clauses, wherein **V** is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from
 - F, -Cl, -Br, -I, -CN, -C(=O)OH, -NH₂, -NO₂, -OH, =O, -SF₅;
 - C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - C(=O)O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - S(=O)₂-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 - 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
 - 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

16. The compound per se, or for use according to any one of the preceding Clauses, wherein V is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from
- 5 -OH, -F, -Cl, -Br, -I, -SH, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -CN, -NO₂, -C(=O)OH, -NH₂, -N(CH₃)₂, -cyclopropyl, or -O-cyclopropyl; preferably selected from -OH, -F, -Cl, -Br, -I, -SH, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -CN, -NO₂, -C(=O)OH, -NH₂, or -N(CH₃)₂;
- C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, -C(=O)NH₂, and -cyclopropyl; preferably selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- OC₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- O(C=O)C₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- 25 -C(=O)OC₁₋₆-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- 30 3-14-membered cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂;
- 35 3-14-membered heterocycloalkyl selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidene, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzo-

- thiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -C₁₋₆-alkyl, C₂₋₆-alkenyl, -C₂₋₆-alkynyl, -OH, =O, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, C(=O)CHF₂, and -C(=O)NH₂.
17. The compound per se, or for use according to any one of the preceding Clauses, wherein V is unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -CN, -OH, =O, -C₁₋₆-alkyl, -CHF₂, -CF₃, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NHC(=O)-O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -OC₁₋₆-alkyl, -OCF₃, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -S(=O)₂-C₁₋₆-alkyl, -azetidine, -C₁₋₆-alkylene-O-tetrahydropyran, or -piperazine substituted with -C₁₋₆-alkyl; or represents oxetanyl, unsubstituted, mono- or polysubstituted.
18. The compound per se, or for use according to any one of the preceding Clauses, wherein V is
- (i) unsubstituted;
- (ii) monosubstituted;
- (iii) disubstituted;
- (iv) trisubstituted; or
- (v) tetrasubstituted.
19. The compound per se, or for use according to any one of the preceding Clauses, wherein R¹ represents -H, -F, -Cl, -Br, -I; -C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C(=O)OC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C(=O)NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C(=O)N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -S(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -S(=O)₂-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁₋₆-alkylene- or -C₁₋₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
20. The compound per se, or for use according to any one of the preceding Clauses, wherein R¹ represents -H, -F, -Cl, -Br, -I, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃, -C(=O)C₁₋₆-alkyl, -C(=O)OC₁₋₆-alkyl, -C(=O)NHC₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)-C₁₋₆-alkyl, -S(=O)₂-C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -cyclopropyl unsubstituted, cyclobutyl unsubstituted, cyclopentyl unsubstituted or cyclohexyl unsubstituted.

21. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**¹ represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -CH₂F, -CHF₂, -CF₃, -cyclopentyl, unsubstituted, or -cyclopropyl, unsubstituted; preferably wherein **R**¹ represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -CH₂F, -CHF₂, -CF₃, or -cyclopentyl, unsubstituted.
- 5 22. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**¹ represents -CH₂F, -CHF₂, -CH₃, or -cyclopropyl, unsubstituted; preferably wherein **R**¹ represents -CH₂F, -CHF₂, or -CH₃.
23. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**² represents -H;
- 10 -C_{1-C6}-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C_{1-C6}-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C_{1-C6}-alkylene- or -C_{1-C6}-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
- 15 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -C_{1-C6}-alkylene- or -C_{1-C6}-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
24. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**² represents -H, -C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃,
20 -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, or -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃.
25. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**² represents -H or -C₁₋₆-alkyl.
26. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ represents
25 -H;
-OH;
-C_{1-C6}-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
-C_{1-C6}-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
27. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ represents -H,
30 -OH, -C₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, or -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃.
28. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ represents -H,
35 -OH, or -C₁₋₆-alkyl, saturated, unsubstituted or monosubstituted with -OH.
29. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁴ represents -H;
-S(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-S(=O)₂-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 40 -C_{1-C6}-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

- C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said
 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in
 each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 5 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-
 heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is
 optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or
 10 unsaturated, unsubstituted, mono- or polysubstituted; or
- 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered
 heteroaryl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case
 saturated or unsaturated, unsubstituted, mono- or polysubstituted.
30. The compound per se, or for use according to any one of the preceding Clauses, wherein **R⁴** represents
- 15 -S(=O)₂C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents
 independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃,
 -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-
 alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -
 C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-
 20 alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -
 C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-
 phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered
 heteroaryl, unsubstituted;
- S(=O)₂(3-14-membered cycloalkyl), wherein said 3-14-membered cycloalkyl is selected from the group
 25 consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or
 unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another
 selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-
 alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -
 N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-
 30 alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-
 alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -
 C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl,
 saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;
- C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents
 35 independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃,
 -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-
 alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -
 C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-
 alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -
 40 C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-

phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;

3-14-membered cycloalkyl or -C₁₋₆-alkylene-(3-14-membered cycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;

3-14-membered heterocycloalkyl or -C₁₋₆-alkylene-(3-14-membered heterocycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazin; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;


-phenyl unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;


- 5-14-membered heteroaryl or -C₁₋₆-alkylene-(5-14-membered heteroaryl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -OH, =O, -OC₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)C(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)₂C₁₋₆-alkyl, -phenyl, -C₁₋₆-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted.
31. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁴ represents -H; -S(=O)₂C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or polysubstituted with -F; -S(=O)₂(3-14-membered cycloalkyl), saturated, unsubstituted; -C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -OH, -OC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -phenyl unsubstituted; 3-14-membered cycloalkyl or -C₁₋₆-alkylene-(3-14-membered cycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -OH, -OC₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl; 3-14-membered heterocycloalkyl or -C₁₋₆-alkylene-(3-14-membered heterocycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydropyrrolo[1,2-a]pyrazin, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolizine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxothiacyclohexane, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -OH, =O, -C₁₋₆-alkyl, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -S(=O)₂C₁₋₆-alkyl, oxetanyl, pyrimidinyl,

- C₁₋₆-alkylene-phenyl;
-phenyl unsubstituted;
5-14-membered heteroaryl or -C₁₋₆-alkylene-(5-14-membered heteroaryl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -OH.
32. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ and **R**⁴ together form a 5- or 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted.
33. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ and **R**⁴ together form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -NH₂, -NHCH₃, -N(CH₃)₂, -C(=O)NH-C₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -C(=O)O-C₁₋₆-alkyl, -NHC(=O)O-C₁₋₆-alkyl, -pyridyl unsubstituted, and 1,2,4-oxadiazole unsubstituted or monosubstituted with -C₁₋₆-alkyl.
34. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**³ and **R**⁴ together form a
pyrrolidine ring, unsubstituted or monosubstituted with -N(CH₃)₂;
piperidine ring, unsubstituted or monosubstituted with a substituent selected from the group consisting of -C₁₋₆-alkyl, -NH₂, -N(CH₃)₂, -C(=O)NH-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkyl, -NHC(=O)O-C₁₋₆-alkyl, and 1,2,4-oxadiazole unsubstituted or monosubstituted with -C₁₋₆-alkyl;
morpholine ring, unsubstituted; or
piperazine ring, unsubstituted or N-substituted with a substituent selected from the group consisting of -C₁₋₆-alkyl and -pyridyl unsubstituted.
35. The compound per se, or for use according to one any one of the preceding Clauses, wherein **R**⁵ and **R**^{5'} independently of one another represent
-H;
-C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
-C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
36. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁵ and **R**^{5'} independently of one another represent -H, -C₁-C₆-alkyl, or -C₁-C₆-alkylene-N(C₁-C₆-alkyl)₂.
37. The compound per se, or for use according to any one of the preceding Clauses, wherein at least one of **R**⁵ and **R**^{5'} does not represent -H.
38. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁶, **R**⁷ and **R**⁸ independently of one another represent
-H;

- F, -Cl, -Br, -I, -OH, -SH, -SF₅, -CN, -NO₂, -C(=O)OH, -NH₂;
 -C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 -O-C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 -NHC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 5 -N(C₁₋₆-alkyl)₂, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 -C(=O)OC₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 -OC(=O)C₁₋₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
 -C₁₋₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
39. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁶, **R**⁷ and **R**⁸
 10 independently of one another represent
 -H, -F, -Cl, -Br, -I, -OH, -SH, -SF₅, -CN, -NO₂, -C(=O)OH, -NH₂,
 -C₁₋₆-alkyl, -CF₃, -CHF₂, -CH₂F,
 -O-C₁₋₆-alkyl, -OCF₃, -OCHF₂, -OCH₂F,
 -NHC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
 15 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
 -N(C₁₋₆-alkyl)₂ unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
 20 -C(=O)OC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
 -OC(=O)C₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
 25 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂; or
 -C₁₋₆-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another
 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂.
40. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁶ represents -H,
 30 -F, -Cl, -CN, or -C₁₋₆-alkyl.
41. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁶ does not
 represent -H.
42. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁷ represents -H,
 -F, -Cl, -CN, or -C₁₋₆-alkyl.
- 35 43. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁷ does not
 represent -H.
44. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁸ represents -H,
 -F, -Cl, -CN, or -C₁₋₆-alkyl.
45. The compound per se, or for use according to any one of the preceding Clauses, wherein **R**⁸ does not
 40 represent -H.

46. The compound per se, or for use according to any one of the preceding Clauses, wherein
- (i) R^6 , R^7 and R^8 each represent -H; or
 - (ii) two of R^6 , R^7 and R^8 represent -H and the other of R^6 , R^7 and R^8 represents -F, -Cl, -CN, or -CH₃; or
 - (iii) one of R^6 , R^7 and R^8 represents -H and the other of R^6 , R^7 and R^8 independently of one another represent -F, -Cl, -CN, or -CH₃.
47. The compound per se, or for use according to any one of the preceding Clauses, which is selected from the group consisting of cpd 001 to cpd 207 as mentioned above and the physiologically acceptable salts thereof.
48. The compound per se, or for use according to any one of the preceding Clauses, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain.
49. The compound per se, or for use according to any one of the preceding Clauses, wherein the pain is post-operative pain.
50. A compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof, as defined in any one of the preceding Clauses, wherein
- (a) Q represents -OR²; and
 - (a-1) R^1 represents -CH₂F, -CHF₂, or -CF₃; and/or
 - (a-2) at least one of R^5 and R^{5*} does not represent -H; and/or
 - (a-3) R^6 does not represent -H; and/or
 - (a-4) R^8 does not represent -H;
 - or
 - (b) Q represents -NR³R⁴; and
 - (b-1) with the proviso that the following compounds and their salts are excluded





; and/or

(b-2) R^1 represents $-CH_2F$, $-CHF_2$, or $-CF_3$, $-CN$, $-propyl$, or $-cyclopropyl$; and/or(b-3) at least one of R^5 and R^{5*} does not represent $-H$; and/or(b-4) R^3 represents $-H$.

51. A pharmaceutical composition or a medicament comprising a compound according to any one of the preceding Clauses.

EXAMPLES


[0175] The following examples are provided for the purpose of illustrating the invention and by no means should be interpreted to limit the scope of the invention.

- [0176] Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reaction and specific conditions described in the schemes and examples. The various starting material used in the schemes are commercially available or may be prepared by methods well within the skill of persons versed in the art. The variables are as defined herein and within the skill of persons versed in the art.

- [0177] Abbreviations used in the instant specification, particularly in the schemes and examples, are as follows: ACN – acetonitrile, AcOH – Acetic acid, ADDP – 1,1'-(Azodicarbonyl)dipiperidine, aq. – Aqueous, AIBN – Azobisisobutyronitrile, CAN – Ceric ammonium nitrate, COMU – (1-Cyano-2-ethoxy-2-oxoethylidenaminoxy)dimethylamino-morpholino-carbenium, hexafluorophosphate, DABCO – 1,4-diazabicyclo[2.2.2]octane, DAST – Diethylaminosulfur trifluoride, DBU – 1,8-Diazabicyclo[5.4.0]undec-7-ene, DCC – N,N'-dicyclohexylcarbodiimide, DCM – Dichloromethane, DEAD – Diethyl azodicarboxylate, DIA – Diastereomer, DIAD – Diisopropyl azodicarboxylate, DEA – Diethylamine, DIPEA – Diisopropyl-ethyl amine, DME – 1,2-Dimethoxyethane, DMF – N,N-Dimethylformamide, DMSO – Dimethylsulfoxide, DTBAD – tert-Butylazodicarboxylate, EDCI or EDC – 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, En – Enantiomer, Et₂O – Diethyl ether, EtOH – Ethanol, EtOAc – Ethyl acetate, Eq. – Equivalent, FA – Formic acid, FCC – Flash column chromatography, h – Hour, HATU – O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, HPLC – High performance liquid chromatography, IPA – isopropyl alcohol, LAH – Lithiumaluminumhydride, LG – Leaving group, MeOH – methanol, MgSO₄ – Magnesium sulfate, min. – Minute, Na₂SO₄ – Sodium sulfate, NBS – N-Bromosuccinimide, NMP – 1-Methyl-2-pyrrolidinone, Pd(PPh₃)₄ – Tetrakis-(triphenylphosphine)-palladium(0), Pd₂(dba)₃ – Tris(dibenzylideneacetone)dipalladium, Pet ether – Petroleum ether, PPh₃ – Triphenylphosphine, PS-DIEA – Diisopropyl-ethyl amine supported on PolyStyrene, PS-PPh₃ – Triphenylphosphine supported on PolyStyrene, PyBop – Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, PTSA – *p*-Toluenesulfonic acid, RF: ratio of frontiers, RM – Reaction mixture, RP – Reverse phase, RT – Room temperature, sat. – Saturated, SEM – [2-(Trimethylsilyl)ethoxy]methyl acetal, SFC –

Supercritical fluid chromatography, SPE - Solid Phase Extraction, TBDMS - Tert-Butyldimethylsilyl ether, TBAF - Tetrabutylammonium fluoride hydrate, TBAI - Tetrabutylammonium iodide, TEA - Triethylamine, THF - Tetrahydrofuran, TFA - Trifluoroacetic acid, TLC - thin layer chromatography, TPP - triphenyl phosphine, IPA - isopropyl alcohol, TMS - trimethyl silyl, T3P - Propylphosphonic anhydride,

- 5 [0178] The compounds of interest having a structure according to the general formula (A) and all other formulas described herein and embodiments thereof can be prepared as outlined in the general chemical scheme 1.




Scheme 1: all R₁, R₂, R₃, R₄ and R₅ are as described for the compounds of the present invention.

- [0179] *para*-Benzoquinone of formula 1, may be condensed with a ketoester of formula 2 (commercially available or synthesized by procedures known to those skilled in the art), wherein R₂ is an ester protecting group (e.g. methyl, ethyl, t-Bu and the like), in the presence of a Lewis acid (e.g., Titanium(IV) chloride, zinc(II) chloride and the like) in a polar solvent (e.g., DCM, MeOH, EtOH, and the like) at a temperature ranging from 0 to 100°C to provide intermediates of formula 4. More detailed information can be found in the following references (*Bioorg. Med. Chem.* 2012, 20, 4237-4244 and FR 1319594). Alternatively, *para*-benzoquinone of formula 1 may be reacted with an enamine of formula 3 (commercially available or synthesized by procedures known to those skilled in the art), in the presence of a protic acid (e.g., trifluoroacetic acid, *para*-toluenesulfonic acid, and the like) in a polar solvent (e.g., DCM, MeOH, EtOH, and the like) at a temperature ranging from 0 to 100°C to provide intermediates of formula 4. More detailed information can be found in the following reference (*J. Heterocyclic Chem.* 2006, 43, 873). Intermediates of formula 4 may then be converted into the desired compounds of formula 7 via nucleophilic substitution using intermediates of formula 5 (commercially available or synthesized), wherein LG is a leaving group, in the presence of a base (e.g., DIPEA, DBU, triethylamine, Cs₂CO₃, and the like) in a polar solvent (e.g., acetonitrile, DMF, NMP, and the like), with or without a chelating agent (e.g., 18-crown-6, cis-anti-cis-dicyclohexano-18-crown-6, and the like) at a temperature ranging from 0 to 100°C. Alternatively, intermediates of formula 4 may also be reacted with intermediates of formula 6 (commercially available or synthesized) in the presence of an azodicarboxylate reagent (e.g., DEAD, DIAD, ADDP, and the like) and a phosphine (e.g., tributylphosphine, triphenylphosphine and the like) in a solvent (e.g., THF, toluene, and the like) at a temperature ranging from 0 to 100°C, to provide the desired compounds of formula 7. Ester derivatives 7 may then be converted into the desired compounds of formula 8 via standard saponification reactions. The desired compounds of formula 10 may be obtained from acid derivatives of formula 8 by reaction with amine derivatives of formula 9 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop and the like) in a polar

aprotic solvent (e.g., DCM, DMF and the like). Alternatively, carboxylic acid derivatives of formula **8**, may be converted into acid chloride derivatives by procedures known to those skilled in the art or as set forth in the examples below, and then reacted with amines of formula **9** to obtain the desired compounds of formula **10** by procedures known to those skilled in the art or as set forth in the examples below.


- 5 [0180] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 2.



Scheme 2: all R1, R2, R3, R4 and R5 are as described for the compounds of the present invention.

- [0181] 5-Hydroxy-benzofuran-3-carboxylic acid derivatives **11** (commercially available or synthesized by procedures known in the art or as set forth in the examples below) may be reacted with amine derivatives of formula **9** (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g. DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g. DCM, DMF and the like) to provide intermediates of formula **12**. Alternatively, compounds of formula **13** (synthesized as described in scheme 1) may be converted into intermediates of formula **12** via a hydrogenation reaction with a reducing agent (e.g., hydrogen gas, ammonium formate, cyclohexadiene and the like) using a catalyst (more preferably Pd or Pt) in a solvent (e.g., THF, EtOH, and the like). Intermediates of formula **12** may then be converted into the desired compounds of formula **10** via nucleophilic substitution using intermediates of formula **5** (commercially available or synthesized), wherein LG is a leaving group, in the presence of a base (e.g., DIPEA, DBU, triethylamine, Cs_2CO_3 , and the like) in a polar solvent (e.g., acetonitrile, DMF, NMP, and the like), with or without a chelating agent (e.g., 18-crown-6, cis-anti-cis-dicyclohexano-18-crown-6, and the like) at a temperature ranging from 0 to 100°C. Alternatively, compounds of formula **12** may also be reacted with intermediates of formula **6** (commercially available or synthesized) in the presence of an azodicarboxylate reagent (e.g., DEAD, ADDP, DIAD, *tert*-butylazodicarboxylate, and the like) and a phosphine (e.g., tributylphosphine, triphenylphosphine and the like) in a solvent (e.g., THF, toluene, and the like) at a temperature ranging from 0 to 100°C, to provide the desired compounds of formula **10**.


[0182] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 3.



Scheme 3: all R1, R2, R3, R4, R5, R7 and R8 are as described for the compounds of the present invention.

[0183] A substituted *para*-Benzoquinone derivatives of formula 14 may be condensed with a ketoester of formula 2 (commercially available or synthesized by procedures known to those skilled in the art), wherein R₂ is an ester protecting group (e.g. methyl, ethyl, t-Bu and the like), in the presence of a Lewis acid (e.g., Titanium(IV) chloride, zinc(II) chloride and the like) in a polar solvent (e.g., DCM, MeOH, EtOH, and the like) at a temperature ranging from 0 to 100°C to provide a mixture of substituted intermediates of formula 15 and 16. More detailed information can be found in the following references (*Bioorg. Med. Chem.* 2012, 20, 4237-4244 and FR 1319594). Intermediates of formula 15 and/or 16 may then be converted into the desired compounds of formula 17 and/or 18 via nucleophilic substitution using intermediates of formula 5 (commercially available or synthesized), wherein LG is a leaving group, in the presence of a base (e.g., DIPEA, DBU, triethylamine, Cs₂CO₃, and the like) in a polar solvent (e.g., acetonitrile, DMF, NMP, and the like), with or without a chelating agent (e.g., 18-crown-6, cis-anti-cis-dicyclohexano-18-crown-6, and the like) at a temperature ranging from 0 to 100°C. Alternatively, intermediates of formula 15 and/or 16 may also be reacted with intermediates of formula 6 (commercially available or synthesized) in the presence of an azodicarboxylate reagent (e.g., DEAD, DIAD, ADDP, and the like) and a phosphine (e.g., tributylphosphine, triphenylphosphine and the like) in a solvent (e.g., THF, toluene, and the like) at a temperature ranging from 0 to 100°C, to provide the desired compounds of formula 17 and/or 18. Ester derivatives 17 and/or 18 may then be converted into the desired carboxylic acid of formula 19 and/or 20 via standard saponification reactions. The desired compounds of formula 21 and/or 22 may be obtained from acid derivatives of formula 19 and/or 20 by reaction with amine derivatives of formula 9 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g., DCM, DMF and the like). A mixture of compounds 21 and 22 may be separated (e.g., silica gel, HPLC, SFC or preparative CFC) to provide the desired compounds of formula 21 or 22.


[0184] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 4.



Scheme 4: all R1, R2, R3, R4, R5, R7 and R8 are as described for the compounds of the present invention.

[0185] Intermediates of formula **4** may be halogenated with a suitable halogenating agent (e.g., Bromine, N-bromosuccinimide and the like) in a solvent (e.g., chloroform, water and the like) to provide the desired intermediates **23**. The desired compounds of formula **26** may be obtained by an Ullmann type reaction with CuCN followed by a Mitsunobu type reaction with intermediates of formula **6** (commercially available or synthesized). Alternatively, the desired compounds of formula **26** may be obtained via a Mitsunobu type reaction with intermediates of formula **6** (commercially available or synthesized) followed by a Suzuki reaction. Ester derivatives **26** may then be converted into the desired compounds of formula **27** via standard saponification reactions. The desired compounds of formula **28** may be obtained from acid derivatives of formula **27** by reaction with amine derivatives of formula **9** (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g., DCM, DMF and the like).

[0186] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 5.



























Scheme 5: all R1, R2, R3 and R4 are as described for the compounds of the present invention.






















[0187] Intermediates of formula 4 may be halogenated with a suitable halogenating agent (e.g. select fluor and the like) in a solvent (e.g. chloroform, acetonitrile and the like) to provide the desired intermediates 29 and 30.



















- 5 Intermediates of formula 29 and/or 30 may be reacted with intermediates of formula 6 (commercially available or synthesized) in the presence of an azodicarboxylate reagent (e.g., DEAD, DIAD, ADDP, and the like) and a phosphine (e.g., tributylphosphine, triphenylphosphine and the like) in a solvent (e.g., THF, toluene, and the like) at a temperature ranging from 0 to 100°C, to provide the desired compounds of formula 31 and/or 32. Ester derivatives 31 and/or 32 may then be converted into the corresponding carboxylic acid of formula 33 and/or 34
- 10 *via* standard saponification reactions. The desired compounds of formula 35 and/or 36 may be obtained from acid derivatives of formula 33 and/or 34 by reaction with amine derivatives of formula 9 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g., DCM, DMF and the like). A mixture of compounds 35 and 36 may be separated (e.g., silica gel, HPLC, SFC or preparative CFC) to
- 15 provide the desired compounds of formula 35 or 36.



















[0188] EXAMPLES
















Structure / CODE	Structure / CODE	Structure / CODE
cpd 001	cpd 011	cpd 021
















		
cpd 002	cpd 012	cpd 022
		
cpd 003	cpd 013	cpd 023
		
cpd 004	cpd 014	cpd 024
		
cpd 005	cpd 015	cpd 025
		
cpd 006	cpd 016	cpd 026
		
cpd 007	cpd 017	cpd 027
		
cpd 008	cpd 018	cpd 028
		
cpd 009	cpd 019	cpd 029



















 cpd 010	 cpd 020	 cpd 030
 cpd 031	 cpd 041	 cpd 051
 cpd 032	 cpd 042	 cpd 052
 cpd 033	 cpd 043	 cpd 053
 cpd 034	 cpd 044	 cpd 054
 cpd 035	 cpd 045	 cpd 055
 cpd 037	 cpd 047	 cpd 057



















 cpd 038	 cpd 048	 cpd 058
 cpd 039	 cpd 049	 cpd 059
 cpd 040	 cpd 050	 cpd 060
 cpd 061	 cpd 071	 cpd 081
 cpd 062	 cpd 072	 cpd 082
 cpd 063	 cpd 073	 cpd 083


















 cpd 064	 cpd 074	 cpd 084
 cpd 065	 cpd 075	 cpd 085
 cpd 066	 cpd 076	 cpd 086
 cpd 067	 cpd 077	 cpd 087
 cpd 068	 cpd 078	 cpd 088
 cpd 069	 cpd 079	 cpd 089



















 cpd 070	 cpd 080	 cpd 090
 cpd 091	 cpd 101	 cpd 111
 cpd 092	 cpd 102	 cpd 112
 cpd 093	 cpd 103	 cpd 113
 cpd 094	 cpd 104	 cpd 114



 cpd 095	 cpd 105	 cpd 115
 cpd 096	 cpd 106	 cpd 116
 cpd 097	 cpd 107	 cpd 117
 cpd 098	 cpd 108	 cpd 118
 cpd 099	 cpd 109	 cpd 119

 cpd 100	 cpd 110	 cpd 120
 cpd 121	 cpd 131	 cpd 141
 cpd 122	 cpd 132	 cpd 142
 cpd 123	 cpd 133	 cpd 143
 cpd 124	 cpd 134	 cpd 144
 cpd 125	 cpd 135	 cpd 145

























 cpd 152	 cpd 162	 cpd 172
 cpd 153	 cpd 163	 cpd 173
 cpd 154	 cpd 164	 cpd 174
 cpd 155	 cpd 165	 cpd 175
 cpd 156	 cpd 166	 cpd 176
 cpd 157	 cpd 167	 cpd 177






















 cpd 158	 cpd 168	 cpd 178
 cpd 159	 cpd 169	 cpd 179
 cpd 160	 cpd 170	 cpd 180
 cpd 181	 cpd 191	 cpd 201
 cpd 182	 cpd 192	 cpd 202
 cpd 183	 cpd 193	 cpd 203

 cpd 184	 cpd 194	 cpd 204
 cpd 185	 cpd 195	 cpd 205
 cpd 186	 cpd 196	 cpd 206
 cpd 187	 cpd 197	 cpd 207
 cpd 188	 cpd 198	 cpd 208
 cpd 189	 cpd 199	 cpd 209
























cpd 226	cpd 227	cpd 228
cpd 229	cpd 230	cpd 231
cpd 232	cpd 233	cpd 234
cpd 235	cpd 236	cpd 237
cpd 238	cpd 239	cpd 240
cpd 241	cpd 242	cpd 243
cpd 244	cpd 245	cpd 246
cpd 247	cpd 248	cpd 249






















		
cpd 250	cpd 251	cpd 252
		
cpd 253	cpd 254	cpd 255
		
cpd 256	cpd 257	cpd 258
		
cpd 259	cpd 260	cpd 261
		
cpd 262	cpd 263	cpd 264
		
cpd 265	cpd 266	cpd 267
		
cpd 268	cpd 269	cpd 270
		
cpd 268	cpd 269	cpd 270

cpd 271	cpd 272	cpd 273
		
cpd 274	cpd 275	cpd 276
		
cpd 277	cpd 278	cpd 279
		
cpd 280	cpd 281	cpd 282
		
cpd 283	cpd 284	cpd 285
		
cpd 286	cpd 287	cpd 288
		
cpd 289	cpd 290	cpd 291
		
cpd 292	cpd 293	cpd 294
		



















cpd 295	cpd 296	cpd 297
cpd 298	cpd 299	cpd 300
cpd 301	cpd 302	cpd 303
cpd 304	cpd 305	cpd 306
cpd 307	cpd 308	cpd 309
cpd 310	cpd 311	cpd 312
cpd 313	cpd 314	cpd 315






















		
cpd 316	cpd 317	cpd 318
		
cpd 319	cpd 320	cpd 321
		
cpd 322	cpd 323	cpd 324
		
cpd 325	cpd 326	cpd 327
		
cpd 328	cpd 329	cpd 330
		
cpd 331	cpd 332	cpd 333
		
cpd 334	cpd 335	cpd 336

cpd 337	cpd 338	cpd 339
cpd 340	cpd 341	cpd 342
cpd 343	cpd 344	cpd 345
cpd 346	cpd 347	cpd 348
cpd 349	cpd 350	cpd 351
cpd 352	cpd 355	cpd 356
cpd 357	cpd 358	cpd 359

		
cpd 360	cpd 361	cpd 362
		
cpd 363	cpd 364	cpd 365
		
cpd 366	cpd 367	cpd 368
		
cpd 369	cpd 370	cpd 371
		
cpd 372	cpd 373	cpd 374
		
cpd 375	cpd 376	cpd 377
		
cpd 378	cpd 379	cpd 380

cpd 381	cpd 382	cpd 383
cpd 384	cpd 385	cpd 386
cpd 387	cpd 388	cpd 389
cpd 390	cpd 391	cpd 392
cpd 393	cpd 394	cpd 395
cpd 396	cpd 397	cpd 398
cpd 399	cpd 400	cpd 401






















		
cpd 402	cpd 403	cpd 404
		
cpd 405	cpd 406	cpd 407
		
cpd 408	cpd 409	cpd 410
		
cpd 411	cpd 412	cpd 413
		
cpd 414	cpd 415	cpd 416
		
cpd 417	cpd 418	cpd 419

























		
cpd 420	cpd 421	cpd 422
		
cpd 423	cpd 424	cpd 425
		
cpd 426	cpd 427	cpd 428
		
cpd 429	cpd 430	cpd 431
		
cpd 432	cpd 433	cpd 434
		
cpd 435	cpd 436	cpd 437
		
cpd 438	cpd 439	cpd 440

























cpd 441	cpd 442	cpd 443
cpd 444	cpd 445	cpd 446
cpd 447	cpd 448	cpd 449
cpd 450	cpd 451	cpd 452
cpd 453	cpd 454	cpd 455
cpd 456	cpd 457	cpd 458
cpd 459	cpd 460	cpd 461

cpd 462	cpd 463	cpd 464
cpd 465	cpd 466	cpd 467
cpd 468	cpd 469	cpd 470
cpd 471	cpd 472	cpd 473
cpd 474	cpd 475	cpd 476
cpd 477	cpd 478	cpd 479
cpd 480	cpd 481	cpd 482

cpd 483	cpd 484	cpd 485
cpd 486	cpd 487	cpd 488
cpd 489	cpd 490	cpd 491
cpd 492	cpd 493	cpd 494
cpd 495	cpd 496	cpd 497
cpd 498	cpd 499	cpd 500
cpd 501	cpd 502	cpd 503

		
cpd 504	cpd 505	cpd 506
		
cpd 507	cpd 508	cpd 509
		
cpd 510	cpd 511	cpd 512
		
cpd 513	cpd 514	cpd 515
		
cpd 516	cpd 517	cpd 518
		
cpd 519	cpd 520	cpd 521
		
cpd 522	cpd 523	cpd 524

		
cpd 525	cpd 526	cpd 527
		
cpd 528	cpd 529	cpd 530
		
cpd 531	cpd 532	cpd 533
		
cpd 534	cpd 535	cpd 536
		
cpd 537	cpd 538	cpd 539
		
cpd 540	cpd 541	cpd 542
		
cpd 543	cpd 544	cpd 545
		
cpd 546	cpd 547	cpd 548

























		
cpd 549	cpd 550	cpd 551
		
cpd 552	cpd 553	cpd 554
		
cpd 555	cpd 556	cpd 557
		
cpd 558	cpd 559	cpd 560
		
cpd 561	cpd 562	cpd 563
		
cpd 564	cpd 565	cpd 566
		
cpd 567	cpd 568	cpd 569
		

























cpd 570	cpd 571	cpd 572
cpd 573	cpd 574	cpd 575
cpd 576	cpd 577	cpd 578
cpd 579	cpd 580	cpd 581
cpd 582	cpd 583	cpd 584
cpd 585	cpd 586	cpd 587
cpd 588	cpd 589	cpd 590
cpd 591	cpd 592	cpd 593

cpd 594	cpd 595	cpd 596
cpd 597	cpd 598	cpd 599
cpd 600	cpd 601	cpd 602
cpd 603	cpd 604	cpd 605
cpd 606	cpd 607	cpd 608
cpd 609	cpd 610	cpd 611
cpd 612	cpd 613	cpd 614

cpd 615	cpd 616	cpd 617
cpd 618	cpd 619	cpd 620
cpd 621	cpd 622	cpd 623
cpd 624	cpd 625	cpd 626
cpd 627	cpd 628	cpd 629
cpd 630	cpd 631	cpd 632
cpd 633	cpd 634	cpd 635
cpd 636	cpd 637	cpd 638

cpd 639	cpd 640	cpd 641
cpd 642	cpd 643	cpd 646
cpd 647	cpd 648	cpd 649
cpd 650	cpd 651	cpd 652
cpd 653	cpd 654	cpd 655
cpd 656	cpd 657	cpd 658
cpd 659	cpd 660	cpd 661

		
cpd 662	cpd 663	cpd 664
		
cpd 665	cpd 666	cpd 667
		
cpd 668	cpd 669	cpd 670
		
cpd 671	cpd 672	cpd 673
		
cpd 674	cpd 675	cpd 676
		
cpd 677	cpd 678	cpd 679
		
cpd 680	cpd 681	cpd 682
		
cpd 683	cpd 684	cpd 685

		
cpd 686	cpd 687	cpd 688
		
cpd 689	cpd 690	cpd 691
		
cpd 692	cpd 693	cpd 694
		
cpd 695	cpd 696	cpd 697
		
cpd 698	cpd 699	cpd 700
		
cpd 701	cpd 702	cpd 703
		
cpd 704	cpd 705	cpd 706
		
cpd 707	cpd 708	cpd 709

cpd 710	cpd 711	cpd 712
cpd 713	cpd 714	cpd 715
cpd 716	cpd 717	cpd 718
cpd 719	cpd 720	cpd 721
cpd 722	cpd 723	cpd 724
cpd 725	cpd 726	cpd 727
cpd 728	cpd 729	cpd 730
cpd 731	cpd 732	cpd 733

[0193] The reactions were, if necessary, carried out under an inert atmosphere (mostly argon and N₂). The number of equivalents of reagents and the amounts of solvents employed as well as the reaction temperatures and times can vary slightly between different reactions carried out by analogous methods. The work-up and purification methods were adapted according to the characteristic properties of each compound and can vary slightly for analogous methods. The yields of the compounds prepared are not optimized.

[0194] The indication „equivalents“ („eq.“ or “eq” or “equiv.”) means molar equivalents, „RT“ or “rt” means room temperature T (23 ± 7 °C), „M“ are indications of concentration in mol/l, „sol.“ means solution, "conc." means concentrated. The mixing ratios of solvents are usually stated in the volume / volume ratio.

[0195] Key analytical characterization was carried out by means of ¹H-NMR spectroscopy and/or mass spectrometry (MS, m/z for [M+H]⁺ and/or [M-H]⁻) for all the exemplary compounds and selected intermediate products. In certain cases, where e.g., regioisomers and/or diastereomers could be/were formed during the reaction, additional analytics, such as, e.g., ¹³C NMR and NOE (nuclear overhauser effect) NMR experiments were in some cases performed.

[0196] Analytical instruments employed were e.g., for NMR analysis a BRUKER 400MHz or a BRUKER 500MHz machine (Software Topspin), alternatively a BRUKER AVANCE 300MHz and 400Mhz was employed. For LC/MS analysis e.g., an Agilent 1290 infinity,Mass:6150 SQD(ESI/APCI) or an Agilent 1200 SERIES,Mass:6130 SQD(ESI/APCI) (Software Chemistation) was employed. Analytical HPLCs were measured e.g., on Waters (Software Empower), an Agilent-1200-ELSD (Software Chemistation) or an Agilent-1260 (Software OpenLAB). Analytical SFC were performed e.g., on a PIC solution (Software: SFC PICLAB ONLINE), a WATERS-X5 (Software MASSLYNX) or a WATERS-UPC2 (Empower).

[0197] Preparative HPLC were performed e.g., on a Waters 2998 (Software Empower) or a YMC (Software K-Prep). Preparative SFC were performed e.g., on a Waters,SFC- 200 (Software Chromscope or Super chrome), a Waters,SFC-80 (Super chrome) or a PIC,PIC-175 (Software S10-100).

[0198] Structures of example compounds that contain stereocentres are drawn and named with absolute stereochemistry, if known. In case of unknown absolute stereochemistry, the compounds can be either racemic, a mixture of diastereomers, a pure diastereomer of unknown stereochemistry, or a pure enantiomer of unknown stereochemistry. **Dia 1** and **Dia 2** means that diastereoisomers were separated but the stereochemistry is unknown. **En 1** and **En 2** means that both enantiomers were separated but the absolute configuration is unknown. No suffix given after the compound code means that a compound containing stereocentres was obtained as a racemic mixture or a mixture of diastereomers, respectively, unless the chemical name of the compound specifies the exact stereochemistry.

[0199] The LC/MS analysis mentioned in the experimental part were also performed on a Dionex Ultimate 3000 HPLC system (equipped with a PDA detector) connected to a mass spectrometer Brucker Esquire 6000 (equipped with a multimode source, ESI/APCI) (Method L in the table below). Or the LC/MS analysis mentioned in the experimental part were performed on a Waters system combining an Acquity UPLC H-Class equipped with a Acquity UPLC PDA Detector and an Acquity TQ Detector (ESI) (Method U in the table below).

[0200] Conditions used for the HPLC analysis in experimental part. The LC/MS analysis mentioned in the experimental part were performed on a Dionex Ultimate 3000 HPLC system (equipped with a PDA detector) connected to a mass spectrometer Brucker Esquire 6000 (equipped with a multimode source, ESI/APCI). The separations were performed with a SunFireC18, 3.5µm 3.0x100mm, column equipped with a SunFire C18, 3.5µm,

- 3.0x20mm Guard column or a X-Bridge C18 100x3.0mm column equipped with a X-Bridge C18, 3.5µm, 3.0x20mm Guard column thermostated to 30°C and the DAD acquisition wavelength was set in the range of 190–420 nm (Method L in the table below). Elutions were carried out with the methods described in the following tables. Solvent A: : Formic Acid LC-MS grade 0.1% in milliQ water Solvent B: NH₄OAc (LC-MS grade) 10mMol in milliQ water, adjusted at pH10 with an aq. solution of NH₃, LC-MS grade. Solvent C: Acetonitrile LC-MS grade.

LC/MS Method	System	Time (min)	Solvents			Flow (mL/min)	Column
			A (%)	B (%)	C (%)		
L1	Dionex Ultimate 3000 HPLC	0	80	-	20	1	SunFire C18
		0.2	80	-	20	1	
		7	40	-	60	1	
		8	10	-	90	1	
		10.8	10	-	90	1	
		11	80	-	20	1	
		14	80	-	20	1	
L2	Dionex Ultimate 3000 HPLC	0	50	-	50	1	SunFire C18
		0.2	50	-	50	1	
		6	10	-	90	1	
		10.8	10	-	90	1	
		11	50	-	50	1	
		14	50	-	50	1	
L3	Dionex Ultimate 3000 HPLC	0	-	80	20	1	X-Bridge C18
		0.2	-	80	20	1	
		7	-	40	60	1	
		8	-	10	90	1	
		10.8	-	10	90	1	
		11	-	80	20	1	
		14	-	80	20	1	
L4	Dionex Ultimate 3000 HPLC	0	-	50	50	1	X-Bridge C18
		0.2	-	50	50	1	
		6	-	10	90	1	
		10.8	-	10	90	1	
		11	-	50	50	1	
		14	-	50	50	1	
L5	Dionex Ultimate 3000 HPLC	0	95	-	5	1	SunFire C18
		1	95	-	5	1	
		7	50	-	50	1	
		8	10	-	90	1	
		10.8	10	-	90	1	

L6	<i>Dionex Ultimate 3000 HPLC</i>	11	95	-	5	1	X-Bridge C18
		14	95	-	5	1	
		0	-	95	5	1	
		1	-	95	5	1	
		7	-	50	50	1	
		8	-	10	90	1	
		10.8	-	10	90	1	
		11	-	95	5	1	
		14	-	95	5	1	

- [0201] Conditions used for the UPLC analysis in experimental part. The LC/MS analysis mentioned in the experimental part were performed on a Waters system combining an Acquity UPLC H-Class equipped with a Acquity UPLC PDA Detector and an Acquity TQ Detector (ESI). The separations were performed with an Acquity UPLC HSS C18, 2.1x50mm, 1.8 μ M column equipped with a prefilter and thermostated at 40°C or an Acquity UPLC BEH C18, 2.1x50mm, 1.7 μ M column equipped with a prefilter and thermostated at 40°C and the PAD acquisition wavelength was set in the range of 210–420 nm (Method U in the table below). Elutions were carried out with the methods described in the following table. Solvent A: Formic Acid LC-MS grade 0.1% in milliQ water Solvent B: NH₄OAc (LC-MS grade) 10mMol in milliQ water, adjusted at pH10 with an aq. solution of NH₃, LC-MS grade. Solvent C: Acetonitrile LC-MS grade.

LC/MS Method	System	Time (min)	Solvents			Flow (mL/min)	Column
			A (%)	B (%)	C (%)		
U1	<i>Waters UPLC</i>	0	95	-	5	0.5	Acquity UPLC HSS C18
		3.18	50	-	50	0.5	
		4	10	-	90	0.5	
		5	10	-	90	0.5	
U2	<i>Waters UPLC</i>	0	80	-	20	0.5	Acquity UPLC HSS C18
		3.4	40	-	60	0.5	
		4	10	-	90	0.5	
		5	10	-	90	0.5	
U3	<i>Waters UPLC</i>	0	50	-	50	0.5	Acquity UPLC HSS C18
		3.5	10	-	90	0.5	
		5	10	-	90	0.5	
U4	<i>Waters UPLC</i>	0	-	95	5	0.5	Acquity UPLC BEH C18
		3.18	-	50	50	0.5	
		4	-	10	90	0.5	
		5	-	10	90	0.5	
U5	<i>Waters UPLC</i>	0	-	80	20	0.5	Acquity UPLC BEH C18
		3.4	-	40	60	0.5	
		4	-	10	90	0.5	
		5	-	10	90	0.5	


U6	<i>Waters UPLC</i>	0	-	50	50	0.5	Acquity UPLC BEH C18
		3.5	-	10	90	0.5	
		5	-	10	90	0.5	

[0202] Preparative HPLC purifications mentioned in this experimental part have been carried out with the following system: a Waters 2489 UV/Visible Detector, a Waters 2545 Binary Gradient Module, a Waters Fraction Collector III and a Waters Dual Flex Injector. The separations were performed with a X-Bridge Prep C18 column, 100x19 mm, 5 μ m column equipped with a X-Bridge C18, 19x10 mm, 5 μ m Guard column or with a SunFire Prep C18 ODB column (5 μ m; 19 x 100 mm) equipped with a SunFire C18 guard column (5 μ m; 19 x 10 mm). Elutions were carried out with the methods described in the following tables, and detection wavelengths were fixed at 210 and 254 nm. Solvent A: Formic Acid LC-MS grade 0.1% in milliQ water Solvent B: NH₄OAc (LC-MS grade) 10mMol in milliQ water, adjusted at pH10 with an aq. solution of NH₃, LC-MS grade. Solvent C: Acetonitrile LC-MS grade.

HPLC Method	Time (min)	Solvent		Flow (mL/min)	Column
		A (%)	B (%)		
H1	0	80	20	20	X-Bridge Prep C18
	2	80	20	20	
	8	10	90	20	
	10.8	10	90	20	
	11	80	20	20	
	16	80	20	20	
H2	0	95	5	20	SunFire Prep C18 ODB
	2	95	5	20	
	8	50	50	20	
	9	10	90	20	
	13	10	90	20	
	14	95	5	20	
	16	95	5	20	

10

Synthesis of 2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 018**).



[0203] *Step 1:* To a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.100 g; 0.45 mmol) in THF (10 mL) and NMP (1 mL) was added cesium carbonate (0.444 g; 1.36 mmol) and the RM was stirred at RT for 25 min. Then, 2-(bromomethyl)-5-(trifluoromethyl)furan (0.104 mg; 0.45 mmol) was added and the stirred solution was heated at 95°C until the consumption of 5-hydroxy-2-methylbenzofuran-3-carboxylate. The mixture was cooled down to RT, poured in water and extracted twice with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by FC on silica gel using a gradient of EtOAc (0% to 80%) in heptane to afford 0.167 g (100%) of ethyl 2-methyl-5-((5-


15

(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylate.

[0204] *Step 2*: To a solution of ethyl 2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylate (0.167 g; 0.45 mmol) in a mixture of water-EtOH-MeOH-THF (6:3:3:1, 12 mL) was added sodium hydroxide (0.102 g; 1.8 mmol) and the RM was heated under reflux until the consumption of ethyl 5-(benzyloxy)-2-methylbenzofuran-3-carboxylate. After cooling, the volatiles were removed under reduced pressure and the remaining residue was dissolved in water and washed with DCM. The mixture was acidified with an aq. solution of hydrochloric acid (6 N) until pH~2 and extracted with EtOAc. The resulting organic layer was washed with water and brine, dried over magnesium sulfate and filtered to afford 147.6 mg (89%) of 2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 018**).

[0205] **Cpd 016** and **cpd 017** were prepared in a manner similar (use of appropriate reagents and purification methods known to those skilled in the art) to **cpd 018**.

Synthesis of 2-methyl-5-((2-(trifluoromethyl)benzyl)oxy)benzofuran-3-carboxylic acid (**cpd 101**).



[0206] *Step 1*: Tributylphosphine (1.7 mL; 6.5 mmol) was added dropwise to a stirred mixture of methyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (1 g; 4.6 mmol), 2-(trifluoromethyl)pyridin-3-yl)methanol (1.28 g; 6.9 mmol) and ADDP (1.66 g; 6.5 mmol) in dry THF (5 mL) under argon. The mixture was stirred for 2h and was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc (0-20%) in heptane to afford 1.4 g (83%) of methyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate. *M/Z*(+): 366 (M+H). *M/Z*(-): 364 (M-H).

[0207] *Step 2*: To a solution of methyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.40 g; 3.8 mmol) in a mixture of MeOH-THF (1:1, 40 mL) was added a solution of sodium hydroxide (2 N; 5 mL; 40 mmol) and the RM was heated at 75°C overnight. After cooling, the volatiles were removed under reduced pressure and the remaining residue was dissolved in water. The mixture was acidified with a solution of HCl (6 N) until pH~5. The white precipitate was washed with water and dried under reduced pressure to afford 1.30 g (96%) of 2-methyl-5-((2-(trifluoromethyl)benzyl)oxy)benzofuran-3-carboxylic acid (**cpd 101**).

[0208] **Cpd 099**, **cpd 100** and **cpd 102** were prepared in a manner similar (use of appropriate reagents and purification methods known to those skilled in the art) to **cpd 101**.

[0209] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 101**:

Cpd. Nr.	[M+H] ⁺ (m/z)
208	304.0
210	372.1
211	288.1
212	304.1
214	298.1
216	304.1


Cpd. Nr.	[M+H] ⁺ (m/z)
228	303.1
235	337.0
239	328.1
240	302.1
242	302.1
248	318.1

Cpd. Nr.	[M-H] ⁻ (m/z)
261	297.0
263	297.0
679	288.1
681	332.1
713	285.1

217	298.1
218	263.1
219	285.0
220	337.1
223	318.0
224	318.1
227	314.2

249	287.1
257	299.1
260	304.0
262	304.0
264	285.0
268	318.1
269	314.1

Synthesis of 2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxylic acid (cpd 008).



[0210] *Step 1:* Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (100 mg; 0.45 mmol), (1-methyl-1H-pyrazol-5-yl)methanol (0.075 g; 0.68 mmol) and PPh₃ (119 mg; 0.45 mmol) were dissolved in THF (5 mL) and cooled down to 0°C. Then DIAD (0.134 mL; 0.68 mmol) was added dropwise and the RM was stirred 36h at RT. The volatiles were removed under reduced pressure and the residue was diluted with DCM and washed successively with an aq. solution of NaOH (1 N), water and brine. The organic layer was dried over magnesium sulfate, filtered and the solvent was removed under reduced pressure. The compound was purified by FCC on silica gel using a gradient of EtOAc (20 to 100%) in heptane to afford 0.071 g (50%) of the desired compound.


[0211] *Step 2:* An aq. solution of NaOH (2 N; 6 mL; 12 mmol) was added to a solution of ethyl 2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxylate (0.071 g; 0.25 mmol) in MeOH (4 mL) and ethanol (2 mL) and the mixture was stirred for 4h at 80°C. After cooling, the mixture was diluted with water and washed with DCM. The aq. layer was acidified till pH=4 with an aq. solution of HCl (6 N). The solid formed was filtered and dried to afford 33 mg (51%) of 2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxylic acid (cpd 008).

[0212] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to cpd 008: Cpd 001, 002, 004, 005, 006, 007, 009, 010, 011, 012, 013 and 014.

[0213] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to cpd 008:

Cpd. Nr.	[M+H] ⁺ (m/z)
255	288.1
266	328.1
267	323.1

Synthesis of 2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylic acid (cpd 215).



[0214] *Step 1:* To a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.4 g, 1.8 mmol) and (5-methylisoxazol-3-yl) methyl methanesulfonate (0.52 g, 2.7 mmol) in acetonitrile (25 mL) was added Cs₂CO₃ (1.18 g, 3.6 mmol) at RT. The reaction mixture was heated 70 °C and maintained at this temperature for 16 h. Reaction progress was monitored by TLC. The reaction mixture was filtered and concentrated under reduced pressure to give the crude compound. The crude was purified by 100-200 mesh silica-gel column chromatography using 5% ethyl acetate in pet ether as an eluent to afford ethyl 2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylate (0.4 g, 70%) as a pale yellow thick mass. TLC system: 30% Ethyl acetate in pet-ether; RF: 0.2.


[0215] *Step 2:* 2N aqueous NaOH (5 mL) was added to a stirred solution of ethyl 2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylate (0.4 g, 1.26 mmol) in methanol (5 mL) and THF (5 mL) at RT and the resulting reaction mixture was stirred at RT for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (10 mL) and acidified to pH ~2 with 1N aq. HCl (10 mL), the precipitated solid was filtered and dried under vacuum to afford 2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylic acid (250 mg, 70%) as a white solid. TLC system: 50% Ethyl acetate in pet-ether; RF: 0.2. [M+H]⁺ (m/z): 288.1

[0216] The following compounds were prepared in a manner similar (use of appropriate reagents (including mesylates, chlorides and bromides) and purification methods known to the person skilled in the art) to **cpd 215**:

Cpd. Nr.	[M+H] ⁺ (m/z)
209	358.1
213	383.3
221	364.1
226	334.0
667	301.2
671	349.1
675	315.2
689	327.1
693	358.0
703	324.2

Cpd. Nr.	[M+H] ⁺ (m/z)
237	334.0
250	314.1
256	314.0
258	277.2
669	335.1
673	288.1
677	302.2
691	355.1
699	298.1
707	299.1

Synthesis of 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 225**).



20


[0217] *Step 1:* To a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.900 g, 4.09 mmol) in THF (30 mL), was added NaH (60%) (0.313 g, 8.18 mmol) lot wise at 0 °C under argon atmosphere, followed by the addition of 3-(chloromethyl)pyridin-2-amine (2239-1) (0.871 g, 6.13 mmol) at 0 °C under argon atmosphere. The reaction mixture was heated up to 60 °C for 18 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material. The crude was purified by column chromatography over silica

25

gel (100-200 mesh) using 0-30% ethyl acetate in pet-ether as an eluent to afford ethyl 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (0.30 g, 23%) as a white solid. TLC system: 50% EtOAc in Pet ether; Rf: 0.3.

[0218] *Step 2:* To a pre-stirred solution of ethyl 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (0.30 g, 0.92 mmol), in THF:MeOH:H₂O (1:1:1, 30 ml), was added NaOH (0.11 g, 2.76 mmol) at RT, then the reaction was heated to 50 °C, and the reaction mixture was stirred for 6 h at 50 °C. Reaction progress was monitored by TLC. The reaction mixture was concentrated to get the crude material, which was diluted with ice water and pH was adjusted to ~2 with 1N aq. HCl solution to give a solid. The obtained solid was filtered and dried to afford 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (0.22 g, 80%) as an off-white solid. TLC system: 10% MeOH in CH₂Cl₂; Rf: 0.2. [M+H]⁺ (m/z): 299.1


Synthesis of 2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (cpd 247).



[0219] *Step 1:* To a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (800 g, 3.636 mmol) and (2-methylpyridin-3-yl)methyl methanesulfonate (1.4 g 7.272 mmol) in DMF (5 mL) at 0 °C was added K₂CO₃ (1.5 g, 10.909 mmol). The reaction mixture was allowed to come to RT and was stirred for 12 h at the same temperature. Reaction progress was monitored by TLC. The reaction mixture was quenched with ice water (100 mL) and stirred for 30 minutes. The solid material was collected by filtration and dried to afford 1.2 g (92%) of ethyl 2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylate as an off white solid. TLC system: 20% Ethyl acetate in pet-ether; RF: 0.20

[0220] *Step 2:* A solution of ethyl 2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.2 g, 3.692 mmol), NaOH (295 mg, 7.384 mmol) in EtOH: THF: H₂O (2: 2: 1, 5.0 mL) was stirred at 70 °C for 16 h. The reaction progress was monitored by TLC. The solvent was distilled off, then water was added (20 mL) to the crude residue and the aqueous phase was washed with diethyl ether (2 x 10 mL). The aqueous layer was acidified with 2N HCl, the resulting precipitated solid was collected by filtration, washed with water (10 mL) and dried under reduced pressure to afford 2-methyl-5-((2-methyl-4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 91%) as an off-white solid. TLC system: 10% MeOH in dichloromethane; RF: 0.10. [M+H]⁺ (m/z): 298.1

Synthesis of 5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (cpd 241).



[0221] *Step 1:* To a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (5 g, 22.7 mmol), and (5-methoxypyridin-2-yl)methanol (3.79 g, 27.2 mmol) in THF (150 mL) was added ADDP (11.4 g, 46 mmol)


followed by Bu₃P (9.2 g, 46 mmol) at 0 °C. The reaction mixture was stirred at RT for 16 hours and was then concentrated under reduced pressure. The residue was partitioned between water and ethyl acetate. After separation, the aqueous layer was extracted with ethyl acetate (150 mL x 2). The combined organic extracts were concentrated under reduced pressure to give a residue. The residue was purified by flash chromatography (silica gel, 100 – 200 mesh size) using a gradient of ethyl acetate (5–40%) in hexane to afford ethyl 5-((5-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (3 g, 8.7 mmol, 38%) as a pale yellow solid. TLC system: 30% EtOAc in Pet ether; RF: 0.35.

[0222] *Step 2:* To a stirred solution of ethyl 5-((5-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (500 mg, 1.4 mmol) in CH₂Cl₂ (20 mL) was added portion wise AlCl₃ (390 mg, 2.9 mmol) at 0 °C, the reaction mixture was then stirred at 50 °C for 2 hours. Reaction progress was monitored by LCMS. After completion of the reaction, the reaction mass was concentrated under reduced pressure to give a residue. The residue was treated with sat. NaHCO₃ solution (pH ~ 7) and was partitioned between water and dichloromethane. After separation, the aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic extracts were concentrated under reduced pressure to afford ethyl 5-((5-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (180 mg, 5 mmol) as a pale yellow solid. TLC system: 50% EtOAc in pet ether; RF: 0.3

[0223] *Step 3:* To a stirred solution of ethyl 5-((5-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (600 mg, 1.8 mmol) in DMF (20 mL) was added (2-bromoethoxy)(tert-butyl)dimethylsilane (657 mg, 2.7 mmol) at 0 °C, the reaction mixture was then stirred at 60 °C for 6 hours. Reaction progress was monitored by LCMS. After completion of the reaction, the reaction mass was partitioned between water and ethyl acetate. After separation, the aqueous layer was extracted with ethyl acetate (50 mL x 2). Combined organic extracts were concentrated under reduced pressure to afford ethyl 5-((5-(2-((tert-butyl)dimethylsilyl)oxy)ethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (600 mg, 1.2 mmol) as a pale yellow solid. TLC system: 30% EtOAc in Pet ether; RF: 0.7.

[0224] *Step 4:* To a stirred solution of ethyl 5-((5-(2-((tert-butyl)dimethylsilyl)oxy)ethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylate (600 mg, 1.2 mmol) in THF (20 mL) was added NaOH (148 mg, 3 mmol) in water (3 ml), and MeOH (3 ml) at 0 °C, the reaction mixture was then stirred at RT for 16 hours. Reaction progress was monitored by LCMS. After completion of the reaction, the reaction mass was concentrated under reduced pressure. The residue was stirred in 1N HCl (pH ~2) for 30 min and was then partitioned between water and dichloromethane. After separation, the aqueous layer was extracted with dichloromethane (50 mL x 2). Combined organic extracts were concentrated under reduced pressure to afford 5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (300 mg, 8 mmol) as an off - white solid. TLC system: 5% MeOH in dichloromethane; RF: 0.4. [M+H]⁺ (m/z): 344.0

Synthesis of 5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (cpd 222).




[0225] *Step 1:* To a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (2.5 g, 0.011 mmol) in acetonitrile (50 mL) was added Cs₂CO₃ (7.3 g 0.022 mmol), 2-chloro-3-(chloromethyl) pyridine (2.1 g, 0.0132 mmol) under argon atmosphere at RT. The reaction mixture was heated to 80 °C for 16 h. The reaction

progress was monitored by TLC. The reaction mixture was filtered and the filter cake was washed with acetonitrile (50 mL), and the filtrate was concentrated under reduced pressure to give the crude material. The crude material was purified by grace chromatography using 0-20% ethyl acetate in pet-ether as an eluent to afford ethyl 5-((2-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (2.0 g, 63%) as an off-white solid. TLC system: 30% EtOAc in Pet ether; RF: 0.6.

[0226] *Step 2:* A solution of ethyl 5-((2-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (500 mg, 1.44 mmol) and N,N-dimethyl amine solution in ethanol (10 mL, 5 M) was heated to 150 °C in a microwave for 2 h. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to give the crude material. The crude material was purified by Grace flash chromatography using 0-5% ethyl acetate in pet-ether as an eluent to afford ethyl 5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (180 mg, 39%) as an off-white solid. TLC system: 30% EtOAc in Pet ether; RF: 0.5.

[0227] *Step 3:* To a stirred solution of ethyl 5-((2-(dimethyl amino) pyridin-3-yl) methoxy)-2-methylbenzofuran-3-carboxylate (300 mg, 0.847 mmol), in THF: MeOH: H₂O (1:1:0.5, 25 ml) was added NaOH (170 mg, 4.27 mmol) at RT and the mixture was heated to 50 °C. The reaction mixture was stirred for 4 h at 50 °C and reaction progress was monitored by TLC. The reaction mixture was concentrated under vacuum and diluted with ice water, the pH was adjusted to ~2 with 1N aq. HCl solution to give a solid which was filtered and dried to afford 5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (170 mg, 61%) as a white solid. TLC system: 30% EtOAc in Pet ether; RF: 0.1. [M+H]⁺ (m/z): 327.2.

Synthesis of 5-((2-Cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (cpd 701).




Step 1: To a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (500 mg, 2.283 mmol) and (2-bromopyridin-3-yl)methanol (643.4 mg, 3.42 mmol) in THF (10 mL) was added ADDP (806.08 mg, 3.196 mmol) and n-Bu₃P (646.5 mg, 3.196 mmol) at RT. The RM was stirred for 16 h at RT. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL) and extracted with ethyl acetate (2 x 50 mL). Combined organic layers were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and evaporated under vacuum. The crude was purified by flash column chromatography using 0.1% formic acid in water and acetonitrile in water as an eluent to afford ethyl 5-((2-bromopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (520 mg, crude) as yellow solid. Proceeded to next step without purification.

Step 2 : Pd(PPh₂)₂Cl₂ (45.04 mg, 0.06 mmol) was added to a stirred solution of ethyl 5-((2-bromopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (250 mg, 0.6426 mmol), cyclopropylboronic acid (83.38 mg, 0.9640 mmol), K₃PO₄ (409.15 mg, 1.9278 mmol) in 1,4-dioxane (10 mL) and water (4 mL) at RT. Reaction mixture was degassed with Ar gas for 15 minutes at RT. The reaction mixture was heated to 100 °C and stirred for 16 hours at 100 °C. The reaction progress monitored by TLC. Reaction mass was filtered over celite bed, filtrate was diluted with water (20 mL) and extracted with ethyl acetate (2 x 50 mL). Combined organic layers were concentrated under reduced pressure to get crude. Crude was purified by Grace flash column chromatography using 0.1% formic acid in water and acetonitrile as an eluent to afford ethyl 5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (150 mg, crude) as a brown solid. Proceeded to next step without purification. TLC system: 100% Ethyl acetate, RF: 0.4.

Step 3 : A solution of NaOH (91.4 mg, 2.285 mmol) in water (8 mL) was added to a stirred solution of ethyl 5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (80 mg, 0.228 mmol) in methanol (2 mL) and THF (2 mL) at RT. The resulting reaction mixture was stirred for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure and diluted with water (15 mL), pH was adjusted to ~5 with 1N HCl solution. The precipitated solid was extracted with ethyl acetate (2 x 50 mL). Combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to afford 5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**6**) (100 mg, crude) as a brown gummy liquid. Proceeded to next step without purification. TLC system: 10% MeOH in dichloromethane; Rf: 0.2.


Synthesis of 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 230**).



[0228] *Step 1*: To a stirred solution of ethyl 2-formyl-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.5 g, 13.8 mmol) in CH₂Cl₂ (100 mL) was added DAST (4.47 g, 28 mmol) at 0 °C and the reaction mixture was stirred for 16 h at RT, the reaction progress was monitored by TLC. Ice cold water was added to the reaction mixture and aq. NaHCO₃ solution was added to get to pH ~7, followed by extraction with ethyl acetate (3 x 100 mL). The combined extracts were washed with brine (150 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the material crude (1.4 g). The crude was purified by column chromatography using silica gel (100-200 mesh) and 20% ethyl acetate in pet ether as eluent to afford ethyl 2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylate (1 g) as a white solid. TLC system: 20% Ethyl acetate in pet-ether; Rf: 0.6.

[0229] *Step 2*: To a stirred solution of ethyl 2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylate (1 g, 1.4 mmol), was added LiOH.H₂O (110 mg, 2.8 mmol) in THF: H₂O: MeOH (3:1:1) (25 mL) at RT under an argon atmosphere. The reaction mixture was stirred for 2 h at RT. The reaction progress was monitored by TLC. The solvents were removed and the reaction mixture was treated with citric acid to adjust the pH to ~1 and the resulting precipitate was filtered. The solid was dried under vacuum to afford 2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (1 g, 68%) as an off-white solid. TLC system: 5% MeOH in CH₂Cl₂; Rf: 0.2. [M+H]⁺ (m/z): 350.0.

Synthesis of 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 236**).




[0230] *Step 1*: To a stirred solution of ethyl 5-((2-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (4.0 g, 11.59 mmol, 1.0 eq) in DMSO (40 mL), at 0 °C was added K₂CO₃ (15.99 g, 115.90 mmol, 10 eq) at 0 °C and the mixture was stirred for 5 min. Azetidine (5.39 g, 57.97 mmol, 5 eq) was added to the reaction and the mixture was stirred for 18 h at 120 °C. Reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (50 mL), the product was extracted with EtOAc (300 mL). The ethyl acetate layer was washed with ice water (50 mL) and brine (25 mL) and was then dried over anhydrous Na₂SO₄, filtered and concentrated to get the crude product, which was purified by Grace flash column chromatography using 20% EtOAc-pet ether as eluent to afford ethyl 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-

carboxylate (0.380 g, 9%, Off-white solid). TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.3.

[0231] *Step 2:* To a stirred solution of ethyl 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (0.700 g, 1.91 mmol, 1.0 eq), in THF:MeOH:H₂O (1:1:1) (60 ml), was added NaOH (0.29 g, 5.73 mmol, 3.0 eq) at RT, the mixture was then heated up to 50 °C. The reaction mixture was stirred for 18 h at 50 °C and reaction progress was monitored by TLC. The reaction mixture was concentrated to get the crude material which was diluted with ice water and the pH was adjusted to 2 with 1N HCl solution causing precipitation. The contents were further stirred for 30 min, the solids were then filtered off and dried to afford 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (0.400 g, 61% white solid). TLC system: 100% Ethyl acetate; Rf: 0.2. [M+H]⁺ (m/z): 339.0.

Synthesis of 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (cpd 238).




[0232] *Step 1:* To a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.8 g, 3.63 mmol, 1.0 eq) in ACN (10 ml) at 0 °C was added Cs₂CO₃ (3.55 g, 10.89 mmol, 3 eq) and the mixture was stirred for 5 minutes followed by the addition of 3-(bromomethyl)picolinonitrile (0.85 g, 4.36 mmol, 1.2 eq) at 0 °C. The reaction mixture was stirred for 18 h at RT, monitored by TLC. The reaction mixture was diluted with ice water (100 ml) and extracted with EtOAc (300 ml). The organic layer was washed with ice water (100 ml) and brine (50 ml), dried over anhydrous Na₂SO₄, filtered and concentrated to get the crude product, which was purified by Grace flash column chromatography using eluent 20% EtOAc in pet ether to afford ethyl 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (1.0 g, 81%, off-white solid). TLC system: 20% EtOAc-pet ether; 2:8; Rf: 0.3.

[0233] *Step 2:* To ethyl 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (1.0 g, 2.97 mmol, 1.0 eq), in THF:MeOH:H₂O (1:1:1) (120 ml) was added NaOH (0.35 g, 8.92 mmol, 3.0 eq) at RT, the reaction mixture was then heated to 50 °C for 18 h, the reaction progress was monitored by TLC. The reaction mixture was concentrated and diluted with ice water, the pH was adjusted to ~2 with 1N HCl solution to give a precipitate while stirring for 30 min. The precipitate was filtered off and dried under vacuum to afford a mixture of 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 238**) and 5-((2-carbamoylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (0.75 g, crude). [M+H]⁺ (m/z): 309.0, TLC system: 50% EtOAc-pet ether; Rf: 0.1.

[0234] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 238**:

Cpd. Nr.	[M+H] ⁺ (m/z)
259	288.1
687	355.1
709	340.2

Synthesis of 2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylic acid (cpd 252).



[0235] *Step 1:* DABCO (2.78 g, 24.75 mmol) was added to a stirred mixture of 3-bromo-4-hydroxybenzaldehyde (5.0 g, 24.75 mmol) and ethyl but-2-ynoate (3.32 g, 29.70 mmol) in acetonitrile (100 mL) at room temperature and the resulting reaction mixture was then heated to reflux for 4 h. The solvent was distilled off under reduced pressure, the residue was diluted with ethyl acetate (300 mL) and the resulting solution was sequentially washed with 1N HCl (100 mL), aq. 1N NaOH (2 x 75 mL), water (100 mL), brine (150 mL) and was then dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography over silica-gel (100-200 mesh) using 10% ethyl acetate in pet-ether as an eluent to afford ethyl 3-(2-bromo-4-formylphenoxy)but-2-enoate (1.5 g, 29%) as an off-white solid. TLC system: 20% Ethyl acetate in pet-ether; R_f: 0.7.

[0236] *Step 2:* A solution mixture of ethyl 3-(2-bromo-4-formylphenoxy)but-2-enoate (1.2 g, 3.821 mmol) and TEA (0.21 mL, 1.528 mmol) in acetonitrile (25.0 mL) was degassed with argon for 5 min and then was added bis(tri-tert-butylphosphine)palladium(0)] (195 mg, 0.382 mmol). The resulting reaction mixture was heated to reflux for 2 h. The reaction progress was monitored by TLC. (Note: Another batch on 250 mg scale using the same procedure was combined with this reaction mixture for work-up). The reaction mixture was directly concentrated under reduced pressure. The crude was partitioned between water (100 mL) and ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 5-formyl-2-methylbenzofuran-3-carboxylate (1.0 g, 90%) as an off white crystalline solid. TLC system: 10% Ethyl acetate in pet-ether; R_f: 0.7.

[0237] *Step 3:* NaBH₄ (398 mg, 10.775 mmol) was added portionwise to a solution mixture of ethyl 5-formyl-2-methylbenzofuran-3-carboxylate (1.0 g, 4.310 mmol) in EtOH: THF (1:1) (40.0 mL) at 0 °C and the resulting reaction mixture was stirred for 30 min. The reaction mixture was then quenched with water (5.0 mL) and was concentrated under reduced pressure. The crude compound was diluted with ethyl acetate (50 mL), washed with water (2 x 50 mL), brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 5-(hydroxymethyl)-2-methylbenzofuran-3-carboxylate (900 mg, crude) as a colorless oil. TLC system: 20% Ethyl acetate in pet-ether; R_f: 0.4.


[0238] *Step 4:* A mixture of ethyl 5-(hydroxymethyl)-2-methylbenzofuran-3-carboxylate (700 mg, 2.991 mmol), TPP (1.17 g, 4.487 mmol) and CBr₄ (1.48 g, 4.487 mmol) in THF (40.0 mL) was stirred at 0 °C was then warmed to ambient temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ethyl acetate (100 mL), washed with NaHCO₃ solution (50 mL), water (50 mL), brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 5-(bromomethyl)-2-methylbenzofuran-3-carboxylate (1.25 g, crude) as a pale yellow thick gummy mass. TLC system: 10% Ethyl acetate in pet-ether; R_f: 0.6.

[0239] *Step 5:* To a suspension of 2-(trifluoromethyl)pyridin-3-ol (600 mg, 3.680 mmol) and K₂CO₃ (1.26 g, 9.20 mmol) in acetonitrile (30 mL) was added ethyl 5-(bromomethyl)-2-methylbenzofuran-3-carboxylate (1.32 g,

4.41 mmol) and the resulting reaction mixture was maintained at 90 °C for 1 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ethyl acetate (100 mL) and was filtered. The filtrate was washed with water (100 mL), brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography over silica-gel (100-200 mesh) using 20% ethyl acetate in pet-ether as an eluent to afford ethyl 2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylate (800 mg, 58%) as a red solid. TLC system: 20% Ethyl acetate in pet-ether; Rf: 0.5.

[0240] *Step 6:* To a stirred solution of ethyl 2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylate (800 mg, 2.110 mmol) in ethanol:THF (1:1) (40 mL) was added a solution of NaOH (253 mg, 6.332 mmol) dissolved in water (10 mL) and the resulting reaction mixture was maintained under stirring at 60 °C for 1 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to room temperature and poured into ice cold water (100 mL), acidified with 1N HCl to pH~5.0 and extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with water (100 mL) followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylic acid (800 mg, crude) as a red solid. TLC system: 10% MeOH in dichloromethane; Rf: 0.4. [M+H]⁺ (m/z): 352.0.

Synthesis of 2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (cpd 251).




[0241] *Step 1:* 2-(Trifluoromethyl)pyridin-3-ylmethanol (0.887 mg, 5.01 mmol), ADDP (0.946 mg, 4.67 mmol) and tri-*n*-butylphosphine (1.18 g, 4.67 mmol) were added sequentially to a pre-stirred solution of ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 3.34 mmol) in THF (50 mL) at 0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and the stirred for 2 h. The reaction progress was monitored by TLC. The reaction mixture was poured into water (80 mL) followed by extraction with ethyl acetate (2 x 60 mL). The combined organic layers were sequentially washed with water (30 mL), brine (30 mL), were then dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford ethyl 4-bromo-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.600 g, crude) as a pale yellow liquid. TLC system: 20% Ethyl acetate in pet-ether; Rf: 0.6.

[0242] *Step 2:* A suspension of ethyl 4-bromo-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.6 g, 1.31 mmol), methylboronic acid (0.157 g, 2.62 mmol) and K₂CO₃ (0.542 g, 3.93 mmol) in 1,4-dioxane:water (9:1) (10 mL) in a sealed tube was degassed with argon for 10 min and then Pd(PPh₃)₄ (0.151 g, 0.13 mmol) was added. The resulting reaction mixture was again degassed for 10 minutes and was then heated to 120 °C for 16 h. The reaction progress was monitored by LC-MS. The reaction mixture was cooled to room temperature and filtered through a celite pad, the celite pad was washed with ethyl acetate (2 x 30 mL). The combined filtrate was dried over anhydrous Na₂SO₄ and evaporated *in vacuo*. The crude product was purified by flash column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford ethyl 2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.5 g, 71%) as a colorless liquid. TLC system: 20% Ethyl acetate in pet-ether; Rf: 0.7.

[0243] *Step 3:* A solution of NaOH (0.203 g, 5.08 mmol) in water (4 mL) was added to a pre-stirred solution ethyl 2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.5 g, 1.27 mmol) in a mixture of methanol:THF (1:1) (14 mL) and the resulting reaction mixture was heated to 60 °C for 4 h. The reaction progress was monitored by TLC. The reaction mixture was cooled and poured into ice cold water (30 mL) and was acidified with 1N HCl to pH~2. The crude product was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water (30 mL), brine (30 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.350 g, 65%) as an off-white solid. This crude product was used for next step without any further purification. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.3. [M+H]⁺ (m/z): 366.1

Synthesis of 2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (cpd 265).



[0244] *Step 1:* To a stirred solution of benzoquinone (1.5 g, 13.8 mmol) in IPA (50 mL) was added ZnCl₂ (9.4 g, 69.44 mmol) followed by the addition of methyl 3-cyclopropyl-3-oxopropanoate (7.8 g, 55.55 mmol) at RT. The reaction mixture was stirred for 6 h at reflux, the reaction progress was monitored by TLC. Ice cold water was added to the reaction mixture and the mixture was then extracted with ethyl acetate (2 x 300 mL). The combined extracts were washed with brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material (3 g). The crude material was purified by column chromatography using silica gel (100-200 mesh) and 20% ethyl acetate in pet ether as an eluent to afford methyl 2-cyclopropyl-5-hydroxybenzofuran-3-carboxylate (800 mg, 74%) as a brown solid. TLC system: 50% ethyl acetate in pet-ether; Rf: 0.63.


[0245] *Step 2:* To a stirred solution of methyl 2-cyclopropyl-5-hydroxybenzofuran-3-carboxylate (300 mg, 1.29 mmol) in CH₃CN (25 mL) was added Cs₂CO₃ (1.2 g, 3.87 mmol) followed by the addition of (4-methylthiazol-5-yl)methyl methanesulfonate (370 mg, 1.93 mmol) at 0 °C under an argon atmosphere. The reaction mixture was stirred for 16 h at 50 °C. The reaction progress was monitored by TLC. Solvents were removed, ice cold water was added to the reaction mixture and the mixture was extracted with ethyl acetate (2 x 100 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material (400 mg). The crude was purified by column chromatography using silica gel (100-200 mesh) and 25% ethyl acetate in pet ether as an eluent to afford methyl 2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (200 mg, 45%) as a brown solid. TLC system: 50% ethyl acetate in pet-ether; Rf: 0.42.

[0246] *Step 3:* To a stirred solution of methyl 2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (200 mg, 0.583 mmol) in MeOH & THF (1:1, 10 mL) was added 2N NaOH (4 mL) at 0 °C, then the reaction mixture was stirred for 4 h at 50 °C. Reaction progress was monitored by TLC. The reaction mixture was concentrated, acidified to pH ~2 with 1N aq HCl and extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to get crude 2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (120 mg, crude) as an off-white solid. [M+H]⁺ (m/z): 330.1

[0247] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 265**:

Cpd. Nr.	[M+H] ⁺ (m/z)
231	378.1

5 Synthesis of *tert*-butyl 3-(((3-(ethoxycarbonyl)-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidine-1-carboxylate (**cpd 079**), 5-((1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 019**) and 2-methyl-5-(pyrrolidin-3-ylmethoxy)benzofuran-3-carboxylic acid (**cpd 003**).




[0248] *Step 1*: To a cold solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.110 g; 0.5 mmol), *tert*-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (0.148 g; 0.75 mmol) and PS-PPh₃ (loading ~1.83 mmol/g; 0.546 g; 1 mmol) in THF (4 mL by mmol of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate) was slowly added a solution of DIAD (0.148 mL; 0.75 mmol) in THF (0.4 mL). The RM was stirred at RT for 18h and the volatiles were removed under reduced pressure. The crude material was purified by FCC on silica gel using a gradient of DCM (0% to 100%) in heptane to furnish 0.057 g (28%) of *tert*-butyl 3-(((3-(ethoxycarbonyl)-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidine-1-carboxylate (**cpd 079**).

15 [0249] *Step 2* : To a solution of *tert*-butyl 3-(((3-(ethoxycarbonyl)-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidine-1-carboxylate (**cpd 079**) (0.057 g; 0.141 mmol) in a mixture of MeOH-EtOH (2:1; 4.2 mL) was added an aq. solution of NaOH (1 N; 4.2 mL; 4.2 mmol) and the RM was heated under reflux for 18h. After cooling, the volatiles were removed under reduced pressure and the remaining residue was solubilized in water. The mixture was acidified with an aq. solution of HCl (6 N) until pH~2. The white precipitate was washed with water and dried under high vacuum to furnish 0.052 g (98%) of 5-((1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 019**).

[0250] *Step 3* : To a solution of 5-((1-(*tert*-butoxycarbonyl)pyrrolidin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (**cpd 019**) (0.050 g; 0.133 mmol) in THF (1 mL) was added a solution of HCl (4 N in dioxane; 1 mL) and the RM was stirred for 18h. The volatiles were removed under reduced pressure and the remaining residue was dried under high vacuum to furnish 0.029 g (70%) of 3-(((3-carboxy-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidin-1-ium chloride (**cpd 003**).

[0251] **Cpd 015** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 019**.

30 Synthesis of 2-methyl-N-(1-methylpiperidin-4-yl)-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxamide (**cpd 069**).




[0252] *Step 1* : HATU (235 mg; 0.62 mmol) was added to a solution of 2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 018**) (140 mg; 0.41 mmol) and DIPEA (0.21 mL; 1.2 mmol) in DCM (5 mL). After 4h at RT, 1-methylpiperidin-4-amine (**I-7**) (59 mg; 0.51 mmol) was added and the RM was stirred overnight. The RM was then diluted with DCM and washed successively with a sat. solution of sodium hydrogen carbonate and brine. The organic layer was dried over magnesium sulfate and filtered. The volatiles were removed under reduced pressure and the crude material was purified by FCC on silica gel using a gradient of MeOH (0% to 20%) in DCM to afford 128 mg (71%) of 2-methyl-N-(1-methylpiperidin-4-yl)-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxamide (**cpd 069**).

[0253] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) to **cpd 069**:

Cpd 037, 039, 047, 049, 052, 054, 058, 059, 060, 061, 072, 078, 097, 098, 104, 107, 109, 117, 119, 128, 129, 132 – En1, 132 – En2, 133, 135 – En1, 135 – En 1, 139, 142, 143, 146, 148 – En1, 148 – En2, 150, 152, 154, 156, 158, 159 – En1, 159 – En2, 161, 167, racemic 170, 171, 178, 181, 192, 200, racemic 203, 204, 206, 270 – En 1, 270 – En 2, 274, 275, 308, 309, 312, 314, 315 – En 1, 315 – En 2, 316 – En 1, 316 – En 2, 317 – En 1, 317 – En 2, 322, 323, 331, 334, 337, 339, 341, 343, 344, 345, 346, 351, 352, 357, 358, 359, 370, 371, 372, 373, 374, 384, 385, 390, 391, 392, 393, 394, 399, 400, 401 – En 1, 401 – En 2, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 481, 482, 483, 484, 485, 486, 489 – En 1, 489 – En 2, 490 – En 1, 490 – En 2, 491 – En 1, 491 – En 2, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 504, 505, 506, 507, 523, 524, 525, 526, 527, 528, 529, 531 – En 1, 531 – En 2, 532 – En 1, 532 – En 2, 533 – En 1, 533 – En 2, 534 – En 1, 534 – En 2, 535 – En 1, 535 – En 2, 536 – En 1, 536 – En 2, 537, 574, 576, 602, 603, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, Cpd 623 – En 1, Cpd 623 – En 2, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 641 – En 1, 641 – En 2, 642 – En 1, 642 – En 2, 643 – En 1, 643 – En 2, 646 – En 1, 646 – En 2, 647 – En 1, 647 – En 2, 648 – En 1, 648 – En 2, 649, 651, 652, 659, 660, 661 – En 1, 661 – En 2, 664, 665, 666, 668, 670, 672, 674, 676, 678, 680, 682, 683, 684, 685, 686, 688, 690, 692, 694, 695, 696, 697, 698, 700, 702, 704, 705, 706, 708, 710, 711, 712, 714, 715, 716, 718, 721, 722 – En 1, 722 – En 2, 723 – En 1, 723 – En 2, 724 – En 1, 724 – En 2, 726 – En 1, 726 – En 2, 727 – En 1, 727 – En 2, 727 – En 3, 727 – En 4, 738 – En 1, 738 – En 2, 739 – En 1, 739 – En 2, 741

Synthesis of 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxamide (cpd 035**)**



[0254] *Step 1*: Oxalyl chloride (0.300 mL; 2.96 mmol) and DMF (2 drops) were added to a mixture of 2-methyl-


5-(thiophen-3-ylmethoxy)benzofuran-3-carboxylic acid (**Cpd 011**) (100 mg; 0.35 mmol) in DCM (5 mL). The resulting mixture was stirred for 4 h. The RM was concentrated under reduced pressure to afford 2-methyl-5-(thiophen-3-ylmethoxy)benzofuran-3-carbonyl chloride.

[0255] *Step 2:* A solution of 2-methyl-5-(thiophen-3-ylmethoxy)benzofuran-3-carbonyl chloride dissolved in DCM (3 mL) was added to a mixture of 3-aminopyrrolidin-2-one (0.052 g; 0.520 mmol) and DIPEA (0.121 mL; 0.520 mmol). The RM was stirred at RT for 18h. The solid formed was filtered off and purified by FCC on silica gel using a gradient of MeOH (0% to 20%) in DCM to afford 0.023 g (18%) 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxamide (**cpd 035**).

[0256] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 035**:

Cpd 036, 080, 081, 082, 083, 084 and 085.

Synthesis of tert-butyl (S)-3-(2-methyl-5-((5-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (**cpd 073**).




[0257] *Step 1:* Tert-butyl (S)-3-aminopyrrolidine-1-carboxylate (1.1 g; 5.7 mmol) was added to a solution of 5-hydroxy-2-methylbenzofuran-3-carboxylic acid (1 g; 5.2 mmol), HATU (1.98 g; 5.2 mmol) and DIPEA (2.7 mL; 15.6 mmol) in DMF (10 mL). After 60 h, the reaction was concentrated under reduced pressure. The residue was partitioned between water and EtOAc. After separation, the aq. layer was extracted twice with EtOAc. Combined EtOAc extracts were dried over magnesium sulphate, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of MeOH (0 to 6%) in DCM to afford 0.94 g (50%) of tert-butyl-(S)-3-(5-hydroxy-2-methylbenzofuran-3-carboxamido)pyrrolidine-1-carboxylate. M/Z(+): 361 (M+H). M/Z(-): 359 (M-H). ¹H NMR (DMSO-d₆, 300 MHz) δ ppm: 9.26 (s, 1H), 8.17 (d, J = 6.4 Hz, 1H), 7.32 (d, J = 9.0 Hz, 1H), 6.99 (d, J = 1.88 Hz, 1H), 6.70 (dd, J = 8.9, 2.1 Hz, 1H), 4.35-4.50 (m, 1H), 3.51-3.3.65 (m, 1H), 3.35-3.49 (m, 1H), 3.15-3.31 (m, 1H), 2.53 (s., 3H), 2.02 - 2.19 (m, 1H), 1.84 - 1.99 (m, 1H), 1.41 (s, 9H).

[0258] *Step 2:* Tributylphosphine (0.155 mL; 0.583 mmol) was added dropwise to a stirred mixture of tert-butyl-(S)-3-(5-hydroxy-2-methylbenzofuran-3-carboxamido)pyrrolidine-1-carboxylate (0.150 g; 0.416 mmol), (5-methylpyridin-3-yl)methanol (0.081 g; 0.624 mmol) and ADDP (0.150 g; 0.583 mmol) in dry THF (5 mL) under argon. The mixture was stirred for 2h and then the reaction was concentrated under reduced pressure. The residue was purified twice by FCC on silica gel using a gradient of MeOH (0-6%) in DCM for the first time and a gradient of MeOH (0-4%) in EtOAc for the second time to afford 0.113 g (58%) of tert-butyl (S)-3-(2-methyl-5-((5-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (**cpd 073**).

[0259] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 073**:

Cpd 026, 027, 030, 031, 032, 033, 034, 038, 040, 042, 043, 044, 046, 051, 057, 064, 065, 066, 077, 078; 086; 087; 088; 089; 090; 091; 092; 093; 094; 095 and 096.


(S)-2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide (**cpd 028**).



[0260] A solution of hydrogen chloride in 1,4-dioxane (4 M; 4 mL; 16 mmol) was added to a solution of tert-butyl (S)-3-(2-methyl-5-((5-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (**cpd 073**) (0.105 g; 0.22 mmol) in DCM (3 mL). The mixture was stirred overnight at RT and was concentrated under reduced pressure. The residue was then purified by column of supported SiliaBond-PropylSulfonic Acid using a gradient of a solution of 3N ammonia in MeOH (0-100%) in DCM to afford 78 mg (95%) of (S)-2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide (**cpd 028**).

[0261] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 028**:

10 **Cpd 020, 021, 022, 023, 034, 025, 029, 048, 050, 053, 055, 056, 062, 063, 067, 068, 070, 071, 074, 075 and 076.**
Synthesis of 2-methyl-N-(1-methylpiperidin-4-yl)-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxamide (**cpd 041**).



[0262] *Step 1:* 5-(Benzyloxy)-2-methylbenzofuran-3-carboxylic acid (2.6 g; 9.2 mmol), HATU (5.2 g; 13.8 mmol; 1.5) and DIPEA (4.8 mL; 27.6 mmol) were dissolved in DCM (50 mL). After 4 h of stirring at RT, 1-methylpiperidin-4-amine (1.2 mL; 9.7 mmol) was added and the RM was stirred at RT overnight. The RM was diluted in 80 mL of DCM and washed with a sat. solution of sodium hydrogen carbonate and brine. The solvent was removed under reduced pressure. The residue was purified by FCC on silica gel using a gradient of MeOH (0-20%) in DCM to afford 1.4 g (48%) of 5-(benzyloxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide. ¹H NMR (DMSO d₆, 300 MHz) δ ppm 7.89 (d, 1H); 7.50-7.29 (m, 6H); 7.22 (d, 1H); 6.96 (dd, 1H); 5.13 (s, 2H); 3.85-3.65 (m, 1H); 2.75 (br d, 2H); 2.56 (s, 3H); 2.16 (s, 3H); 1.98 (ddd, 2H); 1.85-1.74 (m, 2H); 1.67-1.51 (m, 2H).


[0263] *Step 2:* A suspension of 5-(benzyloxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide (500 mg; 1.32 mmol) and Pd/C (70 mg, 0.065 mmol) in THF (13 mL) was stirred at RT under an atmospheric pressure of hydrogen until disappearance of the starting material. The RM was then filtered through a pad of Celite and the filtrate was evaporated under reduced pressure to afford 350 mg (92%) of 5-hydroxy-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide, which was used without further purification. ¹H NMR (DMSO d₆, 300 MHz) δ (ppm): 9.25 (s, 1H); 7.84 (d, 1H); 7.31 (d, 1H); 6.99 (d, 1H); 6.69 (dd, 1H); 3.80-3.65 (m, 1H); 2.80-2.70 (m, 2H); 2.52 (s, 3H); 2.16 (s, 3H); 2.04-1.89 (m, 2H); 1.84-1.74 (m, 2H); 1.58 (ddd, 2H).

30 [0264] *Step 3:* To a cold solution of 5-hydroxy-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide (75 mg, 0.26 mmol), thiophen-2-ylmethanol (45 mg; 0.39 mmol) and PS-PPh₃ (1.8 mmol/g; 289 mg; 0.52 mmol) in THF (3 mL) was slowly added a solution of DIAD (75 μL; 0.39 mmol) in THF (0.8 mL). The RM was stirred

at RT for 18h and the volatiles were removed under reduced pressure. The crude material was purified by preparative HPLC (method H1) to furnish 8 mg (8%) of 2-methyl-N-(1-methylpiperidin-4-yl)-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxamide (**cpd 041**).

[0265] **Cpd 045** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 041**.

Synthesis of N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 105**)




Step 1: To a stirred solution **cpd 101** (250 mg, 0.71 mmol) in DCM (50 mL), DIPEA (0.3 mL, 1.78 mmol), HATU (297 mg, 0.78 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1-carboxylate (237 mg, 1.07 mmol) in DCM (1 mL) were added at RT. The RM was stirred for 18 h. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with DCM (300 mL), washed with sat. NaHCO₃ (50 mL), water (2 x 50 mL) and brine solution (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by Grace FCC using eluent 50% EtOAc-Pet ether to afford tert-butyl 3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (350 mg, 88%).

[0266] *Step 2:* To a stirred solution of tert-butyl 3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (350 mg, 0.63 mmol) in DCM (20 mL), TFA (1 mL) was added at 0 °C. The RM was stirred for 18 h at RT. Reaction progress was monitored by TLC. The RM was concentrated and diluted with DCM (300 mL), washed with sat. NaHCO₃ (2 x 50 mL) and brine solution (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with Et₂O (10 mL) to afford **cpd 105** (250 mg, 77% over 2 steps). A preparative chiral SFC was performed to provide **cpd 105 - En 1** and **cpd 105 - En 2**.

[0267] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 105**:

Cpd 103 – En1, 103 – En2, 106 – En1, 106 – En2, 111 – En1, 111 – En2, 115 – En1, 115 – En2, 125 – En1, 125 – En2, 205 – En1, 205 – En2, 207 – En1, 207 – En2, 173, 189, 190, 310 – En 1, 310 – En 2, 313 – En 1, 313 – En 2, 336 – En 1, 336 – En 2, 338 – En 1, 338 – En 2, 342 – En 1, 342 – En 2, 538 – En 1, 539 – En 1, 539 – En 2, 540 – En 1, 540 – En 2, 541 – En 1, 541 – En 2, 542 – En 1, 542 – En 2, 543 – En 1, 543 – En 2, 544 – En 1, 544 – En 2, 545 – En 1, 545 – En 2, 546 – En 1, 547 – En 1, 547 – En 2, 548 – En 1, 548 – En 2, 549 – En 1, 549 – En 2, 550 – En 1, 550 – En 2, 551 – En 1, 551 – En 2, 552 – En 1, 552 – En 2, 553 – En 1, 553 – En 2, 554 – En 1, 554 – En 2, 555 – En 1, 555 – En 2, 556 – En 1, 556 – En 2, 557 – En 1, 557 – En 2, 558 – En 1, 558 – En 2, 559 – En 1, 559 – En 2, 560 – En 1, 560 – En 2, 561 – En 1, 561 – En 2, 562 – En 1, 562 – En 2, 563 – En 1, 563 – En 2, 564 – En 1, 564 – En 2, 565 – En 1, 565 – En 2, 566 – En 1, 566 – En 2, 567 – En 1, 567 – En 2, 568 – En 1, 568 – En 2, 569 – En 1, 569 – En 2, 570 – En 1, 570 – En 2, 571 – En 1, 571 – En 2, 572 – En 1, 572 – En 2, 573 – En 1, 573 – En 2, 635 – En 1, 635 – En 2, 636 – En 1, 636 – En 2, 637 – En 1, 637 – En 2, 638 – En 1, 638 – En 2, 639 – En 1, 639 – En 2, 663, 717.


Synthesis of N-(1-((dimethylamino)methyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (cpd 108).



- [0268] *Step 1*: 37% Formaldehyde in water (0.21 mL, 2.5 mmol) was added to a pre-stirred solution of **cpd 137** (100 mg, 0.26 mmol) in MeOH (10 mL) at 0°C under argon atmosphere. Then, glacial acetic acid (2 drops) and NaCNBH₃ (32.6 mg, 0.51 mmol) were added to the reaction. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was poured into water (25 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layer was washed with sat. NaHCO₃ (25 mL), water (25 mL) and brine (25 mL), dried over Na₂SO₄ and excess solvent was removed under reduced pressure. The crude product was purified by flash chromatography using 0-50% acetonitrile in 0.1% FA as an eluent followed by reverse phase prep-HPLC to afford **cpd 108** (55 mg, 51%).

[0269] **Cpd 140** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 108**:

- 15 Synthesis of N-(3,3-difluoropiperidin-4-yl)-4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (cpd 112)



- [0270] *Step 1*: 2-(Trifluoromethyl)pyridin-3-yl)methanol (2.23 g, 12.6 mmol), ADDP (2.96 g, 11.7 mmol) and tri-n-butylphosphine (2.37 g, 11.7 mmol) were added to a mixture of ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (2.0 g, 8.4 mmol) in THF (50 mL) at 0°C under argon atmosphere. The RM was allowed to attain RT and was stirred for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine (2 x 100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 10-20% EtOAc in pet-ether as an eluent followed by reverse phase prep-HPLC to afford a mixture of ethyl 4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (300 mg, 8%) and ethyl 6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (400 mg, 11%).

- [0271] *Step 2*: 2N NaOH (10 mL) was added to a solution of ethyl 4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (250 mg, 0.62 mmol) in a mixture of MeOH (15 mL) and THF (5 mL) at RT. The resulting RM was heated at 80°C for 3 h. The reaction progress was monitored


by TLC. The RM was cooled to RT, poured into ice cold water (50 mL) and acidified with 1N HCl to pH~2. The crude product was extracted with EtOAc (3 x 50 mL), washed with water (100 mL), followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (220 mg, 95%). The crude product was used

5 for next step without purification.

[0272] *Step 3* : To a solution of a mixture of 4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (200 mg, 0.54 mmol) and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (191 mg, 0.81 mmol) in DMF (15 mL) was added DIPEA (0.2 mL, 1.08 mmol) followed by HATU (412 mg, 1.08 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT and stirred for 1 h. The reaction progress was monitored by TLC. The RM was diluted with ice cold water (50 mL) and filtered. The solid thus obtained was washed with water (50 mL) and dried under reduced pressure to afford tert-butyl 3,3-difluoro-4-(4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate (250 mg, 78%).

[0273] *Step 4* : 4M HCl in dioxane (5 mL) was added dropwise to a solution of tert-butyl 3,3-difluoro-4-(4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate (0.25 g, 0.42 mmol) in DCM (20 mL) at 0°C under an argon atmosphere. The RM was warmed to RT and stirred for 5 h. The reaction progress was monitored by TLC. The excess solvents were evaporated in vacuo and the residue was cooled to 0°C, basified with sat. NaHCO₃ to pH ~9 and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford **cpd 112** (200 mg, 96%). A preparative chiral SFC was performed on the racemic mixture of **cpd 112** to afford **cpd 112 – En 1** and **cpd 112 – En 2**.

Synthesis of N-(3,3-difluoropiperidin-4-yl)-6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 113**) and N-(3,3-difluoropiperidin-4-yl)-7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 176**)



25

[0274] *Step 1*: To a pre-stirred solution of CAN (27.41 g, 50.00 mmol) in water (60 mL) was added 2-fluorobenzene-1,4-diol (3.0 g, 23.80 mmol) at 0°C. The resulting RM was stirred at RT for 4 h. The reaction progress was monitored by TLC. The organic compound was extracted with Et₂O (3 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and filtered. The clear filtrate was

passed through a silica gel column, eluted with diethyl ether and the collected fractions were evaporated in vacuo to afford 2-fluorocyclohexa-2,5-diene-1,4-dione (2.5 g, 84%).

[0275] *Step 2:* To a pre-stirred solution of 2-fluorocyclohexa-2,5-diene-1,4-dione (2.5 g, 20.16 mmol) in toluene (30 mL) was added ethyl 3-oxobutanoate (7.86 g, 60.48 mmol) followed by anhydrous ZnCl_2 (3.29 g, 24.19 mmol) at RT under argon atmosphere. The resulting RM was heated to reflux and maintained at this temperature for 16 h using a Dean-Stark apparatus. The reaction progress was monitored by TLC. The RM was cooled to RT, filtered through a celite pad and the celite pad was washed with EtOAc (70 mL). The combined clear filtrate was concentrated under reduced pressure. The crude product was purified by FCC over silica gel using 0-10% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 7-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.8 g, 21%).

[0276] *Step 3:* (2-(Trifluoromethyl)pyridin-3-yl)methanol (1.11 g, 6.30 mmol), ADDP (1.48 g, 5.88 mmol) and tri-*n*-butylphosphine (1.38 mL, 5.88 mmol) were added sequentially to a pre-stirred solution of mixture of ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 4.20 mmol) in THF (30 mL) at RT under argon atmosphere. The RM was stirred for 2 h at the same temperature. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was sequentially washed with water (50 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.1 g, 66%). The crude product was used for further step without purification.

[0277] *Step 4:* A solution of NaOH (0.44 g, 11.08 mmol) in water (8 mL) was added dropwise to a pre-stirred solution of a mixture of ethyl 6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.1 g, 2.77 mmol) in a mixture of MeOH (15 mL) and THF (7 mL) at RT. The resulting RM was heated to 60°C and maintained for 4 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (50 mL) and acidified with 1N HCl to a pH~2. The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) followed by brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford a mixture of 6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 99%). This crude product was used for next step without purification.

[0278] *Step 5:* To a pre-stirred solution of mixture of 6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 2.71 mmol) and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (0.74 g, 3.25 mmol) in DMF (20 mL) was added DIPEA (1.45 mL, 8.13 mmol) followed by HATU (2.05 g, 5.42 mmol) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stir for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL) and the organic compound was extracted with EtOAc (2 x 70 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified


by column chromatography over silica using 0-55% EtOAc and pet-ether as an eluent to afford a mixture of tert-butyl 3,3-difluoro-4-(6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate and tert-butyl 3,3-difluoro-4-(7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate (1.0 g, 62%).

- 5 [0279] *Step 6:* 4.0 M HCl in dioxane (13.62 mL, 13.62 mmol) was added dropwise to a pre-stirred solution of mixture of tert-butyl 4-(6-chloro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate and tert-butyl 4-(7-chloro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (1.0 g, 1.70 mmol) in DCM (15 mL) at 0°C. The RM was allowed to attain RT and stirred for 6 h. The reaction progress was monitored by TLC. The RM was concentrated under reduced pressure, the residue was basified with sat. NaHCO₃ (100 mL) and the organic compound was extracted with 10% MeOH in DCM (3 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as an eluent to afford a mixture **cpd 113** and **cpd 176** (0.72 g, 87%). A preparative chiral SFC
- 10 was performed on the mixture of racemic **cpd 113** and racemic **cpd 176** to provide **cpd 113 - En 1**, **cpd 113 - En 2**, **cpd 176 - En 1** and **cpd 176 - En 2**.

[0280] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for the synthesis of **cpd. 113** and **cpd. 176**: **Cpd. 572 - En 1**, **572 - En 2**, **573 - En 1**, **573 - En 2**.


20

Synthesis of N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 114**)



- [0281] *Step 1:* To a pre-stirred solution of **cpd 102** (0.3 g, 0.989 mmol) and 2-(1-aminocyclobutyl)ethan-1-ol (0.148 g, 1.285 mmol) in DMF (10 mL) was added DIPEA (0.675 mL, 3.959 mmol) followed by HATU (0.752 g, 1.978 mmol) at 0°C under argon atmosphere. The RM was stirred for 1 h at same temperature. The reaction progress was monitored by LC-MS. The RM was diluted with sat. NaHCO₃ (80 mL) and then the crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified
- 25 by reverse phase prep-HPLC to afford **cpd 114** (0.18 g, 45%)
- 30

Synthesis of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)benzofuran-3-carboxamide (**cpd 116**)




[0282] *Step 1:* To a solution of **cpd 102** (600 mg, 1.98 mmol) in DCM (10 ml) at 0 °C, DIPEA (1.77 ml, 9.90 mmol, 5 eq) was added dropwise at 0 °C and the RM stirred for 10 min. Tert-Butyl 3-aminopyrrolidine-1-carboxylate (552 mg, 2.97 mmol) and HATU (1.12 g, 2.97 mmol) were added to the RM. After completion of addition, the ice bath was removed and the RM was stirred at RT for 16 h. Reaction progress was monitored by TLC. The RM was extracted with DCM (2 X 100 ml), the combined organic layer was washed with water (100 mL) and brine (100 ml), dried over anhydrous Na₂SO₄, filtered, and concentrated to afford crude 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.03 g).

[0283] *Step 2:* To a solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 2.12 mmol) in DCM (15 ml) at 0 °C, 4M aq. HCl (3 ml, 5.3 mmol) was added dropwise over 5 min at 0 °C and then the ice bath was removed. The RM was stirred at RT for 16 h. Reaction progress was monitored by TLC. The reaction was directly concentrated to get the crude product, which was washed with Et₂O (15 ml) to afford pure 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide hydrochloride (700 mg, 94%).

[0284] *Step 3:* To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide hydrochloride (700 mg, 1.71 mmol) in acetonitrile (20 ml), Cs₂CO₃ (328 mg, 5.13 mmol) and CF₂CH₂OTf (598 mg, 2.57 mmol) were added at RT. The resulting mixture was stirred for 3 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was cooled to 0 °C, quenched with ice-cold water (100 ml), and extracted with EtOAc (2x100 ml). The combined organic layer was washed with water (120 ml) and brine solution (120 ml), dried over anhydrous Na₂SO₄, and concentrated to afford a residue. This residue was purified by FCC using 80% EtOAc in pet ether as eluent to afford **cpd 116** (280 mg, 74%). **Cpd 116** was further purified by normal phase SFC-Prep to yield 190 mg (24 %) of **cpd 116**. A preparative chiral SFC was performed on the racemic mixture of **cpd 116** to afford **cpd 116 En 1** and **cpd 116 En 2**.

25 Synthesis of N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 120**)




[0285] *Step 1:* To a suspension of 60% NaH (314 g, 7.852 mmol) in DMF (10 mL) under argon atmosphere at 0 °C, **cpd 064** (850 mg, 1.963 mmol) in DMF (5 mL) and methyl 2-bromoacetate (450.4 mg, 2.944 mmol) were added at 0 °C. The RM was stirred at RT for 3 h. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with ice-water (150 mL), extracted with EtOAc (3 x 300 mL), and the combined organic layer was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by FCC to afford the crude product (650 mg).

[0286] *Step 2*: To a solution of methyl 2-(3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidin-1-yl)acetate (600 mg, 1.18 mmol) in MeOH (15 mL) under an argon atmosphere at 0 °C, NaBH₄ (136.5 mg, 4.15 mmol) was added portionwise and then the solution was heated to 80 °C for 3 h. Reaction progress was monitored by TLC. After completion of the reaction, the RM was quenched with acetone (25 mL) and ice-water (150 mL), extracted with EtOAc (3 x 300 mL), and the combined organic layer was washed with brine solution (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by FCC to afford **cpd 120** (280 mg, 30% over 2 steps). A preparative chiral SFC was performed on racemate **cpd 120** to afford **cpd 120 – En 1** and **cpd 120 – En 2**.

[0287] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 120 – En 1** and **cpd 120 – En 2**:

Cpd 134 – En1, 134 – En2, 151 – En1 and 151 – En2.

Synthesis of N-(3-(2-hydroxyethyl)tetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 121**)



[0288] *Step 1*: To a stirred solution of dihydrofuran-3(2H)-one (5.0 g, 58.11 mmol) in toluene (60 mL), was added Ph₃P=CHC(O)OCH₂CH₃ (23.22 mL, 69.74 mmol), and then the RM was heated to 110 °C and stirred for 16 h. Reaction progress was monitored by TLC. After completion of the reaction, the RM was cooled to RT, and concentrated to yield the crude product, which was purified by Grace FCC using 20% EtOAc in Pet ether as eluent to afford ethyl (Z)-2-(dihydrofuran-3(2H)-ylidene)acetate (7.2 g, 80%).

[0289] *Step 2*: To a stirred solution of ethyl (Z)-2-(dihydrofuran-3(2H)-ylidene)acetate (5.0 g, 32.05 mmol) in toluene (60 mL), was added methanolic NH₃ (7M, 25 mL, 128.2 mmol), and then the RM was heated to 80 °C and stirred for 16 h in a steel bomb. The reaction progress was monitored by TLC. The RM was cooled to RT and concentrated to give the crude methyl 2-(3-(aminotetrahydrofuran-3-yl)acetate (4.7 g, 92%).


[0290] *Step 3*: To a stirred solution of **cpd 102** (800 mg, 2.64 mmol) in DCM (30 mL), were added DIPEA (1.89 mL, 10.56 mmol) and HATU (1.5 g, 3.96 mmol), followed by addition of methyl 2-(3-(aminotetrahydrofuran-3-yl)acetate (629 mg, 3.96 mmol) at 0 °C and the RM was stirred for 2 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with water (100 mL), and extracted with DCM (100 mL). The combined organic layer was washed with water (30 mL) and brine solution (25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to afford the crude product which was purified by Grace FCC using 3% MeOH in DCM as eluent to afford methyl 2-(3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydrofuran-3-yl)acetate (650 mg, 55%).

[0291] *Step 4*: To a stirred solution of methyl 2-(3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydrofuran-3-yl)acetate (650 mg, 1.463 mmol) in THF (20 mL) at -30 °C, was added LAH powder (61.19 mg, 1.61 mmol) portionwise. The RM was slowly warmed to RT and stirred for 2 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was quenched with sat. Na₂SO₄ solution (100 mL), and extracted with EtOAc (100 mL). The combined organic layer was washed with water (30 mL) and brine solution (25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to afford the crude product which was purified by Grace FCC using 6% MeOH in CH₂Cl₂ as eluent to afford **cpd 121** (210 mg, 35%). A preparative

chiral SFC was performed on racemic **cpd 121** to provide **cpd 121 - En 1** and **cpd 121 - En 2**.

[0292] **Cpd 126 - En 1** and **cpd 126 - En 2** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 121 - En 1** and **cpd 121 - En 2**.

5 Synthesis of 7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide (**cpd 122**) and 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 182**)



[0293] *Step 1:* (4-Methylthiazol-5-yl)methanol (0.65 g, 5.04 mmol), ADDP (1.18 g, 4.70 mmol) and tri-
 10 butylphosphine (1.15 mL, 4.70 mmol) were added sequentially to a pre-stirred solution of ethyl 7-fluoro-5-
 hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate
 (0.8 g, 3.36 mmol) in THF (30 mL) at 0°C under an argon atmosphere. The RM was allowed to attain RT and
 stirred for 2 h. The reaction progress was monitored by TLC. The RM was poured into water (50 mL) and extracted
 with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL). The
 organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was
 15 purified by FCC over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 6-fluoro-
 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-fluoro-2-methyl-5-((4-
 methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.7 g, 59%).

[0294] *Step 2:* A solution of NaOH (0.27g, 6.87 mmol) in water (5 mL) was added to a pre-stirred solution of
 ethyl 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate compound and ethyl 7-
 20 fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.6 g, 1.71 mmol) in a mixture of
 MeOH (6 mL) and THF (3 mL) at RT. The resulting RM was heated to 60°C and maintained at this temperature
 for 4 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (50
 mL), and acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (2 x 50 mL). The combined
 organic layer was washed with water (2 x 50 mL), followed by brine (50 mL), dried over anhydrous Na₂SO₄ and
 25 concentrated under reduced pressure to afford a mixture of 6-fluoro-2-methyl-5-((4-methylthiazol-5-
 yl)methoxy)benzofuran-3-carboxylic acid (**cpd 243**) and 7-fluoro-2-methyl-5-((4-methylthiazol-5-
 yl)methoxy)benzofuran-3-carboxylic acid (**cpd 245**) (0.6 g, 92%).

[0295] *Step 3:* To a pre-stirred solution of a mixture of 6-fluoro-2-methyl-5-((4-methylthiazol-5-
 yl)methoxy)benzofuran-3-carboxylic acid and 7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-
 3-carboxylic acid (600 mg, 1.86 mmol), and methyl 4-aminotetrahydro-2H-pyran-4-carboxylate (0.356 g, 2.24
 30 mmol) in DMF (10 mL) was added DIPEA (0.96 mL, 5.60 mmol) followed by HATU (1.41 g, 3.72 mmol) at 0°C
 under an argon atmosphere. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was
 monitored by TLC. The RM was diluted with water (50 mL) and then the organic compound was extracted with


EtOAc (2 x 50 mL), and washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-55% EtOAc and pet ether as an eluent to afford a mixture of methyl 4-(6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido) tetrahydro-2H-pyran-4-carboxylate and methyl 4-(7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)-tetrahydro-2H-pyran-4-carboxylate (0.5 g, 57%).

[0296] *Step 4:* NaBH₄ (1.02 g, 27.05 mmol) was added portionwise to a pre-stirred solution of a mixture of methyl 4-(6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido) tetrahydro-2H-pyran-4-carboxylate and methyl 4-(7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylate (0.5 g, 1.08 mmol) in a mixture of MeOH (10 mL) and THF (5 mL) at 0°C. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and the organic compound was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as an eluent to afford a mixture of **cpd 122** and **cpd 182** (0.28 g, 59%). A preparative chiral SFC was performed on a mixture of **cpd 111** and **182** to provide **cpd 122** and **cpd 182**.

[0297] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described in the synthesis of **cpd. 112** and **cpd. 182**: **Cpd. 360 - En 1, 360 - En 2, 361, 362, 364, 365 - En 1, 365 - En 2, 366, 367, 369, 587, 588**.

[0298] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for step 3 in the synthesis of **cpd. 243** and **cpd. 245**: **Cpds. 244, 246**.

Synthesis of N-(4,4-difluoro-1-methylpyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide (**cpd 124**)




[0299] *Step 1:* To a stirred solution of **cpd 105** (400 mg, 0.88 mmol) in MeOH (20 mL), 37% HCHO (0.5 mL) and acetic acid (0.1 mL) were added at 0 °C. The RM was stirred for 30 min at 0 °C and then added NaCNBH₃ (109 mg, 1.76 mmol) at 0 °C. The RM was stirred for 18 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was quenched with water (50 mL). The product was extracted with EtOAc (3 x 100 mL), and the combined organic layer was washed with sat. NaHCO₃ (50 mL) and brine solution (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with Et₂O (10 mL) to afford **cpd 124** (370 mg, 90%). A preparative chiral SFC was performed on the racemic mixture of **cpd 124** to provide **cpd 124 - En 1** and **cpd 124 - En 2**.

[0300] The following compounds were prepared in a manner similar (use of appropriate reagents and purification

methods known to the person skilled in the art) to **cpd 105**:


Cpd 110 – En1, 110 – En2, 118 – En1, 118 – En2, 123 – En1, 123 – En2, 130 – En1, 130 – En2, 131 – En1, 131 – En2, 141 – En1, 141 – En2, 163 – En1 and 163 – En2.

Synthesis of N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 127**)




[0301] *Step 1*: To a pre-stirred solution of **cpd 101** (0.52 g, 1.480 mmol) and 2-(1-aminocyclobutyl)ethan-1-ol (0.222 g, 1.924 mmol) in DMF (20 mL) was added DIPEA (1.01 mL, 5.920 mmol) followed by HATU (1.13 g, 2.96 mmol) at 0°C under an argon atmosphere. The RM was stirred for 2 h at same temperature. The reaction progress was monitored by LC-MS. The RM was diluted with sat. NaHCO₃ (100 mL) and then the crude product was extracted with EtOAc (2 x 60 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by reverse phase prep-HPLC to afford **cpd 127** (0.110 g, 16%).

Synthesis of N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 136**)



[0302] A solution of N-(1-(cyanomethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (450 mg, 1.048 mmol) in MeOH (10 mL) was added to a slurry of Raney-Ni (200 mg) in MeOH (10 mL), dropwise at RT. The RM was stirred under H₂ balloon pressure for 16 h. The RM was filtered through a celite pad and the celite pad was washed with MeOH (80 mL). The combined clear filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase prep-HPLC to afford **cpd 136** (0.3 g, 66%).

Synthesis of N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 137**)




[0303] *Step 1*: To a solution of **cpd 102** (2.0 g, 6.6 mmol) and 1-aminocyclobutane-1-carbonitrile (950 mg, 9.9 mmol) in DMF (20 mL) was added DIPEA (2.43 mL, 13.2 mmol) followed by HATU (5.0 g, 13.2 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT and stirred for 1 h. The reaction progress was monitored by TLC. The RM was quenched with cold water (120 mL), the precipitated solid was filtered and dried under reduced pressure to afford N-(1-(cyanocyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-

carboxamide (1.7 g, 68%).

[0304] *Step 2:* To a pre-stirred solution of N-(1-cyanocyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (500 mg, 1.3 mmol) in a mixture of MeOH (10 mL) and THF (5 mL) was added $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ (468 mg, 1.96 mmol) followed by NaBH_4 (150 mg, 3.9 mmol) at 0°C. The RM was stirred for 30 min at same temperature. The reaction progress was monitored by LC-MS. The RM was poured into water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0-20% acetonitrile in 0.1% FA as an eluent, followed by reverse phase prep-HPLC to afford **cpd 137** (80 mg, 16%).

Synthesis of 2-methyl-N-(1H-pyrazol-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 138**)




[0305] *Step 1:* To a stirred solution of 1H-pyrazol-3-amine (5 g, 60.24 mmol) in DMF (50 mL), was added NaH (60% in oil) (4.819 g, 120.48 mmol) at 0 °C. The RM was stirred for 30 min at 0 °C and SEMCl (11.7 mL, 66.26 mmol) was added at 0 °C. The RM was stirred for 1 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with EtOAc (700 mL). The organic layer was washed with water (5 x 100 mL) and brine (100 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated to give the crude product. The crude product was purified by Grace FCC using 100% EtOAc as eluent to afford 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-amine (2.3 g, 18%).

[0306] *Step 2:* To a stirred solution of **cpd 101** (200 mg, 0.56 mmol) in DCM (10 mL), was added DIPEA (0.3 mL, 1.71 mmol), HATU (325 mg, 0.85 mmol) and 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-amine (182 mg, 0.85 mmol) at RT. The RM was stirred for 18 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with DCM (200 mL), the organic layer was washed with water (2 x 50 mL), sat. NaHCO_3 (50 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated to give the crude product. The residue was purified by Grace FCC using 45% EtOAc in Pet ether as eluent to get 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)benzofuran-3-carboxamide (100 mg, 32%).

[0307] *Step 3:* To a stirred solution of 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)benzofuran-3-carboxamide (100 mg, 0.18 mmol) in DCM (10 mL), TFA (0.5 mL) was added at 0 °C. The RM was stirred for 24 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was poured into ice water (20 mL), basified to pH ~9 using sat. NaHCO_3 solution (20 mL), and the product was extracted with DCM (3 x 50 mL). The combined organic layer was washed with brine solution (50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated to give the crude product. The residue was purified by Grace FCC using 100% EtOAc as eluent to afford **cpd 138**. The product was purified further by HPLC.


Synthesis of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(((2,2,2-trifluoroethyl)amino)methyl)cyclobutyl)-benzofuran-3-carboxamide (cpd 145)




[0308] *Step 1:* 2,2,2-Trifluoroacetaldehyde monohydrate (77% in water, 0.85 mL, 5.1 mmol) was added to a solution of **cpd 137** (200 mg, 0.51 mmol) in MeOH (15 mL) at 0°C under an argon atmosphere. Then, glacial acetic acid (3 drops) and NaCNBH₃ (65 mg, 1.0 mmol) were added to the reaction. The resulting RM was heated at 80°C for 16 h. The RM was cooled to RT, poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with sat. NaHCO₃ (25 mL), water (50 mL) and brine (50 mL), dried over Na₂SO₄ and excess solvent was removed under reduced pressure. The crude product was purified by flash chromatography using 0-50% acetonitrile in 0.1% FA as an eluent followed by reverse phase prep-HPLC to afford **cpd 145** (30 mg, 12%).

[0309] **Cpd 153** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 145**.

Synthesis of N-(4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide (cpd 147)



[0310] *Step 1:* To a stirred solution of 3,6-dioxabicyclo[3.1.0]hexane (0.2 g, 2.27 mmol) in EtOH (10 mL) in a 100 mL steel bomb was added aq. NH₄OH (5 mL), and the steel bomb was closed tightly. The RM was heated up to 80 °C for 18 h in the steel bomb. Reaction progress was monitored by TLC. After completion of the reaction, the RM was concentrated to give the crude product, and the crude product was co-distilled with toluene three times to give 4-aminotetrahydrofuran-3-ol (0.16 g, 65%).




[0311] *Step 2:* To a solution of **cpd 101** (0.35 g, 0.99 mmol) in DCM (20 mL), were added DIPEA (0.91 mL, 4.98 mmol) and HATU (0.568 g, 1.49 mmol), at 0 °C, followed by a solution of 4-aminotetrahydrofuran-3-ol (0.151 g, 1.49 mmol) in DCM, dropwise at 0 °C. Then the RM was stirred for 3 h at RT, and the reaction monitored by TLC. After completion of the reaction, the RM was diluted with water (20 mL), extracted with DCM (3 x 30 mL), and the combined organic layer was washed with water (50 mL) and brine solution (25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to yield the crude product. The crude product was purified by FCC using 60% EtOAc-pet ether as eluent to afford **cpd 147** (0.30 g, 69%). A preparative chiral SFC was performed on racemic **cpd 147** to afford **cpd 147 Dia 1 - En 1** and **cpd 147 Dia 1 - En 2**.

[0312] **Cpd 162 – Dia 1 – En 1**, **162 – Dia 1 – En2**, **386 – En 1**, **386 – En 2**, **387 – En 1**, **387 – En 2**, **388 – En 1**,

388 - En 2, 389 - En 1, 389 - En 2, 653 - En 1, 653 - En 2, 654 - En 1, 654 - En 2, 655 - En 1, 655 - En 2, 656 - En 1, 656 - En 2 were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 147 – Dia 1 - En 1** and **cpd 147 – Dia 1 - En 2**.

Synthesis of 2-methyl-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide (**cpd 149**)




[0313] *Step 1:* To a stirred solution of **cpd 101** (400 mg, 1.14 mmol) in DCM (15 mL), DIPEA (0.5 mL, 2.85 mmol) and HATU (476 mg, 1.25 mmol) were added at RT. The RM was stirred for 5 min at RT and tert-butyl 3-aminopyrrolidine-1-carboxylate (233 mg, 1.25 mmol) was added at RT. The RM was stirred for 18 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was diluted with DCM (200 mL). The organic layer was washed with sat. NaHCO₃ solution (100 mL), water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by Grace FCC using 45% EtOAc in Pet ether as eluent to afford tert-butyl 3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (450 mg, 76%).

[0314] *Step 2:* To a stirred solution of tert-butyl 3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (450 mg, 0.86 mmol) in DCM (10 mL), 4N HCl in dioxane (5 mL) was added at 0 °C. The RM was stirred for 18 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was concentrated and dried to afford 2-methyl-N-(pyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (520 mg, crude product).

[0315] *Step 3:* To a stirred solution of 2-methyl-N-(pyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (500 mg, 1.02 mmol) in CH₃CN (50 mL), Cs₂CO₃ (1.33 g, 4.07 mmol) and CF₃CH₂OTf (472 mg, 2.03 mmol) were added at RT. The RM was heated to 50 °C and stirred for 1 h at 50 °C. Reaction progress was monitored by LCMS. After completion of the reaction, the RM was cooled to RT, diluted with EtOAc (250 mL), washed with water (2 x 50 mL) and brine solution (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by RP-Prep HPLC to afford **cpd 149** (280 mg, 64% over 2 steps). A preparative chiral SFC was performed on racemic **cpd 149** to provide **cpd 149 - En 1** and **cpd 149 - En 2**.

Synthesis of N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 155**) and 2,2,2-trifluoroethyl 3,3-difluoro-4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (**cpd 172**)




[0316] *Step 1:* To a solution of **cpd 106** (400 mg, 0.982 mmol) in DMF (20 mL), Cs₂CO₃ (958 mg, 2.948 mmol)

was added at RT. The RM was stirred for 5 min at RT and then $\text{CF}_3\text{CH}_2\text{OTf}$ (342 mg, 1.474 mmol) was added at RT. The RM was stirred for 16 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the mixture was diluted with water (100 ml) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by RP-Prep HPLC to afford a mixture of **cpd 155** and **cpd 172** (320 mg, 45%). A preparative chiral SFC was performed on the mixture of racemic **cpd 155** and racemic **cpd 152** to afford **cpd 155 – En 1**, **cpd 155 – En 2**, **cpd 172- En 1** and **cpd 172- En 2**.


[0317] Racemic **Cpd 175** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 155 – En 1**, **cpd 155 – En 2**, **cpd 172 – En1** and **cpd 172 – En 2**.

10 Synthesis of N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 157**)



[0318] *Step 1*: To a stirred solution of **cpd 105** (600 mg, 1.318 mmol) in DMF (20 ml), NaH (56.9 mg, 3.954 mmol) was added at 0 °C. The RM was stirred for 5 min at 0 °C and then $\text{CF}_3\text{CH}_2\text{OTf}$ (609 mg, 2.637 mmol) was added at 0 °C. The reaction was stirred for 18 h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the mixture was diluted with ice water (50 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by RP-Prep HPLC to afford **cpd 157** (170 mg, 24%). A preparative chiral SFC was performed on racemic **cpd 157** to afford **cpd 157 – En 1** and **cpd 157- En 2**.

20 Synthesis of N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 160**)



[0319] *Step 1*: To a suspension of 60% NaH (240 mg, 6.21 mmol) in DMF (5.0 ml), **cpd 042** (800 mg, 2.07 mmol) in DMF (10 ml) and (2-bromoethoxy)(tert-butyl)dimethylsilane (980 mg, 4.14 mmol) was added at 0 °C and the RM was allowed to rise to RT and was stirred for 16 h. Reaction progress was monitored by TLC. The RM was extracted with DCM (2 X 100 ml), the combined organic layer was washed with water (50 mL) and brine solution (50 ml), and then dried over anhydrous Na_2SO_4 , filtered, and concentrated to afford N-(1-(2-((tert-butyl)dimethylsilyloxy)ethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (850 mg, crude).


30 [0320] *Step 2*: To a solution of N-(1-(2-((tert-butyl)dimethylsilyloxy)ethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (850 mg, 1.63 mmol) in THF (15 ml) at 0 °C, TBAF (2.45 ml, 2.45 mmol), was added dropwise at 0 °C and the RM was stirred at RT for 2 h. Reaction progress was monitored by TLC. The RM was extracted with EtOAc (2 X 100 ml), the combined organic layer was washed

with water (150 mL) and brine solution (150 mL); dried over anhydrous Na_2SO_4 , filtered, and concentrated to afford the crude product, which was purified by FCC to afford the desired product **cpd 160** (190 mg). A preparative chiral SFC was performed on the racemic mixture of **cpd 160** to provide **cpd 160 - En 1** and **cpd 160 - En 2**. **Cpd 402** was isolated as a byproduct that occurred during the synthetic sequence.

- [0321] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 160**: **Cpds. 403 - En 1, 403 - En 2, 404 - En 1, 404 - En 2, 405 - En 1, 405 - En 2, 409 - En 1, 409 - En 2, 410 - En 1, 410 - En 2**,

[0322]

- 10 Synthesis of N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 164**)



- [0323] *Step 1*: (2-Methylpyridin-4-yl)methanol (1.8 g, 13.63 mmol), ADDP (3.2 g, 13.63 mmol) and tri-n-butyl phosphine (50% in EtOAc) (3.1 mL, 12.72 mmol) were added to a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (2.0 mg, 9.09 mmol) in THF (30 mL) at 0°C under argon atmosphere. The resulting RM was stirred at rt for 24h. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0.1% FA and acetonitrile as eluent to afford ethyl 2-methyl-5-((2-methylpyridin-4-yl)methoxy)benzofuran-3-carboxylate (1.2 g, 40%).

- [0324] *Step 2*: A solution of 2-methyl-5-((2-methylpyridin-4-yl)methoxy)benzofuran-3-carboxylate (1.2 g, 5.08 mmol) and 4 M NaOH (10 mL) solution in MeOH:THF (1:1) (24 mL) was heated to 80°C and maintained for 2 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (100 mL), acidified with 1N HCl and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford 2-methyl-5-((2-methylpyridin-4-yl)methoxy)benzofuran-3-carboxylic acid (800 mg, 72%).

- [0325] *Step 3*: To a stirred solution of 3-amino-1-(2-hydroxyethyl)pyrrolidin-2-one hydrochloride (0.362 g, 2.02 mmol) in DMF (10 mL) were added DIPEA (2.4 mL, 13.46 mmol) followed by 2-methyl-5-((2-methylpyridin-4-yl)methoxy)benzofuran-3-carboxylic acid (0.5 g, 1.68 mmol) and HATU (1.0 g, 3.36 mmol) sequentially at 0°C under an argon atmosphere. The resulting RM was allowed warm to RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was diluted with ice cold water (100 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0.1% FA and acetonitrile as eluent to afford **cpd 164**. A preparative chiral SFC was performed on racemic **cpd 164** to afford **cpd 164 - En 1** and **cpd 164 - En 2**.

[0326] The following compounds were prepared in a manner similar (use of appropriate reagents and purification


methods known to the person skilled in the art) to **cpd 164 - En 1** and **cpd 164 - En 2**:

cpd 169 - En 1, **169 - En 2**, **180 - En 1** and **180 - En 2**.

[0327] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to step 3 in the preparation of **cpd 164 - En 1** and **cpd 164 - En 2**

5 **req: Cpd. 335 - En 1**, **335 - En 2**, **340 - En 1**, **340 - En 2**, **348 - En 1**, **348 - En 2**, **406 - En 1**, **406 - En 2**, **407 - En 1**, **407 - En 2**, **408 - En 1**, **408 - En 2**.

Synthesis of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzofuran-3-carboxamide (**cpd 166**)




[0328] *Step 1*: To a stirred solution of **cpd 102** (500 mg, 1.65 mmol) in DCM (50 ml), were added DIPEA (1.4 ml, 8.25 mmol) and HATU (940 mg, 2.47 mmol), followed by tert-butyl 4-aminopiperidine-1-carboxylate (495 mg, 2.47 mmol) and the RM was stirred for 2 h at RT. Reaction progress was monitored by TLC. The RM was diluted with water (100 ml), extracted with EtOAc (3x50 ml), washed with water (50 ml) and brine (30 ml), dried over anhydrous Na₂SO₄, filtered and concentrated to give the crude product. The crude product was purified by Grace FCC using 20% EtOAc in Pet ether as eluent to afford tert-butyl 4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate (600 mg, 75%).

[0329] *Step 2*: To a solution of tert-butyl 4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate (600 mg, 1.237mmol) in DCM (80 ml) at 0 °C, 4N HCl in dioxane (2.3 ml, 9.277 mmol) was added dropwise over 5 min at 0 °C, and the ice bath was removed. The RM was stirred at RT for 16 h. Reaction progress was monitored by TLC. The RM was directly concentrated to afford the crude product, which was washed with Et₂O (15 ml) to afford 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(piperidin-4-yl)benzofuran-3-carboxamide hydrochloride (700 mg crude).

[0330] *Step 3*: To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(piperidin-4-yl)benzofuran-3-carboxamide (700 mg, 1.71 mmol) in acetonitrile (40 ml), Cs₂CO₃ (167 mg, 5.13 mmol) and CF₃CH₂OTf (595 mg, 2.57 mmol) were added at RT. The resulting RM was stirred for 4h at RT. Reaction progress was monitored by TLC. After completion of the reaction, the RM was quenched with ice-cold water (100 ml), and extracted with EtOAc (2x100 ml). The combined organic layer was washed with water (120 ml) and brine (120 ml), dried over anhydrous Na₂SO₄, and concentrated to afford a residue, which was purified by Grace FCC using 80% EtOAc in pet ether as eluent to afford **cpd 166** (150 mg, 14%).

[0331] **Cpd 168** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 166**.

Synthesis of 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 177**)



[0332] *Step 1:* To a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (5.0 g, 22.7 mmol) in acetonitrile (300 mL) was added selectfluor (9.65 g, 27.2 mmol) at RT under argon atmosphere. The resulting RM was stirred for 16 h at same temperature. The reaction progress was monitored by TLC. The excess solvent was removed under reduced pressure and the crude compound was dissolved in EtOAc (500 mL). The above solution was washed with water (2 x 250 mL) and brine (250 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica using 0-20% EtOAc in pet-ether as an eluent followed by a flash chromatography using 0-47% of acetonitrile in 0.1% FA in water as an eluent to afford a mixture of ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 19%).

[0333] *Step 2:* (4-Methylthiazol-5-yl)methanol (1.23 g, 9.5 mmol), ADDP (2.81 g, 11.1 mmol) and tri-n-butylphosphine (2.75 mL, 11.1 mmol) were added sequentially to a solution of a mixture of ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.9 g, 7.98 mmol) in THF (100 mL) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stir for 1 h. The reaction progress was monitored by TLC. The RM was poured into water (200 mL) and extracted with EtOAc (2 x 250 mL). The combined organic layer was washed with water (200 mL) and brine (200 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica using 0-30% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (1.5 g, 54%).


[0334] *Step 3:* 2N NaOH in water (20 mL) was added to a solution of a mixture of ethyl 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.8 g, 2.29 mmol) in a mixture of MeOH (20 mL) and THF (5 mL) at RT. The resulting RM was heated to 80°C for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (100 mL), and acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with water (2 x 100 mL) followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0-50% of acetonitrile in 0.1% FA in water as eluent to afford 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 233**) (280 mg, 38%). The corresponding undesired acid from was separately collected.

[0335] *Step 4:* To a pre-stirred solution of 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (250 mg, 0.77 mmol) and methyl 4-aminotetrahydro-2H-pyran-4-carboxylate (185.7 mg, 1.10 mmol) in DMF (5 mL) was added DIPEA (0.28 mL, 1.55 mmol) followed by HATU (592 mg, 1.55 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT and stirred for 1 h. The reaction progress was monitored

by TLC. The RM was quenched with cold water (20 mL) and the solid was filtered and dried under reduced pressure to afford methyl 4-(4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylate (260 mg, 74%).

- [0336] *Step 4:* NaBH₄ (507 mg, 13.5 mmol) was added portionwise to a pre-stirred solution of methyl 4-(4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylate (250 mg, 0.54 mmol) in a mixture of MeOH (10 mL) and THF (10 mL) at 0°C. The resulting RM was heated to 50°C and maintained at this temperature for 16 h. The reaction progress was monitored by TLC. The RM was cooled to RT, diluted with water (50 mL) and the organic compound was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-50% acetonitrile and 0.1% FA in water as an eluent to afford **cpd 177** (50 mg, 21%).

- Synthesis of N-(3,3-difluoropiperidin-4-yl)-2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 179**) and N-(3,3-difluoropiperidin-4-yl)-2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 183**)



- [0337] *Step 1:* To a solution of 2-methylcyclohexa-2,5-diene-1,4-dione (20.0 g, 163.93 mmol) in toluene (500 mL) was added ethyl 3-oxobutanoate (63.9 g, 491.79 mmol) and anhydrous ZnCl₂ (26.8 g, 196.71 mmol) at RT under argon atmosphere. The resulting RM was refluxed for 16 h using a Dean-Stark apparatus. The reaction progress was monitored by TLC. The RM was cooled to RT, filtered through a celite pad and the celite pad was washed with EtOAc (300 mL). The filtrate was concentrated under reduced pressure. The crude product was purified by FCC over silica using 0-10% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 5-hydroxy-2,7-dimethylbenzofuran-3-carboxylate and ethyl 5-hydroxy-2,6-dimethylbenzofuran-3-carboxylate (20.0 g, 52%).
- [0338] *Step 2:* (2-(Trifluoromethyl)pyridin-3-yl)methanol (11.35 g, 64.10 mmol), ADDP (15.0 g, 59.82 mmol) and tri-n-butylphosphine (14.75 mL, 59.82 mmol) were added sequentially to a solution of mixture of ethyl 5-hydroxy-2,7-dimethylbenzofuran-3-carboxylate and ethyl 5-hydroxy-2,6-dimethylbenzofuran-3-carboxylate (10.0 g, 42.73 mmol) in THF (200 mL) at 0°C under argon atmosphere. The RM was allowed to attain RT and was stirred for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with water (200 mL) and brine (200 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (8.0 g, 47%).

[0339] *Step 3:* A solution of NaOH (2.03g, 50.89 mmol) in water (50 mL) was added to a solution of mixture of


ethyl 2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (5.0 g, 12.72 mmol) in a mixture of MeOH (50 mL) and THF (50 mL) at RT. The RM was heated to 60°C for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT and poured into ice cold water (200 mL), then acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 100 mL) followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford a mixture of 2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (3.5 g, 76%). The crude product thus obtained was used for next step without further purification.

[0340] *Step 4:* To a solution of a mixture of 2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (2.0 g, 5.47 mmol) in DMF (50 mL) were added tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (1.5 g, 6.57 mmol), DIPEA (2.9 mL, 16.41 mmol) and HATU (4.1 g, 10.94 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT for 3 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL) and the crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica using 0-55% EtOAc and pet-ether as an eluent to afford a mixture of tert-butyl 4-(2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate and tert-butyl 4-(2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (1.5 g, 48%).

[0341] *Step 5:* TFA (1.5 mL) was added dropwise to a pre-stirred solution of a mixture of tert-butyl 4-(2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate and tert-butyl 4-(2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (1.0 g, 1.71 mmol) in DCM (10 mL) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was concentrated under reduced pressure and basified with sat. NaHCO₃ solution (pH~8). The crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (100 mL), followed by brine (100 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-50% acetonitrile and 0.1% FA in water as an eluent to afford a mixture of **cpd 179** and **cpd 183** (450 mg, 84%). A preparative chiral SFC was performed on the racemate **cpd 179** and the racemate **cpd 183** to provide **cpd 179 - En 1**, **cpd 179 - En 2**, **cpd 183 - En 1** and **cpd 183 - En 2**.

[0342] The following compounds were prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 179 - En 1**, **cpd 179 - En 2**, **cpd 183 - En 1** and **cpd 183 - En 2**. **Cpd : 165 – En1**, **165 – En2**, **184 – En1**, **184 – En2**, **174** and **187**.

Synthesis of N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 185**) and N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 186**)




[0343] *Step 1:* (4-Methylthiazol-5-yl)methanol (8.26 g, 64.10 mmol), ADDP (15.0 g, 59.82 mmol) and tri-*n*-butylphosphine (14.75 mL, 59.82 mmol) were added sequentially to a pre-stirred solution of a mixture of ethyl 5-hydroxy-2,7-dimethylbenzofuran-3-carboxylate and ethyl 5-hydroxy-2,6-dimethylbenzofuran-3-carboxylate (10.0 g, 42.73 mmol) in THF (200 mL) at 0°C under an argon atmosphere. The RM was allowed to attain RT and was stirred for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with water (200 mL) and brine (200 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (8.0 g, 57%).

[0344] *Step 2:* A solution of NaOH (0.927g, 23.18 mmol) in water (14 mL) was added to a pre-stirred solution of a mixture of ethyl 2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (2.0 g, 5.79 mmol) in a mixture of MeOH (20 mL) and THF (20 mL) at RT. The resulting RM was heated to 60°C and maintained for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (100 mL) and acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 100 mL), followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford a mixture of 2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid and 2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.6 g, 89%). The crude product thus obtained was used for next step without further purification.

[0345] *Step 3:* To a pre-stirred solution of a mixture of 2,7-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3- and 2,6-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 3.15 mmol) and (4-aminotetrahydro-2H-pyran-4-yl)methanol (0.619 g, 4.73 mmol) in DMF (10 mL) was added DIPEA (1.69 mL, 9.45 mmol), followed by HATU (2.39 g, 6.30 mmol) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 3 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL), and the crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-55% EtOAc and pet-ether as an eluent to afford a mixture of **cpd 186** and **cpd 185** (0.5 g, 57%). A preparative chiral SFC was performed on a mixture of **cpd 186** and **185** to provide **cpd 186** and **cpd 185**.

Synthesis of 7-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 188**)




[0346] *Step 1:* (4-Methylthiazol-5-yl)methanol (0.47 g, 3.67 mmol), ADDP (0.64 g, 3.42 mmol) and tri-n-butylphosphine (0.80 mL, 3.42 mmol) were added sequentially to a pre-stirred solution of ethyl 6-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.6 g, 2.44 mmol) in THF (30 mL) at 0°C under argon atmosphere. The RM was allowed to attain RT and stirred for 2 h. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.6 g, 68%).

[0347] *Step 2:* A solution of NaOH (0.26 g, 6.74 mmol) in water (8 mL) was added dropwise to a solution of ethyl 6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.6 g, 1.68 mmol) in a mixture of MeOH (10 mL) and THF (5 mL) at RT. The resulting RM was heated to 60°C and maintained at this temperature for 4 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (50 mL) and acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) followed by brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford a mixture of 6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid and 7-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.55 g, 99%).

[0348] *Step 3:* To a solution of a mixture of 6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid and 7-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.55 g, 1.67 mmol), and methyl 4-aminotetrahydro-2H-pyran-4-carboxylate (0.31 g, 2.01 mmol) in DMF (10 mL) was added DIPEA (0.86 mL, 5.03 mmol) followed by HATU (1.27 g, 3.35 mmol) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and the organic compound was extracted with EtOAc (2 x 50 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-55% EtOAc in pet ether as an eluent to afford a mixture of methyl 4-(6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylate and methyl 4-(7-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylate (0.5 g, 63%). *Step 4:* NaBH₄ (1.01 g, 26.65 mmol) was added portionwise to a pre-stirred solution of a mixture of methyl 4-(6-chloro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)tetrahydro-2H-pyran-4-

carboxylate and methyl 4-(7-chloro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)-tetrahydro-2H-pyran-4-carboxylate (0.5 g, 1.06 mmol) in a mixture of MeOH (10 mL) and THF (5 mL) at 0°C. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and then the crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as an eluent followed by RP prep-HPLC to afford **cpd 188** (25 mg, 5%).

Synthesis of 4-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide (cpd 191)



[0349] *Step 1:* NBS (24.2 g, 136.22 mmol) was added to a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (20.0 g, 90.81 mmol) in acetonitrile (600 mL) at RT under an argon atmosphere. The RM was stirred for 16 h at same temperature. The reaction progress was monitored by TLC. The RM was diluted with water (300 mL) and acidified with 1N-HCl to pH~2. The crude product was extracted with EtOAc (2 x 300 mL). The combined organic layer was washed with water (200 mL) followed by brine (200 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc and pet-ether as an eluent to afford ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylate (5.0 g, 19%).

[0350] *Step 2:* CuCN (0.74 g, 8.36 mmol) was added to a solution of ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 3.44 mmol) in N,N-dimethylformamide (25 mL) at RT under an argon atmosphere. The resulting mixture was heated to 160°C and maintained for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 50 mL) followed by brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford ethyl 4-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.45 g, 55%).

[0351] *Step 3:* (2-(Trifluoromethyl)pyridin-3-yl)methanol (0.65 g, 3.67 mmol), ADDP (0.861 g, 3.41 mmol) and tri-n-butylphosphine (0.84 mL, 3.41 mmol) were added sequentially to a pre-stirred solution of ethyl 4-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.6 g, 2.44 mmol) in THF (20 mL) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica gel using 0-20% EtOAc in pet-ether as an


eluent to afford ethyl 4-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.45 g, crude). The crude product thus obtained was used for next step without further purification.

[0352] *Step 4:* A solution of NaOH (0.178 g, 4.45 mmol) in water (5.0 mL) was added to a solution of ethyl 5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxylate (0.450 g, 1.11 mmol) in a mixture of MeOH (10 mL) and THF (10 mL) at RT. The resulting RM was heated to 60°C and maintained for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (50 mL) and acidified with 1N HCl (pH~2). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (2 x 50 mL) followed by brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 4-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.4 g, crude). The crude product thus obtained was used for next step without further purification.

[0353] *Step 5:* To a solution of a mixture of 4-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.4 g, 1.06 mmol) and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (0.376 g, 1.59 mmol) in DMF (10 mL) was added DIPEA (0.50 mL, 3.18 mmol) followed by HATU (0.805 g, 2.12 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT and stirred for 3 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL), and the crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-55% EtOAc and pet-ether as an eluent to afford tert-butyl 4-(4-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (0.3 g, crude).

[0354] *Step 6:* To a solution of tert-butyl 4-(4-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (0.3 g, 0.50 mmol) in DCM (2.5 mL) was added TFA (2.5 mL) dropwise at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was concentrated under reduced pressure, and the residue was basified with NaHCO₃ (pH~8). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) followed by brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0-50% acetonitrile in 0.1% FA in water as an eluent to afford racemic **cpd 191** (0.21 g, 89%). A preparative chiral SFC was performed on the racemic mixture of **cpd 191** to afford **cpd 191 – En 1** and **cpd 191 – En 2**.

Synthesis of 4-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 193**)




[0355] *Step 1:* (4-Methylthiazol-5-yl)methanol (0.31 g, 2.44 mmol), ADDP (0.57 g, 2.28 mmol) and tri-n-butylphosphine (0.56 mL, 2.28 mmol) were added sequentially to a pre-stirred solution of ethyl 4-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.4 g, 1.63 mmol) in THF (20 mL) at 0°C under an argon atmosphere. The RM was allowed to warm to RT and stirred for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed

with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica using 0-20% EtOAc in pet-ether as an eluent to afford ethyl 4-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.300 g, 52%). The crude product thus obtained was used for next step without further purification.

- 5 [0356] *Step 2:* A solution of NaOH (0.13 g, 3.38 mmol) in water (5.0 mL) was added to a pre-stirred solution of ethyl 5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxylate (0.30 g, 0.84 mmol) in MeOH (10 mL) and THF (10 mL) at RT. The resulting RM was heated to 60 °C and maintained at this temperature for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT, poured into ice cold water (50 mL), acidified with 1N HCl (pH~2.0) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (2
- 10 x 50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 4-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.20 g, crude). The crude product thus obtained was used for next step without further purification.


- [0357] *Step 3:* To a pre-stirred solution of 4-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.20 g, 0.61 mmol) and (4-aminotetrahydro-2H-pyran-4-yl)methanol (0.12 g, 0.92 mmol) in DMF (5 mL) were added DIPEA (0.29 mL, 1.83 mmol) followed by HATU (0.46 g, 1.22 mmol) at 0°C under an argon atmosphere. The RM was stirred at room temperature for 3 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by RP-HPLC to afford **cpd 193** (0.90 g, 60%).

- 20 Synthesis of 6-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 194**)



- [0358] *Step 1:* To a solution of a mixture of 6-cyano-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.2 g, 0.60 mmol) and (4-aminotetrahydro-2H-pyran-4-yl)methanol (0.15 g, 1.21 mmol) in DMF (5 mL) was added DIPEA (0.32 mL, 1.82 mmol) followed by HATU (0.46 g, 1.21 mmol) at 0 °C under an argon atmosphere. The resulting RM was stirred at RT for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% FA in water and acetonitrile as an
- 25 eluent to afford **cpd 194** (85 mg, 32%).
- 30

Synthesis of 6-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 195**) and 7-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 196**)



[0359] *Step 1:* To a pre-stirred solution of CAN (199.18 g, 363.32 mmol) in water (500 mL) was added 2-chlorobenzene-1,4-diol (25.0 g, 173.01 mmol) at 0°C. The resulting RM was stirred at RT for 4 h. The reaction progress was monitored by TLC. The organic compound was extracted with Et₂O (3 x 200 mL). The combined organic layer was washed with brine (50 mL) and dried over anhydrous Na₂SO₄. The dried organic layer was passed through a silica gel column using diethyl ether as eluant and thus collected fractions were concentrated under reduced pressure to afford 2-chlorocyclohexa-2,5-diene-1,4-dione (20 g, 83%).

[0360] *Step 2:* To a pre-stirred solution of 2-chlorocyclohexa-2,5-diene-1,4-dione (20 g, 140.84 mmol) in toluene (300 mL) was added ethyl 3-oxobutanoate (54.92 g, 422.53 mmol) followed by anhydrous ZnCl₂ (23.0 g, 169.0 mmol) at RT under argon atmosphere. The resulting RM was heated to reflux and maintained for 16 h using Dean-Stark apparatus. The reaction progress was monitored by TLC. The RM was cooled to RT, filtered through a celite pad and the celite pad was washed with EtOAc (500 mL). The combined clear filtrate was concentrated under reduced pressure. The crude product was purified by FCC over silica gel using 0-10% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 6-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate (7.0 g, 20%).

[0361] *Step 3:* A solution of a mixture of ethyl 6-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 3.93 mmol) and Zn(CN)₂ (2.01 g, 17.71 mmol) in dimethylacetamide (12 mL) was degassed with argon for 10 min. To the above RM, Pd(P(t-Bu)₃)₂ (0.60 g, 1.18 mmol) was added in one portion and it was then degassed for 5 min. The resulting mixture was heated to 160°C and maintained at this temperature for 2 h under microwave heating. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a mixture of ethyl 6-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.6 g, 62.5%).

[0362] *Step 4:* (2-(Trifluoromethyl)pyridin-3-yl)methanol (1.30 g, 7.34 mmol), ADDP (1.72 g, 6.85 mmol) and tri-*n*-butylphosphine (1.60 mL, 6.85 mmol) were added to a solution of a mixture of ethyl 6-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.2 g, 4.89

mmol) in THF (30 mL) at RT under an argon atmosphere. The RM was stirred for 2 h at same temperature. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was sequentially washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford a regioisomeric mixture of ethyl 6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.2 g, 60%).


[0363] *Step 5:* A solution of NaOH (0.47 g, 11.88 mmol) in water (8 mL) was added dropwise to a solution of a mixture of ethyl 6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate and ethyl 7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1.2 g, 2.97 mmol) in a mixture of MeOH:THF (2:1) (23 mL) at RT. The resulting RM was heated to 60°C for 4 h. The reaction progress was monitored by TLC. The RM was cooled to RT and poured into ice cold water (50 mL), and acidified with 1N HCl to a pH~2. The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford a regioisomeric mixture of 6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 90%). This crude regioisomeric mixture was used in the next step without any separation.

[0364] *Step 6:* To a pre-stirred solution of a mixture of 6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid and 7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 2.65 mmol), and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (0.90 g, 3.97 mmol) in DMF (20 mL) was added DIPEA (1.36 mL, 7.95 mmol) followed by HATU (2.02 g, 5.31 mmol) at 0°C under an argon atmosphere. The RM was allowed to attain RT and stirred for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL) and the organic compound was extracted with EtOAc (2 x 70 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica using a gradient mixture of 0-55% EtOAc in pet-ether as an eluent to afford a regioisomeric mixture of tert-butyl 4-(6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate and tert-butyl 4-(7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (1.0 g, 63%).

[0365] *Step 7:* 4.0 M HCl in dioxane (10.0 mL) was added dropwise to a solution of a mixture of tert-butyl 4-(6-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate and tert-butyl 4-(7-cyano-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (1.0 g, 1.68 mmol) in DCM (15 mL) at 0°C. The RM was allowed to attain RT and was stirred for 5 h. The reaction progress was monitored by TLC. The RM was concentrated under reduced pressure. The residue was basified with sat. NaHCO₃ (100 mL) and the organic compound was extracted with 10% MeOH in DCM (3 x 50 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0.1% FA in water and acetonitrile as an eluent to afford

an isomeric mixtures of racemic **cpd 195** and racemic **cpd 196** (0.60 g, 72%). A preparative chiral SFC was performed on the regioisomeric mixture of **cpd 195** and **cpd 196** to afford **cpd 195 – En 1**, **cpd 195 – En 2**, **cpd 196 – En 1** and **cpd 196 – En 2**.

Synthesis of (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide (**cpd 747**)




Step 1 : To a stirred solution of methyl 2-cyclopropyl-5-hydroxybenzofuran-3-carboxylate (250 mg, 1.082 mmol) in THF (20 mL) was added ADDP (0.54 g, 2.164 mmol), n-Bu₃P (2.1 mL, 2.164 mmol) and followed by addition of pyridin-2-ylmethanol (140 mg, 1.298 mmol) at 0 °C. The RM was stirred for 16 h at RT and the reaction progress was monitored by TLC. The RM was diluted with water (40 mL) and extracted with ethyl acetate (3 x 50 mL). Combined extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get crude. Crude was purified by column chromatography over silica gel (100-200 mesh) using 5% ethyl acetate in pet-ether as an eluent to afford methyl-2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylate (**3**) (150 mg, 43%) as an off-white solid. TLC system: 20% ethyl acetate in pet ether; RF: 0.42.

Step 2 : To a stirred solution of 2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylate (150 mg, 0.464 mmol) in MeOH: THF (1:1, 20 mL) was added 2N aqueous NaOH (4 mL) at RT. The RM was stirred for 16 h at RT and the reaction progress was monitored by TLC. The RM was concentrated, acidified to pH ~2 with 1N HCl. The precipitated solid was filtered and dried under vacuum to afford 2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylic acid (120 mg.) as an off-white solid. Crude used in the next step without purification. TLC system: 70% ethyl acetate in Pet ether; RF: 0.30.

Step 3 : To a stirred solution of 2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylic acid (0.120 mg, 0.388 mmol) in DMF (5 mL) was added DIPEA (0.2 mL, 1.553 mmol), HATU (0.295 g, 0.776 mmol) at RT and followed by addition of (S)-2-amino-3-hydroxypropanamide-HCl (0.081 mg, 0.582 mmol). The RM was stirred for 16 h at RT. Reaction progress was monitored by TLC. The RM was diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get crude. The crude was purified by GRACE flash column chromatography using 0.1% aqueous formic acid and acetonitrile as an eluent to afford (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide (**cpd 747**) (35 mg, 19% over 2 steps).

The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 747** : **Cpds: 748, 749, 750, 751**.

Synthesis of 2-(difluoromethyl)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide (**cpd 198**)



- [0366] *Step 1:* To a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (5.0 g, 22.7 mmol) in DCM (100 mL) was added imidazole (3.09 g, 45.4 mmol) followed by TBDMS-Cl (4.10 g, 27.2 mmol) at 0°C under argon atmosphere. The RM was warmed to RT and stirred for 16 h. The reaction progress was monitored by TLC.
- 5 The RM was poured into water (100 mL) and extracted with DCM (3 x 100 mL). The combined organic layer was washed with water (2 x 100 mL) followed by brine (200 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by FCC over silica-gel using 5% EtOAc in pet-ether as an eluent to obtain ethyl 5-((tert-butyldimethylsilyl)oxy)-2-methylbenzofuran-3-carboxylate (5.1 g, 68%).
- [0367] *Step 2:* To a solution of ethyl 5-((tert-butyldimethylsilyl)oxy)-2-methylbenzofuran-3-carboxylate (6.0 g, 17.9 mmol) in 1,4-dioxane (250 mL) was added SeO₂ (39.8 g, 358 mmol) at RT under argon atmosphere. The resulting RM was heated to 120°C for 48 h. The reaction progress was monitored by TLC. The RM was cooled to RT and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by FCC over silica gel using 2% EtOAc in pet-ether as an eluent to afford ethyl 5-((tert-butyldimethylsilyl)oxy)-2-formylbenzofuran-3-carboxylate (2.6 g, 42%).
- 10 [0368] *Step 3:* To a solution of ethyl 5-((tert-butyldimethylsilyl)oxy)-2-formylbenzofuran-3-carboxylate (2.6 g, 7.7 mmol) in DCM (100 mL) was added DAST (3.0 mL, 23.3 mmol) at 0°C under argon atmosphere. The RM was allowed to warm to RT and stirred for 3 h. The reaction progress was monitored by TLC. The RM was diluted with DCM (100 mL), washed with sat. NaHCO₃ solution (100 mL), water (100 mL), and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 5-((tert-butyldimethylsilyl)oxy)-2-(difluoromethyl)benzofuran-3-carboxylate (2.4 g, crude product).
- 15 [0369] *Step 4:* To a solution of ethyl 5-((tert-butyldimethylsilyl)oxy)-2-(difluoromethyl)benzofuran-3-carboxylate (2.4 g, 6.48 mmol) in THF (50 mL) was added TBAF (1 M in THF) (12.9 mL, 12.9 mmol) at 0°C under argon atmosphere. The RM was allowed to warm to RT and stirred for 1 h. The reaction progress was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (200 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 2-(difluoromethyl)-5-hydroxybenzofuran-3-carboxylate (1.8 g, crude). This crude product was used for next step without further purification.
- 25 [0370] *Step 5:* (4-Methylthiazol-5-yl)methanol (1.36 g, 10.5 mmol), ADDP (2.48 g, 9.8 mmol) and tri-n-butylphosphine (1.99 g, 9.8 mmol) were added sequentially to a solution of ethyl 2-(difluoromethyl)-5-hydroxybenzofuran-3-carboxylate (1.8 g, 7.0 mmol) in THF (150 mL) at 0°C under an argon atmosphere. The resulting RM was stirred at RT for 3 h. The reaction progress was monitored by TLC. The RM was poured into water (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using 0-20% EtOAc in pet-ether as an eluent to afford ethyl 2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (1.5 g, 55% for 3
- 30
- 35

steps).


[0371] *Step 6:* 2 M NaOH (20 mL) solution was added to a solution of ethyl 2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (800 mg, 2.17 mmol) in MeOH (25 mL) and THF (10 mL) at RT. The resulting RM was heated to 60°C for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT and poured into ice cold water (100 mL) and acidified with 1N HCl. The crude product was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 229**) (400 mg, 55%).

[0372] *Step 7:* To a solution mixture of 2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.4 g, 1.17 mmol) and 3-amino-1-(2-hydroxyethyl)pyrrolidin-2-one hydrochloride (255 mg, 1.41 mmol) in DMF (25 mL) were added DIPEA (0.43 mL, 2.35 mmol) followed by HATU (0.897 g, 2.35 mmol) at 0°C under an argon atmosphere. The resulting RM was stirred at RT for 1 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography using 0.1% FA in water and acetonitrile as an eluent to afford **cpd 198** (190 mg, 35%). A preparative chiral SFC was performed on the racemic mixture of **cpd 198** to afford **cpd 198 – En 1** and **cpd 198 – En 2**.

[0373] **Cpd 197** was prepared in a manner similar (use of appropriate reagents and purification methods known to the person skilled in the art) to **cpd 198 – En 1** and **cpd 198 – En 2**.

[0374] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 198**: **Cpds 742, 743, 744, 745, 746**.

Synthesis of 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 199**)



[0375] *Step 1:* To a pre-stirred solution of ethyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (2.0 g, 5.27 mmol) in 1,4-dioxane (150 mL) was added SeO₂ (3.51 g, 31.6 mmol) at RT under argon atmosphere. The resulting RM was heated to 120°C and maintained under stirring for 16 h. Additional amount of SeO₂ (5.8 g, 52.7 mmol) was added and the reaction was continued for another 24h. The reaction progress was monitored by TLC. The RM was cooled to RT, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by FCC with silica gel using 10% EtOAc in pet-ether as an eluent to afford ethyl 2-formyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (900 mg, 43%).


[0376] *Step 2:* To a solution of ethyl 2-formyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.8 g, 2.03 mmol) in DCM (25 mL) was added DAST (0.53 mL, 4.07 mmol) at 0 °C under argon atmosphere. The RM was allowed to cool to RT and was stirred for 2 h. The reaction progress was monitored by TLC. The RM was diluted with DCM (100 mL), washed with sat. NaHCO₃ solution (100 mL), water (50 mL),
 5 brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 2-(difluoromethyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (800 mg). This crude product was used for next step without further purification.

[0377] *Step 3:* An aq. NaOH (2M solution) (25 mL) was added to a solution of ethyl 2-(difluoromethyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (700 mg, 1.68 mmol) in MeOH (15 mL) and
 10 THF (5 mL) at RT. The resulting RM was heated to 60°C for 3 h. The reaction progress was monitored by TLC. The RM was cooled to RT and poured into ice cold water (100 mL), acidified with 1N HCl and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 100 mL), brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 2-(difluoromethyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (600 mg, crude product).

[0378] *Step 4:* To a pre-stirred solution of mixture of 2-(difluoromethyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.5 g, 1.29 mmol) and tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (0.365 g, 1.55 mmol) in DMF (25 mL) was added DIPEA (0.47 mL, 2.58 mmol) followed by HATU (0.982 g, 2.58 mmol) at 0°C under argon atmosphere. The RM was allowed to attain RT and was stirred for 1 h. The reaction progress was monitored by TLC. The RM was diluted with water (100 mL), and extracted with EtOAc
 20 (2 x 100 mL). The combined organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel using a gradient mixture of 0-25% EtOAc in pet-ether as an eluent to afford tert-butyl 4-(2-(difluoromethyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (0.6 g, 55% over 3 steps).

[0379] *Step 5:* HCl (4M in dioxane) (15 mL) was added dropwise to a solution of 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (0.6 g, 0.99 mmol) in DCM (50 mL) at 0°C under an argon atmosphere. The RM was warmed to RT and stirred for 4 h. The reaction progress was monitored by TLC. The solvents were evaporated in vacuo. The resulting crude residue was partitioned between sat. NaHCO₃ (pH ~9) and EtOAc (3 x 50 mL). The combined organic layer was washed with
 30 water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (0.4 g, 80%). A preparative chiral SFC was performed on the racemic mixture of **cpd 199** to afford **cpd 199 – En 1** and **cpd 199 – En 2**.

Synthesis of N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 201**)
 35




[0380] *Step 1:* To a pre-stirred solution of 1-(tert-butyl) 3-ethyl 3-aminoazetidine-1,3-dicarboxylate (0.483 g,

1.98 mmol) in DMF (10 mL) was added DIPEA (3.5 mL, 19.80 mmol) followed by **cpd 102** (0.6 g, 1.98 mmol) and HATU (1.5 g, 3.96 mmol) sequentially at 0°C under an argon atmosphere. The RM was heated to 55°C and stirred for 2 h. The reaction progress was monitored by TLC. The RM was diluted with ice cold water (100 mL) and extracted with EtOAc (150 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% FA in water and acetonitrile as an eluent to afford 1-(tert-butyl) 3-ethyl 3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)azetidine-1,3-dicarboxylate (0.45 g, 42 %).

[0381] *Step 2:* NaBH₄ (0.113 g, 2.97 mmol) was added in small portions to a solution of 1-(tert-butyl) 3-ethyl 3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)azetidine-1,3-dicarboxylate (0.45 g, 0.85 mmol) in MeOH (10 mL) at 0°C and the resulting RM was stirred at RT for 2 h. The reaction progress was monitored by TLC. The RM was cooled to 0°C, diluted with water (30 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)azetidine-1-carboxylate (0.4 g, crude). This crude product was used for next step without further purification.

[0382] *Step 3:* To a pre-stirred solution of tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)azetidine-1-carboxylate (0.4 g, crude) in DCM (5.0 mL) was added TFA (1.0 mL) dropwise at 0°C under an argon atmosphere. The RM was allowed to warm to room temperature and stirred for 5h. The reaction progress was monitored by LC-MS. The RM was concentrated under reduced pressure. The crude product was purified by RP prep-HPLC to afford **cpd 201** (75 mg, 25%).

Synthesis of N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 202**)




[0383] *Step 1:* To a solution of 1-(tert-butyl) 3-ethyl 3-aminoazetidine-1,3-dicarboxylate (0.417 g, 1.709 mmol) in DMF (10 mL) were added DIPEA (3.0 mL, 17.094 mmol), **cpd 101** (0.6 g, 1.709 mmol) and HATU (1.2 g, 3.418 mmol) sequentially at 0°C under an argon atmosphere. The resulting RM was heated to 55°C for 2 h. The reaction progress was monitored by TLC. The RM was diluted with ice cold water (100 mL) and extracted with EtOAc (150 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography using a gradient mixture of 30-50% of EtOAc in pet ether as an eluent to afford 1-(tert-butyl) 3-ethyl 3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)azetidine-1,3-dicarboxylate (0.45 g, 42%).

[0384] *Step 2:* NaBH₄ (0.074 g, 1.94 mmol) was added in small portions to a solution of 1-(tert-butyl) 3-ethyl 3-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)azetidine-1,3-dicarboxylate (0.45 g, 0.779 mmol) in MeOH (10 mL) at 0°C and the resulting RM was stirred at RT for 2 h. The reaction progress was monitored by TLC. The RM was cooled to 0°C, diluted with water (30 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)azetidine-1-carboxylate (0.4 g, crude). This

crude product was used for next step without further purification.


- [0385] *Step 3:* To a solution of tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)azetidine-1-carboxylate (0.4 g, crude) in MeOH (15.0 mL) was added acetyl chloride (2.6 mL) dropwise at 0°C under an argon atmosphere. The RM was allowed to attain RT and was stirred for 24h. The reaction progress was monitored by LC-MS. The RM was concentrated under reduced pressure. The crude product was purified by reverse phase prep-HPLC to afford **cpd 202** (100 mg, 30%).

Synthesis of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (cpd 232).



- [0386] *Step 1:* To a pre-stirred solution mixture of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (0.2 g, 0.66 mmol), HATU (0.501 g, 1.32 mmol) and DIPEA (0.24 mL, 1.32 mmol) in DMF (10 mL) was added ammonium chloride (0.176 g, 3.3 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice cold water (50 mL) and the precipitated solid was collected by filtration and dried under vacuum. The solid was washed with diethyl ether (20 mL) and dried to afford 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (130 mg, 65%) as an off white solid. TLC system: 100% Ethyl acetate; R_f : 0.15.

- [0387] Synthesis of (S)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (cpd 279)




- [0387] *Step 1:* To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (150 mg, 0.495 mmol), HATU (376.2 mg, 0.99 mmol) and DIPEA (0.36 mL, 1.98 mmol) in DMF (10 mL) was added L-alaninamide hydrochloride (61.6 mg, 0.495 mmol) at 0 °C and the resulting reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mass was diluted with water (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting compound was washed with n-pentane (2 x 10 mL) and was then filtered off to afford (S)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (79 mg, 44%) as an off white solid. TLC: 10% Methanol in dichloromethane; R_f : 0.4.

[0388] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art)

as described for **cpd 279**: **Cpds. 271, 272, 273, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 318, 319, 320, 321, 324, 375, 376, 377, 378, 379, 380, 381, 382, 383, 395 - Dia 1, 395 - Dia 2, 396 - En 1, 396 - En 2, 397 - En 1, 397 - En 2, 398, 411 - En 1, 411 - En 2, 432 - En 1, 432 - En 2, 433 - En 1, 433 - En 2, 434 - En 1, 434 - En 2, 435 - En 1, 435 - En 2, 437 - En 1, 437 - En 2, 438, 439, 440, 441, 442, 443, 444, 445 - En 1, 445 - En 2, 446 - En 1, 446 - En 2, 447 - En 1, 447 - En 2, 448 - En 1, 448 - En 2, 449 - En 1, 449 - En 2, 450 - En 1, 450 - En 2, 451 - En 1, 451 - En 2, 452 - En 1, 452 - En 2, 453 - En 1, 453 - En 2, 454, 455 - En 1, 455 - En 2, 456 - En 1, 456 - En 2, 457 - En 1, 457 - En 2, 458 - En 1, 458 - En 2, 459 - En 1, 459 - En 2, 460 - En 1, 460 - En 2, 461 - En 1, 461 - En 2, 462 - En 1, 462 - En 2, 463 - En 1, 463 - En 2, 464 - En 1, 464 - En 2, 465 - En 1, 465 - En 2, 466 - En 1, 466 - En 2, 467 - En 1, 467 - En 2, 468 - En 1, 468 - En 2, 469 - En 1, 469 - En 2, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 502, 503, 509, 577, 578, 579, 580, 581, 582, 584, 586, 590 - En 1, 590 - En 2, 591 - En 1, 591 - En 2, 592 - En 1, 592 - En 2, 593 - En 1, 593 - En 2, 594 - En 1, 594 - En 2, 595 - En 1, 595 - En 2, 596 - En 1, 596 - En 2, 597 - En 1, 597 - En 2, 598 - En 1, 598 - En 2, 600 - En 1, 600 - En 2, 601 - En 1, 601 - En 2, 650, 662.**

15

Synthesis of 2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 311**).



[0389] *Step 1*: To a stirred solution of 2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.5 g, 9 mmol) in CH_2Cl_2 (30 mL) were added DIPEA (0.23 g, 1.8 mmol) and HATU (0.69 g, 1.8 mmol) at 0 °C followed by the addition of tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (273 mg, 1.1 mmol). The reaction mixture was stirred for 16 h at RT, the reaction progress was monitored by TLC. The reaction mixture was diluted with water (150 mL) and extracted with CH_2Cl_2 (3 x 100 mL). The combined extracts were washed with brine (150 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude material (0.7 g). The crude compound was purified by silica gel (100-200 mesh) column chromatography to afford 2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxamide (0.35 g) as a white solid. TLC system: 5% MeOH in CH_2Cl_2 ; Rf: 0.3.


[0390] *Step 2*: To a stirred solution of tert-butyl 3,3-difluoro-4-(5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate (0.25 g, 1.5 mmol) in acetonitrile (15 mL), was added TMSCl (0.26 g, 2.4 mmol) followed by NaI (0.350 g, 2.4 mmol) at 0 °C and the reaction mixture was stirred for 3 h at 70 °C. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (150 mL) and extracted with EtOAc (2 x 20 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude material (500 mg, LCMS: 45%) as an off-white solid. The crude material was purified by reverse phase prep-HPLC purification to afford 2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (130 mg) as an off-white solid. TLC system: 10% Methanol in Dichloromethane; Rf: 0.3.

[0391] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or

racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 311**: **Cpds. 349 - En 1, 349 - En 2, 350 - En 1, 350 - En 2, 408 - En 1, 408 - En 2, 420, 430, 436 - En 1, 436 - En 2, 443, 459 - En 1, 459 - En 2, 479, 485, 494, 495, 521 - En 1, 521 - En 2, 535 - En 1, 535 - En 2, 585, 596 - En 1, 596 - En 2, 614, 628, 630, 648 - En 1, 648 - En 2.**

5

Synthesis of 2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 318**).



[0392] *Step 1*: To a pre-stirred solution of 2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylic acid (400 mg, 1.320 mmol) in CH_2Cl_2 (30 mL) were added DIPEA (0.9 mL, 5.280 mmol) and methyl 1-aminocyclobutane-1-carboxylate hydrochloride (304 mg, 1.848 mmol) followed by HATU (702 mg, 1.848 mmol) at 0 °C under an argon atmosphere. The reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give the crude material, which was purified by flash chromatography with silica gel (100-200 mesh) using 30% ethyl acetate in pet ether as an eluent to afford methyl 1-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylate (300 mg, 55%) as an off-white solid. TLC system: 80% EtOAc in Pet ether; RF: 0.66

[0393] *Step 2*: To a pre-stirred solution of methyl 1-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylate (300 mg, 0.724 mmol), in THF: MeOH (1:1, 20 mL), was added 2N NaOH (3.5 mL) at RT, then the reaction mixture was heated to 60 °C. The reaction mixture was stirred at this temperature for 3 h, and the reaction progress was monitored by TLC. The reaction mixture was concentrated, diluted with ice water, the pH was adjusted to ~2 with 1N aq. HCl solution to give a solid. The solid was filtered off and dried under reduced pressure to afford 1-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylic acid (300 mg, crude) as an off-white solid. TLC system: 80% EtOAc in Pet ether; RF: 0.24.


[0394] *Step 3*: To a pre-stirred solution of 1-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylic acid (300 mg, 0.750 mmol) in CH_2Cl_2 (30 mL) were added DIPEA (0.5 mL, 3.00 mmol) and methylamine (2M in THF) (2.1 mL, 1.05 mmol) followed by HATU (399 mg, 1.05 mmol) at 0 °C under an argon atmosphere. The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with water (1 x 20 mL) and brine (1 x 30 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford the crude material, which was purified by

30

flash chromatography with silica gel (100-200 mesh) using 20% ethyl acetate in pet ether as eluent to afford 2-methyl-N-(1-(methylcarbamoyl) cyclobutyl)-5-((2-methylthiazol-5-yl) methoxy) benzofuran-3-carboxamide (**cpd 318**) (85 mg, 28% over two steps) as a white solid. TLC system: 50% EtOAc in Pet ether; RF: 0.54.

- [0395] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods known to the person skilled in the art) as described for **cpd 318**: **cpds. 319, 320, 324, 725 – En 1, 725 – En 2, 740 – En 1, 740 – En 2.**

Synthesis of 5-((2-cyanopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide (**cpd 325**) and 3-(((3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)methyl)picolinamide (**cpd 347**)




- [0396] *Step 1:* To a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.8 g, 3.63 mmol, 1.0 eq) in ACN (10 ml) at 0 °C was added Cs_2CO_3 (3.55 g, 10.89 mmol, 3 eq) and the mixture was stirred for 5 minutes, followed by the addition of 3-(bromomethyl)picolinonitrile (0.85 g, 4.36 mmol, 1.2 eq) at 0 °C. The reaction mixture was stirred for 18 h at RT, monitored by TLC. The reaction mixture was diluted with ice water (100 ml) and extracted with EtOAc (300 ml). The organic layer was washed with ice water (100 ml) and brine (50 ml), dried over anhydrous Na_2SO_4 , filtered and concentrated to get the crude product, which was purified by Grace flash column chromatography using eluent 20% EtOAc in pet ether to afford ethyl 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (1.0 g, 81%, off-white solid). TLC system: 20% EtOAc-pet ether; 2:8; Rf: 0.3.

- [0397] *Step 2:* To ethyl 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylate (1.0 g, 2.97 mmol, 1.0 eq), in THF:MeOH:H₂O (1:1:1) (120 ml) was added NaOH (0.35 g, 8.92 mmol, 3.0 eq) at RT, the reaction mixture was then heated to 50 °C for 18 h, the reaction progress was monitored by TLC. The reaction mixture was concentrated and diluted with ice water, the pH was adjusted to ~2 with 1N HCl solution to give a precipitate while stirring for 30 min. The precipitate was filtered off and was dried under vacuum to afford a mixture of 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid and 5-((2-carbamoylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (0.75 g, crude). TLC system: 50% EtOAc-pet ether; Rf: 0.1.

- [0398] *Step 3:* To a pre-stirred solution of a mixture of 5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid, 5-((2-carbamoylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (0.70 g, 2.27 mmol, 1 eq) and (4-aminotetrahydro-2H-pyran-4-yl)methanol (0.35 g, 2.72 mmol, 1.2 eq) in CH_2Cl_2 (100 mL) was added DIPEA (2.0 mL, 11.35 mmol, 5 eq) followed by HATU (1.29 g, 3.40 mmol, 1.5 eq) at 0 °C under an argon atmosphere. The reaction mixture was stirred at room temperature for 3 h and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (100 mL) and extracted with CH_2Cl_2 (2 x 100 mL). The combined organic layers were washed with water (100 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 and

concentrated under reduced pressure to afford the crude material, which was purified by column chromatography/prep HPLC to afford 3-(((3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)methyl)picolinamide (**cpd 325**) (0.110 g, 8% over 2 steps) and 5-((2-cyanopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide (**cpd 347**) (0.130 g, 10% over 2 steps) as white solids.

Synthesis of 4-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 328**) and 6-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 362**)



10

[0399] *Step 1:* To a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (15 g, 68.18 mmol) in acetonitrile (500 mL) was added selectfluor (28.72 g, 81.13 mmol) at RT under an argon atmosphere. The reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The solvent was removed under reduced pressure to give a residue. The residue was dissolved in ethyl acetate (1000 mL), washed with water (500 mL) and brine (250 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material. The crude product was purified by column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford mixture of ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (3.0 g, 18%) as a yellow solid. TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.5.

[0400] *Step 2:* (4-Methylthiazol-5-yl)methanol (4.06 g, 31.51 mmol), ADDP (10.58 g 42.01 mmol) and tri-n-butyl phosphine (10.60 ml 42.01 mmol) were added sequentially to a pre-stirred solution of a mixture of ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (5.0 g, 21.00 mmol) in THF (500 mL) at 0 °C under an argon atmosphere. The reaction mixture was stirred at room temperature for 1 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (2 x 500 mL). The combined organic layers were washed with water (250 mL) and brine (250 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material. The crude material was purified by column chromatography over silica gel (100-200 mesh) using 0-30% ethyl acetate in pet-ether as eluent to afford a mixture of ethyl 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (6.0 g, 81%) as white solid. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.4.

[0401] *Step 3:* 2N NaOH in water (40 mL) was added to a pre-stirred solution of mixture of ethyl 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (6.0 g, 17.19 mmol) in a mixture of methanol (40 mL) and


THF (10 mL) at RT. The reaction mixture was heated to 80 °C for 3 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to RT and then concentrated under reduced pressure to get the crude material. The crude material was poured into ice water (100 mL), acidified to pH~2 with 1N HCl, the obtained white solid was filtered off and was washed with water (20 mL) to afford a mixture of 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 233**) and 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (**cpd 243**) (4.5 g, 81%) as white solid. TLC system: 80% Ethyl acetate in pet-ether; Rf: 0.2.

[0402] *Step 4:* To a stirred solution of a mixture of 4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid compound and 6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1:1) (550 mg, 1.71 mmol) in DMF (10 ml), were added DIPEA (1.2 mL, 6.84 mmol), HATU (970 mg, 2.57 mmol) and (3-(methylamino)oxetan-3-yl)methanol (260 mg, 2.57 mmol) at 0 °C and the reaction mixture was stirred for 2 h at RT. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude compound (715 mg, LCMS: 37% & 23% ratio). The crude compound was purified by reverse phase prep-HPLC purification (column: INERTSIL-ODS 2 (250*19 mm), 5 µm, mobile phase: A: 10 mM Ammonium Bi Carbonate in H₂O, B: MeCN, Gradient: 0/30, 8/55, 9/55, 9.1/98, 11/98, 11.1/30, 14/30; flow rate: 18 mL/min; diluent: MeCN+H₂O+THF) to afford **cpd. 328** (325 mg) and **cpd. 362** (170.9 mg) as an off-white solid.

[0403] The following compounds were prepared in a similar manner (use of appropriate reagents and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpds 328** and **362**: **Cpd. 326 - En 1, 326 - En 2, 327, 330, 360 - En 1, 360 - En 2, 361, 364, 572 - En 1, 572 - En 2, 583, 587.**

[0404] The following compounds were prepared in a similar manner (use of appropriate reagents and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpds 233**: **Cpd 234.**

Synthesis of 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 329**) and 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 363**)




[0405] *Step 1:* To a pre-stirred solution of a mixture of 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide (**cpd 330**) and 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide (**cpd 364**) (1.5 g, 3.37 mmol) in acetonitrile (100 mL) was added NaI (0.99 g, 6.75 mmol) at 0 °C followed by the dropwise addition of TMSCl (0.91 mL, 6.75 mmol) at 0 °C under an argon atmosphere. The reaction mixture was heated to 40 °C for 24 h. The reaction progress was monitored by TLC. The reaction mixture

was diluted with water (100 mL) and extracted with 10% Methanol in CH₂Cl₂ (2 x 100 mL). The combined organic layers were washed with water (100 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the crude product, which was purified by prep-HPLC purification to afford 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 329**) (135 mg) as an off-white solid and 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide (**cpd 363**) (30 mg) as a white solid.

[0406] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods known to the person skilled in the art) as described for **cpds 329** and **363**: **Cpd.**

Synthesis of 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide (**cpd 332**)



[0407] *Step 1:* To a stirred solution of 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (500 mg, 1.48 mmol) in DMF (20 mL) were added DIPEA (1.0 mL, 5.95 mmol), HATU (787 mg, 2.07 mmol) and ethyl 3-amino-2-oxopiperidine-3-carboxylate (385 mg, 2.07 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT, and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (40 mL) and brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to get the crude material. The crude material was purified by Grace chromatography using 35% EtOAc in pet ether as an eluent to afford ethyl 3-(5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-2-oxopiperidine-3-carboxylate (350 mg, 46%) as a brown solid. TLC system: 60% Ethyl acetate in per ether; RF: 0.48.


[0408] *Step 2:* To a stirred solution of ethyl 3-(5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-2-oxopiperidine-3-carboxylate (350 mg, 0.69 mmol) in MeOH (40 mL) was added NaBH₄ (131 mg, 3.47 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure, diluted with water (100 mL), and extracted with ethyl acetate (2 x 100 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to get the crude material which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide (250 mg, 78%) as an off-white solid. TLC system: 100% EtOAc; RF: 0.24.

[0409] A preparative chiral SFC was performed on the racemic mixture of **cpd 332** to afford **cpd 332 – En 1** and **cpd 332 – En 2**.

The following compounds were prepared in a similar manner (use of appropriate reagents and purification methods

(including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 332**: **Cpds. 333 - En 1, 333 - En 2, 355 - En 1, 355 - En 2, 356 - En 1, 356 - En 2, 510 - En 1, 510 - En 2, 511 - En 1, 511 - En 2, 512 - En 1, 512 - En 2, 513 - En 1, 513 - En 2, 514 - En 1, 514 - En 2, 515 - En 1, 515 - En 2, 516 - En 1, 516 - En 2, 517 - En 1, 517 - En 2, 518 - En 1, 518 - En 2, 519 - En 1, 519 - En 2, 520 - En 1, 520 - En 2, 521 - En 1, 521 - En 2, 522 - En 1, 522 - En 2, 719 - En 1, 719 - En 2, 732 - En 1, 732 - En 2, 733 - En 1, 733 - En 2, 734 - En 1, 734 - En 2, 735 - En 1, 735 - En 2, 736 - En 1, 736 - En 2, 737 - En 1, 737 - En 2.**


Synthesis of N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 399**)



[0410] *Step 1*: To a suspension of N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 418**) (300 mg, 0.866 mmol) and CuI (30.6 mg, 0.168 mmol) in acetonitrile (20 mL) was added a solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid (215 mg, 1.209 mmol) in acetonitrile (3 mL) at room temperature and the resulting reaction mixture was heated to 50 °C - 55 °C for 1 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated under reduced pressure to give the crude material which was purified by GRACE flash chromatography using 0.1% of formic acid in water and acetonitrile as an eluent to afford N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 399**) (40 mg, 12%) as a white solid. TLC system: 50% Ethyl acetate in pet-ether; R_f : 0.8

[0411] The following compounds were prepared in a similar manner (use of appropriate reagents and purification methods known to the person skilled in the art) as described for **cpd 399**: **cpd 400**.


Synthesis of (R)-N-(1-(1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 401 - En 1**)



[0412] *Step 1*: EDC.HCl (0.378 g, 1.9801 mmol), HOBt (267 mg, 1.9801 mmol) and DIPEA (510 mg, 3.960 mmol) were added sequentially to a stirred solution of (S)-2-amino-2-(1H-benzo[d]imidazol-2-yl)ethan-1-ol hydrochloride (400 mg, 1.3201 mmol) in DMF (5.0 mL) at room temperature. The resulting reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice cold water (50 mL) and the precipitated solid was filtered and dried under vacuum to afford (S)-N-(1-(1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 401 - En 1**) (140 mg) as a white solid. TLC system: 100% Ethyl acetate ; R_f : 0.2.

[0413] The following compounds were prepared in a similar manner (use of appropriate reagents and purification methods known to the person skilled in the art) as described for **cpd 401 – En 1: cpd 401 – En 2**.

5 Synthesis of N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 413**)



[0414] *Step 1:* To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 3.3 mmol) in DMF (10 mL) was added DIPEA (1.7 mL, 9.9 mmol), HATU (2.5 g, 6.6 mmol) at 0 °C followed by addition of methyl aziridine-2-carboxylate (0.45 g, 4.95 mmol). The reaction mixture was then warmed to room temperature and stirred for 16 h at the same temperature. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined extracts were washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford methyl 1-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbonyl)aziridine-2-carboxylate (1.0 g, crude) as a pale green gum. TLC system: 10% MeOH in dichloromethane; RF: 0.6.

[0415] *Step 2:* To a stirred solution of methyl 1-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbonyl)aziridine-2-carboxylate (1.0 g, 2.591 mmol) in dimethylamine (69.5 mmol, 5.8 g of dimethylamine HCl) was therefore treated with TEA (10 mL) in CHCl₃ (10 mL)) at RT was added boron trifluoride diethyl etherate (0.3 mL, 2.59 mmol) at 0 °C, then the reaction mixture was stirred for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined extracts were washed with brine (2 x 20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude compound, which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile to afford methyl 3-(dimethylamino)-2-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)propanoate (650 mg, 59%) as a pale yellow gum. TLC system: 80% EtOAc in pet-ether; RF: 0.3.


[0416] *Step 3:* To a stirred solution of methyl 3-(dimethylamino)-2-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)propanoate (300 mg, 0.694 mmol) in MeOH (10 mL) was added NaBH₄ (131.8 mg, 3.47 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT and the reaction progress was monitored by TLC. Then the reaction mixture was evaporated under reduced pressure, diluted with water (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated to get the crude material which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 413**) (130 mg, 46%) as an off-white gum. TLC system: 10% Methanol in dichloromethane; RF: 0.4

[0417] A preparative chiral SFC was performed on the racemic mixture of **cpd 413** to afford **cpd 413 – En 1** and **cpd 413 – En 2**.

[0418] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art)

as described for **cpd 413**: **412 - En 1, 412 - En 2, 446 - En 1, 446 - En 2, 449 - En 1, 449 - En 2, 450 - En 1, 450 - En 2, 487 - En 1, 487 - En 2, 488 - En 1, 488 - En 2, 575 - En 1, 575 - En 2.**

Synthesis of N-(1-amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 432**)



[0419] *Step 1*: To a stirred solution of methyl ((benzyloxy)carbonyl)serinate (1.0 g, 3.95 mmol) in chloroform (10 mL) was added PCl_5 (0.4 mL, 4.34 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (2 x 20 mL). The combined extracts were washed with sat. NaHCO_3 solution (2 x 20 mL) and brine (2 x 20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude compound, which was purified by column chromatography using silica gel (100-200) and 10% ethyl acetate in pet ether as an eluent to afford methyl 2-(((benzyloxy)carbonyl)amino)-3-chloropropanoate (500 mg, 47%) as an off-white solid. TLC system: 30% EtOAc in Pet ether; RF: 0.6.

[0420] *Step 2*: To a stirred solution of 1H-1,2,4-triazole (200 mg, 2.89 mmol) in chloroform (10 mL) was added methyl 2-(((benzyloxy)carbonyl)amino)-3-chloropropanoate (946 mg, 3.47 mmol) at RT. To the reaction mixture was added DBU (878 mg, 5.78 mmol) at 0 °C then the reaction mixture was stirred for 16 h at 60 °C. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (3 x 30 mL). The combined extracts were washed with brine (2 x 20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude compound, which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford methyl 2-(((benzyloxy)carbonyl)amino)-3-(1H-1,2,4-triazol-1-yl)propanoate (500 mg, 57%) as a pale yellow gum. TLC system: 50% EtOAc in Pet ether; RF: 0.6.

[0421] *Step 3*: To a stirred solution of methyl 2-(((benzyloxy)carbonyl)amino)-3-(1H-1,2,4-triazol-1-yl)propanoate (400 mg, 1.31 mmol) in MeOH (10 mL) was added 10% Pd/C (170 mg) at RT. The reaction mixture was stirred for 2 h at RT under H_2 (balloon atmosphere). The reaction progress was monitored by TLC. The reaction mixture was diluted with MeOH (10 mL), filtered through a celite bed and the celite bed was washed with MeOH (2 x 10 mL). The filtrate was concentrated under reduced pressure to afford methyl 2-amino-3-(1H-1,2,4-triazol-1-yl)propanoate (200 mg, 42%) as a pale yellow gum. TLC system: 5% MeOH in dichloromethane; RF: 0.4.

[0422] *Step 4*: To a stirred solution of 2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (300 mg, 0.99 mmol) and methyl 2-amino-3-(1H-1,2,4-triazol-1-yl)propanoate (175 mg, 1.48 mmol) in DMF (10 mL) were added DIPEA (0.5 mL, 2.97 mmol) and HATU (752 mg, 1.98 mmol) at 0 °C under an argon atmosphere.


The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC, the reaction mixture was diluted with cold water (25 mL) and extracted with ethyl acetate (2 x 40 mL). The combined organic layers were washed with water (15 mL) and brine (15 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the crude product which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford methyl 2-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)-3-(1H-1,2,4-triazol-1-yl)propanoate (200 mg, 44%) as an off-white gum. TLC system: 10% MeOH in dichloromethane; R_f: 0.3

[0423] *Step 5:* A stirred solution of methyl 2-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)-3-(1H-1,2,4-triazol-1-yl)propanoate (200 mg, 0.439 mmol) in 7.0 M NH₃ in methanol (20 mL) was stirred for 16 h at RT and the reaction progress was monitored by TLC. Then the reaction mixture was evaporated under reduced pressure to get the crude compound, which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford (120 mg, 62%) of N-(1-amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 432**) as an off-white gum. TLC system: 10% MeOH in dichloromethane; R_f: 0.2

[0424] A preparative chiral SFC was performed on the racemic mixture of **cpd 432** to afford **cpd 432 – En 1** and **cpd 432 – En 2**.

[0425] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 432**: **729 – En 1**, **729 – En 2**.

Synthesis of N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 447**)



[0426] *Step 1:* 2-Amino-3-hydroxypropanamide.HCl (686 mg, 6.600 mmol) was added to a stirred solution of 2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (500 mg, 1.65 mmol), HATU (1.14 g, 3.00 mmol) and DIPEA (0.88 mL, 4.95 mmol) in DMF (10 mL) at room temperature. The resulting reaction mixture was stirred at room temperature and under argon atmosphere for 2 h. The reaction progress was monitored by TLC. (Note: Another batch was repeated on 500 mg scale and both the reaction mixtures were mixed together for work-up). The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 453**) (600 mg, 46%) as an off-white solid. TLC system: 100% Ethyl acetate; R_f: 0.2.


[0427] *Step 2:* A solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid (68.5 mg, 0.38 mmol) in acetonitrile (1 mL) at 50 °C was added to a suspension of N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (150 mg, 0.38 mmol) and CuI (78.0 mg, 0.38 mmol) in

acetonitrile (5 mL) and the mixture was heated to 50 °C for 16 h under an argon atmosphere. The reaction progress was monitored by TLC. (Note: Another batch was repeated on 150 mg scale, both the reaction mixtures were mixed together for work-up). The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated under reduced pressure. The crude compound was purified by GRACE flash chromatography using 0.1% of formic acid in water and acetonitrile as an eluent to afford N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 447**) (120 mg, 35%) as a white solid. TLC system: 100% Ethyl acetate; R_f: 0.4.

[0428] A preparative chiral SFC was performed on the racemic mixture of **cpd 447** to afford **cpd 447 – En 1** and **cpd 447 – En 2**.

- [0429] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 447**: **448 – En 1**, **448 – En 2**.

- Synthesis of N-(3-(dimethylamino)oxetane-3-carbonyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 508**), N-(3-carbamoyloxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 589**) and N-(3-cyanooxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 599**)



- [0430] *Step 1*: To a solution of 3-Oxetanone (3 g, 41.66 mmol) in CH₂Cl₂ (50 mL) was added 33% methyl amine in ethanol (39 mL, 416.6 mmol) and the solution was cooled to 0 °C. TMSCN (8.3 mL, 66.66 mmol) was added slowly dropwise for 15 min to the reaction mixture and stirring was continued for 48 h at RT. The reaction mixture was diluted with dichloromethane (100 mL), washed with water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give the crude material, which was purified by grace column chromatography using 2% methanol in dichloromethane as an eluent to afford 3-(methylamino)oxetan-3-carbonitrile (350 mg) as a light brown liquid. TLC system: 5% Methanol in dichloromethane; R_f: 0.4.


- [0431] *Step 2*: To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (500 mg, 1.65 mmol) in dichloromethane (30 mL), was added thionyl chloride (0.24 mL, 3.30 mmol) at 0 °C and the mixture was then heated to 40 °C for 2 h. The reaction progress was monitored by TLC. After completion of the reaction volatiles were removed under reduced pressure. To this was added an already prepared mixture of 3-(methylamino)oxetan-3-carbonitrile (369 mg, 3.30 mmol) in dichloromethane (20 mL), the mixture was cooled to 0 °C followed by the addition of triethyl amine (1.15 mL, 8.25 mmol). The reaction mixture was stirred for 16 h at RT, reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and

extracted with dichloromethane (2 x 50 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material (0.6 g) which was purified by grace column chromatography to afford **cpd 599** (300 mg) as an off - white solid. TLC system: 5% Methanol in dichloromethane; Rf: 0.6.

- 5 [0432] *Step 3:* To a solution of N-(3-cyanooxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (1 g, 2.51 mmol) in THF (50 mL) was added NaOH (201 mg, 5.03 mmol) at 0 °C. 30% H₂O₂ in water (0.2 mL, 2.51 mmol) was added slowly (dropwise) over 5 min to the reaction mixture and the mixture was then stirred for 1 h at RT. The reaction progress was monitored by TLC. The reaction mixture was diluted with dichloromethane (100 mL). The organic layer was washed with water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material which was purified by grace chromatography using 3% Methanol in dichloromethane as an eluent to afford N-(3-carbamoyloxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 589**) (530 mg) as an off-white solid. TLC system: 5% Methanol in Dichloromethane; Rf: 0.2.

- 10 [0433] *Step 4:* To a solution of N-(3-carbamoyloxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (500 mg, 1.20 mmol) in THF (50 mL) was added 60% NaH (72.2 mg, 1.80 mmol) at 0 °C, and the mixture was stirred for 15 min. MeI (0.082 mL, 1.32 mmol) was added slowly (dropwise) over 5 min to the reaction mixture and the mixture was stirred for 2 h at 0 °C . The reaction progress was monitored by TLC. The reaction mixture was diluted with dichloromethane (100 mL). The organic layer was washed with water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material, which was purified by prep-HPLC to afford N-(3-(dimethylamino)oxetane-3-carbonyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 508**) (60 mg) as an off-white solid. TLC system: 5% Methanol in Dichloromethane; Rf: 0.5.

25 Synthesis of N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 530**).



- 30 [0434] *Step 1:* To a stirred solution of 3-amino-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (0.6 g, 2.606 mmol) in dichloromethane (10 mL) and MeOH (5 mL) was added a 0.6 M TMS-diazomethane solution in n-Hexane (8.6 mL, 5.212 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT. Reaction progress was monitored by TLC. The reaction mixture was diluted with water (20 mL) and extracted with dichloromethane (2 x 20 mL). The combined extracts were washed with brine (2 x 20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the crude product of 1-(tert-butyl) 3-methyl 3-aminopyrrolidine-

1,3-dicarboxylate (0.6 g) as a pale yellow gum. TLC system: 5% MeOH in dichloromethane; RF: 0.3.

[0435] *Step 2:* To a stirred solution of 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid (300 mg, 0.99 mmol) in DMF (10 mL) were added DIPEA (0.53 mL, 2.97 mmol), HATU (564.3 mg, 1.485 mmol) and 1-(tert-butyl) 3-methyl 3-aminopyrrolidine-1,3-dicarboxylate (0.45 g, 4.95 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined extracts were washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material, which was purified by column chromatography over silica gel (100-200 mesh) using 40% ethyl acetate in pet-ether as an eluent to afford 1-(tert-butyl) 3-methyl 3-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1,3-dicarboxylate (330 mg, 62%) as a pale green gum. TLC system: 10% MeOH in dichloromethane; RF: 0.5.


[0436] *Step 3:* To a stirred solution of 1-(tert-butyl) 3-methyl 3-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1,3-dicarboxylate (300 mg, 0.566 mmol) in MeOH (15 mL) was added NaBH₄ (107.8 mg, 2.834 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT and the reaction progress was monitored by TLC. The reaction mixture was evaporated under reduced pressure, diluted with water (20 mL), and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford (250 mg, 85%) of tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate as an off-white gum. TLC system: 10% Methanol in dichloromethane; RF: 0.2

[0437] *Step 4:* To a stirred solution of tert-butyl 3-(hydroxymethyl)-3-(2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate (250 mg, 0.498 mmol) in dichloromethane (10 mL) was added TFA (0.4 mL) at 0 °C. The reaction mixture was stirred for 6 h at RT and the reaction progress was monitored by TLC. The reaction mixture was diluted with dichloromethane (50 mL). The organic layer was washed with saturated NaHCO₃ solution (2 x 20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated to get the crude material which was purified by GRACE flash chromatography using 0.1% aqueous formic acid in acetonitrile as an eluent to afford N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (100 mg, 50%) as an off-white gum. TLC system: 10% Methanol in dichloromethane; RF: 0.1.

[0438] A preparative chiral SFC was performed on the racemic mixture of **cpd 530** to afford **cpd 530 – En 1** and **cpd 530 – En 2**.

[0439] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 530 – En 1 & cpd 530 – En 2**: **Cpds. 728 – En 1, 728 – En 2**.

35 Synthesis of N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide (**cpd 730**).



Step 1: To a stirred solution of ethyl 3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (3.0 g, 14.42 mmol) in DMF (50 mL) was added K_2CO_3 (3.98 g, 28.84 mmol) at RT. The RM was cooled to 0 °C, and added SEM-Cl (3.0 mL, 17.30 mmol). The RM was stirred at 0 °C for 1 h and reaction progress was monitored by TLC. The reaction mixture was diluted with water (100 mL), and extracted with ethyl acetate (2 x 100 mL). Combined organic layers were washed with water (3 x 100 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get a crude. Crude was purified by column chromatography using silica gel (100-200 mesh) and 10% ethyl acetate in pet ether as an eluent to afford ethyl 3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carboxylate (2.8 g, 58%) as a solid. TLC system: 10% ethyl acetate in pet ether; Rf: 0.6.

Step 2 : To a stirred solution of ethyl 3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carboxylate (2.8 g, 8.28 mmol) in THF (50 mL) was added 1M LAH solution in THF (12.4 mL, 12.42 mmol) at 0 °C. The RM was stirred at 0 °C for 2 h and the reaction progress was monitored by TLC. Reaction mixture was quenched with aq. sat. sodium sulphate solution at 0 °C, diluted with ethyl acetate (50 mL), filtered through celite bed, and celite bed was washed with ethyl acetate (50 mL). Combined filtrate was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford (3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methanol (2.5 g). TLC system: 10% ethyl acetate in pet ether; RF: 0.23.

Step 3 : To a stirred solution of (3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methanol (1.5 g, 5.06 mmol) in DCM (50 mL) was added triethylamine (1.4 mL, 10.13 mmol) and followed by addition of Mesyl Chloride (0.58 mL, 7.60 mmol) at 0 °C. The RM was stirred for 16 h at RT and the reaction progress was monitored by TLC. The RM was diluted with water (40 mL) and extracted with DCM (3 x 50 mL). Combined extracts were washed with brine (20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford (3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl methanesulfonate (1.7 g) as a brown liquid. Proceeded to next step without further purification; TLC system: 10% ethyl acetate in pet ether; RF: 0.7.

Step 4 : To a stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (1.5 g, 6.81 mmol) in acetonitrile (100 mL) was added Cs_2CO_3 (6.6 g, 20.45 mmol) and followed by addition of (3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl methanesulfonate (2.7 g, 7.49 mmol) at 0 °C. The RM was stirred for 6 h at 80 °C and the reaction progress was monitored by TLC. The RM was filtered and washed the filter bed with ethyl acetate (100 mL). Filtrate was concentrated under reduced pressure to get crude. Crude was purified by column chromatography over silica gel (100-200 mesh) using 10% ethyl acetate in pet-ether as an eluent to afford ethyl 2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-

yl)methoxy)benzofuran-3-carboxylate (1.3 g, 59% over 3 steps) as an off-white solid. TLC system: 20% ethyl acetate in pet ether; RF: 0.7.

Step 5 : To a stirred solution of ethyl 2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylate (1.3 g, 2.61 mmol) in MeOH: THF: H₂O (1:1:0.5, 50 mL) was added NaOH (1.0 g, 26.10 mmol) at RT. The RM was stirred for 4 h at 50 °C and the reaction progress was monitored by TLC. The RM was concentrated, acidified to pH ~2 with aq. 1N HCl solution, and stirred for 20 minutes. The precipitated solid was filtered, washed with water (10 mL) and dried under vacuum to afford 2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g) as an off-white solid. TLC system: 20% ethyl acetate in pet ether; RF: 0.1

Step 6 : To a stirred solution of 2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid (1.0 g, 2.12 mmol) in DMF (20 mL) was added HATU (1.21 g, 3.19 mmol), DIPEA (1.5 mL, 8.51 mmol) at 0 °C and followed by addition of ethyl 3-amino-2-oxopyrrolidine-3-carboxylate (548 mg, 3.19 mmol). The RM was stirred for 16 h at RT and reaction progress was monitored by TLC. The RM was diluted with water (100 mL), and extracted with ethyl acetate (2 x 100 mL). Combined organic layers were washed with water (3 x 100 mL), brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ethyl 3-(2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamido)-2-oxopyrrolidine-3-carboxylate (1.0 g) as a brown residue. TLC system: 60% ethyl acetate in pet ether; RF: 0.2.

Step 7 : To a stirred solution of ethyl 3-(2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamido)-2-oxopyrrolidine-3-carboxylate (1.0 g, 1.60 mmol) in MeOH (20 mL) was added NaBH₄ (608 mg, 16.02 mmol) at 0 °C. The RM was stirred for 16 h at RT and reaction progress was monitored by TLC. The RM was concentrated, diluted with water (50 mL), and extracted with ethyl acetate (2 x 100 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide (800 mg, crude) as a thick residue. TLC system: 60% ethyl acetate in pet-ether; RF: 0.2.


Step 8 : To a stirred solution of N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide (800 mg, 1.37 mmol) in DCM (30 mL) was added TFA (5 mL) at 0 °C. The RM was stirred for 6 h at RT and the reaction progress was monitored by TLC. The reaction mixture was concentrated, basified to pH ~8 with aq. sat NaHCO₃ solution and extracted with ethyl acetate (2 x 100 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get crude. Crude was purified by Grace flash chromatography using 0.1% formic acid in acetonitrile as an eluent to afford N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide (**Cpd 730**) (500 mg, 34% for 4 steps).

[0440] A preparative chiral SFC was performed on the racemic mixture of **cpd 730** to afford **cpd 730 – En 1** and **cpd 730 – En 2**.

[0441] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art)

as described for **cpd 730 – En 1** and **cpd 730 – En 2**: **Cpds. 731 – En 1, 731 – En 2**.

Synthesis of N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((6-methoxypyridin-2-yl)methoxy)benzofuran-3-carboxamide (**cpd 569**).



[0442] *Step 1*: To a pre-stirred solution mixture of 5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid (1.0 g, 3.19 mmol), HATU (1.8 g, 4.79 mmol) and DIPEA (3.4 mL, 6.38 mmol) in DMF (20.0 mL) was added tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (0.904 g, 3.83 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. (Note: Another 1.0 g of 5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid was similarly reacted using the same procedure and was combined with the reaction described in detail for work-up). The combined reaction mixture was diluted with ice cold water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (2 x 100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as an eluent to afford tert-butyl 3,3-difluoro-4-(5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate (1.2 g, 36%) as an off-white solid. TLC system: 50% Ethyl acetate in pet ether; R_f: 0.4.

[0443] *Step 2*: HCl (4.0 M in dioxane) (10 mL) was added dropwise to a pre-stirred solution of tert-butyl 3,3-difluoro-4-(5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate (600 mg, 1.12 mmol) in dichloromethane (5 mL) at 0 °C under an argon atmosphere. The resulting reaction mixture was allowed to attain room temperature and was stirred for 5 h. The reaction progress was monitored by TLC. (Note: 600 mg of tert-butyl 3,3-difluoro-4-(5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate was similarly treated following the same procedure and was combined with the reaction mixture for work-up). The combined reaction mixture was concentrated under reduced pressure, the residue was basified with saturated NaHCO₃ (80 mL) solution and the organic compound was extracted with 10% methanol in dichloromethane (3 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as an eluent to afford N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide (900 mg, 92%) as an off-white solid. TLC system: 5% Methanol in dichloromethane; R_f: 0.2.

[0444] *Step 3*: TMS-Cl (189 mg, 1.740 mmol) was slowly added to a pre-stirred mixture of N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide (500 mg, 1.156 mmol) and NaI (347 mg, 2.32 mmol) in acetonitrile (10 mL) at room temperature and the resulting reaction mixture was heated to 60 °C for 24h. The reaction progress was monitored by TLC. (Note: 400 mg of N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide was similarly reacted following the same procedure and was combined with the reaction mixture for work-up). The combined reaction mixture was cooled to room temperature, quenched with brine solution (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under


reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as an eluent to afford N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxamide (340 mg, 33%) as an off white solid. TLC system: 5% MeOH in dichloromethane; R_f : 0.3.

- 5 [0445] A preparative chiral SFC was performed on the racemic mixture of **cpd 569** to afford **cpd 569 – En 1** and **cpd 569 – En 2**.

[0446] The following compounds were prepared in a similar manner (use of appropriate reagents (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art) as described for **cpd 569**: **Cpds. 564 – En 1, 564 – En 2, 569 – En 1, 569 – En 2, 637 – En 1, 637 – En 2, 640 – En**

10 **1, 640 – En 2**.

Synthesis of 4-(((3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)methyl)-1-methylene-1H-1,2,3-triazol-1-ium (**cpd 604**) and N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 605**)




15

[0447] *Step 1*: Methyl iodide (55.5 mL, 891.7 mmol) was added dropwise to a suspension of NaN_3 (27.8 g, 428.1 mmol) and prop-2-yn-1-ol (20.0 g, 356.7 mmol) in DMF (200 mL) at room temperature under an argon atmosphere. The reaction mixture was heated to 130 °C for 18 h. The reaction progress was monitored by TLC. The reaction mixture was cooled and treated with 200 mL of diethyl ether and the precipitate was removed by filtration. The filtrate was concentrated under reduced pressure. The crude compound was subjected to distillation at 130°C to obtain a mixture of (1-methyl-1H-1,2,3-triazol-5-yl)methanol and (1-methyl-1H-1,2,3-triazol-4-yl)methanol (6.0 g, 15%) as a pale yellow liquid. TLC system: 5% Methanol in dichloromethane; R_f : 0.2.

- 20 [0448] *Step 2*: Thionyl chloride (4.7 mL, 66.3 mmol) was added dropwise to a mixture of (1-methyl-1H-1,2,3-triazol-5-yl)methanol and (1-methyl-1H-1,2,3-triazol-4-yl)methanol (5.0 g, 44.2 mmol) in dichloromethane (50 mL) at 0 °C under an argon atmosphere. The reaction mixture was heated to 40 °C and was stirred for 4 h. Excess thionyl chloride and solvent were then evaporated *in vacuo*. The residue was cooled to 0 °C, basified with saturated NaHCO_3 to pH ~9 and extracted with dichloromethane (3 x 50 mL). The combined organic layer was washed with water (100 mL) and brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford a mixture of 5-(chloromethyl)-1-methyl-1H-1,2,3-triazole and 4-(chloromethyl)-1-methyl-1H-1,2,3-triazole (4.2 g, 71%) as a pale yellow liquid. TLC system: 50% Ethyl acetate in pet-ether; R_f : 0.5.
- 25
- 30

- [0449] *Step 3:* NaH (60%) (1.9 g, 81.6 mmol) was added in small portions to a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (6.0 g, 27.2 mmol) and a mixture of 5-(chloromethyl)-1-methyl-1H-1,2,3-triazole and 4-(chloromethyl)-1-methyl-1H-1,2,3-triazole (4.2 g, 32.7 mmol) in DMF (50 mL) at 0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and was stirred for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (100-200 mesh) using a gradient mixture of 0-40% ethyl acetate in pet-ether as an eluent to afford a mixture of ethyl 2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylate (**cpd 253**) and ethyl 2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylate (**cpd 254**) (2.2 g, 22%) as a pale yellow semi solid. TLC system: 70% Ethyl acetate in pet-ether; R_f: 0.2.
- [0450] *Step 4:* A solution of NaOH (1.1 g, 27.9 mmol) in water (15 mL) was added to a pre-stirred solution of a mixture of ethyl 2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylate and ethyl 2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylate (2.2 g, 6.98 mmol) in methanol: THF (1:1) (40 mL) at room temperature and the resulting reaction mixture was heated to 60 °C for 3 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to room temperature and poured into ice cold water (100 mL), acidified with 1N HCl to pH~2.0 and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (100 mL) followed by brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford a mixture of 2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylic acid and 2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylic acid (1.7 g, 85%) as a pale yellow solid. TLC system: 5% Methanol in dichloromethane; R_f: 0.2.
- [0451] *Step 5:* (4-Aminotetrahydro-2H-pyran-4-yl)methanol (164.3 mg, 1.25 mmol) was added to a stirred solution of a mixture of 2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylic acid and 2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylic acid (300 mg, 1.04 mmol), HATU (790.8 mg, 2.08 mmol) and DIPEA (0.56 mL, 3.12 mmol) in DMF (10 mL). The resulting reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as an eluent followed by chiral-SFC to afford N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide (**cpd 605**) (90 mg) and N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxamide (**cpd 604**) (50 mg) as off-white solids. TLC system: 70% Ethyl acetate in pet-ether; R_f: 0.4.
- 35 Synthesis of N3-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-2,3-dicarboxamide (**cpd 657**).



[0452] *Step 1:* To a stirred solution of ethyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (4 g, 10.5 mmol) in 1,4-dioxane (50 ml) was added SeO_2 (24 g, 21.1 mmol) at RT and the reaction mixture was stirred for 48 h at 120 °C, the reaction progress was monitored by TLC. The reaction mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure to get the crude material (6 g), which was purified by silica gel (100-200 mesh) column chromatography to afford (1 g, 24 %) as a pale yellow solid. TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.4

[0453] *Step 2:* To a stirred solution of ethyl 2-formyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (1 g, 2.54 mmol) in ethanol (50 ml) was added $\text{NH}_2\text{OH}\cdot\text{HCl}$ (880 mg, 12.8 mmol) and pyridine (405 mg, 4.1 mmol) at RT and the resulting reaction mixture was then heated to 80 °C for 6 h. Ice cold water was added to the reaction mixture and the mixture was then extracted with EtOAc (2x10 mL). The combined organic layers were washed with water (50 mL) and brine (20 mL), dried over anhydrous Na_2SO_4 , filtered and evaporated under reduced pressure to get the crude material which was used in the next step without further purification. TLC system: 100% Ethyl acetate in pet-ether; Rf: 0.2

[0454] *Step 3:* To a stirred solution of (E)-N-(3-(ethoxycarbonyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-2-yl)formimidic acid (1 g, 2.4 mmol) in THF (50 ml) were added DIPEA (0.722 g, 3 mmol) and T_3P (2.64 g, 3 mmol) at 0 °C and the resulting reaction mixture was stirred at RT for 16 h. Ice cold water was added to the reaction mixture and the mixture was extracted with EtOAc (2x10 mL). The combined organic layers were washed with water (50 mL) and brine (20 mL), dried over anhydrous Na_2SO_4 , filtered and evaporated under reduced pressure to get the crude material which was purified by flash column chromatography over neutral alumina using 20% ethyl acetate in pet-ether as an eluent to afford ethyl 2-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (0.5 g, 52%) as an off-white solid. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.7

[0455] *Step 4:* To ethyl 2-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylate (550 mg, 1.4 mmol) was added $\text{LiOH}\cdot\text{H}_2\text{O}$ (110 mg, 2.8 mmol) in THF:H₂O (20 mL) at RT under an argon atmosphere. The reaction mixture was stirred for 2 h at RT. The reaction progress was monitored by TLC. The reaction mixture was acidified to pH ~1 with citric acid and the resulting precipitate was filtered off. The solid obtained was dried under vacuum to afford 2-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.35 g, 68%) as an off-white solid. TLC system: 5% MeOH in CH_2Cl_2 ; Rf: 0.2.


[0456] *Step 5:* To a stirred solution of 2-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid (0.35 g, 9 mmol) in CH_2Cl_2 (30 ml) were added DIPEA (0.23 g, 1.8 mmol) and HATU (0.69 g, 1.8 mmol) at 0 °C followed by the addition of tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (273 mg, 1.1 mmol), then the reaction mixture was stirred for 6 h at RT, and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (150 mL), and extracted with CH_2Cl_2 (3 x 100 mL). The combined organic

extracts were washed with brine (150 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude compound (0.5 g) which was used without further purification in the next step.

[0457] *Step 6:* To a stirred solution of tert-butyl 4-(2-cyano-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate (25 mg, 0.043 mmol) in 1,4-dioxane (10 mL), were added 4 M HCl in 1,4-dioxane (5 mL) at 0 °C and the mixture was stirred for 2 h at RT, the reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to get the crude compound (30 mg, LCMS: 88%). The crude compound was purified by prep-SFC to afford of (12 mg) as an off-white solid. TLC system: 10% Methanol in Dichloromethane; Rf: 0.3.

[0458] **Cpd 657** can be obtained in enantiomerically pure form as **cpd 657 – En 1** and **cpd 657 – En 2** using a chiral SFC separation of the product obtained after step 5. Both obtained enantiomers are then forwarded independently to obtain **cpd 657 – En 1** and **cpd 657 – En 2**.

Synthesis of N3-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-2,3-dicarboxamide (**cpd 658**).




[0459] *Step 1:* PTSA (0.051 g, 0.3 mmol) was added to a stirred solution of ethyl 5-(benzyloxy)-2-formylbenzofuran-3-carboxylate (1 g, 3 mmol) and ethylene glycol (0.925 g, 15.4 mmol) in toluene (20 mL) at RT. The resulting reaction mixture was stirred at 120 °C for 12 h using a Dean-stark apparatus. The reaction mixture was evaporated under reduced pressure to get a residue. The residue obtained was dissolved in ethyl acetate (20 mL) and washed with sat. NaHCO_3 solution (100 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and evaporated under reduced pressure to get the crude material which was purified by neutral alumina column chromatography using 20% ethyl acetate in pet ether to afford ethyl 5-(benzyloxy)-2-(1,3-dioxolan-2-yl)benzofuran-3-carboxylate (900 mg, 81 %) as an off-white solid. TLC system: 20% EtOAc in Hexane; Rf: 0.4.

[0460] *Step 2:* To a stirred solution of ethyl 5-(benzyloxy)-2-(1,3-dioxolan-2-yl)benzofuran-3-carboxylate (0.9 g, 2.4 mmol) in ethanol (20 mL) was added 10% Pd/C (150 mg, 10 mol%), and then the reaction mixture was stirred for 6 h under H_2 atm pressure (60 psi) at RT, the reaction progress was monitored by TLC. The reaction mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure to get the crude material (1 g) as a colorless oil, which was used in the next step without further purification. TLC system: 40% Ethyl acetate in pet-ether; Rf: 0.5.


- [0461] *Step 3:* (4-Methylthiazol-5-yl)methanol (2044-6) (0.229 g, 1.7 mmol), ADDP (0.604 g, 2.4 mmol) and tri-n-butylphosphine (0.484 g, 2.4 mmol) were added sequentially to a pre-stirred solution of ethyl 2-(1,3-dioxolan-2-yl)-5-hydroxybenzofuran-3-carboxylate (0.45 g, 1.6 mmol) in THF (15 mL) at RT under an argon atmosphere. The reaction mixture was stirred for 18 h at RT and the reaction progress was monitored by TLC. The reaction mixture was filtered and washed with diethyl ether (300 mL), the filtrate was concentrated under reduced pressure to give the crude material which was purified by flash column chromatography over neutral alumina using 10% ethyl acetate in pet-ether as an eluent to afford ethyl 2-(1,3-dioxolan-2-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.2 g, 30%) as an off-white solid. TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.35
- [0462] *Step 4:* To a stirred solution of ethyl 2-(1,3-dioxolan-2-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (100 mg, 2.57 mmol) in CH₂Cl₂ (10 mL) was added TFA (58 mg, 5.14 mmol) at 0 °C and the resulting reaction mixture was stirred at rt for 16 h. After completion of the reaction, ice-cold water was added to the reaction mixture and the mixture was extracted with CH₂Cl₂ (2x10 mL). The combined organic layers were washed with sat. NaHCO₃ solution (50 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure to get the crude material, which was used in the next step without further purification. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.3
- [0463] *Step 5:* To a stirred solution of ethyl 2-formyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (50 mg, 0.14 mmol) in ethanol (10 mL) were added NH₂OH.HCl (39 mg, 5 mmol) and pyridine (22 mg, 2.8 mmol) at RT and the resulting mixture was stirred at 90 °C for 6 h. After completion of the reaction ice-cold water was added to the reaction mixture and the mixture was extracted with CH₂Cl₂ (2x10 mL). The combined organic layers were washed with sat. NaHCO₃ solution (50 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure to get the crude material, which was used in the next step without further purification. TLC system: 100% Ethyl acetate in pet-ether; Rf: 0.2.
- [0464] *Step 6:* To a stirred solution of (E)-ethyl 2-((hydroxyimino)methyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (1 g, 2.8 mmol) in THF (50 mL) were added DIPEA (0.722 g, 3 mmol) and T₃P (2.64 g, 3 mmol) at 0 °C and the resulting reaction mixture was then stirred at RT for 16 h. Ice cold water was added to the reaction mixture and the mixture was extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure to get the crude material which was purified by flash column chromatography over neutral alumina using 20% ethyl acetate in pet-ether as an eluent to afford ethyl 2-cyano-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.3 g, 31%) as an off-white solid. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.6.
- [0465] *Step 7:* To a stirred solution of ethyl 2-cyano-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylate (0.15 g, 4 mmol) in THF (50 mL) were added (4-aminotetrahydro-2H-pyran-4-yl)methanol (0.068 g, 5.2 mmol) and 2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine (0.108 g, 7.8 mmol) at RT and the resulting reaction mixture was heated to 80 °C for 40 min. Ice cold water was added to the reaction mixture and the mixture was extracted with EtOAc (2x10 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure to get the crude compound, which was purified by reverse phase prep-HPLC purification to afford 13 mg of **cpf 658** as an off-white solid. TLC system: 50% Ethyl acetate in pet-ether; Rf: 0.2.

Synthesis of small synthetic intermediates used for the synthesis of cpds. 001-666




[0466] *Step 1:* A solution of methyl S-methyl-L-cysteinate (1) (2.0 g, 0.013 mmol) and 7 M NH₃ solution in methanol (20 mL) in a sealed tube was heated to 90 °C and stirred for 16 h at the same temperature. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure, and was then co-distilled with EtOAc (2 x 20 mL). To the reaction mixture was added EtOAc (30 mL), the reaction mixture was then stirred for 2 h, and the solid was filtered off and dried to afford (R)-2-amino-3-(methylthio)propanamide (1.6 g, 88%) as a brown solid. TLC system: 5% Methanol in dichloromethane; RF: 0.1

[0467] *Step 2:* To a stirred solution of (R)-2-amino-3-(methylthio) propanamide (1.0 g, 0.007 mmol) in methanol and water (2: 1), was added oxone (5.0 g, 0.008 mmol) at RT. The reaction mixture was stirred for 16 h at RT. The reaction mixture was concentrated under reduced pressure, and was then co-distilled with methanol (2 x 20 mL) to afford (R)-2-amino-3-(methylsulfonyl)propanamide (6.0 g crude) as a white solid which was used without any further purification.



[0468] *Step 1:* To a stirred solution of methyl S-methyl-L-cysteinate (1.0 g, 6.71 mmol) and THF (20 mL) was added 1 M LAH solution in THF (8 mL, 8.0 mmol) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C. The reaction progress was monitored by TLC. Then the reaction mixture was quenched with saturated Na₂SO₄ solution and was filtered. The filtrate was concentrated under reduced pressure to afford (R)-2-amino-3-(methylthio)propan-1-ol (800 mg, crude) as a thick residue. TLC system: 10% Methanol in dichloromethane; RF: 0.1


[0469] *Step 2:* To a stirred solution of (R)-2-amino-3-(methylthio)propan-1-ol (800 mg, 6.61 mmol) in methanol and water (2:1) was added oxone (4.4 g, 7.27 mmol) at RT. The reaction mixture was stirred for 16 h at RT. The reaction mixture was concentrated under reduced pressure, and was then co-distilled with methanol (2 x 20 mL) to afford (R)-2-amino-3-(methylsulfonyl)propan-1-ol (5.1 g crude) as a white solid, which was used without any further purification.



[0470] *Step 1:* EDC.HCl (1.3 g, 4.87 mmol), HOBt (0.98 g, 7.31 mmol), DIPEA (2.5 mL, 14.63 mmol) and 3,3-difluoropyrrolidine (0.837 g, 5.85 mmol) were added sequentially to a stirred solution of (tert-butoxycarbonyl)-L-serine (1.0 g, 4.87 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice cold water (100 mL) and the precipitated solid was filtered and dried under vacuum to afford t-butyl


(S)-(1-(3,3-difluoropyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl)carbamate (650 mg, crude) as a yellow solid. TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.5.

[0471] *Step 2:* 4M HCl in 1,4-dioxane (6.5 mL) was added to t-butyl (S)-(1-(3,3-difluoropyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl)carbamate (0.650 g, 2.210 mmol) at room temperature under an argon atmosphere. The resulting reaction mixture was stirred at room temperature for 30 min. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford ((S)-2-amino-1-(3,3-difluoropyrrolidin-1-yl)-3-hydroxypropan-1-one (450 mg, crude) as an off-white solid. TLC system: 30% ethyl acetate in pet-ether; Rf: 0.3.



[0472] *Step 1:* To a stirred solution of 2-(benzyloxycarbonylamino)-3-hydroxypropanoic acid (2 g, 0.3 mmol) and methanamine hydrochloride (0.616 g, 9.2 mmol) in DCM (30 mL) was added DIPEA (0.077 g, 6 mmol) followed by HATU (0.228 g, 6 mmol) at 0 °C and the resulting mixture was stirred at RT for 18 h. Ice cold water was added to the reaction mixture and the mixture was extracted with DCM (2x50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure to get the crude material, which was purified by neutral alumina column chromatography using 5% methanol in CHCl₃ as eluent. All appropriate fractions were combined and evaporated under reduced pressure to get benzyl 3-hydroxy-1-(methylamino)-1-oxopropan-2-ylcarbamate (1 g) as pale yellow solid. TLC system: 20% Methanol in CHCl₃; Rf: 0.3

[0473] *Step 2:* To a stirred solution of benzyl 3-hydroxy-1-(methylamino)-1-oxopropan-2-ylcarbamate (1 g, 3.9 mmol) in methanol (50 mL) was added Pd/C (200 mg, 10 mol%) under a nitrogen atmosphere and the reaction mixture was stirred under H₂ pressure of 50 psi for 16 h at RT. The reaction mixture was then filtered through a pad of celite and the celite bed was washed with methanol (40 mL). The filtrate was evaporated under reduced pressure to afford crude 2-amino-3-hydroxy-N-ethylpropanamide (0.35 g) as a colorless semi-solid residue. The crude product thus obtained was used in the next step without further purification. TLC system: 20% Ethyl acetate in pet-ether; Rf: 0.1.




[0474] *Step 1:* At 0 °C, ethyl 2-chloro-2-oxoacetate (3.6 mL, 30.985 mmol) was added drop-wise to a solution of cyclobutanamine (2.0 g, 28.169 mmol) and Et₃N (8.6 mL, 61.971 mmol) in diethyl ether (20 mL). The resulting reaction mixture was stirred at 0 °C to RT for 1 h. The reaction progress was monitored by TLC. The reaction mixture was filtered and the filtrate washed with diethyl ether (2 x 100 mL). The filtrate was concentrated under reduced pressure to afford ethyl 2-(cyclobutylamino)-2-oxoacetate (3.0 g, 62%) as a brown oil. This crude compound was used without further purification. TLC system: 10% MeOH in dichloromethane; Rf: 0.5.

[0475] *Step 2:* A solution of LAH (1 M in THF, 35 mL, 35.08 mmol) was added to a suspension of ethyl 2-(cyclobutylamino)-2-oxoacetate (3.0 g, 17.54 mmol) in THF at 0 °C and the resulting reaction mixture was

stirred at 0 °C-RT for 3 h. The reaction was monitored by TLC. The reaction mixture was quenched with aq. 1M NaOH solution (5 mL) at 0 °C under stirring. The solids were filtered off, and the filter cake was washed with 10% MeOH in dichloromethane. The filtrate was concentrated under reduced pressure to afford N-cyclobutyl-2-hydroxyacetamide (1.8 g, 79%) as a pale yellow solid. This compound was used in the next step without any further purification. TLC system: 10% MeOH in dichloromethane; Rf: 0.3.

[0476] *Step 3:* LiAlH₄ (1M solution in THF) (16.7 mL, 16.74 mmol) was added to a suspension of N-cyclobutyl-2-hydroxyacetamide (1.8 g, 13.95 mmol) in THF at 0 °C and the resulting reaction mixture was heated to 70 °C for 16 h. The reaction was monitored by TLC. The reaction mixture was quenched with aq. 1M NaOH solution (5 mL) at 0 °C under stirring, the precipitated solids were filtered off, the filter cake was washed with 10% MeOH in dichloromethane. The combined filtrate was dried over anhyd. Na₂SO₄ and concentrated under reduced pressure to afford 2-(cyclobutylamino)ethan-1-ol (1.0 g, 62%) as a brown gummy solid. TLC system: 10% Methanol in dichloromethane; Rf: 0.2



[0477] *Step 1:* To a pre-stirred mixture of benzene-1,2-diamine (1.0 g, 9.250 mmol), HATU (4.210 g, 11.10 mmol) and DIPEA (4.8 mL, 27.75 mmol) in DMF (10.0 mL) was added O-benzyl-N-(tert-butoxycarbonyl)-D-serine (3.0 g, 10.175 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (75 mL) and extracted with ethyl acetate (2 x 80 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated to give the crude material which was purified by column chromatography over silica-gel (100-200 mesh) eluting with 25% ethyl acetate in pet-ether as an eluent to afford tert-butyl (S)-(1-((2-aminophenyl)amino)-3-(benzyloxy)-1-oxopropan-2-yl)carbamate (1.1 g) as a yellow semi-solid. TLC system: 5% Methanol in dichloromethane; Rf: 0.1.


[0478] *Step 2:* A solution of tert-butyl (S)-(1-((2-aminophenyl)amino)-3-(benzyloxy)-1-oxopropan-2-yl)carbamate (500 mg, 1.298 mmol) and acetic acid (5.0 mL) was stirred at 80 °C for 1 h. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford tert-butyl (R)-(1-(1H-benzo[d]imidazol-2-yl)-2-(benzyloxy)ethyl)carbamate (400 mg, crude) as a colorless semi solid. This crude compound was directly used in the next step. TLC system: 5% methanol in dichloromethane; Rf: 0.7.

[0479] *Step 3:* A solution of tert-butyl (R)-(1-(1H-benzo [d]imidazol-2-yl)-2-(benzyloxy)ethyl)carbamate (2.3 g, 6.259 mmol) and HCl (4 M in dioxane) (23.0 mL) was stirred at room temperature for 1 h. The reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford (R)-1-(1H-benzo[d]imidazol-2-yl)-2-(benzyloxy)ethan-1-amine hydrochloride (1.8 g, crude) as a pale yellow semi-solid. This crude was directly used in the next step. TLC system: 5% Methanol in dichloromethane; Rf: 0.3.

[0480] *Step 4:* 10% Pd-C (230 mg) was added to a stirred solution of (R)-1-(1H-benzo[d]imidazol-2-yl)-2-(benzyloxy) ethan-1-amine hydrochloride (0.500 g, 1.872 mmol) in ethyl acetate (30 mL) and concentrated HCl (0.5 mL) at room temperature. The resulting reaction mixture was stirred at room temperature under hydrogen gas balloon pressure for 16 h. The reaction progress was monitored by TLC. The reaction mixture was filtered through a celite bed. The filtrate was concentrated under reduced pressure to afford (R)-2-amino-2-(1H-


benzo[d]imidazol-2-yl)ethan-1-ol hydrochloride (400 mg, crude) as an off-white solid. TLC system: 30% ethyl acetate in pet-ether; Rf: 0.2.

[0481] (S)-2-amino-2-(1H-benzo[d]imidazol-2-yl)ethan-1-ol hydrochloride can be prepared using the same synthetic sequence starting from O-benzyl-N-(tert-butoxycarbonyl)-L-serine.




[0482] *Step 1:* To a pre-stirred solution of methyl 1-methyl-1H-pyrazole-5-carboxylate (5 g, 35.71 mmol) in acetonitrile (200 mL) was added selectfluor (28.72 g, 42.85 mmol) and acetic acid (5 mL) at 0 °C under an argon atmosphere. The reaction mixture was heated up to 120 °C for 24 h. The reaction progress was monitored by TLC. The excess solvent was removed under reduced pressure and the crude product was dissolved in ethyl acetate (500 mL). The ethyl acetate layer was washed with water (250 mL) and brine (150 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material, which was purified by silica gel (100-200 mesh) column chromatography using 0-20% ethyl acetate in pet-ether as an eluent to afford methyl 4-fluoro-1-methyl-1H-pyrazole-5-carboxylate (0.8 g, 14%) as an off-white solid. TLC system: 20% EtOAc in Pet ether; Rf: 0.4.

[0483] *Step 2:* To a stirred solution of methyl 4-fluoro-1-methyl-1H-pyrazole-5-carboxylate (0.8 g, 5.06 mmol, 1 eq) in THF (30 mL) at 0 °C, was added LAH (1M) (6 mL, 6.07 mmol, 1.2 eq) solution in THF drop wise at 0 °C under an argon atmosphere. The reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC. The reaction mixture was quenched with sat. Na₂SO₄ solution and extracted with 10% methanol in dichloromethane (2 x 50 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude material, which was purified by column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford (4-fluoro-1-methyl-1H-pyrazol-5-yl)methanol (0.45 g, 69%) as a colorless liquid. TLC system: 20% EtOAc in Pet ether; Rf: 0.3.




[0484] *Step 1:* To a stirred solution of (3-(trifluoromethyl)-1H-pyrazol-4-yl)methanol (600 mg, 3.61 mmol, 1.0 eq) and dichloromethane (50 mL) was added phosphorous tribromide (0.51 mL, 5.42 mmol, 1.5 eq) at 0 °C under an argon atmosphere. The reaction mixture was stirred for 2 h at 0 °C. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice water (100 mL) and extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 4-(bromomethyl)-3-(trifluoromethyl)-1H-pyrazole (430 mg, 52%) as a thick residue. TLC system: 5% methanol in dichloromethane; Rf: 0.7.



[0485] *Step 1:* To a stirred solution of 2-oxo-1,2-dihydropyridine-3-carbaldehyde (10 g, 81.3 mmol, 1.0 eq) in DMF (10 ml) was added Cs_2CO_3 (31.7 g, 97.56 mmol, 1.2 eq) followed by MeI (6.07 ml, 97.56 mmol, 1.2 eq) at 0 °C. The reaction mixture was stirred for 3 h at RT and the reaction progress was monitored by TLC. After completion of the reaction, the mixture was diluted with water (30 ml) and extracted with EtOAc (3 x 50 ml). The combined organic layers were washed with water (20 ml) and brine (20 ml), dried over anhydrous Na_2SO_4 , filtered and concentrated to afford 1-methyl-2-oxo-1,2-dihydropyridine-3-carbaldehyde (6.8 g, 61%, off-white solid). TLC system: 40% EtOAc/Pet ether; RF: 0.4.

[0486] *Step 2:* To a stirred solution of 1-methyl-2-oxo-1,2-dihydropyridine-3-carbaldehyde (6.8 g, mmol, 1.0 eq) in methanol (10 ml) was added NaBH_4 (208.6 mg, 6.347 mmol, 1.2 eq) at 0 °C. The reaction mixture was stirred for 3 h at RT and the reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (30 ml) and extracted with EtOAc (3 x 50 ml). The combined organic layers were washed with water (20 ml) and brine (20 ml), dried over anhydrous Na_2SO_4 , filtered and concentrated to get the crude material which was purified by Grace flash column chromatography to afford 3-(hydroxymethyl)-1-methylpyridin-2(1H)-one (3.5 g, 52%, off-white solid). TLC system: 40% EtOAc/Pet ether; RF: 0.4.

[0487] *Step 3:* To a stirred solution of 3-(hydroxymethyl)-1-methylpyridin-2(1H)-one (600 g, 4.37 mmol, 1.0 eq) in CH_2Cl_2 (15 ml) was added Et_3N (1.5 ml, 10.86 mmol, 2.5 eq) followed by methanesulfonyl chloride (0.5 ml, 6.52 mmol, 1.5 eq) at 0 °C. The reaction mixture was stirred for 3 h at RT and the reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (30 ml) and extracted with EtOAc (3 x 50 ml). The combined organic layers were washed with water (20 ml) and brine (20 ml), dried over anhydrous Na_2SO_4 , filtered and concentrated to get (1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl methanesulfonate (365 mg crude, yellow color liquid). TLC system: 40% EtOAc/Pet ether; RF: 0.75. Note: (1-Methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl methanesulfonate was unstable even in work up and distillation at RT under vacuum. Crude was directly taken to next step.




[0488] *Step 1:* Thionyl chloride (5 mL) was added dropwise to a solution of 6-oxo-1,6-dihydropyridine-2-carboxylic acid (12.0 g, 86.26 mmol) in ethanol (300 mL) at 0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and stirred for 16 h. The excess of thionyl chloride and solvent was evaporated in vacuo and the residue was cooled to 0 °C, the remains were basified with saturated NaHCO_3 to pH ~9 and the resulting mixture was extracted with ethyl acetate (3 x 200 mL). The combined organic layer was washed with water (200 mL) and brine (200 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to afford ethyl 6-oxo-1,6-dihydropyridine-2-carboxylate (8.0 g, 57%) as an off-white solid. TLC system: 50% Ethyl acetate in pet-ether; RF: 0.5.

[0489] *Step 2:* Methyl iodide (8.1 g, 57.48 mmol) was added to a suspension of ethyl 6-oxo-1,6-dihydropyridine-2-carboxylate (8.0 g, 47.90 mmol) and Cs_2CO_3 (46.7 g, 143.71 mmol) in DMF (100 mL) at

0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and was stirred for 5 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with ice cold water (200 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica-gel (100-200 mesh) using a solvent gradient mixture of 0-30% ethyl acetate in pet-ether to obtain ethyl 1-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (2.0 g) & ethyl 6-methoxypicolinate (2.5 g, 52%) as pale yellow solid.

[0490] *Step 3:* NaBH₄ (1.25 g, 33.14 mmol) was added in small portions to a solution of ethyl 1-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (2.0 g, 11.04 mmol) in t-butanol (50 mL) at room temperature. The reaction mixture was heated to 60 °C, and was then stirred for 1 h before being rapidly cooled to room temperature. Methanol (2.5 mL) was added dropwise to the reaction mixture was then heated to 60°C for 3 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to 0 °C and was diluted with water (100 mL). The mixture was extracted with 10% methanol in dichloromethane (2 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 6-(hydroxymethyl)-1-methylpyridin-2(1H)-one (1.2 g 80%) as a pale yellow thick mass. TLC system: 100% Ethyl acetate; Rf: 0.2.

[0491] *Step 4:* Methanesulfonyl chloride (1.2 mL) was added dropwise to a solution mixture of 6-(hydroxymethyl)-1-methylpyridin-2(1H)-one (1.2 g, 8.63 mmol) and TEA (3.5 mL, 25.89 mmol) in dichloromethane (30 mL) at 0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and was stirred for 3 h. The reaction progress was monitored by TLC. The solvents were evaporated in vacuo and the residue was cooled to 0 °C, basified with saturated NaHCO₃ to a pH ~8 and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford (1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methyl methanesulfonate (2.4 g, crude) as a pale yellow thick mass. The resulting crude product was used for next step without further purification. TLC system: 30% Ethyl acetate in pet-ether; Rf: 0.5




[0492] *Step 1:* To a stirred solution of 2-hydroxynicotinic acid (3.0 g, 21.58 mmol) in ethanol (50 mL) was added SOCl₂ (21 mL) at room temperature, and reaction mixture was heated to 90 °C for 8 h. The reaction progress was monitored by TLC. The mixture was cooled to RT, the volatiles were evaporated under reduced pressure and ice-cold water (400 ml) was added to the reaction mixture. The pH was adjusted to ~7 – 8 with NaHCO₃ powder and the mixture was then extracted with chloroform (3 x 500 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get ethyl 2-hydroxynicotinate (1.0 g, 27%, crude) as an off-white solid. TLC system: 100% Ethyl acetate; Rf: 0.43. The material was used in the next step without further purification.

[0493] *Step 2:* To a stirred solution of ethyl 2-hydroxynicotinate (500 mg, 2.99 mmol) in acetonitrile (10 mL) was added 6M KOH (6 mL) followed by the addition of difluoromethyl trifluoromethanesulfonate (1.7 g, 8.98 mmol) at 0 °C under an argon atmosphere. The reaction mixture was stirred for 16 h at RT. The reaction progress

was monitored by TLC. Solvents were removed under vacuum and ice cold water was added to the reaction mixture. The mixture was then extracted with ethyl acetate (2 x 100 mL). The combined extracts were washed with brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford crude 2-(difluoromethoxy) nicotinic (500 mg) as a yellow solid, which was used in the next step without further purification. TLC system: 10% MeOH in CH₂Cl₂; RF: 0.38.


[0494] *Step 3:* To a stirred solution of 2-(difluoromethoxy) nicotinic acidoxylate (500 mg, 2.64 mmol) in THF (15 mL) was added NaBH₄ (201 mg, 5.29 mmol) followed by the addition of BF₃ etherate (0.7 mL, 5.29 mmol) at 0 °C. The reaction mixture was heated to 80 °C for 16 h. The reaction progress was monitored by TLC. The reaction mixture was concentrated, diluted with H₂O (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum to get the crude material, which was purified by flash chromatography to afford (2-(difluoromethoxy) pyridin-3-yl) methanol (100 mg, 19% over 2 steps) as a colorless liquid. TLC system: 80% Ethyl acetate in pet ether; RF: 0.56.

[0495] *Step 4:* To a stirred solution of (2-(difluoromethoxy) pyridin-3-yl) methanol (100 mg, 0.57 mmol) in dichloromethane (10 mL) was added Et₃N (0.1ml, 0.85 mmol) followed by the addition of MsCl (98 mg, 0.85 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford crude (2-(difluoromethoxy) pyridin-3-yl) methyl methanesulfonate (150 mg) as a brown solid. TLC system: 50% EtOAc in pet-ether; RF: 0.62. Crude was used in the next step without further purification and analytical data.




[0496] *Step 1:* To a stirred solution of 2-methylnicotinaldehyde (1.0 g, 8.26 mmol) in dichloromethane (50 mL) was added DAST (1.63 mL, 12.3 mmol) at 0 °C and reaction mixture was stirred for 2 h at RT. The reaction progress was monitored by TLC, reaction mass was diluted with dichloromethane (100 mL) and washed with water (2 x 50 mL) followed by brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material, which was purified by Grace flash chromatography using 20% ethyl acetate in pet ether as an eluent to afford 3-(difluoromethyl)-2-methylpyridine (500 mg, 42%) as a thick colorless liquid. TLC system: 30% Ethyl acetate in pet-ether; RF: 0.3.

[0497] *Step 2:* To a stirred solution of 3-(difluoromethyl)-2-methylpyridine (500 mg, 3.49 mmol) in carbon tetra chloride (30 mL) were added NBS (742 mg, 4.19 mmol) and AIBN (58 mg, 0.349 mmol) at 0 °C under an argon atmosphere. The reaction mixture was stirred for 16 h at 80 °C. The reaction progress was monitored by TLC. The reaction mass was diluted with dichloromethane (100 mL) and was washed with water (2 x 50 mL) followed by brine (50 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to get the crude material, which was purified by Grace flash chromatography using 15% ethyl acetate in pet ether as an eluent to afford 2-(bromomethyl)-3-(difluoromethyl)pyridine (150 mg, 20%). TLC system: 30% Ethyl acetate in pet-ether; RF: 0.6




[0498] *Step 1:* To a stirred solution of methyl 1H-pyrazole-5-carboxylate (1.5 g, 11.90 mmol) in CH_3CN (50 mL) was added Cs_2CO_3 (11.6 g, 35.712 mmol) followed by the addition of 2,2-difluoroethyl trifluoromethanesulfonate (3.8 g, 17.857 mmol) at RT and the reaction mixture was then heated to 70 °C for 2 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (100 mL) and was extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed with brine (30 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to get the crude material, which was purified by flash chromatography using 10% ethyl acetate in pet ether as eluent to afford methyl 1-(2, 2-difluoroethyl)-1H-pyrazole-5-carboxylate (1 g) as a colorless liquid. (TLC: 40% Ethyl acetate in pet ether: R_f = 0.68)

[0499] *Step 2:* To a stirred solution of methyl 1-(2, 2-difluoroethyl)-1H-pyrazole-5-carboxylate (1 g, 5.263 mmol) in MeOH (30 mL), was added NaBH_4 (600 mg, 15.789 mmol) at 0 °C and the reaction mixture was stirred at reflux for 16 h. The reaction progress was monitored by TLC. The reaction mixture was concentrated, diluted with water (120 mL) and extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed with brine (20 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to afford (1-(2, 2-difluoroethyl)-1H-pyrazol-5-yl)methanol (900 mg, crude) as a colorless liquid. The obtained crude material was used in the next step without further purification. (TLC: 100% Ethyl acetate: R_f = 0.2).



[0500] *Step 1:* To a stirred solution of methyl 1-methyl-1H-pyrazole-5-carboxylate (700 mg, 5.00 mmol) in Acetic acid (15 mL) was added NaOCl (2.2 g, 30.00 mmol) at 0 °C. The RM was stirred for 2 h at RT and the reaction progress was monitored by TLC. The RM was concentrated under reduced pressure, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). Combined extracts were washed with brine (20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography by using 5% ethyl acetate in pet ether as eluents.


[0501] *Step 2:* To a stirred solution of methyl 4-fluoro-1-methyl-1H-pyrazole-5-carboxylate (0.8 g, 5.06 mmol 1 eq) in THF (30 mL) at 0 °C, was added LAH (1M) (6 mL, 6.07 mmol, 1.2 eq) solution in THF drop wise at 0 °C under an argon atmosphere. The RM was stirred at RT for 2 h. The reaction progress was monitored by TLC. The reaction mixture was quenched with sat. Na_2SO_4 solution and extracted with 10% methanol in dichloromethane (2 x 50 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give the crude material, which was purified by column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford (4-fluoro-1-methyl-1H-pyrazol-5-yl)methanol (0.45 g, 69%) as a colorless liquid. TLC system: 20% EtOAc in Pet ether; R_f : 0.3.



[0502] *Step 1:* To a stirred solution of ethyl 1-isopropyl-1H-pyrazole-5-carboxylate (1.5 g, 8.287 mmol) in Acetic acid (15 mL) was added NaOCl (3.3 mL, 49.723 mmol) at 0 °C. The RM was stirred for 6 h at RT, and the reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). Combined extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (100-200 mesh) using 15% ethyl acetate in pet-ether as an eluent to afford ethyl 4-chloro-1-isopropyl-1H-pyrazole-5-carboxylate (500 mg, 28%). TLC system: 30% ethyl acetate in pet ether; RF: 0.68

[0503] *Step 2:* To a stirred solution of methyl 4-fluoro-1-methyl-1H-pyrazole-5-carboxylate (0.8 g, 5.06 mmol 1 eq) in THF (30 mL) at 0 °C, was added LAH (1M) (6 mL, 6.07 mmol, 1.2 eq) solution in THF drop wise at 0 °C under an argon atmosphere. The RM was stirred at RT for 2 h. The reaction progress was monitored by TLC. The RM was quenched with sat. Na₂SO₄ solution and extracted with 10% methanol in dichloromethane (2 x 50 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (100-200 mesh) using 0-20% ethyl acetate in pet-ether as an eluent to afford (4-fluoro-1-methyl-1H-pyrazol-5-yl)methanol (0.45 g, 69%) as a colorless liquid. TLC system: 20% EtOAc in Pet ether; Rf: 0.3.

[0504] *Step 3:* To a pre-stirred solution of (4-chloro-1-isopropyl-1H-pyrazol-5-yl) methanol (350 mg, 2.011 mmol) in dichloromethane (15 mL) was added triethylamine (0.5 mL, 4.02 mmol) and mesyl chloride (0.2 mL, 3.016 mmol) at 0°C and the RM was stirred at RT for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and extracted with dichloromethane (2 x 30 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford (4-chloro-1-isopropyl-1H-pyrazol-5-yl) methyl methanesulfonate (450 mg, crude) as a color less liquid. Crude was used in the next without further purification. TLC system: 20% ethyl acetate in pet ether; RF: 0.75.



[0505] *Step 1:* To a pre-stirred solution of (1-isopropyl-1H-pyrazol-5-yl) methanol (500 mg, 3.571 mmol) in dichloromethane (15 mL) was added triethylamine (1 mL, 7.142 mmol) and mesyl chloride (0.4 mL, 5.357 mmol) at 0°C. The RM was stirred at RT for 16 h. The reaction progress was monitored by TLC. The RM was diluted with water (50 mL) and extracted with dichloromethane (2 x 30 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford ((1-isopropyl-1H-pyrazol-5-yl) methyl methanesulfonate (550 mg, crude) as a color less liquid. Crude was used in next without further purification. TLC system: 50% ethyl acetate in pet ether; RF: 0.65.




Step 1: To a pre-stirred solution of (2,4-dimethyloxazol-5-yl)methanol (500 mg, 3.937 mmol) in DCM (50 mL)


was added triethylamine (1.6 mL, 11.811 mmol) and Mesyl chloride (676.1 mg, 5.905 mmol) at 0°C and the RM was stirred at RT for 3 h. The RM was diluted with water (25 mL) and extracted with dichloromethane (2 x 25 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and evaporated under vacuum at 35 °C to afford (2, 4-dimethylthiazol-5-yl) methyl methanesulfonate (560 mg, crude) as a brown liquid. TLC system: 30% Ethyl acetate in Pet ether; RF: 0.6. Proceeded to next step without purification and based on TLC.




- 5 *Step 1:* To a stirred solution of (1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methanol (200 mg, 1.11 mmol) in DCM (10 mL), was added CBr₄ (551 mg, 1.66 mmol) and followed by addition of TPP (582 mg, 2.62 mmol) at 0 °C. The RM was stirred at RT for 3 h. The reaction progress was monitored by TLC. The RM was diluted with water (30 mL) and extracted with dichloromethane (2 x 40 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and evaporated under reduced pressure to afford 5-(bromomethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole (235.5 mg, crude) as an off-white solid. Proceeded to next step without further purification and based on TLC. TLC system: 30% ethyl acetate in pet ether; RF: 0.3.




- 10 *Step 1:* To a stirred solution of (1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methanol (1.0 g, 6.570 mmol) in dichloromethane (20 mL) was added Et₃N (2.7 mL, 19.71 mmol) and followed by addition of mesyl chloride (1.12 g, 9.855 mmol) at 0 °C. The RM was stirred at RT for 2 h and the reaction progress was monitored by TLC. The RM was diluted with water (30 mL) and extracted with dichloromethane (2 x 30 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and evaporated under reduced pressure to afford (1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methyl methanesulfonate (1.4 g, crude) as a pale brown liquid. Crude was used in the next step without purification and based on TLC. TLC system: 40% Ethyl acetate in pet ether; RF: 0.5.



- 20 *Step 1:* To a stirred solution of (1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methanol (400 mg, 2.222 mmol) in dichloromethane (20 mL) was added triethylamine (673 mg, 6.666 mmol) and followed by addition of methane sulfonyl chloride (379 mg, 3.333 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (40 mL) and extracted with dichloromethane (3 x 50 mL). Combined extracts were washed with brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford (1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl methanesulfonate (3) (360 mg) as a pink solid. Crude was used in the next step without purification.
- 25 TLC system: 20% Ethyl acetate in pet ether; RF: 0.54



- Step 1* : To a stirred solution of (3-cyclopropylpyridin-2-yl) methanol (500 mg, 3.355 mmol) in DCM (25 mL) was added triethylamine (1 mL, 6.711 mmol) and mesyl chloride (0.4 mL, 5.032 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 16 h. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (2 x 50 mL). Combined organic layer were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford (3-cyclopropylpyridin-2-yl) methyl methanesulfonate (650 mg, crude) as a brown liquid. Crude was used in the next without further purification. TLC system: 50% Ethyl acetate in pet ether; RF: 0.68.



- Step 1* : To a stirred solution of methyl 2-fluoronicotinate (2 g, 12.90 mmol) in DMF (50 mL) was added Cs₂CO₃ (6.2 g, 19.354 mmol) and followed by addition of cyclopropanol (1.1 g, 19.354 mmol) at RT. The reaction mixture was stirred for 16 h at 80 °C, and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 40 mL). Combined organic layers were washed with water (40 mL), brine (40 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude. Crude was purified by column chromatography using silica gel (100-200 mesh size) and 20% ethyl acetate in pet ether as an eluent to afford methyl 2-cyclopropoxynicotinate (1.0 g, 40%) as a brown liquid. TLC system: 40% Ethyl acetate in Pet ether; RF: 0.62.

- Step 2* : To a stirred solution of methyl 2-cyclopropoxynicotinate (1.0 g, 5.181 mmol) in THF (15 mL) was added 1M LAH (5 mL, 5.181 mmol) at 0 °C. The reaction mixture was stirred for 6 h at RT, and the reaction progress was monitored by TLC. The reaction mixture was quenched with Aq Na₂SO₄ and stirred for 10 min, solid was filtered and the filtrate was dried under vacuum to afford (2-cyclopropoxy)pyridin-3-yl methanol (600 mg, crude) as a brown liquid. TLC system: 50% Ethyl acetate; RF: 0.20.

- Step 3* : To a stirred solution of (2-cyclopropoxy)pyridin-3-yl methanol (500 mg, 3.030 mmol) in CCl₄ (20 mL) was added PPh₃ (1.58 g, 6.060 mmol) and followed by addition of CBr₄ (2.0 g, 6.060 mmol) at 0 °C. The reaction mixture was stirred for 16 h at RT, and the reaction progress was monitored by TLC. The reaction mixture was diluted with water (50 mL), and extracted with ethyl acetate (3 x 40 mL). Combined organic layers were washed with water (20 mL), brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford crude. Crude was purified by column chromatography using silica gel (100 - 200 mesh size) and 15% ethyl acetate in pet ether as an eluent to afford 3-(bromomethyl)-2-cyclopropoxy pyridine (800 mg) as a brown liquid. TLC system: 40% Ethyl acetate in Pet ether; RF: 0.71.

[0506] Analytical data

Cpd	[M+H] ⁺ (m/z) :	[M-H] ⁻ (m/z) :	LC/MS Method	RT (min.)	¹ H NMR (δ ppm)
001	-	271	L1	7.6	(300 MHz, DMSO-d ₆): 12.94 (1H, s); 7.78 (1H, s); 7.68 (1H, s); 7.45 - 7.53 (2H, m); 6.96 (1H, dd); 6.60 (1H, br s); 4.99 (2H, s); 2.71 (3H, s)
002	274	272	L1	6.2	-
003	276	274	L5	5.1	-
004	284	282	L5	6.1	(300 MHz, DMSO-d ₆): 8.58 (d, 2H); 7.43 - 7.56 (4H, m); 7.02 (1H, dd); 5.22 (2H, s); 2.71 (3H, s)
005	284	282	L5	7.8	(300 MHz, DMSO-d ₆): 8.51 - 8.65 (1H, m); 7.96 (1H, s); 7.83 (1H, td); 7.72 (1H, d); 7.53 (1H, d); 7.19 - 7.39 (2H, m); 6.77 - 6.97 (1H, m); 5.16 (2H, s); 2.66 (3H, s)
006	284	282	L1	3.5	(300 MHz, DMSO-d ₆): 8.70 (1H, s); 8.55 (1H, d); 7.91 (1H, d); 7.33 - 7.61 (3H, m); 6.99 - 7.16 (1H, m); 5.19 (2H, s); 2.71 (3H, s)
007	285	283	L5	7.6	(300 MHz, DMSO-d ₆): 12.96 (1H, br s); 9.22 (1H, dd); 7.82 - 7.92 (1H, m); 7.67 - 7.80 (1H, m); 7.45-7.54 (2H, m); 7.05 (1H, dd); 5.27 - 5.63 (2H, m); 2.71 (3H, s)
008	287	285	L1	6.6	(300 MHz, DMSO-d ₆): 7.48 - 7.73 (2H, m); 7.37 (1H, d); 6.92 - 7.08 (1H, m); 6.37 (1H, d); 5.20 (2H, s); 3.85 - 3.98 (3H, m); 2.71 (3H, s)
009	287	285	L1	6.5	-
010	287	285	L1	6.0	-
011	-	287	L1	9.2	(300 MHz, DMSO-d ₆): 12.04 (1H, br s); 7.53 - 7.63 (2H, m); 7.42 - 7.51 (2H, m); 7.21 (1H, dd); 6.97 (1H, dd); 5.11 (2H, s); 2.71 (3H, s)
012	-	287	L1	8.9	-
013	290	288	L1	7.0	(300 MHz, DMSO-d ₆): 12.96 (1H, br s); 7.85 (1H, d); 7.78 (1H, d); 7.39 - 7.60 (2H, m); 7.04 (1H, dd); 5.48 (2H, s); 2.71 (3H, s)
014	290	288	L1	6.7	-
015	0	289	L1	7.3	-
016	302	300	L1	8.4	-
017	340	338	L2	4.8	-
018	-	339	L1	8.8	-
019	-	374	L1	9.1	-
020	342	-	L6	6.80	-
021	352	350	L3	4.30	(DMSO d ₆ , 300 MHz): 8.87 (2 H, d); 8.12 (2 H, d); 7.51 (1 H, d); 7.34 (1 H, br s); 7.08-7.03 (1 H, m); 5.51 (2 H, s); 4.60-4.50 (1 H, m); 3.01 - 3.55 (4 H, m); 2.59 (3 H, s); 2.30-2.19 (1 H, m); 1.92 - 2.10 (1 H, m)
022	352	350	L3	4.90	(DMSO d ₆ -D ₂ O, 300 MHz): 8.93 (1H, s); 8.79 (1H, d); 8.58 (1H, d); 7.01 (1H, dd); 7.53 (1H, d); 7.34 (1H, d); 7.08 (1H, dd); 5.36 (1H, s); 4.51 - 4.69 (1H, m); 3.22 - 3.62 (2H, m); 2.61 (1H, s); 2.20 - 2.43 (1H, m); 1.91 - 2.16 (1H, m)
023	355	-	L3	4.40	-
024	358	356	L6	7.20	-
025	358	-	L3	4.70	(DMSO d ₆ -D ₂ O, 300 MHz): 7.86 (1 H, d); 7.76 (1 H, d); 7.52 (1 H, d); 7.32 (1 H, d); 6.98 - 7.12 (1 H, m); 5.49 (2 H, s); 4.6-4.5 (1 H, m); 3.6-3.2 (4 H, m); 2.61 (3 H, s); 2.40-2.2 (1 H, m); 2.18-1.97 (1H, m)

Cpd	[M+H] ⁺ (m/z) :	[M-H] ⁻ (m/z) :	LC/MS Method	RT (min.)	¹ H NMR (δ ppm)
026	366	364	U5	1.8	(300 MHz, DMSO-d ₆): 8.43 - 8.73 (1 H, m); 8.01 - 8.25 (1 H, m); 7.70 - 7.96 (2 H, m); 7.20 - 7.65 (4 H, m); 7.05-6.95 (1 H, m); 5.08 - 5.30 (2 H, s) 4.35 - 4.76 (1 H, m) 3.51-3.54 (1 H, m) 2.94 - 3.27 (4 H, m) 2.61 (3 H, s) 1.92 - 2.17 (1 H, m)
027	366	-	U5	1.6	-
028	366	364	U5	2.24	(DMSO d ₆ , 300 MHz): 8.52 (br. s., 1H), 8.42 (br. s., 1H), 8.27 (d, 1H), 7.73 (br. s., 1H), 7.49 (d, 1H), 7.31 (br. s., 1H), 7.00 (d., 1H), 5.18 (br. s., 2H), 4.48 (br. s., 1H), 3.06-3.30 (m, 2H), 2.87 - 3.03 (m, 2H), 2.61 (s., 3H), 2.34 (s, 3H), 2.00 - 2.21 (m, 1H), 1.74 - 1.96 (m, 1H).
029	366	-	U5	2.20	(CDCl ₃ , 300 MHz): 7.61 (1 H, t); 7.29 - 7.42 (2 H, m); 7.22 - 7.43 (1 H, m); 7.27 (1 H, s); 7.16 (1 H, d); 7.03 - 7.13 (1 H, m); 6.95 (1 H, dd); 6.18-6.30 (1 H, m); 5.22 (2 H, s); 4.40 - 4.82 (1 H, m); 3.06 - 3.39 (2 H, m); 2.90-3.10 (2 H, m); 2.68 (3 H, s); 2.58 (3 H, s); 2.08 - 2.38 (1 H, m); 1.59 - 1.98 (1 H, m)
030	397	-	U4	2.4	-
031	366	364	U4	2.5	-
032	367	365	U5	1.3	-
033	367	365	U5	2.4	-
034	367	-	U5	2.3	-
035	371	-	U3	0.6	-
036	372	370	U2	2.01	(300 MHz, DMSO-d ₆): 8.15 (1H, d); 7.89 (1H, s); 7.85 (1H, d); 7.79 (1H, d); 7.50 (1H, d); 7.41 (1H, d); 7.03 (1H, dd); 5.47 (2H, s); 4.59 (1H, m); 3.25 (3H, dd); 2.62 (3H, s); 1.80 - 2.19 (m, 1H)
037	380	-	U5	2.05	-
038	380	-	U5	2.2	(300 MHz, CDCl ₃): 8.52 (1 H, s); 8.41 (1 H, s); 7.64 (1 H, s); 7.35 - 7.39 (1 H, m); 7.34 (1 H, s); 6.82 - 7.01 (1 H, m); 6.38 - 6.56 (1 H, m); 5.72 - 6.00 (1 H, m); 5.11 (2 H, s); 4.54 (1 H, d); 3.48 (2 H, dd); 2.83 - 3.08 (1 H, m); 2.58 - 2.77 (3 H, m); 2.37 (3 H, s); 1.86 - 2.23 (1 H, m)
039	380	378	L3	4.50	-
040	383	381	U5	2.0	(300 MHz, DMSO-d ₆) : 8.42 - 8.53 (m, 2H), 8.23 (d, 1H), 7.46 (d, 1H), 7.23 (d, 1H), 7.12 (d, 1H), 6.96 (dd, 1H), 5.09 (s, 2H), 4.41 - 4.57 (m, 1H), 3.91 (s, 3H), 3.80 - 3.89 (m, 2H), 3.69 - 3.78 (m, 1H), 3.61 (dd, 1H), 2.57 (s, 3H), 2.08 - 2.23 (m, 1H), 1.85 - 2.02 (m, 1H).
041	385	-	L3	6.5	-
042	386	-	U5	1.8	-
043	386	384	U5	2.0	(400 MHz, DMSO-d ₆): 8.14 (1 H, d); 7.88 (1 H, s); 7.46 - 7.54 (1 H, m), 7.41 (1 H, d); 7.30 (1 H, s); 6.86 - 7.09 (1 H, m); 5.41 (2 H, s); 4.53 - 4.67 (1 H, m); 3.14 - 3.27 (2 H, m); 2.62 (3 H, s); 2.30-2.45 (4 H, m) 1.97 - 2.17 (1 H, m)
044	394	392	U5	2.1	-
045	394	-	L3	4.8	-
046	396	394	U5	2.4	(300 MHz, DMSO-d ₆) : 8.12 - 8.22 (m, 2H), 7.89 (s, 1H), 7.84 (d, 1H), 7.47 (d., 1H), 7.37 (d, 1H), 7.04 (dd, 1H), 6.97 (dd., 1H), 5.08 (s, 2H), 4.51 - 4.65 (m, 1H), 3.93 (s, 3H), 3.20 - 3.31 (m, 2H), 2.62 (s, 3H), 2.30 - 2.44 (m, 1H), 1.93-2.11 (m, 1H).

Cpd	[M+H] ⁺ (m/z) :	[M-H] ⁻ (m/z) :	LC/MS Method	RT (min.)	¹ H NMR (δ ppm)
047	397	395	U4	3.15	(DMSO d6, 400 MHz): 8.58 (1H,m); 7.84 (1H, td); 7.54 (1H, d); 7.48-7.42 (2H, m); 7.34 (1H,ddd); 7.26 (1H,d); 6.99 (1H,dd); 5.21 (2H, s); 4.92 (1H,t); 3.72-3.58 (6H,m); 2.60 (3H, s), 2.20 (1H,m); 2.16 (1H,m); 1.63 (2H, ddd).
048	402	-	U4	2.38	(DMSO d6, 300 MHz): 8.58 (1H,d); 8.22 (1H,d); 7.82 (1H, td); 7.54 (1H, d); 7.48 (1H, d); 7.00 (1H,dd); 5.19 (2H, s); 4.57-4.38 (1H,m); 3.11-3.07 (1H,m); 2.95-2.76 (2H,m); 2.66-2.57 (4H,m); 1.79-1.65 (2H,m).
049	403	401	U5	1.95	-
050	408	-	U5	1.10	(CDCl ₃ , 300 MHz): 7.81 (1 H, d); 7.33 - 7.43 (2 H, m); 7.27-7.30 (1 H, m); 6.89 - 7.08 (1 H, m); 6.05 (1 H, d); 5.43 (2 H, s); 3.30-3.40 (1 H, m); 3.17 (1 H, d); 2.73 - 3.07 (2 H, m); 2.71 (3 H, s); 2.20-2.25 (1 H, m)
051	410	408	U5	2.9	(300MHz, CDCl ₃): 8.14 (1H, dd); 7.77 (1H, d); 7.34 (1H, d); 7.18 (1H, d); 6.97-6.90 (2H, m); 5.67 (1H, d); 5.10 (2H, m); 4.10-3.96 (4H, m); 2.83 (2H, d); 2.69 (3H, s); 2.32 (3H, s); 2.20 (2H, t); 2.09 (2H, m).
052	411	409	U4	3.18	-
053	416	414	U4	3.41	-
054	417	415	U5	2.24	(CDCl ₃ , 300 MHz): 8.72 (1 H, s); 7.38 (1 H, d); 7.12 - 7.31 (2 H, m); 6.95 (1 H, dd); 5.79 (1 H, s); 5.23 (2 H, s); 4.56 (1 H, br. s.); 3.68 - 3.98 (6 H, m); 2.71 (3 H, s); 2.49 (3 H, s); 1.85 - 2.12 (4 H, m)
055	366	364	U5	2.24	-
056	422	420	U4	2.76	(CDCl ₃ , 300 MHz): 8.72 (1 H, s); 7.37 (1 H, d); 6.83 - 7.00 (1 H, m); 6.02 (1 H, d); 5.23 (2 H, s); 3.28 - 3.46 (1 H, m); 3.13-3.20 (1 H, m); 2.75 - 3.04 (2 H, m); 2.71 (3 H, s); 2.50 (3 H, s); 2.15-2.25 (1 H, m); 1.61 - 1.79 (1 H, m) 1.25 (2 H, s)
057	427	425	U5	3.3	-
058	427	425	U5	2.56	-
059	430	428	L3	6.00	-
060	430	428	L6	7.70	-
061	430	428	L6	7.70	-
062	432	430	U5	2.98	(CDCl ₃ 300 MHz): 8.00 - 8.29 (1 H, m); 7.75 (1 H, d); 7.36 (1 H, d); 7.20 - 7.26 (1 H, m); 6.82 - 7.03 (2 H, m); 6.01 (1 H, d); 5.11 (2 H, s); 4.45 - 4.74 (1 H, m); 4.01 (3 H, s); 3.30-3.40 (1 H, m); 3.10-3.20 (1 H, m); 2.75 - 3.02 (2 H, m) 2.71 (3 H, s) 2.15-2.25 (1 H, m); 1.15 - 1.37 (1 H, m)
063	432	-	U5	3.17	(CDCl ₃ , 300 MHz): 7.58 (1 H, t); 7.35 (1 H, d); 7.27.21 (1 H, d); 7.08 (1 H, d); 6.98 (1 H, dd) 6.66 (1 H, d); 6.00 (1 H, d); 5.14 (2 H, s); 4.44 - 4.73 (1 H, m); 3.94 (3 H, s); 3.26 - 3.44 (1 H, m); 3.10-3.20 (1 H, d); 2.74 - 3.02 (2 H, m); 2.70 (3 H, s); 2.17 (1 H, d); 1.50 - 1.69 (1 H, m); 1.25 (1 H, s)
064	434	432	U5	2.5	(300 MHz, DMSO-d6) : 8.74 (d, 1H), 8.28 (d, 1H), 8.19 (d, 1H), 7.90 (s, 1H), 7.79 (dd., 1H), 7.50 (d, 1H), 7.38 (d, 1H), 6.99 (dd, 1H), 5.33 (s, 2H), 4.59 (q, 1H), 3.19 - 3.31 (m, 2H), 2.62 (s, 3H), 2.31 - 2.42 (m, 1H), 1.93-2.11 (m, 1H).
065	434	432	U5	2.9	-
066	434	432	U5	2.8	-

Cpd	[M+H] ⁺ (m/z) :	[M-H] ⁻ (m/z) :	LC/MS Method	RT (min.)	¹ H NMR (δ ppm)
067	436	434	U5	2.87	(DMSO d ₆ , 300 MHz): 8.42 (1 H, d); 8.26 (1 H, d); 8.06 (1 H, d); 7.41 - 7.60 (2 H, m); 7.24 (1 H, d); 7.02 (1 H, dd); 5.19 (2 H, s); 4.34 - 4.69 (1 H, m); 3.04 - 3.20 (1 H, m); 2.69 - 3.01 (3 H, m); 2.55-2.68 (5 H, m); 1.59 - 1.91 (2 H, m)
068	436	-	U5	2.69	(CDCl ₃ , 300 MHz): 8.77 (1 H, s); 8.50 (1 H); 7.32 - 7.48 (2 H, m); 7.22 - 7.32 (1 H, m); 6.91 - 7.08 (1 H, m); 6.08 (1 H, d); 5.05 - 5.34 (2 H, m); 4.43 - 4.79 (1 H, m); 3.25-3.40 (1 H, m); 3.05 - 3.23 (1 H, m); 2.76 - 3.04 (2 H, m); 2.55 - 2.75 (3 H, m); 2.20 (1 H, d); 1.94 (1 H, br. s.); 1.38 - 1.76 (1 H, m); 0.62 - 0.96 (1 H, m)
069	437	435	L3	7.20	-
070	441	-	U5	2.33	-
071	445	-	U5	3.37	(DMSO d ₆ , 300 MHz): 8.19 (1 H, d); 7.38 - 7.56 (2 H, m); 7.15 - 7.26 (1 H, m); 6.88 - 7.05 (1 H, m); 6.68 (1 H, d); 6.46 - 6.60 (1 H, m); 4.88 - 5.09 (2 H, m); 4.36 - 4.62 (1 H, m); 3.05 - 3.20 (1 H, m); 3.02 (6 H, s); 2.75 - 2.96 (2 H, m); 2.54 - 2.70 (4 H, m); 1.61 - 1.86 (2 H, m)
072	465	463	U4	3.76	-
073	361	359	U5	3.5	-
074	470	468	U5	3.10	(CDCl ₃ , 300 MHz): 8.66 (1 H, d); 8.19 (1 H, d); 7.50 - 7.72 (1 H, m); 7.38 (1 H, d); 7.21 (1 H, d); 6.89 - 7.02 (1 H, m); 6.02 (1 H, d); 5.35 (2 H, s); 3.20-3.50 (2H, m); 2.74 - 3.11 (2 H, m); 2.70 (3 H, s) 2.05 - 2.28 (1 H, m); 1.25 (3 H, s); 0.87 (1 H, d)
075	470	468	U5	3.18	-
076	470	468	U4	3.78	-
077	520	518	U5	1.5	-

cpd	[M+H] ⁺ (m/z)	¹ H NMR (δ ppm)
103 - En 1	422.1	(DMSO-d ₆) δ = 1.85-1.96 (m, 1H), 2.04-2.13 (m, 1H), 2.41-2.45 (m, 4H), 2.57 (s, 3H), 2.62-2.69 (m, 2H), 2.89-2.99 (m, 2H), 4.30-4.41 (m, 1H), 5.30 (s, 2H), 6.97 (dd, 1H), 7.21 (d, 1H), 7.47 (d, 1H), 8.08 (d, 1H), 8.98 (s, 1H).
104	375.1	(DMSO-d ₆) δ = 1.34 (s, 6H), 2.42 (s, 3H), 2.57 (s, 3H), 3.48 (d., 2H), 5.04 (t, 1H), 5.31 (s, 2H), 6.95 (dd, 1H), 7.2 (s, 1H), 7.25 (s, 1H), 7.45 (d, 1H), 8.98 (s, 1H).
105 - En 1	456.3	(DMSO-d ₆) δ = 2.59 (s, 3H), 2.85 - 3.01 (m, 3H), 3.17 - 3.21 (m, 2H), 4.57 - 4.65 (m, 1H), 5.33 (s, 2H), 7.01 (dd, 1H), 7.25 (d, 1H), 7.52 (d, 1H), 7.77 - 7.80 (m, 1H), 8.20 - 8.33 (m, 2H), 8.73 (d, 1H).
106 - En 1	408.1	(DMSO-d ₆) δ = 2.32 (s, 3H), 2.59 (s, 3H), 2.83 - 3.06 (m, 3H), 3.21 - 3.27 (m, 2H), 4.57 - 4.66 (m, 1H), 5.32 (s, 2H), 6.98 (dd, 1H), 7.25 (d, 1H), 7.49 (d, 1H), 8.18 (br d, 1H), 8.98 (s, 1H).
107	386.8	(DMSO-d ₆): δ = 8.98 (s, 1H), 7.75 (s, 1H), 7.45 (d, 1H), 7.27 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 4.90 (t, 1H), 3.66 (d, 2H), 2.58 (s, 3H), 2.42 (s, 3H), 2.38-2.29 (m, 2H), 2.15-2.09 (m, 2H), 1.90-1.81 (m, 1H), 1.80-1.70 (m, 1H).
108	414.1	(DMSO-d ₆): δ = 8.98 (s, 1H), 7.80 (s, 1H), 7.47 (d, 1H), 7.30 (d, 1H), 6.96 (dd, 1H), 5.31 (s, 2H), 2.70 (s, 2H), 2.65-2.55 (m, 5H), 2.42 (s, 3H), 2.24 (s, 6H), 2.10-2.00 (m, 2H), 1.99-1.86 (m, 1H), 1.79-1.70 (m, 1H).

109	423.1	(DMSO-d ₆) δ = 1.33 (s, 6H), 2.60 (s, 3H), 3.49-3.53 (m, 2H), 5.01-5.04 (m, 1H), 5.31 (s, 2H), 6.97 (d, 1H), 7.23 (d, 2H), 7.48 (d, 1H), 7.78 (s, 1H), 8.26 (d, 1H), 8.73 (s, 1H).
110 - En 1	436.1	(DMSO): δ = 1.86 (m, 2H), 2.15 – 2.21 (m, 1H), 2.25 (s, 3H), 2.34 - 2.44 (m, 5H), 2.569 (s, 3H), 2.77-2.80 (m, 1H), 3.04-3.11 (m, 1H), 4.31-4.41 (m, 1H), 5.30 (s, 2H), 6.95-6.98 (dd, 1H), 7.21 (s, 1H), 7.47 (d, 1H), 8.20 (d, 1H), 8.98 (s, 1H).
111 - En 1	470.2	(DMSO-d ₆) δ = 1.85 - 2.11 (m, 2H), 2.31-2.32 (m, 1H), 2.50 - 2.69 (m, 5H), 2.89 - 2.96 (m, 2H), 4.31 - 4.38 (m, 1H), 5.31 (s, 2H), 7.00 (dd, 1H), 7.22 (d, 1H), 7.50 (d, 1H), 7.77 - 7.80 (m, 1H), 8.10 (d, 1H), 8.25 (d, 1H), 8.73 (d, 1H).
112 - En 1	488.1	(DMSO-d ₆) δ = 8.74 (d, 1H), 8.42 (d, 1H), 8.25 (d, 1H), 7.82-7.79 (m, 1H), 7.39-7.36 (m, 1H), 7.24 (t, 1H), 5.36 (s, 2H), 4.50-4.37 (m, 1H), 3.12-3.04 (m, 1H), 2.95-2.72 (m, 2H), 2.70-2.52 (m, 1H), 2.52 (s, 3H), 2.45-2.35 (m, 1H), 1.82-1.75 (m, 1H), 1.68-1.55 (m, 1H).
113 - En 1	488.2	(DMSO-d ₆) δ = 8.75 (d, 1H), 8.30-8.24 (m, 2H), 7.82-7.79 (m, 1H), 7.67 (d, 1H), 7.37 (d, 1H), 5.37 (s, 2H), 4.52-4.42 (m, 1H), 3.14-3.07 (m, 1H), 2.94-2.72 (m, 2H), 2.60-2.56 (m, 4H), 2.49-2.39 (m, 1H), 1.82-1.68 (m, 2H).
114	401.1	(DMSO-d ₆): δ = 8.99 (s, 1H), 7.95 (s, 1H), 7.45 (d, 1H), 7.27 (d, 1H), 6.96-6.93 (m, 1H), 5.32 (s, 2H), 4.57 (t, 1H), 3.57-3.53 (m, 2H), 2.51 (s, 3H), 2.49-2.43 (m, 2H), 2.42 (s, 3H), 2.09-2.04 (m, 4H), 1.80-1.62 (m, 2H).
115 - En 1	422.1	(DMSO-d ₆) δ = 2.02-2.13 (m, 1H), 2.45-2.51 (m, 4H), 2.54 (s, 1H), 2.58-2.65 (m, 3H), 2.67- 2.73 (m, 2H), 2.98 (d, 2H), 4.11-4.13 (m, 1H), 5.32 (s, 2H), 6.95-6.98 (m, 1H), 7.26 (s, 1H), 7.47 (d, 1H), 7.87 (d, 1H), 8.98 (s, 1H)
116	454.1	(DMSO) δ = 1.80-1.84 (m, 1H), 2.12 – 2.19 (m, 1H), 2.43 (s, 3H), 2.56 (s, 3H), 2.68-2.75 (m, 2H), 2.84-2.89 (m, 1H), 3.02-3.05 (m, 1H), 3.26-3.30 (m, 2H), 4.39-4.43 (m, 1H), 5.31 (s, 2H), 6.94-6.96 (dd, 1H), 7.23 (s, 1H), 7.45 (d, 1H), 8.12 (d, 1H), 8.98 (s, 1H)
117	435.1	(DMSO) δ = 8.73 (d, 1H), 8.26 (d, 1H), 7.78 (t, 2H), 7.47 (d, 1H), 7.27 (d, 1H), 6.99-6.96 (m, 1H), 5.32 (s, 2H), 4.88 (t, 1H), 3.65 (d, 2H), 2.58 (s, 3H), 2.33-2.24 (m, 2H), 2.16-2.09 (m, 2H), 1.90-1.81 (m, 1H), 1.80-1.70 (m, 1H)
118 - En 1	436.1	(DMSO-d ₆) δ = 2.00-2.14 (m, 7H), 2.41 (s, 3H), 2.67-2.50 (m, 3H), 2.69-2.78 (m, 2H), 4.44-4.53 (m, 1H), 5.30 (s, 2H), 6.97 (dd, 1H), 7.25 (d, 1H), 7.47 (m, 1H), 8.15 (d, 1H), 8.98 (s, 1H).
119	402.1	(DMSO-d ₆) δ = 8.99 (s, 1H), 8.68 (s, 1H), 7.51-7.45 (m, 2H), 7.23-7.20 (m, 2H), 7.00-6.97 (m, 1H), 5.35 (s, 2H), 4.88-4.86 (m, 2H), 4.69-4.67 (m, 2H), 2.66 (s, 3H), 2.43 (s, 3H).
120 - En 1	478.2	(DMSO): δ = 1.96 – 2.01 (m, 1H), 2.32-2.38 (m, 1H), 2.61 (s, 3H), 3.13-3.19 (m, 1H), 3.36-3.47 (m, 3H), 3.52 (m, 2H), 4.65-4.72 (m, 2H), 5.32 (s, 2H), 6.97-7.005 (dd, 1H), 7.36 (s, 1H), 7.49 (d, 1H), 7.77-7.80 (m, 2H), 8.19-8.27 (dd, 1H), 8.735 (s, 1H).
121	417.1	(DMSO-d ₆) δ = 1.93-1.97 (m, 1H), 2.03-2.07 (m, 1H), 2.12-2.16 (m, 1H), 2.41-2.46 (s, 4H), 2.55 (s, 3H), 3.52 – 3.54 (m, 2H), 3.61 (d, 1H), 3.80-3.83 (m, 2H), 4.09 (d, 1H), 4.49 (s, 1H), 5.31 (s, 2H), 6.93-6.95 (dd, 1H), 7.2 (s, 1H), 7.45 (d, 1H), 7.86 (s, 1H), 8.98 (s, 1H).
122	435.1	(DMSO-d ₆): δ = 8.99 (s, 1H), 7.60 (d, 1H), 7.43-7.41 (m, 2H), 5.37 (s, 2H), 4.89 (br s, 1H), 3.73-3.56 (m, 6H), 2.59 (s, 3H), 2.41 (s, 3H), 2.16 (d, 2H), 1.65-1.59 (m, 2H).
123 - En 1	422.1	(DMSO-d ₆) δ = 2.29 (s, 3H), 2.42 (s, 3H), 2.51 - 2.58 (m, 1H), 2.61 (s, 3H), 2.68 - 2.71 (m, 1H), 3.17 - 3.25 (m, 2H), 4.68 - 4.76 (m, 1H), 5.31 (s, 2H), 6.98 (dd, 1H), 7.23 (d, 1H), 7.48 (d, 1H), 8.27 (br d, 1H), 8.98 (s, 1H).
124 - En 1	470.1	(DMSO-d ₆) δ = 2.29 (s, 3H), 2.45 - 2.49 (m, 1H), 2.56 - 2.62 (m, 3H), 2.66 - 2.69 (m, 1H), 3.17 - 3.25 (m, 2H), 4.67 - 4.75 (m, 1H), 5.33 (s, 2H), 6.99 - 7.02 (m, 1H), 7.24 (d, 1H), 7.51 (d, 1H), 7.77 - 7.80 (m, 1H), 8.24 - 8.30 (m, 2H), 8.73 (d, 1H).
125 - En 1	470.1	(DMSO-d ₆) δ = 2.04 - 2.11 (m, 1H), 2.32 - 2.35 (m, 1H), 2.50 (br s, 1H), 2.58 (s, 3H), 2.67-2.82 (m, 2H), 2.98 (d, 2H), 4.06-4.12 (m, 1H), 5.33 (s, 2H), 7.00 (dd, 1H), 7.26 (d, 1H), 7.50 (d, 1H), 7.77 - 7.80 (m, 1H), 7.90 (d, 1H), 8.26 (d, 1H), 8.73 (d, 1H).
126 - En 1	465.1	(DMSO-d ₆) δ = 1.93 (td, 1H), 2.03 (td, 1H), 2.12 - 2.18 (m, 1H), 2.39 - 2.46 (m, 1H), 2.56 (s, 3H), 3.47 - 3.56 (m, 2H), 3.60 (d, 1H), 3.80 (dd, 2H), 4.08 (d, 1H), 4.47 (d, 1H), 5.31 (s, 2H), 6.99 (dd, 1H), 7.21 (d, 1H), 7.49 (d, 1H), 7.79 (dd, 1H), 7.88 (s, 1H), 8.26 (d, 1H), 8.72 (d, 1H).
127	449.1	(DMSO-d ₆): δ = 8.37 (d, 1H), 8.26 (d, 1H), 7.97 (s, 1H), 7.80-7.77 (m, 1H), 7.48 (d, 1H), 7.27 (d, 1H), 6.99-6.97 (m, 1H), 5.33 (s, 2H), 4.53 (t, 1H), 3.56-3.51 (m, 2H), 2.58 (s, 3H), 2.46-2.40 (m, 2H), 2.10-2.02 (m, 4H), 1.99-1.72 (m, 2H).
128	403.1	(DMSO-d ₆) δ = 8.98 (s, 1H), 8.37 (s, 1H), 7.47 (m, 1H), 7.31 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 4.75-4.74 (m, 2H), 4.53-4.51 (m, 3H), 3.59-3.56 (m, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 2.25 (t, 2H).

129	451.1	(DMSO-d6) δ = 8.74 (d, 1H), 8.39 (s, 1H), 8.26 (d, 1H), 7.80-7.77 (m, 1H), 7.51-7.49 (m, 1H), 7.31 (d, 1H), 7.00 (dd, 1H), 5.32 (s, 2H), 4.73 (d, 2H), 4.53-4.48 (m, 3H), 3.59-3.54 (m, 2H), 2.61 (s, 3H), 2.25 (t, 2H).
130 - En 1	484.1	(DMSO): δ = 1.8 - 1.813 (m, 2H), 2.14 - 2.17 (m, 1H), 2.21 (s, 3H), 2.32 - 2.41 (m, 1H), 2.54 (s, 3H), 2.77-2.79 (m, 1H), 3.03-3.09 (m, 1H), 4.33-4.40 (m, 1H), 5.30 (s, 2H), 6.98-7.01 (dd, 1H), 7.221 (s, 1H), 7.50 (d, 1H), 7.76-7.80 (m, 1H), 8.21 - 8.21-8.26 (m, 2H), 8.73 (d, 1H).
131 - En 1	484.2	(DMSO-d6) δ = 2.07 - 2.33 (m, 7H), 2.57 (s, 3H), 2.61 - 2.77 (m, 2H), 4.43 - 4.53 (m, 1H), 5.31 (s, 2H), 7.00 (dd, 1H), 7.22 (d, 1H), 7.51 (d, 1H), 7.77 - 7.80 (m, 1H), 8.17 (d, 1H), 8.26 (d, 1H), 8.73 (d, 1H).
132 - En 1	403.1	(DMSO-d6) δ = 2.04-2.07 (m, 1H), 2.23-2.25 (m, 1H), 2.42 (s, 3H), 2.57 (s, 3H), 3.66 - 3.71 (m, 2H), 3.78-3.82 (m, 3H), 3.92 (d, 1H), 5.07 (s, 1H), 5.30 (s, 2H), 6.93-6.95 (dd, 1H), 7.25 (s, 1H), 7.47 (d, 1H), 7.84 (s, 1H), 8.98 (s, 1H).
133	475.1	(DMSO-d6) δ = 8.73 (d, 1H), 8.37 (s, 1H), 8.26 (d, 1H), 7.80-7.77 (m, 1H), 7.49 (d, 1H), 7.34-7.33 (m, 1H), 7.00-6.98 (m, 1H), 5.32 (s, 2H), 5.18 (t, 1H), 4.66 (d, 2H), 4.55 (d, 2H), 3.76 (d, 2H), 2.61 (s, 3H).
134 - En 1	500.2	(DMSO-d6): δ = 2.49 - 2.58 (m, 6H), 2.69 - 2.80 (m, 1H), 3.24 - 3.31 (m, 2H), 3.51 (s, 2H), 4.54 (s, 1H), 4.65 - 4.73 (m, 1H), 5.32 (s, 2H), 7.01 (dd, 1H), 7.24 (d, 1H), 7.51 (d, 1H), 7.77 - 7.80 (m, 1H), 8.26 (t, 2H), 8.73 (d, 1H).
135 - En1	451.0	(DMSO-d6) δ = 2.06 (td, 1H), 2.22 (td, 1H), 2.58 (s, 3H), 3.63 - 3.73 (m, 2H), 3.75 - 3.82 (m, 3H), 3.92 (d, 1H), 5.05 (t, 1H), 5.32 (s, 2H), 6.98 (dd, 1H), 7.25 (d, 1H), 7.48 (d, 1H), 7.78 (dd, 1H), 7.86 (s, 1H), 8.25 (d, 1H), 8.72 (d, 1H).
136	434.1	(DMSO-d6) δ = 8.73 (d, 1H), 8.26 (d, 1H), 7.82-7.76 (m, 1H), 7.75 (s, 1H), 7.48 (d, 1H), 7.30 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 2.87 (s, 2H), 2.60 (s, 3H), 2.42-2.35 (m, 2H), 2.09-2.00 (m, 2H), 1.90-1.80 (m, 1H), 1.79-1.52 (m, 3H).
137	468.1	(DMSO-d6) δ = 8.98 (s, 1H), 7.79 (s, 1H), 7.45 (d, 1H), 7.26 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 3.29-3.26 (m, 2H), 3.05 (d, 2H), 2.58 (s, 3H), 2.41 (s, 3H), 2.40-2.32 (m, 3H), 2.15-2.08 (m, 2H), 1.90-1.81 (m, 1H), 1.80-1.73 (m, 1H).
138	383.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.69 (s, 3H), 3.75 (s, 3H), 5.34 (s, 2H), 6.31 (d, 1H), 6.98 (dd, 1H), 7.39-7.40 (m, 2H), 7.53 (d, 1H), 8.98 (s, 1H), 10.0 (s, 1H).
139	373.1	(DMSO-d6) δ = 0.75-0.78 (m, 4H), 2.42 (s, 3H), 2.56 (s, 3H), 3.55 (d, 2H), 4.77 (t, 1H), 5.32 (s, 2H), 6.93 (dd, 1H), 7.26 (s, 1H), 7.44 (d, 1H), 8.14 (s, 1H), 8.98 (s, 1H).
140	462.2	(DMSO-d6) δ = 8.73 (d, 1H), 8.26 (d, 1H), 7.83 (s, 1H), 7.82-7.78 (m, 1H), 7.50 (d, 1H), 7.28 (d, 1H), 6.99 (dd, 1H), 5.31 (s, 2H), 2.68 (s, 2H), 2.59 (s, 3H), 2.58-2.51 (m, 2H), 2.21 (s, 6H), 2.10-2.01 (m, 2H), 1.95-1.85 (m, 1H), 1.80-1.70 (m, 1H).
141 - En 1	484.2	(DMSO-d6) δ = 1.95 - 2.10 (m, 1H), 2.12 - 2.15 (m, 1H), 2.29 - 2.49 (m, 5H), 2.67 (s, 3H), 2.82-2.93 (m, 2H), 4.19 - 4.21 (m, 1H), 5.33 (s, 2H), 7.01 (dd, 1H), 7.25 (d, 1H), 7.51 (d, 1H), 7.77 - 7.80 (m, 1H), 7.84 (br d, 1H), 8.26 (d, 1H), 8.73 (d, 1H).
142	388.8	(DMSO-d6) δ = 8.98 (s, 1H), 8.33 (s, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 5.20 (t, 1H), 4.67 (d, 2H), 4.54 (d, 2H), 3.77 (d, 2H), 2.60 (s, 3H), 2.43 (s, 3H).
143	431.1	(DMSO) δ = 2.63 (s, 3H), 3.82 (s, 3H), 5.34 (s, 2H), 7.02 (br dd, 1H), 7.31 (d, 1H), 7.51-7.54 (m, 2H), 7.77-7.80 (m, 1H), 8.01 (s, 1H), 8.27 (d, 1H), 8.73 (d, 1H), 10.07 (s, 1H).
144	369.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.62 (s, 3H), 5.32 (s, 2H), 6.63 (s, 1H), 6.94-6.97 (dd, 1H), 7.3 (s, 1H), 7.47 (d, 1H), 7.67 (s, 1H), 8.97 (s, 1H), 10.45 (s, 1H), 12.43 (s, 1H).
145	468.1	(DMSO-d6) δ = 8.98 (s, 1H), 7.79 (s, 1H), 7.45 (d, 1H), 7.26 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 3.29-3.26 (m, 2H), 3.05 (d, 2H), 2.58 (s, 3H), 2.41 (s, 3H), 2.40-2.32 (m, 3H), 2.15-2.08 (m, 2H), 1.90-1.81 (m, 1H), 1.80-1.73 (m, 1H).
146	431.1	(DMSO) δ = 2.63 (s, 3H), 3.78 (s, 3H), 5.32 (s, 2H), 6.57 (s, 1H), 7.00 (dd, 1H), 7.30 (s, 1H), 7.51 (d, 1H), 7.61 (d, 1H), 7.77-7.79 (m, 1H), 8.27 (d, 1H), 8.73 (d, 1H), 10.46 (s, 1H).
147 - Dia 1 - En 1	437.1	(DMSO-d6) δ = 2.56 (s, 3H), 3.56 (dd, 1H), 3.65 (dd, 1H), 3.88 - 3.92 (m, 1H), 3.99 - 4.02 (m, 1H), 4.23 (s, 2H), 5.30 (t, 3H), 6.99 (dd, 1H), 7.23 (d, 1H), 7.50 (d, 1H), 7.77 - 7.80 (m, 1H), 8.17 (dd, 1H), 8.25 (d, 1H), 8.73 (t, 1H).
148	421.1	(DMSO) δ = 1.89-1.92 (m, 1H), 2.14-2.18 (m, 1H), 2.57 (s, 3H), 3.58-3.61 (m, 1H), 3.71 - 3.75 (m, 1H), 3.81 - 3.89 (m, 2H), 4.42-4.47 (m, 1H), 5.32 (s, 2H), 7.00 (dd, 1H), 7.23 (s, 1H), 7.50 (d, 1H), 7.77-7.80 (m, 1H), 8.20 (d, 2H), 8.26 (d, 2H), 8.73 (d, 1H).
149	502.2	(DMSO-d6): δ = 1.78 - 1.82 (m, 1H), 2.12 - 2.16 (m, 1H), 2.57 (s, 3H), 2.66 - 2.77 (m, 2H),

		2.82 - 2.89 (m, 1H), 3.02 - 3.07 (m, 1H), 3.25 - 3.32 (m, 2H), 4.37 - 4.45 (m, 1H), 5.31 (s, 2H), 6.98 - 7.00 (m, 1H), 7.22 (d, 1H), 7.49 (d, 1H), 7.79 (dd, 1H), 8.15 (d, 1H), 8.26 (d, 1H), 8.73 (d, 1H).
150	369.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.63 (s, 3H), 5.34(s, 2H), 6.97-6.99 (m, 1H), 7.32 (s, 1H), 7.50 (d, 1H), 7.67 (br s, 1H), 7.98 (br s, 1H), 8.98 (s, 1H), 10.0 (s, 1H), 12.62 (br s, 1H).
151 - En 1	452.2	(DMSO-d6) δ = 2.41 (s, 3H), 2.53-2.61 (m, 6H), 2.73-2.78 (m, 1H), 3.25-3.28 (m, 2H), 3.50-3.51 (m, 2H), 4.54 (m, 1H), 4.65-4.75 (m, 1H), 5.31 (s, 2H), 6.96-6.98 (dd, 1H), 7.23 (s, 1H), 7.48 (d, 1H), 8.25 (d, 1H), 8.98 (s, 1H).
152	383.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.62 (s, 3H), 3.82 (s, 3H), 5.33 (s, 2H), 6.98 (dd, 1H), 7.30 (s, 1H), 7.49 (d, 1H), 7.56 (s, 1H), 8.01 (s, 1H), 8.98 (s, 1H), 10.04 (s, 1H).
153	516.2	(DMSO-d6) δ = 8.73 (d, 1H), 8.25 (d, 1H), 7.82-7.77 (m, 2H), 7.48 (d, 1H), 7.26 (d, 1H), 6.99 (dd, 1H), 5.32 (s, 2H), 3.29-3.25 (m, 2H), 3.04 (d, 2H), 2.58 (s, 3H), 2.38-2.28 (m, 3H), 2.13-2.08 (m, 2H), 1.91-1.72 (m, 2H).
154	431.1	(DMSO-d6): δ = 2.70 (s, 3H), 3.74 (s, 3H), 5.35 (s, 2H), 6.32 (s, 1H), 7.04 (dd, 1H), 7.37 - 7.41 (m, 2H), 7.56 (d, 1H), 7.76-7.79 (m, 1H), 8.27 (d, 1H), 8.74 (d, 1H), 10.04 (s, 1H).
155 - En 1	490.1	(DMSO-d6) δ = 2.42 (s, 3H), 2.58 (s, 3H), 2.88-2.92 (m, 1H), 3.04-3.07 (m, 1H), 3.38-3.44 (m, 4H), 4.74-4.82 (m, 1H), 5.31 (s, 2H), 6.96 (dd, 1H), 7.24 (d, 1H), 7.48 (d, 1H), 8.31 (d, 1H), 8.98 (s, 1H).
156	398.8	(DMSO-d6) δ = 8.99 (s, 1H), 8.14 (d, 1H), 7.46 (d, 1H), 7.24 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 4.64 (s, 2H), 4.52 (s, 2H), 4.28-4.21 (m, 1H), 2.61-2.55 (m, 5H), 2.42 (s, 3H), 2.30-2.23 (m, 2H).
157 - En 1	538.1	(DMSO-d6): δ = 2.60 (s, 3H), 2.85 - 2.90 (m, 1H), 3.02- 3.13 (m, 1H), 3.38 - 3.39 (m, 4H), 4.73 - 4.81 (m, 1H), 5.32 (s, 2H), 7.01 (dd, 1H), 7.24 (d, 1H), 7.52 (d, 1H), 7.77 - 7.80 (m, 1H), 8.26 (d, 1H), 8.35 (d, 1H), 8.73 (d, 1H).
158	417.1	(DMSO-d6): δ = 2.64 (s, 3H), 5.34 (s, 2H), 7.02 (dd, 1H), 7.33 (s, 1H), 7.53 (d, 1H), 7.65 (br s, 1H), 7.76-7.79 (m, 1H), 7.99 (br s, 1H), 8.27 (d, 1H), 8.73 (d, 1H), 10.07 (s, 1H), 12.64 (br s, 1H).
159	373.1	(DMSO-d6) δ = 1.89-1.94 (m, 1H), 2.15-2.19 (m, 1H), 2.49 (m, 3H), 2.56 (s, 3H), 3.59 - 3.62 (m, 1H), 3.71-3.75 (m, 1H), 3.83-3.89 (m, 2H), 4.47-4.48 (m, 1H), 5.32 (s, 2H), 6.94-6.96 (dd, 1H), 7.22-7.23 (d, 1H), 7.45-7.46 (d, 1H), 8.18-8.19 (d, 1H), 8.98 (s, 1H).
160	430.1	(DMSO) δ = 1.94 - 2.00 (m, 1H), 2.32 - 2.37 (m, 1H), 2.42 (s, 3H), 2.61 (s, 3H), 3.14 - 3.19 (m, 1H), 3.31 - 3.45 (m, 3H), 3.50 - 3.54 (m, 2H), 4.65 - 4.73 (m, 2H), 5.32 (s, 2H), 6.95 - 6.98 (dd, 1H), 7.36 (s, 1H), 7.47 (d, 1H), 8.17 (d, 1H), 8.98 (s, 1H).
161	383.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.61 (s, 3H), 3.76 (s, 3H), 5.32 (s, 2H), 6.58 (s, 1H), 6.96 (dd, 1H), 7.28 (s, 1H), 7.47 (d, 1H), 7.61 (s, 1H), 8.98 (s, 1H), 10.45 (s, 1H).
162 - Dial - En 1	389.1	(DMSO-d6) δ = 2.42 (s, 3H), 2.56 (s, 3H), 3.57 (dd, 1H), 3.67 (dd, 1H), 3.89 - 3.93 (m, 1H), 3.99 - 4.03 (m, 1H), 4.22 - 4.24 (m, 2H), 5.31 (s, 3H), 6.96 (dd, 1H), 7.22 (d, 1H), 7.47 (d, 1H), 8.14 (d, 1H), 8.98 (s, 1H).
163 - En 1	436.2	(DMSO-d6) δ = 1.9-2.17 (m, 1H), 2.30-2.33 (m, 1H), 2.34-2.37 (m, 3H), 2.39-2.42 (m, 2H), 2.49-2.51 (m, 3H), 2.58 (s, 3H), 2.84- 2.91 (m, 2H), 4.68 - 4.76 (m, 1H), 5.32 (s, 2H), 6.95-6.98 (m, 1H), 7.26 (s, 1H), 7.47 (d, 1H), 7.87 (d, 1H), 8.99 (s, 1H).
164 - En 1	424.2	(DMSO-d6) δ = 8.41 (d, 1H), 8.19 (d, 1H), 7.81 (d, 1H), 7.48 (d, 1H), 7.40 (d, 1H), 7.24 (t, 1H), 7.01 (dd, 1H), 5.16 (s, 2H), 4.73-4.65 (m, 2H), 3.52 (s, 2H), 3.48-3.37 (m, 3H), 3.21-3.14 (m, 1H), 2.63 (s, 3H), 2.53 (s, 3H), 2.40-2.30 (m, 1H), 2.01-1.90 (m, 1H).
165 - En 1	504.1	(DMSO-d6) δ = 8.75 (d, 1H), 8.31 (d, 2H), 7.84-7.81 (m, 2H), 7.37 (s, 1H), 5.39 (s, 2H), 4.49-4.42 (m, 1H), 3.14-3.07 (m, 1H), 2.93-2.72 (m, 2H), 2.60-2.56 (m, 4H), 2.49-2.39 (m, 1H), 1.82-1.68 (m, 2H).
166	468.1	(DMSO) δ = 1.58-1.65 (m, 2H), 1.81-1.83 (m, 2H), 2.42-2.49 (m, 5H), 2.56 (s, 3H), 2.92-2.94 (m, 2H), 3.13-3.20 (m, 2H), 3.78-3.80 (m, 1H), 5.32 (s, 2H), 6.96 (dd, 1H), 7.23 (brs, 1H), 7.45 (d, 1H), 7.86 (brd, 1H), 8.98 (s, 1H).
167	447.1	(DMSO-d6) δ = 8.73 (d, 1H), 8.25 (d, 1H), 8.17 (d, 1H), 7.80-7.77 (m, 1H), 7.49 (d, 1H), 7.23-7.23 (d, 1H), 7.00-6.98 (m, 1H), 5.34 (s, 2H), 4.63 (s, 2H), 4.51 (s, 2H), 4.26-4.21 (m, 1H), 2.60-2.54 (m, 5H), 2.26-2.22 (m, 2H).
168	516.1	(DMSO-d6) δ = 1.55-1.60 (m, 2H), 1.79-1.84 (m, 2H), 2.41 - 2.48 (m, 2H), 2.57 (s, 3H), 2.92 (br d, 2H), 3.10-3.16 (m, 2H), 3.74 - 3.81 (m, 1H), 5.33 (s, 2H), 6.99 (dd, 1H), 7.23 (d, 1H), 7.49 (d, 1H), 7.76-7.80 (m, 1H), 7.89 (d, 1H), 8.26 (d, 1H), 8.73 (d, 1H).

169 - En 1	444.2	(DMSO-d6) δ = 8.99 (s, 1H), 8.36 (d, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 4.72 (t, 1H), 4.62-4.52 (m, 1H), 3.85-3.77 (m, 1H), 3.53-3.48 (m, 2H), 3.42-3.33 (m, 1H), 3.28-3.23 (m, 2H), 2.70-2.62 (m, 1H), 2.58 (s, 3H), 2.43-2.35 (m, 4H).
170	451.1	(DMSO-d6) δ = 2.08 (td, 1H), 2.26 (br s, 1H), 2.76 (s, 3H), 3.80 - 3.91 (m, 3H), 3.95 - 4.02 (m, 1H), 4.57 (br d, 2H), 5.35 (br s, 2H), 7.08 (br dd, 1H), 7.46 (br d, 1H), 7.60 (br d, 1H), 7.80 (br dd, 1H), 8.20 - 8.31 (m, 3H), 8.75 (br d, 1H)
171	383.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.69 (s, 3H), 3.75 (s, 3H), 5.34 (s, 2H), 6.31 (d, 1H), 6.98 (dd, 1H), 7.39-7.40 (m, 2H), 7.53 (d, 1H), 8.98 (s, 1H), 10.0 (s, 1H).
172 - En 1	534.1	(DMSO-d6) δ = 2.41 (s, 3H), 2.59 (s, 3H), 3.50-3.58 (m, 1H), 3.86-3.96 (m, 3H), 4.71-4.77 (m, 2H), 5.08-5.12 (m, 1H), 5.31 (s, 2H), 6.96 (dd, 1H), 7.24 (d, 1H), 7.49 (d, 1H), 8.51 (t, 1H), 8.98 (s, 1H).
173	446.2	(CDCl3) δ = 8.66 (d, 1H), 8.17 (d, 1H), 7.56-7.53 (m, 1H), 7.36 (d, 1H), 7.13 (s, 1H), 6.94 (d, 1H), 5.78 (d, 1H), 5.36 (s, 2H), 4.48-4.42 (m, 1H), 3.72 (s, 2H), 3.61 (s, 2H), 2.74-2.68 (m, 6H), 2.04 (t, 2H).
174	451.1	(DMSO-d6): δ = 8.99 (s, 1H), 7.76 (s, 1H), 7.47-7.43 (m, 2H), 5.39 (s, 2H), 4.91 (t, 1H), 3.73-3.56 (m, 6H), 2.61 (s, 3H), 2.42 (s, 3H), 2.20-2.15 (m, 2H), 1.68-1.59 (m, 2H).
175	582.1	(DMSO-d6): δ = 2.59 (s, 3H), 3.50 - 3.56 (m, 1H), 3.82- 3.96 (m, 3H), 4.70 - 4.77 (m, 2H), 5.05 - 5.15 (m, 1H), 5.32 (s, 2H), 7.02 (dd, 1H), 7.24 (d, 1H), 7.53 (d, 1H), 7.77 - 7.80 (m, 1H), 8.25 (d, 1H), 8.54 (t, 1H), 8.73 (d, 1H).
176 - En 1	488.1	(DMSO-d6) δ = 8.74 (d, 1H), 8.35 (d, 1H), 8.26 (d, 1H), 7.80-7.77 (m, 1H), 7.06-7.03 (m, 2H), 5.32 (s, 2H), 4.51-4.40 (m, 1H), 3.13-3.07 (m, 1H), 2.93-2.78 (m, 2H), 2.65-2.59 (m, 4H), 2.49-2.44 (m, 1H), 1.80-1.65 (m, 2H).
177	435.2	(DMSO-d6): δ 8.98 (s, 1H), 7.72 (s, 1H), 7.34 (d, 1H), 7.23 (t, 1H), 5.37 (s, 2H), 4.81 (t, 1H), 3.71-3.55 (m, 6H), 2.52 (s, 3H), 2.39 (s, 3H), 2.10 (d, 2H), 1.66-1.58 (m, 2H).
178	417.1	(DMSO-d6): δ = 2.54 (s, 3H), 5.29 (s, 2H), 5.65 (s, 2H), 6.02 (d, 1H), 6.99 - 7.01 (m, 1H), 7.16 (d, 1H), 7.53 (d, 1H), 7.75 - 7.78 (m, 1H), 8.16 (d, 1H), 8.23 (d, 1H), 8.71 - 8.72 (m, 1H).
179 - En 1	484.2	(DMSO-d6) δ = 8.74 (d, 1H), 8.29 (d, 1H), 8.20 (d, 1H), 7.82-7.79 (m, 1H), 7.41 (s, 1H), 7.20 (s, 1H), 5.30 (s, 2H), 4.50-4.43 (m, 1H), 3.18-3.05 (m, 1H), 2.95-2.72 (m, 2H), 2.63-2.40 (m, 5H), 2.28 (s, 3H), 1.71-1.64 (m, 2H).
180 - En 1	430.1	(DMSO-d6) δ = 8.99 (s, 1H), 8.36 (d, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 4.72 (t, 1H), 4.62-4.52 (m, 1H), 3.85-3.77 (m, 1H), 3.53-3.48 (m, 2H), 3.42-3.33 (m, 1H), 3.28-3.23 (m, 2H), 2.70-2.62 (m, 1H), 2.58 (s, 3H), 2.43-2.35 (m, 4H).
181	417.1	(DMSO-d6): δ = 2.52 (s, 3H), 4.72 (s, 2H), 5.27 (s, 2H), 7.00-7.03 (m, 1H), 7.10 (d, 1H), 7.47 (s, 1H), 7.54 (d, 1H), 7.60 (s, 1H), 7.76 - 7.78 (m, 1H), 8.22 (d, 1H), 8.72 (d, 1H).
182	435.1	(DMSO-d6): δ = 8.99 (s, 1H), 7.51 (s, 1H), 7.07 (d, 1H), 7.00-6.97 (m, 1H), 5.33 (s, 2H), 4.89 (t, 1H), 3.73-3.57 (m, 6H), 2.62 (s, 3H), 2.42 (s, 3H), 2.16 (d, 2H), 1.65-1.59 (m, 2H).
183 - En 1	484.2	(DMSO-d6) δ = 8.73 (d, 1H), 8.24 (d, 1H), 8.18 (d, 1H), 7.79-7.76 (m, 1H), 7.04 (d, 1H), 6.86 (d, 1H), 5.28 (s, 2H), 4.49-4.40 (m, 1H), 3.13-3.06 (m, 1H), 2.92-2.77 (m, 2H), 2.63-2.56 (m, 4H), 2.49-2.29 (m, 4H), 1.79-1.70 (m, 2H).
184 - En 1	504.1	(DMSO-d6) δ = 8.74 (d, 1H), 8.35 (d, 1H), 8.26 (d, 1H), 7.80-7.77 (m, 1H), 7.19 (dd, 2H), 5.33 (s, 2H), 4.51-4.40 (m, 1H), 3.14-3.07 (m, 1H), 2.93-2.27 (m, 2H), 2.65-2.59 (m, 4H), 2.50-2.44 (m, 1H), 1.80-1.67 (m, 2H).
185	431.1	(DMSO-d6): δ = 8.97 (s, 1H), 7.36 (s, 1H), 7.32 (s, 1H), 7.28 (s, 1H), 5.33 (s, 2H), 4.88 (t, 1H), 3.73-3.59 (m, 6H), 2.59 (s, 3H), 2.42 (s, 3H), 2.23 (s, 3H), 2.22-2.16 (m, 2H), 1.68-1.60 (m, 2H).
186	431.1	(DMSO-d6): δ = 8.97 (s, 1H), 7.32 (s, 1H), 7.08 (d, 1H), 6.81 (d, 1H), 5.28 (s, 2H), 4.88 (t, 1H), 3.72-3.58 (m, 6H), 2.60 (s, 3H), 2.41 (s, 6H), 2.18-2.16 (m, 2H), 1.66-1.60 (m, 2H).
187	451.1	(DMSO-d6) δ = 8.99 (s, 1H), 7.76 (s, 1H), 7.47-7.43 (m, 2H), 5.39 (s, 2H), 4.91 (t, 1H), 3.73-3.56 (m, 6H), 2.61 (s, 3H), 2.42 (s, 3H), 2.20-2.15 (m, 2H), 1.68-1.59 (m, 2H).
188	442.2	(DMSO-d6) δ = 9.01 (s, 1H), 7.63 (s, 1H), 7.58 (d, 1H), 7.56 (d, 1H), 5.39 (s, 2H), 4.91 (t, 1H), 3.73-3.56 (m, 6H), 2.67 (s, 3H), 2.43 (s, 3H), 2.17 (d, 2H), 1.65-1.58 (m, 2H).
189	436.2	(DMSO-d6) δ = 8.73 (d, 1H), 8.26 (d, 1H), 7.80-7.76 (m, 1H), 7.56 (d, 1H), 7.45 (d, 1H), 6.95 (dd, 1H), 6.52-6.13 (br s, 1H), 5.31 (s, 2H), 4.57 (br s, 2H), 3.49-3.38 (m, 6H), 2.64 (s,

		3H).
190	398.2	(CDCl ₃) δ = 8.72 (d, 1H), 7.35 (d, 1H), 7.20 (d, 1H), 6.92 (dd, 1H), 5.81 (d, 1H), 5.23 (s, 2H), 4.50-4.43 (m, 1H), 3.73 (s, 2H), 3.61 (s, 2H), 2.78-2.71 (m, 2H), 2.68 (s, 3H), 2.50 (s, 3H), 2.11-2.05 (m, 2H).
191 - En 1	495.1	(DMSO-d ₆) δ = 8.78-8.74 (m, 2H), 8.30 (d, 1H), 7.92 (m, 1H), 7.86-7.83 (m, 1H), 7.30 (d, 1H), 5.49 (s, 2H), 4.52-4.40 (m, 1H), 3.18-3.07 (m, 1H), 2.93-2.77 (m, 2H), 2.63-2.51 (m, 2H), 2.52 (s, 3H), 1.90-1.84 (m, 1H), 1.70-1.61 (m, 1H).
192	369.1	(DMSO-d ₆) δ = 2.38 (s, 3H), 2.54 (s, 3H), 5.28 (s, 2H), 5.67 (s, 2H), 6.032 (s, 1H), 6.96 (dd, 1H), 7.16 (s, 1H), 7.5 (d, 1H), 8.17 (s, 1H), 8.97 (s, 1H).
193	442.1	(DMSO-d ₆): δ = 9.00 (s, 1H), 7.93 (s, 1H), 7.88 (d, 1H), 7.33 (d, 1H), 5.52 (s, 2H), 4.77 (t, 1H), 3.70-3.55 (m, 6H), 2.56 (s, 3H), 2.44 (s, 3H), 2.11-2.07 (m, 2H), 1.69-1.65 (m, 2H).
194	442.2	(DMSO-d ₆) δ = 9.01 (s, 1H), 8.09 (s, 1H), 7.56 (s, 1H), 7.48 (s, 1H), 5.49 (s, 2H), 4.91 (t, 1H), 3.73-3.56 (m, 6H), 2.65 (s, 3H), 2.45 (s, 3H), 2.19-2.15 (m, 2H), 1.67-1.58 (m, 2H).
195 - En 1	495.1	(DMSO-d ₆) δ = 8.77-8.75 (m, 1H), 8.43 (d, 1H), 8.30 (d, 1H), 8.17 (s, 1H), 7.86-7.83 (m, 1H), 7.39 (s, 1H), 5.46 (s, 2H), 4.52-4.41 (m, 1H), 3.15-3.07 (m, 1H), 2.93-2.80 (m, 2H), 2.63-2.48 (m, 5H), 1.85-1.75 (m, 1H), 1.73-1.65 (m, 1H).
196 - En 1	495.1	(DMSO-d ₆) δ = 8.74 (m, 1H), 8.44 (d, 1H), 8.27 (d, 1H), 7.82-7.77 (m, 1H), 7.65 (d, 1H), 7.53 (d, 1H), 5.37 (s, 2H), 4.53-4.40 (m, 1H), 3.15-3.06 (m, 1H), 2.93-2.75 (m, 2H), 2.65-2.55 (m, 4H), 2.49-1.82-1.78 (m, 1H), 1.72-1.65 (m, 2H).
197	453.1	(DMSO-d ₆) δ = 9.00 (s, 1H), 8.00 (s, 1H), 7.70 (d, 1H), 7.45-7.15 (m, 3H), 5.36 (s, 2H), 4.93 (t, 1H), 3.75-3.56 (m, 6H), 2.42 (s, 3H), 2.21-2.14 (m, 2H), 1.67-1.54 (m, 2H).
198 - En 1	466.1	(DMSO-d ₆) δ = 9.00 (s, 1H), 8.75 (d, 1H), 7.73 (d, 1H), 7.51 (d, 1H), 7.41 (t, 1H), 7.23 (dd, 1H), 5.37 (s, 2H), 4.75-4.68 (m, 2H), 3.58-3.50 (m, 2H), 3.48-3.38 (m, 3H), 3.22-3.14 (m, 1H), 2.43 (s, 3H), 2.42-2.32 (m, 1H), 2.08-1.95 (m, 1H).
199 - En 1	506.1	(DMSO-d ₆) δ = 8.86 (d, 1H), 8.74 (d, 1H), 8.26 (d, 1H), 7.81-7.73 (m, 2H), 7.41-7.14 (m, 3H), 5.35 (s, 2H), 4.58-4.39 (m, 1H), 3.16-3.05 (m, 1H), 2.95-2.78 (m, 2H), 2.68-2.55 (m, 1H), 2.50-2.40 (m, 1H), 1.85-1.76 (m, 1H), 1.75-1.60 (m, 1H).
200	421.1	(DMSO-d ₆) δ = 0.71 - 0.79 (m, 4H), 2.56 (s, 3H), 3.55 (d, 2H), 4.76 (t, 1H), 5.32 (s, 2H), 6.96 (dd, 1H), 7.26 (d, 1H), 7.47 (d, 1H), 7.77 - 7.80 (m, 1H), 8.18 (s, 1H), 8.26 (d, 1H), 8.73 (d, 1H).
201	388.1	(DMSO-d ₆): δ 8.98 (s, 1H), 8.04 (s, 1H), 7.45 (d, 1H), 7.30 (d, 1H), 6.95 (dd, 1H), 5.31 (s, 2H), 4.97 (s, 1H), 3.78 (s, 2H), 3.67 (d, 2H), 3.43 (d, 2H), 2.59 (s, 3H), 2.42 (s, 3H).
202	436.1	(DMSO-d ₆) δ = 8.73 (d, 1H), 8.26 (d, 1H), 8.07 (s, 1H), 7.79 (dd, 1H), 7.47 (d, 1H), 7.31 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.95 (s, 1H), 3.78 (s, 2H), 3.64 (d, 2H), 3.41 (d, 2H), 2.59 (s, 3H).
203	409.1	(DMSO) δ = 2.42 (s, 3H), 2.59 (s, 3H), 3.83 - 3.94 (m, 2H), 4.09-4.16 (m, 1H), 4.31-4.34 (m, 1H), 4.82-4.88 (m, 1H), 5.32 (s, 2H), 6.98 (dd, 1H), 7.25 (s, 1H), 7.49 (d, 1H), 8.39 (d, 1H), 8.98 (s, 1H).
204	400.1	(DMSO) δ = 1.59-1.67 (m, 2H), 2.25 (d, 2H), 2.59 (s, 3H), 3.64 - 3.71 (m, 9H), 4.95 (t, 1H), 5.14 (s, 2H), 6.86 (d, 1H), 7.00 (dd, 1H), 7.18 (d, 1H), 7.33 (d, 1H), 7.36 (s, 1H), 7.46 (d, 1H).
205 - En 1	405.1	(DMSO) δ = 1.74-1.87 (m, 2H), 2.41-2.49 (m, 1H), 2.57-2.59 (m, 4H), 2.78-2.98 (m, 2H), 3.11 - 3.19 (m, 1H), 3.68 (s, 3 H), 4.42-4.53 (m, 1H), 5.12 (s, 2H), 6.86 (d, 1H), 7.02 (dd, 1H), 7.18 (d, 1H), 7.26 (d, 1H), 7.48 (d, 1H), 8.19 (d, 1H).
206	441.2	(DMSO-d ₆) δ = 1.31-1.34 (m, 3H), 1.59-1.66 (m, 2H), 2.15 (d, 2H), 2.59 (s, 3H), 3.56-3.72 (m, 6H), 4.36-4.41 (m, 2H), 4.86 (t, 1H), 5.06 (s, 2H), 6.94-7.01 (m, 2H), 7.23 (d, 1H), 7.40 (s, 1H), 7.46 (d, 1H), 7.78 (m, 1H), 8.11-8.13 (m, 1H).
207 - En 1	446.1	(DMSO-d ₆) δ = 1.32 (t, 3H), 1.68-1.80 (m, 2H), 2.44-2.49 (m, 1H), 2.56-2.63 (m, 4H), 2.77-2.93 (m, 2H), 3.07-3.14 (m, 1H), 4.35-4.52 (m, 3H), 5.05 (s, 2H), 6.95-7.01 (m, 2H), 7.19 - 7.22 (m, 1H), 7.47 (d, 1H), 7.78-7.81 (m, 1H), 8.11-8.13 (m, 1H), 8.22 (d, 1H).
cpd Nr	NMR Data	

232	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.45 (d, 1H), 7.38 (d, 1H), 6.93 (dd, 1H), 5.33 (s, 2H), 2.62 (s, 3H), 2.43 (s, 3H).
270 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.79 (d, 1H), 7.52 – 7.42 (m, 2H), 6.98 (dd, 1H), 5.32 (s, 2H), 4.30 (d, 1H), 3.80 (dd, 1H), 3.68 (dd, 1H), 2.64 (s, 3H), 2.42 (s, 3H).
271	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.88 (d, 1H), 7.47 (s, 1H), 7.47 (d, 1H), 7.36 (d, 1H), 7.09 (s, 1H), 6.96 (dd, 1H), 5.32 (d, 2H), 4.48 (p, 1H), 2.62 (s, 3H), 2.42 (s, 3H), 1.36 (d, 3H).
272	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.59 (s, 1H), 7.52 (d, 1H), 7.48 (d, 1H), 7.35 (s, 1H), 6.97 (dd, 1H), 5.36 – 5.25 (m, 2H), 4.94 (td, 1H), 3.73 (dd, 1H), 3.66 (dd, 1H), 3.07 (s, 3H), 2.63 (s, 3H), 2.42 (s, 3H).
273	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.62 (d, 1H), 7.57 – 7.52 (m, 1H), 7.48 (d, 1H), 7.30 (d, 1H), 7.16 (s, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 4.37 (dd, 1H), 2.61 (s, 3H), 2.41 (s, 3H), 2.17 – 2.04 (m, 1H), 0.95 (dd, 6H).
274	¹ H NMR (500 MHz, DMSO) δ = 7.95 (d, 1H), 7.70 (s, 1H), 7.46 (d, 1H), 7.38 (d, 1H), 6.95 (dd, 1H), 5.31 (d, 2H), 5.16 (t, 1H), 4.57 – 4.51 (m, 1H), 3.60 (dt, 1H), 3.53 – 3.40 (m, 3H), 3.04 (s, 3H), 2.63 (s, 3H), 2.60 (s, 3H).
275	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.96 (d, 1H), 7.47 (d, 1H), 7.41 (d, 1H), 6.96 (dd, 1H), 5.36 – 5.26 (m, 2H), 5.15 (s, 1H), 4.54 (d, 1H), 3.60 (dd, 1H), 3.53 – 3.43 (m, 3H), 3.04 (s, 3H), 2.60 (s, 3H), 2.42 (s, 3H).
276	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.94 (d, 1H), 7.68 (d, 1H), 7.49 (d, 1H), 7.39 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.02 (t, 1H), 4.49 (dt, 1H), 3.72 (t, 2H), 2.63 (d, 6H), 2.42 (s, 3H).
277	¹ H NMR (500 MHz, DMSO) δ = 8.01 (dd, 1H), 7.71 (s, 1H), 7.47 (d, 1H), 7.30 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 5.08 (q, 1H), 4.79 (dq, 1H), 4.14 (dt, 1H), 3.93 (q, 1H), 3.89 – 3.66 (m, 3H), 3.72 – 3.51 (m, 1H), 2.62 (d, 6H), 2.42 (dq, 1H).
278	¹ H NMR (500 MHz, DMSO) δ = 7.86 (d, 1H), 7.72 (s, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 6.96 (dd, 1H), 5.33 (s, 2H), 5.04 (dt, 1H), 4.99 (t, 1H), 3.71 (dt, 1H), 3.65 (dt, 1H), 3.13 (s, 3H), 2.89 (s, 3H), 2.62 (d, 6H).
279	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.88 (d, 1H), 7.47 (s, 1H), 7.47 (d, 1H), 7.36 (d, 1H), 7.09 (s, 1H), 6.96 (dd, 1H), 5.32 (d, 2H), 4.48 (p, 1H), 2.62 (s, 3H), 2.42 (s, 3H), 1.36 (d, 3H).
280	¹ H NMR (500 MHz, DMSO) δ = 8.74 (dd, 1H), 8.27 (dd, 1H), 7.79 (dd, 1H), 7.64 (d, 1H), 7.54 – 7.45 (m, 2H), 7.43 (d, 1H), 7.18 (s, 1H), 7.00 (dd, 1H), 5.32 (s, 2H), 5.00 (t, 1H), 4.48 (dt, 1H), 3.74 (t, 2H), 2.65 (s, 3H).
281	¹ H NMR (400 MHz, DMSO) δ = 8.27 – 8.22 (m, 1H), 7.64 (d, 1H), 7.55 – 7.47 (m, 2H), 7.45 (d, 1H), 7.20 (s, 1H), 7.02 (dd, 1H), 5.53 (s, 2H), 5.02 (t, 1H), 4.49 (dt, 1H), 3.75 (t, 2H), 2.64 (s, 3H).
282	¹ H NMR (500 MHz, DMSO) δ = 7.65 (d, 1H), 7.51 (d, 1H), 7.47 (s, 1H), 7.40 (d, 1H), 7.18 (s, 1H), 6.99 (dd, 1H), 5.45 (d, 2H), 5.01 (t, 1H), 4.47 (dt, 1H), 3.74 (t, 2H), 2.66 (d, 6H).
283	¹ H NMR (400 MHz, DMSO) δ = 7.64 (d, 1H), 7.49 (d, 2H), 7.42 (d, 1H), 7.19 (d, 2H), 6.98 (dd, 1H), 5.13 (s, 2H), 5.07 (t, 1H), 4.49 (dt, 1H), 3.75 (q, 2H), 2.64 (s, 3H), 2.42 (s, 3H).
284	¹ H NMR (500 MHz, DMSO) δ = 8.41 (dd, 1H), 7.83 (dd, 1H), 7.65 (d, 1H), 7.50 (d, 2H), 7.46 (d, 1H), 7.24 (dd, 1H), 7.19 (s, 1H), 7.01 (dd, 1H), 5.16 (s, 2H), 5.05 (s, 1H), 4.48 (dt, 1H), 3.75 (d, 2H), 2.65 (s, 3H), 2.54 (s, 3H).
285	¹ H NMR (500 MHz, DMSO) δ = 7.61 (d, 1H), 7.58 (s, 1H), 7.48 (d, 2H), 7.43 (d, 1H), 7.20 (s, 1H), 6.99 (dd, 1H), 5.13 (s, 2H), 5.03 (t, 1H), 4.49 (dt, 1H), 3.81 – 3.70 (m, 2H), 2.65 (d, 6H).
286	¹ H NMR (500 MHz, DMSO) δ = 13.70 (s, 1H), 8.13 (s, 1H), 7.65 (d, 1H), 7.52 – 7.44 (m, 2H), 7.40 (d, 1H), 7.19 (s, 1H), 6.93 (dd, 1H), 5.06 (s, 2H), 5.04 (s, 1H), 4.48 (dt, 1H), 3.78 – 3.72 (m, 2H), 2.64 (s, 3H).
287	¹ H NMR (500 MHz, DMSO) δ = 8.57 (s, 1H), 8.42 (d, 1H), 7.64 (d, 1H), 7.53 – 7.44 (m, 3H), 7.28 (d, 1H), 7.19 (s, 1H), 7.01 (dd, 1H), 5.17 (s, 2H), 5.02 (t, 1H), 4.48 (dt, 1H), 3.78 – 3.71 (m, 2H), 2.65 (s, 3H), 2.38 (s, 3H).
288	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.63 (d, 1H), 7.49 (d, 1H), 7.47 (s, 1H), 7.42 (d, 1H), 7.21 – 7.17 (m, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.74 (tt, 2H), 2.64 (s, 3H), 2.42 (s, 3H).
289	¹ H NMR (400 MHz, DMSO) δ = 7.62 (d, 1H), 7.53 – 7.45 (m, 2H), 7.42 (d, 1H), 7.19 (s, 1H), 6.99 (dd, 1H), 6.36 (d, 1H), 5.16 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.74 (tt, 2H), 2.64 (s, 3H), 2.41 (d, 3H).
290	¹ H NMR (500 MHz, DMSO) δ = 8.88 (s, 1H), 7.62 (d, 1H), 7.51 – 7.42 (m, 3H), 7.19 (s, 1H), 6.99 (dd, 1H), 5.15 (s, 2H), 5.02 (t, 1H), 4.48 (dt, 1H), 3.75 (tt, 2H), 2.64 (s, 3H), 2.53 – 2.49 (m, 3H).

291	¹ H NMR (500 MHz, DMSO) δ = 8.55 (d, 1H), 7.78 (dd, 1H), 7.62 (d, 1H), 7.48 (s, 1H), 7.48 (d, 1H), 7.42 (d, 1H), 7.28 (d, 1H), 7.19 (s, 1H), 6.98 (dd, 1H), 5.13 (s, 2H), 5.02 (t, 1H), 4.48 (dt, 1H), 3.81 – 3.69 (m, 2H), 2.64 (s, 3H), 2.47 (s, 3H).
292	¹ H NMR (600 MHz, DMSO) δ = 7.60 (d, 1H), 7.47 (d, 2H), 7.35 (d, 1H), 7.16 (s, 1H), 6.94 (dd, 1H), 5.07 – 4.99 (m, 1H), 4.73 (dd, 2H), 4.49 (d, 1H), 4.45 (t, 2H), 4.24 (d, 2H), 3.76 (h, 2H), 3.47 – 3.39 (m, 1H), 2.64 (s, 3H).
293	¹ H NMR (500 MHz, DMSO) δ = 9.22 (dd, 1H), 7.87 (dd, 1H), 7.76 (dd, 1H), 7.64 (d, 1H), 7.52 – 7.45 (m, 3H), 7.21 – 7.17 (m, 1H), 7.04 (dd, 1H), 5.43 (s, 2H), 5.02 (t, 1H), 4.48 (dt, 1H), 3.75 (td, 2H), 2.64 (s, 3H).
294	¹ H NMR (600 MHz, DMSO) δ = 9.18 (d, 1H), 8.83 (d, 1H), 7.67 (dd, 1H), 7.61 (d, 1H), 7.50 (d, 1H), 7.46 (s, 1H), 7.43 (d, 1H), 7.16 (s, 1H), 7.03 (dd, 1H), 5.24 (s, 2H), 4.48 (dt, 1H), 3.79 – 3.71 (m, 2H), 2.64 (s, 3H).
295	¹ H NMR (500 MHz, DMSO) δ = 7.63 (d, 1H), 7.55 – 7.47 (m, 3H), 7.45 (d, 1H), 7.20 (s, 1H), 7.00 (dd, 1H), 6.54 – 6.24 (m, 2H), 5.24 (s, 2H), 5.02 (t, 1H), 4.67 (td, 2H), 4.49 (dt, 1H), 3.75 (tt, 2H), 2.64 (s, 3H).
296	¹ H NMR (500 MHz, DMSO) δ = 8.26 (dd, 1H), 8.06 (dd, 1H), 7.98 – 7.57 (m, 2H), 7.48 (s, 1H), 7.57 – 7.24 (m, 3H), 7.24 – 7.09 (m, 1H), 7.00 (dd, 1H), 5.13 (s, 2H), 5.00 (t, 1H), 4.48 (dt, 1H), 3.87 – 3.62 (m, 2H), 2.65 (s, 3H).
297	¹ H NMR (500 MHz, DMSO) δ = 8.19 (dd, 1H), 7.77 (dd, 1H), 7.63 (d, 1H), 7.53 – 7.45 (m, 2H), 7.42 (d, 1H), 7.18 (s, 1H), 6.94 (ddd, 2H), 5.08 (s, 2H), 5.00 (t, 1H), 4.48 (dt, 1H), 3.75 (td, 2H), 2.86 (s, 6H), 2.64 (s, 3H).
298	¹ H NMR (500 MHz, DMSO) δ = 7.62 (d, 1H), 7.48 (d, 2H), 7.39 (d, 1H), 7.19 (s, 1H), 6.96 (dd, 1H), 5.23 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.80 – 3.70 (m, 2H), 2.64 (s, 3H), 2.57 (s, 3H), 2.32 (s, 3H).
299	¹ H NMR (500 MHz, DMSO) δ = 7.62 (d, 1H), 7.51 – 7.45 (m, 2H), 7.42 (d, 1H), 7.18 (s, 1H), 6.97 (dd, 1H), 5.08 – 4.99 (m, 3H), 4.48 (dt, 1H), 3.81 – 3.69 (m, 2H), 2.64 (s, 3H), 2.58 (s, 3H), 2.42 (s, 3H).
300	¹ H NMR (500 MHz, DMSO) δ = 7.92 (dd, 1H), 7.61 (d, 1H), 7.55 (dd, 1H), 7.51 – 7.46 (m, 2H), 7.44 (d, 1H), 7.21 – 7.17 (m, 1H), 6.99 (dd, 1H), 6.57 (dd, 1H), 5.86 (s, 2H), 5.05 – 4.96 (m, 3H), 4.49 (dt, 1H), 3.81 – 3.70 (m, 2H), 2.64 (s, 3H).
301	¹ H NMR (500 MHz, DMSO) δ = 8.85 – 8.64 (m, 1H), 8.22 – 8.01 (m, 1H), 7.74 – 7.16 (m, 6H), 7.29 – 7.09 (m, 1H), 6.99 (dd, 1H), 5.35 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.75 (td, 2H), 2.64 (s, 3H).
302	¹ H NMR (500 MHz, DMSO) δ = 7.65 (d, 1H), 7.51 (d, 1H), 7.46 (dd, 3H), 7.21 – 7.16 (m, 1H), 7.01 (dd, 1H), 5.18 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.83 (s, 3H), 3.75 (td, 2H), 2.64 (s, 3H).
303	¹ H NMR (500 MHz, DMSO) δ = 7.79 (d, 1H), 7.71 (s, 1H), 7.56 (s, 1H), 7.48 (d, 1H), 7.35 (d, 1H), 7.24 (s, 1H), 6.96 (dd, 1H), 5.33 (s, 2H), 4.66 (ddd, 1H), 3.73 – 3.61 (m, 2H), 3.30 (s, 3H), 2.62 (d, 6H).
304	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.62 (d, 1H), 7.58 – 7.52 (m, 1H), 7.48 (d, 1H), 7.30 (d, 1H), 7.16 (s, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 4.37 (dd, 1H), 2.61 (s, 3H), 2.41 (s, 3H), 2.11 (h, 1H), 0.95 (dd, 6H).
305	¹ H NMR (500 MHz, DMSO) δ = 7.99 – 7.93 (m, 1H), 7.72 (s, 1H), 7.67 (d, 1H), 7.48 (d, 1H), 7.38 (d, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 5.07 (s, 1H), 4.49 (dt, 1H), 3.77 – 3.67 (m, 2H), 2.67 – 2.57 (m, 9H).
306	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.95 (q, 1H), 7.69 (d, 1H), 7.49 (d, 1H), 7.39 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.05 (s, 1H), 4.49 (dt, 1H), 3.72 (d, 2H), 2.63 (d, 6H), 2.42 (s, 3H).
307	¹ H NMR (400 MHz, DMSO) δ = 7.88 (d, 1H), 7.72 (s, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 6.96 (dd, 1H), 5.33 (s, 2H), 5.02 (s, 1H), 4.83 (q, 1H), 3.76 – 3.56 (m, 3H), 3.44 – 3.30 (m, 1H), 2.62 (d, 6H), 1.91 (p, 2H), 1.80 (p, 2H).
308	¹ H NMR (400 MHz, DMSO) δ = 9.01 (s, 1H), 8.71 (s, 1H), 7.69 (d, 1H), 7.58 – 7.06 (m, 3H), 5.37 (s, 2H), 4.82 (t, 1H), 3.57 (d, 2H), 2.44 (s, 3H), 0.80 (dt, 4H).
309	¹ H NMR (400 MHz, DMSO) δ = 9.01 (s, 1H), 8.95 (s, 1H), 7.72 (d, 1H), 7.78 – 7.09 (m, 3H), 5.38 (s, 2H), 5.28 (s, 1H), 4.72 (d, 2H), 4.54 (d, 2H), 3.81 (s, 2H), 2.44 (s, 3H).
310 - En 1	¹ H NMR (400 MHz, DMSO) δ = 9.00 (s, 1H), 8.84 (d, 1H), 7.73 (d, 1H), 7.52 – 7.02 (m, 3H), 5.36 (s, 2H), 4.62 – 4.37 (m, 1H), 3.13 (s, 1H), 3.03 – 2.73 (m, 2H), 2.60 (d, 1H), 2.42 (s, 4H), 1.97 – 1.55 (m, 2H).
311	¹ H NMR (500 MHz, DMSO) δ = 11.77 (s, 1H), 8.00 (s, 1H), 7.80 – 7.48 (m, 2H), 7.48 – 7.04 (m, 4H), 6.22 (t, 1H), 4.94 (s, 2H), 4.92 (s, 1H), 3.81 – 3.46 (m, 6H), 2.17 (d, 2H), 1.60 (ddd, 2H).
312	¹ H NMR (500 MHz, DMSO) δ = 8.17 (dd, 1H), 8.01 (s, 1H), 7.91 – 7.60 (m, 2H), 7.51 – 7.12 (m, 3H), 7.03 (dd, 1H), 5.12 (s, 2H), 4.91 (t, 1H), 3.93 (s, 3H), 3.81 – 3.54 (m, 4H), 3.56 (td, 2H), 2.16 (d, 2H),

	1.72 – 1.47 (m, 2H).
313 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.73 (dd, 1H), 8.30 – 8.20 (m, 2H), 7.78 (dd, 1H), 7.44 (d, 1H), 7.19 (d, 1H), 6.96 (dd, 1H), 5.31 (s, 2H), 4.55 – 4.43 (m, 1H), 3.19 – 3.04 (m, 1H), 2.97 – 2.77 (m, 2H), 2.67 – 2.50 (m, 2H), 1.78 (s, 2H), 1.21 – 0.98 (m, 4H).
314	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.43 – 7.37 (m, 2H), 7.25 (d, 1H), 6.92 (dd, 1H), 5.30 (s, 2H), 4.91 (t, 1H), 3.75 – 3.58 (m, 6H), 2.60 – 2.50 (m, 1H), 2.41 (s, 3H), 2.20 (d, 2H), 1.65 (ddd, 2H), 1.10 (dt, 2H), 1.11 – 1.02 (m, 2H).
315 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.59 (d, 1H), 8.08 (d, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 7.19 (d, 1H), 6.97 (dd, 1H), 5.40 – 5.28 (m, 1H), 5.32 (s, 2H), 2.61 (s, 3H), 2.42 (s, 3H), 1.58 (d, 3H).
316 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.44 (d, 1H), 7.50 (d, 1H), 7.24 (d, 1H), 6.99 (dd, 1H), 5.31 (s, 2H), 5.24 (t, 1H), 4.81 (t, 1H), 3.77 (dp, 2H), 2.59 (s, 3H), 2.42 (s, 3H).
317 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.26 (dd, 1H), 7.69 (d, 1H), 7.53 – 7.45 (m, 2H), 6.99 (dd, 1H), 5.38 – 5.28 (m, 2H), 4.86 (ddd, 1H), 3.92 (td, 2H), 3.55 (ddd, 1H), 3.47 (dd, 1H), 3.38 – 3.32 (m, 1H), 3.10 (ddd, 1H), 2.66 (s, 3H), 2.42 (s, 3H).
318	¹ H NMR (500 MHz, DMSO) δ = 8.24 (s, 1H), 7.70 (s, 1H), 7.50 – 7.43 (m, 2H), 7.37 (d, 1H), 6.97 (dd, 1H), 5.34 (s, 2H), 2.63 (d, 6H), 2.62 (d, 3H), 2.55 (dd, 1H), 2.26 (ddd, 2H), 2.00 – 1.80 (m, 2H).
319	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.24 (s, 1H), 7.50 – 7.42 (m, 2H), 7.37 (d, 1H), 6.97 (dd, 1H), 5.34 (s, 2H), 2.66 – 2.57 (m, 6H), 2.61 – 2.51 (m, 2H), 2.43 (s, 3H), 2.26 (tdt, 2H), 2.00 – 1.79 (m, 2H).
320	¹ H NMR (500 MHz, DMSO) δ = 8.58 (d, 1H), 8.24 (s, 1H), 7.84 (t, 1H), 7.56 (d, 1H), 7.46 (dd, 2H), 7.36 (dd, 2H), 7.01 (d, 1H), 5.23 (s, 2H), 2.65 – 2.59 (m, 5H), 2.24 (q, 2H), 1.93 (s, 1H), 1.86 (d, 1H).
321	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.99 (t, 1H), 7.87 (d, 1H), 7.51 – 7.42 (m, 2H), 6.97 (dd, 1H), 5.33 (s, 2H), 3.88 (d, 2H), 2.67 – 2.60 (m, 6H), 2.43 (s, 3H).
322	¹ H NMR (600 MHz, DMSO) δ = 8.99 (s, 1H), 7.92 (s, 1H), 7.47 (d, 1H), 7.38 (d, 1H), 7.15 (t, 1H), 6.96 (dd, 1H), 5.33 (s, 2H), 3.42 (q, 1H), 3.17 (q, 2H), 2.93 (s, 3H), 2.62 (s, 3H), 2.43 (s, 3H).
323	¹ H NMR (600 MHz, DMSO) δ = 8.99 (s, 1H), 8.08 (t, 1H), 7.48 (d, 1H), 7.43 (d, 1H), 6.97 (dd, 1H), 5.33 (s, 2H), 3.74 (td, 2H), 3.44 (t, 2H), 3.07 (s, 3H), 2.63 (s, 3H), 2.43 (s, 3H).
324	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.67 (s, 1H), 7.72 (d, 1H), 7.54 – 7.43 (m, 2H), 6.99 (dd, 1H), 5.35 (s, 2H), 4.86 (d, 2H), 4.68 (d, 2H), 2.70 – 2.61 (m, 6H), 2.43 (s, 3H).
325	¹ H NMR (400 MHz, DMSO) δ = 8.58 (dd, 1H), 8.15 (dd, 2H), 7.68 – 7.57 (m, 2H), 7.48 (d, 1H), 7.39 (s, 1H), 7.22 (d, 1H), 6.97 (dd, 1H), 5.59 (s, 2H), 4.86 (s, 1H), 3.74 – 3.50 (m, 6H), 2.61 (s, 3H), 2.14 (d, 2H), 1.62 (ddd, 2H).
326 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.43 (d, 1H), 7.35 (dd, 1H), 7.24 (dd, 1H), 5.36 (s, 2H), 4.72 (s, 1H), 4.64 (dt, 1H), 3.56 – 3.32 (m, 5H), 3.18 (dt, 1H), 2.55 (s, 3H), 2.39 (s, 3H), 2.44 – 2.31 (m, 1H), 1.89 (dq, 1H).
327	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.42 (s, 1H), 7.33 (d, 1H), 7.22 (t, 1H), 5.36 (s, 2H), 4.73 (s, 1H), 3.55 (d, 2H), 2.39 (s, 3H), 0.83 – 0.75 (m, 2H), 0.71 – 0.65 (m, 2H).
328	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.65 (s, 1H), 7.36 (dd, 1H), 7.25 (dd, 1H), 5.37 (s, 2H), 5.18 (t, 1H), 4.65 – 4.53 (m, 4H), 3.73 (d, 2H), 2.53 (s, 3H), 2.39 (s, 3H).
329	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 7.72 (s, 1H), 7.62 – 7.54 (m, 1H), 7.39 (dd, 1H), 7.32 (dd, 1H), 7.25 – 7.15 (m, 1H), 6.23 (t, 1H), 4.95 (s, 2H), 4.81 (t, 1H), 3.72 – 3.55 (m, 6H), 2.52 (s, 3H), 2.15 – 2.05 (m, 2H), 1.70 – 1.57 (m, 1H).
330	¹ H NMR (500 MHz, DMSO) δ = 8.17 (dd, 1H), 7.81 (dd, 1H), 7.73 (s, 1H), 7.33 (d, 1H), 7.20 (t, 1H), 7.03 (dd, 1H), 5.13 (s, 2H), 4.81 (t, 1H), 3.91 (s, 3H), 3.72 – 3.56 (m, 6H), 2.52 (s, 3H), 2.14 – 2.06 (m, 2H), 1.63 (ddd, 2H).
331	¹ H NMR (500 MHz, DMSO) δ = 7.47 (d, 1H), 7.37 (s, 1H), 7.32 (d, 1H), 7.26 (d, 1H), 7.10 – 6.85 (m, 2H), 6.55 – 6.13 (m, 1H), 5.18 (s, 2H), 4.91 (t, 1H), 4.58 (td, 2H), 3.82 – 3.52 (m, 6H), 2.60 (s, 3H), 2.20 (d, 2H), 1.76 – 1.51 (m, 2H).
332 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.69 – 7.30 (m, 4H), 7.31 (s, 1H), 6.99 (d, 1H), 6.58 – 6.16 (m, 2H), 5.23 (s, 3H), 4.67 (td, 2H), 3.74 (d, 1H), 3.64 (d, 1H), 3.38 – 3.20 (m, 1H), 3.20 – 3.02 (m, 1H), 2.61 (s, 3H), 2.20 (dt, 2H), 1.79 (q, 2H).
333 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.79 (s, 1H), 7.71 – 7.39 (m, 3H), 7.29 (d, 1H), 6.99 (dd, 1H), 6.59 – 6.16 (m, 2H), 5.23 (s, 3H), 4.68 (td, 2H), 3.61 (q, 2H), 3.41 – 3.08 (m, 2H), 2.60 (s, 3H), 2.63 – 2.28 (m, 2H).
334	¹ H NMR (400 MHz, DMSO) δ = 7.52 (d, 1H), 7.47 (d, 1H), 7.40 (s, 1H), 7.28 (d, 1H), 6.98 (dd, 1H), 6.65 – 6.11 (m, 2H), 5.23 (s, 2H), 4.89 (t, 1H), 4.67 (td, 2H), 3.84 – 3.47 (m, 6H), 2.61 (s, 3H), 2.18

	(d, 2H), 1.67 (d, 0H), 1.64 (s, 1H).
335 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.18 (d, 1H), 8.09 (dd, 1H), 7.60 (dd, 1H), 7.47 (d, 1H), 7.36 (d, 1H), 6.97 (dd, 1H), 6.69 (dd, 1H), 4.95 (s, 2H), 4.70 (dt, 2H), 4.08 (t, 4H), 3.52 (d, 2H), 3.49 – 3.36 (m, 3H), 3.17 (dt, 1H), 2.62 (s, 3H), 2.23 (p, 2H), 2.05 – 1.89 (m, 1H).
336 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.22 (d, 1H), 8.09 (dd, 1H), 7.58 (dd, 1H), 7.47 (d, 1H), 7.21 (d, 1H), 6.97 (dd, 1H), 6.69 (dd, 1H), 4.93 (s, 2H), 4.46 (dd, 1H), 4.07 (t, 4H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 2.43 (s, 1H), 2.23 (p, 2H), 1.83 – 1.62 (m, 2H).
337	¹ H NMR (400 MHz, DMSO) δ = 8.08 (dd, 1H), 7.59 (dd, 1H), 7.46 (d, 1H), 7.41 (s, 1H), 7.25 (d, 1H), 6.96 (dd, 1H), 6.69 (dd, 1H), 4.94 (s, 2H), 4.89 (t, 1H), 4.08 (t, 4H), 3.75 – 3.66 (m, 2H), 3.71 – 3.56 (m, 4H), 2.60 (s, 3H), 2.29 – 2.13 (m, 4H), 1.70 – 1.57 (m, 2H).
338 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.36 – 8.14 (m, 2H), 8.04 (dd, 1H), 7.77 (t, 1H), 7.49 (d, 1H), 7.40 – 7.12 (m, 2H), 7.00 (dd, 1H), 5.24 – 5.00 (m, 2H), 4.47 (dt, 1H), 3.26 – 3.00 (m, 1H), 3.00 – 2.70 (m, 2H), 2.58 (d, 1H), 2.57 (s, 3H), 2.42 (s, 1H), 1.90 – 1.57 (m, 2H).
339	¹ H NMR (500 MHz, DMSO) δ = 8.25 (dd, 1H), 8.04 (dd, 1H), 7.76 (t, 1H), 7.55 – 7.16 (m, 4H), 6.98 (dd, 1H), 5.13 (s, 2H), 4.88 (s, 1H), 3.80 – 3.47 (m, 6H), 2.60 (s, 3H), 2.16 (d, 2H), 1.62 (ddd, 2H).
340 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.67 (dd, 1H), 8.20 (d, 1H), 8.13 (d, 1H), 7.75 – 6.87 (m, 5H), 5.36 (s, 2H), 4.69 (dt, 1H), 3.53 (t, 2H), 3.48 – 3.35 (m, 3H), 3.25 – 3.05 (m, 1H), 2.62 (s, 3H), 2.48 – 2.23 (m, 1H), 1.96 (dq, 1H).
341	¹ H NMR (400 MHz, DMSO) δ = 8.67 (dd, 1H), 8.36 (s, 1H), 8.13 (dd, 1H), 7.78 – 7.36 (m, 2H), 7.48 – 6.86 (m, 3H), 5.36 (s, 2H), 5.28 – 5.06 (m, 1H), 4.67 (d, 2H), 4.55 (d, 2H), 3.77 (d, 2H), 2.61 (s, 3H).
342 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.66 (dd, 1H), 8.22 (d, 1H), 8.12 (d, 1H), 7.77 – 7.37 (m, 2H), 7.37 – 6.86 (m, 3H), 5.34 (s, 2H), 4.73 – 4.20 (m, 1H), 3.11 (s, 1H), 3.02 – 2.65 (m, 2H), 2.57 (s, 3H), 2.42 (s, 1H), 1.93 – 1.53 (m, 2H).
343	¹ H NMR (400 MHz, DMSO) δ = 8.67 (dd, 1H), 8.26 – 8.00 (m, 1H), 7.78 – 7.29 (m, 3H), 7.44 – 6.85 (m, 3H), 5.35 (s, 2H), 4.88 (t, 1H), 3.84 – 3.46 (m, 6H), 2.61 (s, 3H), 2.16 (d, 2H), 1.87 – 1.47 (m, 2H).
344	¹ H NMR (500 MHz, DMSO) δ = 8.18 (dd, 1H), 7.76 (dd, 1H), 7.48 – 7.39 (m, 2H), 7.23 (d, 1H), 6.97 – 6.90 (m, 2H), 5.08 (s, 2H), 4.88 (s, 1H), 3.74 – 3.67 (m, 2H), 3.67 – 3.57 (m, 4H), 2.85 (s, 6H), 2.59 (s, 3H), 2.17 (d, 2H), 1.68 – 1.58 (m, 2H).
345	¹ H NMR (400 MHz, DMSO) δ = 7.45 (d, 1H), 7.40 (s, 1H), 7.23 (d, 1H), 6.93 (dd, 1H), 5.22 (s, 2H), 4.89 (t, 1H), 3.75 – 3.56 (m, 6H), 2.60 (s, 3H), 2.57 (s, 3H), 2.32 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
346	¹ H NMR (500 MHz, DMSO) δ = 7.92 (dd, 1H), 7.51 (dd, 1H), 7.46 (d, 1H), 7.37 (s, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 6.56 (dd, 1H), 5.85 (s, 2H), 4.97 (s, 2H), 4.90 (s, 1H), 3.70 (dt, 2H), 3.66 (s, 2H), 3.61 (td, 2H), 2.61 (s, 3H), 2.17 (d, 2H), 1.64 (ddd, 2H).
347	¹ H NMR (400 MHz, DMSO) δ = 8.75 (dd, 1H), 8.22 (dd, 1H), 7.80 (dd, 1H), 7.50 (d, 1H), 7.43 (s, 1H), 7.30 (d, 1H), 7.01 (dd, 1H), 5.33 (s, 2H), 4.88 (s, 1H), 3.74 – 3.55 (m, 6H), 2.61 (s, 3H), 2.17 (d, 2H), 1.70 – 1.57 (m, 2H).
348 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 8.13 (dd, 1H), 7.82 (dd, 1H), 7.47 (d, 1H), 7.35 (d, 1H), 6.99 (ddd, 2H), 5.07 (s, 2H), 4.77 – 4.61 (m, 1H), 4.39 (q, 2H), 3.52 (q, 2H), 3.49 – 3.36 (m, 3H), 3.17 (dt, 1H), 2.61 (s, 3H), 2.41 – 2.31 (m, 1H), 1.96 (p, 1H), 1.33 (t, 3H), 1.23 (s, 1H).
349 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 7.61 – 7.54 (m, 1H), 7.48 (dd, 2H), 7.42 – 7.31 (m, 2H), 6.95 (dd, 1H), 6.22 (t, 1H), 5.65 (s, 1H), 4.89 (s, 2H), 4.45 – 4.34 (m, 1H), 4.31 (ddd, 1H), 4.02 – 3.90 (m, 2H), 3.63 (dd, 1H), 3.58 (t, 1H), 2.63 (s, 3H).
350 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.15 (d, 1H), 7.54 (dd, 1H), 7.47 – 7.38 (m, 2H), 7.34 (s, 1H), 6.92 (dd, 1H), 6.20 (t, 1H), 4.96 – 4.86 (m, 2H), 4.33 (dt, 1H), 4.19 (tt, 1H), 4.05 (dd, 1H), 3.91 (dd, 1H), 3.63 (dd, 1H), 3.54 (dd, 1H), 2.57 (s, 3H).
351	¹ H NMR (500 MHz, DMSO) δ = 8.73 (d, 1H), 8.11 (d, 1H), 7.69 – 7.16 (m, 5H), 6.96 (dd, 1H), 5.36 (s, 2H), 4.88 (t, 1H), 3.71 (d, 2H), 3.75 – 3.52 (m, 4H), 2.59 (s, 3H), 2.17 (d, 2H), 1.64 (s, 2H).
352	¹ H NMR (500 MHz, DMSO) δ = 8.45 (dt, 1H), 7.79 (ddd, 1H), 7.53 (dt, 1H), 7.45 (d, 1H), 7.40 (s, 1H), 7.30 (d, 1H), 6.96 (dd, 1H), 5.25 (d, 2H), 4.88 (t, 1H), 3.74 – 3.58 (m, 6H), 2.59 (s, 3H), 2.18 (d, 2H), 1.63 (ddd, 2H).
355 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.58 (d, 1H), 7.55 – 7.45 (m, 3H), 7.31 (d, 1H), 7.00 (dd, 1H), 5.22 (t, 1H), 5.17 (s, 2H), 3.83 (s, 3H), 3.73 (dd, 1H), 3.64 (dd, 1H), 3.27 (dt, 1H), 3.16 – 3.09 (m, 1H), 2.60 (s, 3H), 2.27 – 2.14 (m, 2H), 1.85 – 1.73 (m, 1H).
356 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.78 (s, 1H), 7.54 – 7.45 (m, 3H), 7.29 (d, 1H), 6.99 (dd, 1H), 5.19 (d, 3H), 3.83 (s, 3H), 3.60 (qd, 2H), 3.20 (q, 1H), 2.60 (s, 3H), 2.49 – 2.35 (m, 2H).

357	¹ H NMR (400 MHz, DMSO) δ = 7.51 – 7.44 (m, 2H), 7.41 (s, 1H), 7.29 (d, 1H), 6.97 (dd, 1H), 5.17 (s, 2H), 4.89 (s, 1H), 3.83 (d, 3H), 3.76 – 3.56 (m, 6H), 2.60 (s, 3H), 2.18 (d, 2H), 1.64 (ddd, 2H).
358	¹ H NMR (500 MHz, DMSO) δ = 8.28 (dd, 1H), 7.50 – 7.40 (m, 3H), 7.39 (s, 1H), 7.24 (d, 1H), 6.96 (dd, 1H), 5.12 (s, 2H), 4.90 (s, 2H), 4.07 (dd, 2H), 3.74 – 3.57 (m, 8H), 2.59 (s, 3H), 2.21 – 2.13 (m, 2H), 1.63 (ddd, 2H).
359	¹ H NMR (400 MHz, DMSO) δ = 8.58 (d, 1H), 7.77 (td, 1H), 7.62 (dd, 1H), 7.46 (d, 1H), 7.39 (s, 1H), 7.24 (d, 1H), 6.98 (dd, 1H), 5.20 (s, 2H), 4.88 (t, 1H), 3.74 – 3.54 (m, 6H), 2.59 (s, 3H), 2.16 (d, 2H), 1.69 – 1.56 (m, 2H).
360 - En 1	¹ H NMR (400 MHz, DMSO) δ = 9.00 (s, 1H), 8.24 (d, 1H), 7.62 (d, 1H), 7.56 (d, 1H), 5.40 (s, 2H), 4.69 (dt, 1H), 3.53 (s, 2H), 3.51 – 3.36 (m, 3H), 3.18 (dt, 1H), 2.61 (s, 3H), 2.42 (s, 3H), 2.38 (dd, 1H), 1.97 (dq, 1H).
361	¹ H NMR (400 MHz, DMSO) δ = 9.00 (s, 1H), 8.20 (s, 1H), 7.59 (d, 1H), 7.46 (d, 1H), 5.39 (s, 2H), 4.79 (s, 1H), 3.57 (s, 2H), 2.55 (s, 3H), 2.42 (s, 3H), 0.77 (dt, 4H).
362	¹ H NMR (400 MHz, DMSO) δ = 9.00 (s, 1H), 8.39 (s, 1H), 7.62 (d, 1H), 7.51 (d, 1H), 5.40 (s, 2H), 5.22 (s, 1H), 4.68 (d, 2H), 4.56 (d, 2H), 3.79 (d, 2H), 2.60 (s, 3H), 2.42 (s, 3H).
363	¹ H NMR (500 MHz, DMSO) δ = 7.70 (dd, 2H), 7.55 (d, 1H), 7.40 (d, 1H), 6.23 (t, 1H), 4.97 (s, 2H), 4.08 (s, 2H), 3.72 (t, 2H), 3.62 (d, 2H), 2.74 (s, 3H), 1.75 – 1.64 (m, 2H), 1.33 (d, 2H).
364	¹ H NMR (500 MHz, DMSO) δ = 8.17 (dd, 1H), 7.81 (dd, 1H), 7.62 (d, 1H), 7.44 (s, 1H), 7.39 (d, 1H), 7.04 (dd, 1H), 5.14 (s, 2H), 4.88 (t, 1H), 3.93 (s, 3H), 3.74 – 3.62 (m, 4H), 3.58 (td, 2H), 2.60 (s, 3H), 2.15 (d, 2H), 1.62 (ddd, 2H).
365 - En 1	¹ H NMR (500 MHz, DMSO) δ = 9.00 (s, 1H), 8.29 (d, 1H), 7.20 (d, 1H), 7.02 (dd, 1H), 5.34 (s, 2H), 4.68 (dt, 1H), 3.52 (t, 2H), 3.47 – 3.37 (m, 3H), 3.22 – 3.13 (m, 1H), 2.64 (s, 3H), 2.43 (s, 3H), 2.35 (s, 1H), 1.96 (dq, 1H).
366	¹ H NMR (500 MHz, DMSO) δ = 9.00 (s, 1H), 8.25 (s, 1H), 7.10 (d, 1H), 6.98 (dd, 1H), 5.34 (s, 2H), 4.78 (d, 1H), 3.55 (d, 2H), 2.58 (s, 3H), 2.43 (s, 3H), 0.76 (dt, 4H).
367	¹ H NMR (500 MHz, DMSO) δ = 9.00 (s, 1H), 8.44 (s, 1H), 7.16 (d, 1H), 7.02 (dd, 1H), 5.34 (s, 2H), 5.20 (t, 1H), 4.67 (d, 2H), 4.54 (d, 2H), 3.78 (d, 2H), 2.63 (s, 3H), 2.43 (s, 3H).
368	¹ H NMR (400 MHz, DMSO) δ = 11.77 (s, 1H), 7.58 (dd, 1H), 7.51 (s, 1H), 7.39 (d, 1H), 7.05 (d, 1H), 6.96 (dd, 1H), 6.22 (t, 1H), 4.89 (d, 3H), 3.74 – 3.53 (m, 6H), 2.62 (s, 3H), 2.16 (d, 2H), 1.68 – 1.55 (m, 2H).
369	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.82 (dd, 1H), 7.52 (s, 1H), 7.07 (d, 1H), 7.07 – 6.94 (m, 2H), 5.08 (s, 2H), 4.88 (t, 1H), 3.92 (s, 3H), 3.75 – 3.52 (m, 6H), 2.62 (s, 3H), 2.15 (d, 2H), 1.62 (ddd, 2H).
370	¹ H NMR (500 MHz, DMSO) δ = 8.43 (t, 1H), 7.69 (s, 1H), 7.48 (d, 1H), 7.34 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 3.44 (d, 2H), 2.62 (d, 6H), 1.29 – 1.20 (m, 2H), 1.20 – 1.11 (m, 2H).
371	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.45 (t, 1H), 7.49 (d, 1H), 7.36 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 3.44 (d, 2H), 2.62 (s, 3H), 2.41 (s, 3H), 1.26 (q, 2H), 1.15 (q, 2H).
372	¹ H NMR (500 MHz, DMSO) δ = 8.29 (t, 1H), 7.69 (s, 1H), 7.47 (d, 1H), 7.28 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 3.72 (dd, 2H), 2.61 (d, 6H), 1.10 – 0.92 (m, 2H), 0.92 – 0.76 (m, 1H).
373	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 8.30 (t, 1H), 7.48 (d, 1H), 7.29 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 3.72 (dd, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 1.13 – 0.91 (m, 2H), 0.98 – 0.77 (m, 2H).
374	¹ H NMR (600 MHz, CDCl ₃) δ = 8.72 (s, 1H), 7.57 (d, 1H), 7.37 (d, 1H), 7.32 (d, 1H), 6.94 (dd, 1H), 6.57 (s, 1H), 6.33 (d, 1H), 5.25 (s, 2H), 4.73 (d, 2H), 2.74 (s, 3H), 2.50 (s, 3H).
375	¹ H NMR (500 MHz, DMSO) δ = 7.51 (d, 1H), 7.48 – 7.42 (m, 2H), 7.37 (d, 1H), 7.18 (d, 2H), 6.99 (dd, 1H), 5.12 (s, 2H), 5.07 (d, 1H), 4.39 (dd, 1H), 4.14 (td, 1H), 2.65 (s, 3H), 2.41 (s, 3H), 1.14 (d, 3H).
376	¹ H NMR (500 MHz, DMSO) δ = 8.41 (dd, 1H), 7.82 (dd, 1H), 7.54 – 7.47 (m, 2H), 7.46 (s, 1H), 7.40 (d, 1H), 7.24 (dd, 1H), 7.19 – 7.15 (m, 1H), 7.03 (dd, 1H), 5.16 (s, 2H), 5.08 (d, 1H), 4.37 (dd, 1H), 4.14 (td, 1H), 2.65 (s, 3H), 2.53 (s, 3H), 1.14 (d, 3H).
377	¹ H NMR (500 MHz, DMSO) δ = 7.72 (s, 1H), 7.50 (d, 1H), 7.48 – 7.41 (m, 2H), 7.36 (d, 1H), 7.18 (s, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 5.07 (d, 1H), 4.38 (dd, 1H), 4.14 (td, 1H), 2.65 (s, 3H), 2.63 (s, 3H), 1.14 (d, 3H).
378	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.50 (d, 1H), 7.44 (d, 2H), 7.38 (d, 1H), 7.16 (s, 1H), 6.99 (dd, 1H), 5.32 (s, 2H), 5.06 (d, 1H), 4.37 (dd, 1H), 4.19 – 4.09 (m, 1H), 2.65 (s, 3H), 2.42 (s, 3H), 1.14 (d, 3H).
379	¹ H NMR (600 MHz, DMSO) δ = 8.98 (s, 1H), 7.51 (d, 1H), 7.48 – 7.40 (m, 2H), 7.37 (d, 1H), 7.14 (s, 1H), 7.00 (dd, 1H), 5.32 (s, 2H), 5.05 (d, 1H), 4.38 (dd, 1H), 4.15 (t, 1H), 2.66 (s, 3H), 2.42 (s,

	3H), 1.15 (d, 3H).
380	¹ H NMR (500 MHz, DMSO) δ = 8.54 (d, 1H), 7.78 (dd, 1H), 7.50 (d, 1H), 7.46 (s, 1H), 7.45 (d, 1H), 7.38 (d, 1H), 7.27 (d, 1H), 7.19 – 7.15 (m, 1H), 6.99 (dd, 1H), 5.13 (s, 2H), 5.09 (s, 1H), 4.37 (dd, 1H), 4.18 – 4.10 (m, 1H), 2.65 (s, 3H), 2.47 (s, 3H), 1.14 (d, 3H).
381	¹ H NMR (500 MHz, DMSO) δ = 7.62 – 7.28 (m, 5H), 7.28 – 6.90 (m, 2H), 6.59 – 6.16 (m, 2H), 5.24 (s, 2H), 5.07 (s, 1H), 4.67 (td, 2H), 4.38 (dd, 1H), 4.14 (s, 1H), 2.66 (s, 3H), 1.14 (d, 3H).
382	¹ H NMR (500 MHz, DMSO) δ = 7.50 (d, 1H), 7.46 – 7.40 (m, 2H), 7.38 (d, 1H), 7.17 (s, 1H), 6.97 (dd, 1H), 5.23 (s, 2H), 5.06 (d, 1H), 4.37 (dd, 1H), 4.18 – 4.09 (m, 1H), 2.65 (s, 3H), 2.57 (s, 3H), 2.32 (s, 3H), 1.14 (d, 3H).
383	¹ H NMR (500 MHz, DMSO) δ = 7.52 (d, 1H), 7.50 – 7.43 (m, 3H), 7.41 (d, 1H), 7.17 (s, 1H), 7.02 (dd, 1H), 5.17 (s, 2H), 5.06 (d, 1H), 4.37 (dd, 1H), 4.14 (s, 1H), 3.83 (s, 3H), 2.66 (s, 3H), 1.14 (d, 3H).
384	¹ H NMR (500 MHz, DMSO) δ = 8.35 (t, 1H), 7.69 (s, 1H), 7.48 (d, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 4.79 – 4.60 (m, 4H), 3.82 (dd, 2H), 2.61 (d, 6H).
385	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.36 (t, 1H), 7.48 (d, 1H), 7.29 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.79 – 4.60 (m, 4H), 3.82 (dd, 2H), 2.59 (s, 3H), 2.42 (s, 3H).
386 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.70 (s, 1H), 7.48 (dd, 2H), 7.34 (d, 1H), 6.97 (dd, 1H), 5.61 (s, 1H), 5.31 (s, 2H), 4.45 – 4.36 (m, 1H), 4.31 (td, 1H), 4.00 – 3.91 (m, 2H), 3.64 (dd, 1H), 3.58 (t, 1H), 2.63 (d, 6H).
387 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.59 (ddd, 1H), 7.84 (td, 1H), 7.60 – 7.53 (m, 1H), 7.48 (dd, 2H), 7.40 – 7.31 (m, 2H), 7.00 (dd, 1H), 5.60 (s, 1H), 5.19 (s, 2H), 4.46 – 4.30 (m, 1H), 4.30 (s, 1H), 4.01 – 3.90 (m, 2H), 3.64 (dd, 1H), 3.58 (t, 1H), 2.63 (s, 3H).
388 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.13 (d, 1H), 7.69 (s, 1H), 7.46 (d, 1H), 7.21 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 3H), 4.23 (ddq, 2H), 4.01 (dd, 1H), 3.92 (dd, 1H), 3.66 (dd, 1H), 3.56 (dd, 1H), 2.63 (s, 3H), 2.56 (s, 3H).
389 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.13 (d, 1H), 7.84 (td, 1H), 7.54 (d, 1H), 7.47 (d, 1H), 7.35 (ddd, 1H), 7.21 (d, 1H), 6.99 (dd, 1H), 5.31 (s, 1H), 5.20 (s, 2H), 4.23 (s, 2H), 4.01 (dd, 1H), 3.91 (dd, 1H), 3.65 (dd, 1H), 3.56 (dd, 1H), 2.56 (s, 3H).
390	¹ H NMR (500 MHz, DMSO) δ = 8.74 (dd, 1H), 8.28 (d, 1H), 8.18 (d, 1H), 7.83 – 7.76 (m, 2H), 7.50 (d, 1H), 7.42 (d, 1H), 6.99 (dd, 1H), 5.57 (s, 1H), 5.32 (s, 2H), 4.45 – 4.35 (m, 2H), 3.48 – 3.40 (m, 1H), 3.02 – 2.94 (m, 1H), 2.63 (s, 3H).
391	¹ H NMR (500 MHz, DMSO) δ = 8.17 – 8.11 (m, 1H), 7.81 (d, 1H), 7.71 (s, 1H), 7.47 (d, 1H), 7.39 (d, 1H), 6.96 (dd, 1H), 5.58 (s, 1H), 5.32 (s, 2H), 4.40 (dd, 2H), 3.44 (td, 1H), 3.02 – 2.94 (m, 1H), 2.63 (d, 6H).
392	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.15 (d, 1H), 7.80 (d, 1H), 7.48 (d, 1H), 7.41 (d, 1H), 6.97 (dd, 1H), 5.57 (s, 1H), 5.32 (s, 2H), 4.46 – 4.35 (m, 2H), 3.44 (ddd, 1H), 2.98 (dd, 1H), 2.63 (s, 3H), 2.43 (s, 3H).
393	¹ H NMR (400 MHz, DMSO) δ = 8.19 (t, 1H), 7.68 (s, 1H), 7.47 (d, 1H), 7.26 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 3.75 (dt, 2H), 3.66 – 3.47 (m, 4H), 2.61 (d, 6H), 1.91 – 1.66 (m, 4H).
394	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.19 (t, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 3.75 (dt, 2H), 3.57 (dq, 4H), 2.59 (s, 3H), 2.41 (s, 3H), 1.92 – 1.66 (m, 4H).
395 - Dia 1	¹ H NMR (500 MHz, DMSO) δ = 7.64 (s, 1H), 7.57 (d, 1H), 7.50 (s, 1H), 7.44 (d, 1H), 7.37 (d, 1H), 7.21 (s, 1H), 6.94 (dd, 1H), 5.82 (q, 1H), 5.05 (t, 1H), 4.47 (dt, 1H), 3.76 (hept, 2H), 2.62 (s, 3H), 2.58 (s, 3H), 1.65 (d, 3H).
395 - Dia 2	¹ H NMR (500 MHz, DMSO) δ = 7.65 (s, 1H), 7.56 (d, 1H), 7.51 (s, 1H), 7.44 (d, 1H), 7.39 (d, 1H), 7.23 (s, 1H), 6.93 (dd, 1H), 5.82 (q, 1H), 5.02 (t, 1H), 4.49 (dt, 1H), 3.75 (hept, 2H), 2.62 (s, 3H), 2.57 (s, 3H), 1.65 (d, 3H).
396 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.04 (dd, 1H), 7.48 (dd, 1H), 7.33 (dd, 1H), 6.97 (dd, 1H), 5.33 (t, 2H), 4.99 (dp, 1H), 4.88 (t, 1H), 4.67 (t, 1H), 3.65 – 3.59 (m, 1H), 3.59 – 3.41 (m, 2H), 3.01 (d, 3H), 2.62 (d, 3H), 2.43 (d, 3H), 1.33 (t, 3H).
397 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.04 – 7.92 (m, 2H), 7.47 (d, 1H), 7.34 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 4.68 (t, 1H), 4.53 (p, 1H), 3.42 (q, 2H), 3.17 (q, 2H), 2.61 (s, 3H), 2.42 (s, 3H), 1.34 (d, 3H).
398	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.89 (s, 1H), 7.66 (t, 1H), 7.48 (d, 1H), 7.35 (d, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 4.58 (t, 1H), 3.41 (q, 2H), 3.18 (q, 2H), 2.62 (s, 3H), 2.43 (s, 3H), 1.52 (s, 6H).

399	¹ H NMR (400 MHz, DMSO) δ = 8.34 (s, 1H), 7.69 (s, 1H), 7.57 – 7.10 (m, 2H), 6.94 (dd, 1H), 6.73 (t, 1H), 5.31 (s, 2H), 4.01 (s, 2H), 2.63 (s, 3H), 2.54 (s, 3H), 0.89 (d, 4H).
400	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.34 (s, 1H), 7.45 (d, 1H), 7.23 (d, 1H), 6.94 (dd, 1H), 6.73 (t, 1H), 5.31 (s, 2H), 4.02 (s, 2H), 2.55 (s, 3H), 2.42 (s, 3H), 0.89 (dt, 4H).
401 - En 1	¹ H NMR (400 MHz, DMSO) δ = 12.35 (s, 1H), 8.20 (d, 1H), 7.71 (s, 1H), 7.55 – 7.46 (m, 3H), 7.50 (s, 1H), 7.18 – 7.11 (m, 2H), 6.97 (dd, 1H), 5.39 (d, 1H), 5.36 (s, 2H), 5.21 (s, 1H), 4.04 – 3.90 (m, 2H), 2.64 (d, 6H).
402 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.20 (d, 1H), 7.47 (d, 1H), 7.37 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 4.72 – 4.62 (m, 1H), 4.59 (t, 1H), 3.59 – 3.43 (m, 4H), 3.47 – 3.38 (m, 4H), 2.61 (s, 3H), 2.43 (s, 3H), 2.41 – 2.31 (m, 1H), 1.98 (dq, 1H).
403 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.16 (d, 1H), 7.48 (d, 1H), 7.41 (d, 1H), 7.20 (d, 1H), 7.02 (dd, 1H), 6.88 (d, 1H), 5.15 (s, 2H), 4.76 – 4.64 (m, 2H), 3.70 (s, 3H), 3.52 (q, 2H), 3.48 – 3.35 (m, 3H), 3.23 – 3.12 (m, 1H), 2.62 (s, 3H), 2.36 (s, 1H), 2.07 – 1.91 (m, 1H).
404 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.18 (d, 1H), 7.48 (d, 1H), 7.38 (dd, 2H), 6.99 (dd, 1H), 6.39 (d, 1H), 5.20 (s, 2H), 4.73 (d, 1H), 4.73 – 4.63 (m, 1H), 3.85 (s, 3H), 3.53 (q, 2H), 3.49 – 3.37 (m, 3H), 3.18 (dt, 1H), 2.61 (s, 3H), 2.42 – 2.32 (m, 1H), 2.05 – 1.90 (m, 1H).
405	¹ H NMR (400 MHz, DMSO) δ = 8.18 (d, 1H), 7.72 (dd, 1H), 7.61 – 7.53 (m, 1H), 7.46 (d, 1H), 7.33 (d, 1H), 6.95 (dd, 1H), 6.26 (t, 1H), 4.93 (s, 2H), 4.68 (dt, 1H), 3.53 (t, 2H), 3.48 (s, 3H), 3.48 – 3.35 (m, 3H), 3.17 (dt, 1H), 2.61 (s, 3H), 2.42 – 2.32 (m, 1H), 1.98 (dq, 1H).
406 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.18 (d, 1H), 7.84 (td, 1H), 7.56 (dt, 1H), 7.47 (d, 1H), 7.40 – 7.31 (m, 2H), 7.00 (dd, 1H), 5.21 (s, 2H), 4.76 – 4.63 (m, 2H), 3.53 (q, 2H), 3.49 – 3.35 (m, 3H), 3.17 (dt, 1H), 2.61 (s, 3H), 2.36 (s, 1H), 2.05 – 1.89 (m, 1H).
407 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.18 (d, 1H), 7.85 (d, 1H), 7.78 (d, 1H), 7.50 (d, 1H), 7.40 (d, 1H), 7.03 (dd, 1H), 5.47 (s, 2H), 4.76 – 4.63 (m, 1H), 3.53 (q, 1H), 3.48 – 3.35 (m, 3H), 3.23 – 3.12 (m, 1H), 2.62 (s, 3H), 2.36 (s, 1H), 1.98 (dq, 1H).
408 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.19 (d, 1H), 7.57 (dd, 1H), 7.46 (d, 1H), 7.42 – 7.33 (m, 2H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.75 – 4.63 (m, 1H), 3.53 (t, 2H), 3.42 (dt, 3H), 3.19 (dt, 1H), 2.61 (s, 3H), 2.42 – 2.32 (m, 1H), 2.07 – 1.92 (m, 1H).
409 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.22 – 8.13 (m, 2H), 7.83 (dd, 1H), 7.47 (d, 1H), 7.35 (d, 1H), 7.03 (dd, 1H), 6.97 (dd, 1H), 5.08 (s, 2H), 4.75 – 4.63 (m, 2H), 3.93 (s, 3H), 3.53 (q, 2H), 3.47 – 3.35 (m, 3H), 3.22 – 3.13 (m, 1H), 2.61 (s, 3H), 2.35 (q, 1H), 1.97 (dq, 1H).
410 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.92 (s, 1H), 7.47 (d, 1H), 7.22 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 4.68 (s, 1H), 3.53 (t, 2H), 3.49 – 3.35 (m, 3H), 3.22 – 3.13 (m, 1H), 2.58 (s, 3H), 2.43 (s, 3H), 2.03 (ddd, 1H), 1.35 (s, 3H).
411 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.89 (d, 1H), 7.48 (d, 1H), 7.34 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 5.04 (dt, 1H), 4.99 (s, 1H), 3.68 (dd, 1H), 3.13 (s, 3H), 2.89 (s, 3H), 2.61 (s, 3H), 2.42 (s, 3H).
412 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.70 (d, 1H), 7.51 (d, 1H), 7.46 (d, 1H), 7.33 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 4.79 (s, 1H), 4.10 (q, 1H), 3.55 – 3.48 (m, 2H), 2.61 (d, 6H), 2.50 – 2.42 (m, 1H), 2.39 (dd, 1H), 2.20 (s, 6H).
413 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.52 (d, 1H), 7.46 (d, 1H), 7.34 (d, 1H), 6.95 (dd, 1H), 5.31 (d, 2H), 4.78 (s, 1H), 4.10 (d, 0H), 3.52 (tt, 2H), 2.59 (s, 3H), 2.48 – 2.43 (m, 1H), 2.42 (s, 3H), 2.39 (dd, 1H), 2.20 (s, 6H).
414	¹ H NMR (400 MHz, DMSO) δ = 7.74 (s, 1H), 7.69 (s, 1H), 7.45 (d, 1H), 7.27 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 4.91 (t, 1H), 3.66 (d, 2H), 2.63 (s, 3H), 2.58 (s, 3H), 2.33 (q, 1H), 2.18 – 2.05 (m, 3H), 1.86 (dd, 1H), 1.81 – 1.69 (m, 1H).
415	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.84 (td, 1H), 7.74 (s, 1H), 7.55 (dt, 1H), 7.45 (d, 1H), 7.35 (ddd, 1H), 7.28 (d, 1H), 6.98 (dd, 1H), 5.20 (s, 2H), 4.89 (d, 1H), 3.65 (d, 2H), 2.58 (s, 3H), 2.31 (q, 2H), 2.19 – 2.07 (m, 1H), 1.92 – 1.69 (m, 2H).
416	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 7.76 (s, 1H), 7.61 – 7.54 (m, 1H), 7.44 (d, 1H), 7.38 (dd, 1H), 7.24 (d, 1H), 6.93 (dd, 1H), 6.22 (t, 1H), 4.90 (t, 1H), 4.89 (s, 2H), 3.66 (d, 2H), 2.58 (s, 3H), 2.38 – 2.25 (m, 2H), 2.13 (s, 2H), 1.94 – 1.66 (m, 2H).
417	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.82 (dd, 1H), 7.76 (s, 1H), 7.45 (d, 1H), 7.26 (d, 1H), 7.03 (dd, 1H), 6.95 (dd, 1H), 5.07 (s, 2H), 4.89 (t, 1H), 3.93 (s, 3H), 3.65 (d, 2H), 2.58 (s, 3H), 2.37 – 2.23 (m, 2H), 2.13 (ddd, 1H), 1.93 – 1.66 (m, 2H).
418	¹ H NMR (400 MHz, DMSO) δ = 8.14 (s, 1H), 7.69 (s, 1H), 7.44 (d, 1H), 7.26 (d, 1H), 6.93 (dd, 1H), 5.32 (s, 2H), 4.77 (t, 1H), 3.56 (d, 2H), 2.64 (s, 3H), 2.56 (s, 3H), 0.83 (s, 1H), 0.82 – 0.71 (m, 3H).
419	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.14 (s, 1H), 7.84 (td, 1H), 7.55 (d, 1H), 7.44 (d, 1H), 7.35 (ddd, 1H), 7.26 (d, 1H), 6.97 (dd, 1H), 5.21 (s, 2H), 4.76 (t, 1H), 3.55 (d, 2H), 2.56 (s, 3H),

	0.83 – 0.70 (m, 4H).
420	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 8.16 (s, 1H), 7.57 (ddd, 1H), 7.43 (d, 1H), 7.38 (dd, 1H), 7.24 (d, 1H), 6.93 (dd, 1H), 6.23 (t, 1H), 4.90 (s, 2H), 4.76 (s, 1H), 3.56 (s, 2H), 2.56 (s, 3H), 0.76 (dt, 4H).
421	¹ H NMR (400 MHz, DMSO) δ = 8.20 – 8.12 (m, 2H), 7.83 (dd, 1H), 7.44 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 6.95 (dd, 1H), 5.07 (s, 2H), 4.76 (t, 1H), 3.93 (s, 3H), 3.55 (d, 2H), 2.56 (s, 3H), 0.76 (dt, 4H).
422	¹ H NMR (400 MHz, DMSO) δ = 7.48 (d, 1H), 7.37 (d, 1H), 7.19 (d, 1H), 7.04 – 6.96 (m, 2H), 6.88 (d, 1H), 5.18 – 5.08 (m, 4H), 3.68 (d, 5H), 3.56 (dd, 2H), 2.60 (s, 3H), 1.33 (s, 3H).
423	¹ H NMR (400 MHz, DMSO) δ = 7.48 (d, 1H), 7.37 (d, 1H), 7.33 (d, 1H), 7.05 (s, 1H), 6.98 (dd, 1H), 6.39 (d, 1H), 5.18 (s, 2H), 4.98 (t, 2H), 3.85 (s, 3H), 3.65 (dd, 2H), 3.55 (dd, 2H), 2.60 (s, 3H), 1.32 (s, 3H).
424	¹ H NMR (400 MHz, DMSO) δ = 8.74 (d, 1H), 8.27 (d, 1H), 7.79 (dd, 1H), 7.49 (d, 1H), 7.31 (d, 1H), 7.07 (s, 1H), 6.98 (dd, 1H), 5.31 (s, 2H), 4.94 (t, 2H), 3.64 (dd, 2H), 3.55 (dd, 2H), 2.60 (s, 3H), 1.31 (s, 3H).
425	¹ H NMR (400 MHz, DMSO) δ = 7.70 (s, 1H), 7.47 (d, 1H), 7.29 (d, 1H), 7.03 (s, 1H), 6.95 (dd, 1H), 5.31 (s, 2H), 4.98 (t, 2H), 3.65 (dd, 2H), 3.55 (dd, 2H), 2.61 (d, 6H), 1.32 (s, 3H).
426	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.47 (d, 1H), 7.30 (d, 1H), 7.05 (s, 1H), 6.96 (dd, 1H), 5.30 (s, 2H), 4.96 (t, 2H), 3.65 (dd, 2H), 3.55 (dd, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 1.32 (s, 3H).
427	¹ H NMR (600 MHz, DMSO) δ = 9.22 (dd, 1H), 7.86 (dd, 1H), 7.76 (dd, 1H), 7.49 (d, 1H), 7.35 (d, 1H), 7.06 – 7.00 (m, 2H), 5.43 (s, 2H), 4.96 (tq, 2H), 3.66 (dd, 2H), 3.56 (dd, 2H), 2.60 (s, 3H), 1.32 (s, 3H).
428	¹ H NMR (500 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.84 (td, 1H), 7.59 – 7.53 (m, 1H), 7.47 (d, 1H), 7.35 (ddd, 1H), 7.30 (d, 1H), 7.03 (s, 1H), 6.99 (dd, 1H), 5.19 (s, 2H), 4.96 (t, 2H), 3.64 (dd, 2H), 3.55 (dd, 2H), 2.59 (s, 3H), 1.31 (s, 3H).
429	¹ H NMR (600 MHz, DMSO) δ = 9.18 (d, 1H), 8.86 – 8.79 (m, 1H), 7.67 (dd, 1H), 7.49 (d, 1H), 7.30 (d, 1H), 7.05 – 7.00 (m, 2H), 5.24 (s, 2H), 4.98 – 4.92 (m, 2H), 3.64 (dd, 2H), 3.55 (dd, 2H), 2.60 (s, 3H), 1.31 (s, 3H).
430	¹ H NMR (500 MHz, DMSO) δ = 11.77 (s, 1H), 7.58 (ddd, 1H), 7.46 (d, 1H), 7.41 – 7.35 (m, 1H), 7.26 (d, 1H), 7.04 (s, 1H), 6.94 (dd, 1H), 6.22 (t, 1H), 4.95 (t, 2H), 4.88 (s, 2H), 3.64 (dd, 2H), 3.55 (dd, 2H), 2.59 (s, 3H), 1.31 (s, 3H).
431	¹ H NMR (500 MHz, DMSO) δ = 8.16 (dd, 1H), 7.83 (dd, 1H), 7.46 (d, 1H), 7.29 (d, 1H), 7.07 – 6.99 (m, 2H), 6.96 (dd, 1H), 5.06 (s, 2H), 4.94 (t, 2H), 3.93 (s, 3H), 3.64 (dd, 2H), 3.55 (dd, 2H), 2.60 (s, 3H), 1.31 (s, 3H).
432 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.46 (s, 1H), 8.03 (d, 1H), 7.98 (s, 1H), 7.72 (d, 2H), 7.46 (d, 1H), 7.37 (s, 1H), 7.29 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.94 (td, 1H), 4.65 (dd, 1H), 4.60 (dd, 1H), 2.64 (s, 3H), 2.52 (s, 3H).
433 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.88 (d, 1H), 7.48 (d, 2H), 7.38 (dd, 2H), 7.11 (s, 1H), 6.98 (dd, 1H), 6.39 (d, 1H), 5.20 (s, 2H), 4.48 (p, 1H), 3.85 (s, 3H), 2.62 (s, 3H), 1.36 (d, 3H).
434 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.87 (d, 1H), 7.71 (s, 1H), 7.52 – 7.43 (m, 2H), 7.36 (d, 1H), 7.11 (s, 1H), 6.95 (dd, 1H), 5.33 (s, 2H), 4.48 (p, 1H), 2.62 (d, 6H), 1.36 (d, 3H).
435 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.91 – 7.79 (m, 2H), 7.56 (dt, 1H), 7.51 – 7.44 (m, 2H), 7.40 – 7.31 (m, 2H), 7.10 (s, 1H), 7.00 (dd, 1H), 5.21 (s, 2H), 4.47 (p, 1H), 2.62 (s, 3H), 1.36 (d, 3H).
436 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.74 (s, 1H), 7.89 (d, 1H), 7.58 (d, 1H), 7.52 – 7.42 (m, 2H), 7.36 (dd, 2H), 7.07 (s, 1H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.46 (q, 1H), 2.62 (s, 3H), 1.36 (d, 3H).
437 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.83 (dd, 1H), 7.47 (s, 1H), 7.47 (d, 1H), 7.35 (d, 1H), 7.08 (s, 1H), 7.03 (dd, 1H), 6.97 (dd, 1H), 5.08 (s, 2H), 4.47 (p, 1H), 3.93 (s, 3H), 2.62 (s, 3H), 1.35 (d, 3H).
438	¹ H NMR (400 MHz, DMSO) δ = 7.83 (s, 1H), 7.49 (d, 1H), 7.44 (d, 1H), 7.37 (d, 2H), 7.19 (s, 1H), 7.00 (dd, 1H), 6.39 (d, 1H), 5.21 (s, 2H), 3.86 (s, 3H), 2.64 (s, 3H), 1.57 (s, 6H).
439	¹ H NMR (400 MHz, DMSO) δ = 7.81 (s, 1H), 7.48 (d, 1H), 7.39 (d, 1H), 7.37 (s, 1H), 7.19 (s, 1H), 6.97 (dd, 1H), 5.34 (s, 2H), 2.63 (d, 6H), 1.56 (s, 6H).
440	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.82 (s, 1H), 7.48 (d, 1H), 7.40 (d, 1H), 7.16 (s, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 2.64 (s, 3H), 2.42 (s, 3H), 1.56 (s, 6H).

441	¹ H NMR (600 MHz, DMSO) δ = 7.86 (d, 2H), 7.50 (d, 1H), 7.47 – 7.42 (m, 1H), 7.11 (s, 1H), 5.45 (s, 2H), 2.64 (s, 3H), 1.56 (s, 6H).
442	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.89 – 7.79 (m, 2H), 7.57 (dt, 1H), 7.49 (d, 1H), 7.41 (d, 1H), 7.39 – 7.31 (m, 1H), 7.34 (s, 1H), 7.16 (s, 1H), 7.01 (dd, 1H), 5.21 (s, 2H), 2.63 (s, 3H), 1.55 (s, 6H).
443	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 7.82 (s, 1H), 7.63 – 7.55 (m, 1H), 7.47 (d, 1H), 7.42 – 7.31 (m, 3H), 7.12 (s, 1H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 2.63 (s, 3H), 1.55 (s, 6H).
444	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.87 – 7.80 (m, 1H), 7.82 (s, 1H), 7.48 (d, 1H), 7.39 (d, 1H), 7.34 (s, 1H), 7.14 (s, 1H), 7.00 (ddd, 2H), 5.08 (s, 2H), 3.93 (s, 3H), 2.64 (s, 3H), 1.55 (s, 6H).
445 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.69 (d, 2H), 7.51 – 7.44 (m, 2H), 7.32 (d, 1H), 7.13 – 7.09 (m, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.56 (td, 1H), 2.88 (dd, 1H), 2.82 (dd, 1H), 2.62 (d, 6H), 2.34 (s, 3H), 1.75 (ddd, 1H), 0.48 – 0.37 (m, 3H), 0.32 (dt, 1H).
446 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.70 (d, 1H), 7.51 – 7.45 (m, 2H), 7.33 (d, 1H), 7.10 (s, 1H), 6.98 (dd, 1H), 5.31 (d, 2H), 4.55 (td, 1H), 2.88 (dd, 1H), 2.81 (dd, 1H), 2.60 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 1.75 (dq, 1H), 0.45 – 0.37 (m, 3H), 0.40 – 0.29 (m, 1H).
447 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.97 (d, 1H), 7.79 – 7.25 (m, 4H), 7.08 – 6.47 (m, 2H), 5.32 (s, 2H), 4.87 – 4.64 (m, 1H), 4.19 (qd, 2H), 3.33 (s, 2H), 2.63 (d, 5H).
448 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.98 (d, 1H), 7.66 (s, 1H), 7.58 – 7.26 (m, 2H), 7.37 (s, 1H), 6.98 (dd, 1H), 6.72 (t, 1H), 5.31 (s, 2H), 4.75 (td, 1H), 4.19 (qd, 2H), 2.62 (s, 3H), 2.42 (s, 3H).
449 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.77 – 7.69 (m, 2H), 7.59 (s, 1H), 7.47 (d, 1H), 7.41 (d, 1H), 7.14 (s, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.52 (q, 1H), 2.63 (d, 7H), 2.55 (dd, 1H), 2.24 (s, 6H).
450 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.76 (d, 1H), 7.58 (s, 1H), 7.48 (d, 1H), 7.15 – 7.11 (m, 1H), 6.97 (dd, 1H), 5.32 (d, 2H), 4.51 (td, 1H), 2.66 (dd, 1H), 2.62 (s, 3H), 2.55 (dd, 1H), 2.42 (s, 3H), 2.24 (s, 6H).
451 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.63 (d, 1H), 7.53 – 7.43 (m, 3H), 7.19 (t, 2H), 7.02 (dd, 1H), 6.87 (d, 1H), 5.22 (s, 1H), 5.16 (s, 2H), 4.48 (dt, 1H), 3.77 (q, 2H), 3.70 (s, 3H), 2.64 (s, 3H).
452 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.64 (d, 1H), 7.49 (s, 1H), 7.53 – 7.42 (m, 2H), 7.37 (d, 1H), 7.20 (s, 1H), 7.00 (dd, 1H), 6.40 (d, 1H), 5.20 (s, 2H), 5.07 (s, 1H), 4.53 – 4.44 (m, 1H), 3.85 (s, 3H), 3.81 – 3.69 (m, 2H), 2.64 (s, 3H).
453 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.72 (s, 1H), 7.62 (d, 1H), 7.52 – 7.45 (m, 2H), 7.41 (d, 1H), 7.20 (s, 1H), 6.97 (dd, 1H), 5.33 (s, 2H), 5.04 (s, 1H), 4.48 (dt, 1H), 3.78 – 3.72 (m, 2H), 2.63 (m, 6H).
454	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.63 (d, 1H), 7.49 (d, 2H), 7.42 (d, 1H), 7.19 (s, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.02 (s, 1H), 4.48 (dt, 1H), 3.75 (s, 2H), 2.64 (s, 3H), 2.42 (s, 3H).
455 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.84 (td, 1H), 7.62 (d, 1H), 7.57 (dt, 1H), 7.49 (d, 2H), 7.43 (d, 1H), 7.35 (ddd, 1H), 7.19 (s, 1H), 7.01 (dd, 1H), 5.20 (s, 2H), 5.02 (t, 1H), 4.48 (dt, 1H), 3.75 (td, 2H), 2.64 (s, 3H).
456 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.65 (d, 1H), 7.56 – 7.47 (m, 3H), 7.45 (d, 1H), 7.20 (s, 1H), 6.99 (dd, 1H), 6.55 – 6.23 (m, 2H), 5.24 (s, 2H), 5.05 (s, 1H), 4.67 (td, 2H), 4.49 (dt, 1H), 3.75 (dd, 2H), 2.64 (s, 3H).
457 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.67 (dd, 1H), 8.24 – 8.03 (m, 1H), 7.75 – 7.34 (m, 5H), 7.44 – 6.89 (m, 3H), 5.35 (s, 2H), 5.01 (s, 1H), 4.48 (dt, 1H), 3.74 (d, 2H), 2.65 (s, 3H).
458 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.62 (d, 1H), 7.48 (d, 2H), 7.39 (d, 1H), 7.18 (s, 1H), 6.96 (dd, 1H), 5.23 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.74 (td, 2H), 2.64 (s, 3H), 2.57 (s, 3H), 2.32 (s, 3H).
459 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 7.66 – 7.56 (m, 2H), 7.51 – 7.44 (m, 2H), 7.38 (dd, 2H), 7.17 (s, 1H), 6.96 (dd, 1H), 6.22 (t, 1H), 5.04 (s, 1H), 4.90 (s, 2H), 4.47 (dt, 1H), 3.78 – 3.72 (m, 2H), 2.64 (s, 3H).
460 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.65 (d, 1H), 7.51 (d, 1H), 7.46 (dd, 3H), 7.21 – 7.16 (m, 1H), 7.01 (dd, 1H), 5.18 (s, 2H), 5.01 (t, 1H), 4.48 (dt, 1H), 3.83 (s, 3H), 3.75 (td, 2H), 2.64 (s, 3H).
461 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.41 (dd, 1H), 7.83 (dd, 1H), 7.65 (s, 1H), 7.54 – 7.47 (m, 2H), 7.45 (s, 1H), 7.30 (s, 1H), 7.24 (dd, 1H), 7.02 (dd, 1H), 5.17 (s, 2H), 3.97 (d, 1H), 3.77 (d, 1H), 2.66 (s, 3H), 2.54 (s, 3H), 1.53 (s, 3H).
462 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.72 (s, 1H), 7.63 (s, 1H), 7.52 – 7.44 (m, 3H), 7.31 (s, 1H), 6.97 (dd, 1H), 5.33 (s, 2H), 5.14 (s, 1H), 3.97 (d, 1H), 3.77 (d, 1H), 2.64 (d, 6H), 1.53 (s, 3H).
463 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.63 (s, 1H), 7.53 – 7.40 (m, 2H), 7.44 (s, 1H), 7.28 (s, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.16 (s, 1H), 3.96 (d, 1H), 3.76 (d, 1H), 2.65 (s, 3H), 2.42 (s, 3H), 1.53 (s, 3H).

464 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.55 (d, 1H), 7.78 (dd, 1H), 7.64 (s, 1H), 7.52 – 7.45 (m, 2H), 7.45 (s, 1H), 7.33 – 7.24 (m, 2H), 6.98 (dd, 1H), 5.13 (s, 2H), 3.97 (d, 1H), 3.77 (d, 1H), 2.65 (s, 3H), 2.47 (s, 3H), 1.53 (s, 3H).
465 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.74 – 7.38 (m, 5H), 7.30 (s, 1H), 7.00 (dd, 1H), 6.59 – 6.16 (m, 2H), 5.25 (s, 2H), 5.15 (s, 1H), 4.68 (td, 2H), 3.97 (d, 1H), 3.77 (d, 1H), 2.66 (s, 3H), 1.53 (s, 3H).
466 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.64 (s, 1H), 7.54 – 7.45 (m, 3H), 7.43 (s, 1H), 7.28 (s, 1H), 7.02 (dd, 1H), 5.18 (s, 2H), 5.12 (s, 1H), 3.96 (d, 1H), 3.83 (s, 3H), 3.77 (d, 1H), 2.66 (s, 3H), 1.53 (s, 3H).
467 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.81 (d, 1H), 7.57 – 7.52 (m, 1H), 7.48 (d, 1H), 7.35 (d, 1H), 7.25 – 7.20 (m, 1H), 5.32 (s, 2H), 4.66 (ddd, 1H), 3.73 – 3.60 (m, 2H), 3.30 (s, 3H), 2.62 (s, 3H), 2.42 (s, 3H).
468 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.71 (s, 1H), 7.50 (d, 2H), 7.43 (d, 1H), 7.37 (s, 1H), 6.99 (dd, 1H), 5.33 (s, 2H), 4.00 (d, 1H), 3.75 (d, 1H), 3.26 (s, 3H), 2.65 (s, 3H), 2.42 (s, 3H), 1.55 (s, 3H).
469 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.93 (d, 1H), 7.51 – 7.42 (m, 2H), 7.39 (d, 1H), 7.08 (s, 1H), 6.96 (dd, 1H), 5.31 (s, 2H), 4.75 (t, 1H), 4.51 (td, 1H), 3.56 (dt, 2H), 2.63 (s, 3H), 2.42 (s, 3H), 2.03 – 1.81 (m, 2H).
470	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.62 (s, 1H), 7.49 (d, 1H), 7.38 (d, 1H), 7.27 (s, 1H), 7.20 (s, 1H), 6.99 (dd, 1H), 5.32 (s, 2H), 2.99 – 2.87 (m, 3H), 2.63 (s, 3H), 2.42 (s, 3H).
471	¹ H NMR (400 MHz, DMSO) δ = 8.24 (s, 1H), 7.70 (s, 1H), 7.47 (d, 1H), 7.36 (d, 1H), 7.02 – 6.93 (m, 2H), 6.88 (s, 1H), 5.34 (s, 2H), 2.63 (s, 6H), 2.59 – 2.53 (m, 2H), 2.26 (q, 2H), 2.00 – 1.80 (m, 2H).
472	¹ H NMR (400 MHz, DMSO) δ = 8.58 (d, 1H), 8.25 (s, 1H), 7.84 (t, 1H), 7.56 (d, 1H), 7.48 (d, 1H), 7.40 – 7.31 (m, 2H), 7.05 – 6.95 (m, 2H), 6.88 (s, 1H), 5.23 (s, 2H), 2.62 (s, 3H), 2.24 (q, 2H), 1.93 (s, 2H), 1.88 (dd, 2H).
473	¹ H NMR (500 MHz, DMSO-d ₆): δ 8.16 (dd, 1H), 7.82 (dd, 1H), 7.46 (d, 1H), 7.29-7.26 (m, 2H), 7.06-7.00 (m, 1H), 6.96 (dd, 1H), 5.06 (s, 2H), 5.04 (t, 1H), 3.92 (s, 3H), 3.50 (d, 2H), 3.58 (s, 3H), 1.33 (s, 6H).
474	¹ H NMR (500 MHz, DMSO-d ₆): δ 8.98 (s, 1H), 7.58 (d, 1H), 7.46 (d, 1H), 7.33 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.78 (s, 1H), 4.14 - 4.18 (m, 1H), 3.50 - 3.58 (m, 6H), 2.60 (s, 3H), 2.40 – 2.50 (m, 4H), 2.34 - 2.37 (m, 5H).
475	¹ H NMR (400 MHz, DMSO) δ = 8.78 – 8.70 (m, 1H), 8.27 (d, 1H), 7.79 (dd, 1H), 7.48 (d, 1H), 7.36 (d, 1H), 7.20 (s, 1H), 7.05 (s, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 2.61 (s, 3H), 1.35 (q, 2H), 1.01 (q, 2H).
476	¹ H NMR (400 MHz, DMSO) δ = 8.29 (s, 1H), 7.70 (s, 1H), 7.45 (d, 1H), 7.35 (d, 1H), 7.19 (s, 1H), 7.05 (s, 1H), 6.94 (dd, 1H), 5.33 (s, 2H), 2.62 (d, 6H), 1.35 (q, 2H), 1.03 (q, 2H).
477	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.29 (s, 1H), 7.45 (d, 1H), 7.36 (d, 1H), 7.05 (s, 1H), 6.95 (dd, 1H), 5.33 (s, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 1.35 (q, 2H), 1.04 (q, 2H).
478	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.30 (s, 1H), 7.84 (td, 1H), 7.55 (d, 1H), 7.45 (d, 1H), 7.39 – 7.31 (m, 2H), 7.18 (s, 1H), 7.05 (s, 1H), 6.98 (dd, 1H), 5.23 (s, 2H), 2.60 (s, 3H), 1.35 (q, 2H), 1.02 (q, 2H).
479	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 8.32 (s, 1H), 7.62 – 7.54 (m, 1H), 7.44 (d, 1H), 7.41 – 7.30 (m, 2H), 7.20 (s, 1H), 7.04 (s, 1H), 6.94 (dd, 1H), 6.23 (t, 1H), 4.92 (s, 2H), 2.60 (s, 3H), 1.34 (q, 2H), 1.03 (q, 2H).
480	¹ H NMR (400 MHz, DMSO) δ = 8.32 (s, 1H), 8.16 (dd, 1H), 7.83 (dd, 1H), 7.45 (d, 1H), 7.35 (d, 1H), 7.20 (s, 1H), 7.03 (dd, 2H), 6.96 (dd, 1H), 5.09 (s, 2H), 3.93 (s, 3H), 2.60 (s, 3H), 1.34 (q, 2H), 1.01 (q, 2H).
481	¹ H NMR (400 MHz, DMSO) δ = 7.46 (d, 1H), 7.34 (d, 1H), 7.19 (d, 1H), 7.15 (s, 1H), 6.99 (dd, 1H), 6.87 (d, 1H), 5.25 (t, 1H), 5.16 (s, 2H), 3.69 (s, 3H), 3.52 (d, 2H), 2.58 (s, 3H), 1.36 (s, 6H).
482	¹ H NMR (500 MHz, DMSO) δ = 7.46 (d, 1H), 7.37 (d, 1H), 7.29 (d, 1H), 7.20 (s, 1H), 6.97 (dd, 1H), 6.38 (d, 1H), 5.18 (s, 2H), 5.07 (t, 1H), 3.85 (s, 3H), 3.51 (d, 2H), 2.58 (s, 3H), 1.35 (s, 6H).
483	¹ H NMR (400 MHz, DMSO) δ = 7.70 (s, 1H), 7.46 (d, 1H), 7.25 (d, 1H), 7.19 (s, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 5.08 (t, 1H), 3.51 (d, 2H), 2.64 (s, 3H), 2.58 (s, 3H), 1.35 (s, 6H).
484	¹ H NMR (500 MHz, DMSO) δ = 8.58 (dt, 1H), 7.84 (td, 1H), 7.55 (d, 1H), 7.46 (d, 1H), 7.35 (ddd, 1H), 7.25 (d, 1H), 7.18 (s, 1H), 6.98 (dd, 1H), 5.20 (s, 2H), 5.05 (t, 1H), 3.50 (d, 2H), 2.57 (s, 3H), 1.34 (s, 6H).
485	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 7.61 – 7.54 (m, 1H), 7.45 (d, 1H), 7.41 – 7.34 (m, 1H), 7.25 – 7.17 (m, 2H), 6.94 (dd, 1H), 6.22 (t, 1H), 5.03 (t, 1H), 4.89 (s, 2H), 3.50 (d, 2H), 2.57 (s, 3H), 1.34 (s, 6H).

486	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.82 (dd, 1H), 7.45 (d, 1H), 7.27 – 7.17 (m, 2H), 7.03 (dd, 1H), 6.95 (dd, 1H), 5.10 – 4.99 (m, 3H), 3.93 (s, 3H), 3.50 (d, 2H), 2.57 (s, 3H), 1.33 (s, 6H).
487 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.69 (s, 1H), 7.57 (d, 1H), 7.46 (d, 1H), 7.32 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.80 (s, 1H), 4.19 – 4.13 (m, 1H), 3.55 (t, 7H), 2.62 (d, 7H), 2.40 (s, 3H).
488 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 7.58 (d, 1H), 7.47 (d, 1H), 7.34 (d, 1H), 6.98 (dd, 1H), 5.31 (s, 2H), 4.79 (s, 1H), 4.16 (s, 1H), 3.64 – 3.46 (m, 7H), 2.60 (s, 3H), 2.48 (d, 1H), 2.42 (s, 3H).
489 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.73 (dd, 1H), 8.29 – 8.22 (m, 1H), 7.79 (dd, 1H), 7.67 (d, 1H), 7.48 (d, 1H), 7.27 (d, 1H), 6.98 (dd, 1H), 5.32 (d, 2H), 4.76 (t, 1H), 4.08 – 3.97 (m, 1H), 3.48 (dt, 1H), 3.43 – 3.33 (m, 1H), 2.58 (s, 3H), 1.14 (d, 3H).
490 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.69 (s, 1H), 7.63 (d, 1H), 7.45 (d, 1H), 7.26 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.80 (s, 1H), 4.04 (dt, 1H), 3.49 (dd, 1H), 3.39 (dd, 1H), 2.60 (d, 6H), 1.15 (d, 3H).
491 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.65 (d, 1H), 7.46 (d, 1H), 7.27 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.78 (t, 1H), 4.11 – 3.98 (m, 1H), 3.49 (dt, 1H), 3.44 – 3.35 (m, 1H), 2.58 (s, 3H), 2.42 (s, 3H), 1.16 (d, 3H).
492	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.84 (td, 1H), 7.63 (d, 1H), 7.55 (d, 1H), 7.46 (d, 1H), 7.35 (ddd, 1H), 7.26 (d, 1H), 6.99 (dd, 1H), 5.20 (s, 2H), 4.78 (t, 1H), 4.09 – 3.97 (m, 1H), 3.48 (dt, 1H), 3.43 – 3.34 (m, 1H), 2.57 (s, 3H), 1.15 (d, 3H).
493	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.84 (td, 1H), 7.63 (d, 1H), 7.55 (d, 1H), 7.46 (d, 1H), 7.35 (ddd, 1H), 7.27 (d, 1H), 6.99 (dd, 1H), 5.20 (s, 2H), 4.78 (t, 1H), 4.03 (dt, 1H), 3.54 – 3.43 (m, 1H), 3.38 (dt, 1H), 2.57 (s, 3H), 1.15 (d, 3H).
494	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 7.64 (d, 1H), 7.57 (ddd, 1H), 7.45 (d, 1H), 7.38 (dd, 1H), 7.25 (d, 1H), 6.94 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.79 (s, 1H), 4.03 (p, 1H), 3.49 (dd, 1H), 3.39 (dd, 1H), 2.58 (s, 3H), 1.15 (d, 3H).
495	¹ H NMR (400 MHz, DMSO) δ = 11.76 (s, 1H), 7.64 (d, 1H), 7.61 – 7.53 (m, 1H), 7.45 (d, 1H), 7.38 (dd, 1H), 7.25 (d, 1H), 6.94 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.79 (s, 1H), 4.03 (p, 1H), 3.49 (dd, 1H), 3.39 (dd, 1H), 2.58 (s, 3H), 1.15 (d, 3H).
496	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.82 (dd, 1H), 7.66 (d, 1H), 7.45 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 6.96 (dd, 1H), 5.07 (s, 2H), 4.77 (s, 1H), 4.03 (p, 1H), 3.93 (s, 3H), 3.48 (t, 1H), 3.40 (s, 1H), 2.58 (s, 3H), 1.15 (d, 3H).
497	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.82 (dd, 1H), 7.65 (d, 1H), 7.45 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 6.96 (dd, 1H), 5.07 (s, 2H), 4.77 (t, 1H), 4.03 (p, 1H), 3.93 (s, 3H), 3.48 (dt, 1H), 3.43 – 3.34 (m, 1H), 2.58 (s, 3H), 1.15 (d, 3H).
498	¹ H NMR (600 MHz, DMSO) δ = 8.98 (s, 1H), 8.25 (t, 1H), 7.49 (d, 1H), 7.34 (d, 1H), 6.99 (dd, 1H), 6.18 (tt, 1H), 5.33 (s, 2H), 3.72 (tdd, 2H), 2.62 (s, 3H), 2.43 (s, 3H).
499	¹ H NMR (500 MHz, DMSO) δ = 8.35 (t, 1H), 7.69 (s, 1H), 7.48 (d, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.32 (s, 2H), 3.75 (td, 2H), 2.61 (d, 6H), 1.66 (t, 3H).
500	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 8.36 (t, 1H), 7.48 (d, 1H), 7.28 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 3.75 (td, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 1.66 (t, 3H).
501	¹ H NMR (600 MHz, CDCl ₃) δ = 8.73 (s, 1H), 7.45 (d, 1H), 7.36 (d, 1H), 6.94 (dd, 1H), 6.78 (s, 1H), 6.14 (s, 1H), 5.34 (s, 2H), 3.69 – 3.61 (m, 2H), 3.61 – 3.55 (m, 2H), 2.75 (s, 3H), 2.53 (s, 3H), 2.02 (s, 3H).
502	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.87 (d, 1H), 7.85 (s, 1H), 7.50 (d, 1H), 7.45 (d, 1H), 7.00 (dd, 1H), 5.65 (d, 1H), 5.33 (s, 2H), 2.67 (s, 3H), 2.43 (s, 3H).
503	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.94 (t, 1H), 7.52 – 7.41 (m, 2H), 7.42 (s, 1H), 7.07 (s, 1H), 6.97 (dd, 1H), 5.33 (s, 2H), 3.87 (d, 2H), 2.64 (s, 3H), 2.42 (s, 3H).
504	¹ H NMR (500 MHz, DMSO) δ = 8.17 (t, 1H), 7.68 (s, 1H), 7.47 (d, 1H), 7.26 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 3.50 (dd, 2H), 2.61 (d, 6H), 1.37 (d, 6H).
505	¹ H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 8.17 (t, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 3.50 (dd, 2H), 2.60 (s, 3H), 2.41 (s, 3H), 1.37 (d, 6H).
506	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.74 (t, 1H), 7.47 (d, 1H), 7.32 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.61 (s, 1H), 3.28 (d, 2H), 2.61 (s, 3H), 2.41 (s, 3H), 1.15 (s, 6H).
507	¹ H NMR (600 MHz, DMSO) δ = 8.97 (s, 1H), 7.52 (d, 1H), 7.47 (d, 1H), 6.98 (dd, 1H), 5.34 (s, 2H), 4.27 (q, 3H), 3.55 (d, 1H), 2.76 (d, 1H), 2.69 (d, 1H), 2.68 (s, 3H), 2.46 (s, 3H).
508	¹ H NMR (400 MHz, DMSO) δ = 10.65 (s, 1H), 9.00 (s, 1H), 7.54 (d, 1H), 7.37 (s, 1H), 7.02 (dd, 1H), 5.33 (s, 2H), 4.70 (t, 4H), 2.67 (s, 3H), 2.42 (s, 3H), 2.35 (s, 6H).

509	¹ H NMR (400 MHz, DMSO) δ = 9.14 (s, 1H), 8.99 (s, 1H), 7.49 (d, 1H), 7.25 (d, 1H), 6.99 (dd, 1H), 5.33 (s, 2H), 5.02 (d, 2H), 4.78 (d, 2H), 2.85 (s, 6H), 2.60 (s, 3H), 2.41 (s, 3H).
510 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.77–8.71 (m, 1H), 8.31–8.24 (m, 1H), 7.79 (dd, 1H), 7.57 (d, 1H), 7.55–7.47 (m, 2H), 7.29 (d, 1H), 6.99 (dd, 1H), 5.31 (s, 2H), 5.18 (s, 1H), 3.73 (d, 1H), 3.62 (d, 1H), 3.30–3.21 (m, 1H), 3.17–3.09 (m, 1H), 2.60 (s, 3H), 2.23 (dd, 0H), 2.18 (s, 2H), 1.79 (q, 2H).
511 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.59 (d, 1H), 7.53–7.45 (m, 2H), 7.27 (d, 1H), 7.17 (s, 1H), 6.97 (dd, 1H), 5.25 (s, 1H), 5.12 (s, 2H), 3.74 (d, 1H), 3.64 (d, 1H), 3.26 (dd, 1H), 3.16–3.10 (m, 1H), 2.60 (s, 3H), 2.42 (s, 3H), 2.28–2.14 (m, 2H), 1.85–1.72 (m, 2H).
512 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.41 (dd, 1H), 7.83 (dd, 1H), 7.62–7.56 (m, 1H), 7.54–7.46 (m, 2H), 7.32 (d, 1H), 7.25 (dd, 1H), 7.01 (dd, 1H), 5.24 (s, 1H), 5.15 (s, 2H), 3.74 (d, 1H), 3.63 (d, 1H), 3.26 (dd, 1H), 3.17–3.08 (m, 1H), 2.57 (d, 6H), 2.29–2.13 (m, 2H), 1.86–1.73 (m, 2H).
513 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.58 (s, 1H), 7.53–7.45 (m, 2H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 5.21 (t, 1H), 3.74 (dd, 1H), 3.63 (dd, 1H), 3.12 (d, 1H), 2.60 (s, 3H), 2.42 (s, 3H), 2.21 (d, 2H), 1.78 (s, 2H), 1.24 (s, 1H).
514 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.55 (d, 1H), 7.78 (dd, 1H), 7.58 (d, 1H), 7.51 (s, 1H), 7.48 (d, 1H), 7.31–7.24 (m, 2H), 6.98 (dd, 1H), 5.28 (s, 1H), 5.12 (s, 2H), 3.74 (d, 1H), 3.64 (d, 1H), 3.26 (dd, 1H), 3.13 (dd, 1H), 2.60 (s, 3H), 2.47 (s, 3H), 2.27–2.14 (m, 2H), 1.85–1.73 (m, 1H).
515 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.80 (s, 1H), 7.51–7.45 (m, 2H), 7.25 (d, 1H), 7.17 (s, 1H), 6.97 (dd, 1H), 5.22 (t, 1H), 5.12 (s, 2H), 3.67–3.55 (m, 2H), 3.29 (s, 0H), 3.21 (q, 1H), 2.59 (s, 3H), 2.49–2.36 (m, 2H), 2.42 (s, 3H).
516 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.41 (dd, 1H), 7.86–7.77 (m, 2H), 7.53–7.45 (m, 2H), 7.30 (d, 1H), 7.25 (dd, 1H), 7.01 (dd, 1H), 5.22 (s, 1H), 5.15 (s, 2H), 3.67–3.55 (m, 2H), 3.31–3.14 (m, 2H), 2.57 (d, 6H), 2.50–2.37 (m, 1H).
517 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.79 (s, 1H), 7.71 (s, 1H), 7.51 (s, 1H), 7.47 (d, 1H), 7.24 (d, 1H), 6.96 (dd, 1H), 5.32 (s, 2H), 3.63 (d, 1H), 3.58 (d, 1H), 3.30 (d, 1H), 3.21 (q, 1H), 2.61 (d, 6H), 2.48–2.35 (m, 1H).
518 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.78 (s, 1H), 7.53–7.44 (m, 2H), 7.25 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 5.21 (t, 1H), 3.62 (td, 2H), 3.20 (d, 1H), 2.59 (s, 3H), 2.49–2.34 (m, 1H), 2.42 (s, 3H).
519 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.55 (d, 1H), 7.81–7.74 (m, 2H), 7.51–7.44 (m, 2H), 7.31–7.22 (m, 2H), 6.97 (dd, 1H), 5.23 (s, 1H), 5.12 (s, 2H), 3.67–3.54 (m, 2H), 3.21 (q, 1H), 2.59 (s, 3H), 2.47 (s, 3H), 2.45 (d, 0H), 2.44–2.34 (m, 1H).
520 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.58 (d, 1H), 7.88–7.80 (m, 1H), 7.78 (s, 1H), 7.56 (d, 1H), 7.52–7.45 (m, 2H), 7.35 (dd, 1H), 7.27 (d, 1H), 7.00 (dd, 1H), 5.25 (t, 1H), 5.19 (s, 2H), 3.60 (qd, 2H), 3.20 (q, 1H), 2.59 (s, 3H), 2.49–2.37 (m, 3H).
521 - En 1	¹ H NMR (500 MHz, DMSO) δ = 11.77 (s, 1H), 7.78 (s, 1H), 7.59 (dd, 1H), 7.51 (s, 1H), 7.47 (d, 1H), 7.38 (dd, 1H), 7.26–7.22 (m, 1H), 6.95 (dd, 1H), 6.23 (t, 1H), 5.24 (s, 1H), 4.88 (s, 2H), 3.63 (d, 1H), 3.58 (d, 1H), 3.24–3.14 (m, 1H), 2.59 (s, 3H), 2.49–2.36 (m, 1H).
522 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.16 (dd, 1H), 7.84 (dd, 1H), 7.78 (s, 1H), 7.51 (s, 1H), 7.47 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 6.97 (dd, 1H), 5.21 (s, 1H), 5.07 (s, 2H), 3.93 (s, 3H), 3.60 (q, 2H), 3.20 (q, 1H), 2.59 (s, 3H), 2.48–2.37 (m, 1H).
523	¹ H NMR (400 MHz, DMSO) δ = 8.31 (s, 1H), 7.47 (d, 1H), 7.41 (s, 1H), 7.19 (s, 1H), 7.00 (d, 1H), 6.87 (s, 1H), 5.26 (t, 1H), 5.16 (s, 2H), 4.70 (d, 2H), 4.55 (d, 2H), 3.79 (d, 2H), 3.69 (s, 3H), 2.60 (s, 3H).
524	¹ H NMR (400 MHz, DMSO) δ = 8.34 (s, 1H), 7.48 (d, 1H), 7.37 (dd, 2H), 6.99 (dd, 1H), 6.38 (d, 1H), 5.20 (d, 3H), 4.68 (d, 2H), 4.55 (d, 2H), 3.85 (s, 3H), 3.78 (s, 2H), 2.61 (s, 3H).
525	¹ H NMR (400 MHz, DMSO-d ₆) δ = 8.35 (s, 1H), 7.69 (s, 1H), 7.46 (d, 1H), 7.32 (s, 1H), 7.95 (d, 1H), 5.32 (s, 2H), 5.19 (t, 1H), 4.67 (d, 2H), 4.54 (d, 2H), 3.77 (d, 2H), 2.63 (s, 3H), 2.60 (s, 3H).
526	¹ H NMR (400 MHz, DMSO) δ = 8.62–8.55 (m, 1H), 8.33 (s, 1H), 7.84 (td, 1H), 7.56 (d, 1H), 7.47 (d, 1H), 7.39–7.31 (m, 2H), 7.00 (dd, 1H), 5.21 (s, 2H), 5.19 (d, 1H), 4.67 (d, 2H), 4.55 (d, 2H), 3.77 (d, 2H), 2.60 (s, 3H).
527	¹ H NMR (400 MHz, DMSO) δ = 8.33 (s, 1H), 7.85 (d, 1H), 7.79 (d, 1H), 7.49 (d, 1H), 7.38 (d, 1H), 7.03 (dd, 1H), 5.48 (s, 2H), 5.20 (t, 1H), 4.68 (d, 2H), 4.55 (d, 2H), 3.78 (d, 2H), 2.61 (s, 3H).
528	¹ H NMR (400 MHz, DMSO) δ = 8.35 (s, 1H), 8.16 (dd, 1H), 7.88–7.79 (m, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 7.03 (dd, 1H), 6.97 (dd, 1H), 5.19 (t, 1H), 5.08 (s, 2H), 4.67 (d, 2H), 4.55 (d, 2H), 3.93 (s, 3H), 3.77 (d, 2H), 2.61 (s, 3H).
529	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.48 (dd, 1H), 7.08 (d, 1H), 6.96 (dd, 1H), 5.35 (s, 2H), 5.35–5.24 (m, 1H), 4.77 (d, 2H), 4.47–4.39 (m, 2H), 4.00 (d, 2H), 2.87 (s, 3H), 2.45 (d, 6H).

530 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.70 (s, 1H), 7.54 (s, 1H), 7.45 (d, 1H), 7.25 (d, 1H), 6.93 (dd, 1H), 5.31 (s, 2H), 5.08 (s, 1H), 3.66 (dd, 2H), 3.00 (d, 1H), 2.95 – 2.85 (m, 1H), 2.79 (ddd, 1H), 2.63 (s, 3H), 2.56 (d, 4H), 2.06 (ddd, 1H), 1.79 (dt, 1H).
531 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.74 (dd, 1H), 8.27 (d, 1H), 7.79 (dd, 1H), 7.49 (d, 1H), 7.31 (d, 1H), 7.24 (s, 1H), 6.98 (dd, 1H), 5.31 (s, 2H), 4.88 (t, 1H), 4.00 (dd, 1H), 3.76 – 3.60 (m, 3H), 3.47 (dd, 2H), 2.60 (s, 3H), 2.29 (dd, 1H), 1.70 (dt, 2H), 1.51 (d, 1H).
532 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.46 (d, 1H), 7.31 (d, 1H), 7.21 (s, 1H), 6.95 (dd, 1H), 5.30 (s, 2H), 4.90 (t, 1H), 4.05 – 3.96 (m, 1H), 3.76 – 3.61 (m, 3H), 3.51 (d, 1H), 3.46 (s, 1H), 2.60 (s, 3H), 2.42 (s, 3H), 2.31 (d, 1H), 1.75 – 1.65 (m, 2H), 1.52 (d, 1H).
533 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.84 (s, 1H), 7.69 (s, 1H), 7.45 (d, 1H), 7.24 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 5.11 – 5.05 (m, 1H), 3.92 (d, 1H), 3.86 – 3.75 (m, 3H), 3.72 (dd, 1H), 3.66 (dd, 1H), 2.63 (s, 3H), 2.57 (s, 3H), 2.25 (ddd, 1H), 2.06 (dt, 1H).
534 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 7.88 – 7.79 (m, 2H), 7.55 (d, 1H), 7.46 (d, 1H), 7.35 (ddd, 1H), 7.25 (d, 1H), 6.98 (dd, 1H), 5.20 (s, 2H), 5.08 (d, 1H), 3.92 (d, 1H), 3.87 – 3.74 (m, 3H), 3.71 (dd, 1H), 3.65 (dd, 1H), 2.57 (s, 3H), 2.23 (ddd, 1H), 2.06 (dt, 1H).
535 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.77 (s, 1H), 7.85 (s, 1H), 7.61 – 7.54 (m, 1H), 7.45 (d, 1H), 7.41 – 7.34 (m, 1H), 7.22 (d, 1H), 6.94 (dd, 1H), 6.22 (t, 1H), 5.08 (s, 1H), 4.88 (s, 2H), 3.92 (d, 1H), 3.80 (dt, 3H), 3.75 – 3.62 (m, 2H), 2.57 (s, 3H), 2.24 (dt, 1H), 2.06 (dt, 1H).
536 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.88 – 7.79 (m, 2H), 7.45 (d, 1H), 7.24 (d, 1H), 7.03 (dd, 1H), 6.95 (dd, 1H), 5.06 (d, 3H), 3.92 (d, 4H), 3.80 (d, 2H), 3.78 (d, 1H), 3.68 (qd, 2H), 2.57 (s, 3H), 2.23 (dt, 1H), 2.05 (dt, 1H).
537	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.24 (s, 1H), 7.47 (d, 1H), 7.27 (d, 1H), 6.96 (dd, 1H), 5.31 (s, 2H), 5.22 (t, 1H), 3.65 (d, 2H), 2.87 (dd, 4H), 2.58 (s, 3H), 2.42 (s, 3H).
538 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.78 – 8.65 (m, 2H), 8.31 – 8.20 (m, 1H), 7.79 (dd, 1H), 7.33 (dd, 1H), 7.03 (d, 1H), 5.33 – 5.24 (m, 2H), 4.47 (d, 1H), 3.09 (s, 1H), 2.97 – 2.72 (m, 2H), 2.69 – 2.55 (m, 1H), 2.42 (s, 3H), 2.26 (s, 3H), 1.79 (d, 1H), 1.72 – 1.55 (m, 1H), 1.24 (s, 1H).
539 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.33 – 8.21 (m, 2H), 7.91 (d, 1H), 7.79 – 7.64 (m, 2H), 7.60 (dd, 1H), 7.39 (dd, 1H), 5.41 (s, 2H), 4.49 (s, 1H), 3.20 – 3.04 (m, 1H), 2.98 – 2.75 (m, 2H), 2.70 – 2.54 (m, 1H), 2.59 (s, 3H), 1.86 – 1.60 (m, 2H).
540 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.20 (d, 1H), 8.15 (s, 1H), 7.47 (d, 1H), 7.23 (d, 1H), 6.97 (dd, 1H), 5.14 (d, 2H), 4.54 – 4.42 (m, 1H), 4.05 (s, 2H), 3.30 (s, 1H), 3.11 (q, 1H), 2.92 (d, 1H), 2.84 (dd, 1H), 2.62 (d, 1H), 2.57 (s, 3H), 2.44 (s, 1H), 1.73 (ddd, 2H).
541 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.23 (d, 1H), 7.79 (s, 1H), 7.49 (d, 1H), 7.25 (d, 1H), 7.00 (dd, 1H), 5.30 (s, 2H), 4.55 – 4.40 (m, 1H), 4.06 (s, 3H), 3.13 (t, 1H), 2.99 – 2.74 (m, 2H), 2.63 (d, 1H), 2.57 (s, 3H), 1.83 – 1.63 (m, 2H).
542 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.46 (s, 1H), 8.18 (d, 1H), 7.46 (d, 1H), 7.23 (d, 1H), 6.97 (dd, 1H), 5.05 (d, 2H), 4.47 (s, 1H), 3.86 (s, 3H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 2.43 (s, 1H), 1.78 (s, 1H), 1.86 – 1.63 (m, 1H).
543 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.21 (d, 1H), 7.48 (d, 1H), 7.37 (d, 1H), 7.24 (d, 1H), 6.99 (dd, 1H), 6.36 (d, 1H), 5.18 (s, 2H), 4.47 (dd, 1H), 3.85 (s, 3H), 3.21 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.57 (s, 3H), 2.43 (s, 1H), 1.78 (s, 2H), 1.86 – 1.62 (m, 1H).
544 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.20 (d, 1H), 7.71 (d, 1H), 7.55 (d, 1H), 7.46 (d, 1H), 7.18 (s, 1H), 6.95 (d, 1H), 6.26 (t, 1H), 4.92 (t, 2H), 4.47 (s, 1H), 3.48 (s, 3H), 3.39 (s, 2H), 3.11 (s, 1H), 2.97 – 2.75 (m, 2H), 2.59 (d, 3H), 1.78 (s, 1H), 1.71 (d, 1H).
545 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.22 (d, 1H), 7.50 (d, 1H), 7.39 (dd, 1H), 7.24 (d, 1H), 7.03 (dd, 1H), 6.48 – 6.36 (m, 2H), 5.14 (s, 2H), 3.49 (s, 3H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.62 (d, 1H), 2.58 (s, 3H), 2.43 (s, 1H), 1.86 – 1.61 (m, 2H).
546 - En 1	¹ H NMR (DMSO-d ₆) δ = 8.73 (d, 1H), 8.25 (t, 2H), 7.79 (dd, 1H), 7.50 (d, 1H), 7.22 (d, 1H), 7.00 (dd, 1H), 5.31 (s, 2H), 4.37 – 4.58 (m, 1H), 3.04 – 3.17 (m, 1H), 2.74 – 2.96 (m, 2H), 2.59 – 2.72 (m, 1H), 2.58 (s, 3H), 1.63 – 1.85 (m, 2H).
547 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.41 (dd, 1H), 8.22 (d, 1H), 7.80 (dd, 1H), 7.48 (d, 1H), 7.29 – 7.19 (m, 2H), 7.00 (dd, 1H), 5.14 (s, 2H), 4.47 (dd, 1H), 3.12 (s, 0H), 2.92 (d, 1H), 2.84 (dd, 1H), 2.55 (d, 7H), 2.44 (s, 1H), 1.82 – 1.64 (m, 2H).
548 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.70 (d, 1H), 8.20 (d, 1H), 7.49 (d, 1H), 7.41 (d, 1H), 7.19 (d, 1H), 7.02 (dd, 1H), 5.18 (s, 2H), 4.46 (d, 1H), 3.19 – 3.03 (m, 1H), 2.98 – 2.73 (m, 2H), 2.60 (d, 7H), 1.76 (s, 1H), 1.80 – 1.62 (m, 1H).
549 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 7.68 (s, 1H), 7.47 (d, 1H), 7.20 (d, 1H), 6.96 (dd, 1H), 5.31 (s, 2H), 4.48 (s, 1H), 3.12 (s, 1H), 2.92 (d, 2H), 2.80 (d, 1H), 2.60 (s, 1H), 2.60 (d, 6H), 1.77 (s, 2H), 1.78 – 1.66 (m, 0H).

550 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.22 (d, 1H), 7.46 (dd, 1H), 7.17 (d, 1H), 6.94 (dt, 1H), 4.50 (d, 2H), 4.45 (s, 1H), 4.32 (d, 2H), 4.06 (d, 2H), 3.22 – 3.04 (m, 1H), 2.99 – 2.74 (m, 2H), 2.59 (d, 1H), 2.57 (s, 3H), 1.78 (s, 2H), 1.81 – 1.63 (m, 1H), 1.38 (s, 3H).
551 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 7.83 (q, 1H), 7.48 (d, 1H), 7.22 (d, 1H), 6.98 (dd, 1H), 5.16 (s, 2H), 4.47 (s, 1H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.63 (d, 1H), 2.57 (s, 3H), 2.43 (s, 1H), 2.09 (d, 3H), 1.74 (ddd, 2H).
552 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.21 (d, 1H), 7.49 (d, 1H), 7.29 (d, 1H), 7.24 (d, 1H), 7.01 (dd, 1H), 5.38 (s, 2H), 4.46 (dd, 1H), 3.22 – 3.04 (m, 0H), 3.12 (s, 1H), 2.99 – 2.74 (m, 2H), 2.61 (s, 1H), 2.57 (s, 3H), 2.37 (d, 4H), 1.74 (ddt, 2H).
553 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 7.48 (d, 1H), 7.21 (d, 1H), 6.97 (dd, 1H), 6.34 (d, 1H), 5.14 (s, 2H), 4.47 (s, 1H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 2.41 (d, 3H), 1.78 (s, 1H), 1.80 – 1.62 (m, 1H).
554 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.67 (d, 1H), 8.56 (d, 1H), 8.20 (d, 1H), 7.48 (d, 1H), 7.23 (d, 1H), 7.01 (dd, 1H), 5.22 (s, 2H), 4.53 – 4.40 (m, 1H), 3.13 (s, 1H), 2.93 (s, 2H), 2.57 (s, 3H), 1.80 (s, 1H), 1.71 (d, 1H).
555 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 7.54 – 7.43 (m, 2H), 7.23 (d, 1H), 7.00 (dd, 1H), 5.35 (s, 2H), 4.45 (s, 1H), 3.12 (s, 1H), 2.99 – 2.74 (m, 2H), 2.63 (d, 1H), 2.57 (s, 3H), 2.44 (d, 3H), 1.82 – 1.62 (m, 2H).
556 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.19 (d, 1H), 7.71 (d, 1H), 7.60 (d, 1H), 7.47 (d, 1H), 7.23 (d, 1H), 6.99 (dd, 1H), 5.36 (s, 2H), 4.41 – 4.5 (m, 1H), 3.09 – 3.14 (t, 1H), 2.70 – 2.93 (m, 2H), 2.57 – 2.78 (m, 7H), 2.50 (bs, 1H), 1.72 – 1.78 (m, 2H).
557 - En 1	¹ H NMR (400 MHz, DMSO) δ = 9.22 (dd, 1H), 8.21 (d, 1H), 7.85 (dd, 1H), 7.76 (dd, 1H), 7.49 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 5.42 (s, 2H), 4.47 (d, 1H), 3.11 (q, 1H), 2.98 – 2.73 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 1.85 – 1.63 (m, 2H).
558 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.68 (d, 1H), 8.55 (dd, 1H), 8.21 (d, 1H), 7.88 (dt, 1H), 7.53 – 7.37 (m, 2H), 7.23 (d, 1H), 6.99 (dd, 1H), 5.17 (s, 2H), 4.55 – 4.40 (m, 1H), 3.19 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 1.72 (ddd, 2H).
559 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.83 (d, 2H), 8.16 (d, 1H), 7.52 – 7.39 (m, 2H), 7.15 (d, 1H), 6.95 (dd, 1H), 5.28 (s, 2H), 3.10 (s, 1H), 2.98 – 2.72 (m, 2H), 2.56 (s, 4H), 2.42 (s, 1H), 1.81 – 1.60 (m, 2H).
560 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.21 (d, 1H), 7.84 (d, 1H), 7.78 (d, 1H), 7.49 (d, 1H), 7.25 (d, 1H), 7.03 (dd, 1H), 5.45 (s, 2H), 3.20 – 3.04 (m, 1H), 2.99 – 2.74 (m, 2H), 2.63 (d, 1H), 2.57 (s, 3H), 2.44 (s, 1H), 1.78 (s, 1H), 1.86 – 1.62 (m, 1H).
561 - En 1	¹ H NMR (400 MHz, DMSO) δ = 9.11 (d, 1H), 8.21 (d, 1H), 7.99 (d, 1H), 7.48 (d, 1H), 7.22 (d, 1H), 6.98 (dd, 1H), 5.40 (s, 2H), 4.45 (s, 0H), 3.20 – 3.04 (m, 1H), 2.98 – 2.74 (m, 2H), 2.61 (t, 1H), 2.57 (s, 3H), 1.74 (dt, 2H).
562 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.40 (d, 1H), 7.36 (dd, 1H), 7.24 (dd, 1H), 5.37 (s, 2H), 3.08 (q, 1H), 2.96 – 2.72 (m, 2H), 2.59 (d, 2H), 2.51 (s, 3H), 2.39 (s, 3H), 1.79 (dt, 1H), 1.63 (qd, 1H).
563 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.20 (d, 1H), 7.46 (d, 1H), 7.20 (d, 1H), 6.94 (dd, 1H), 5.22 (s, 2H), 4.47 (s, 1H), 3.12 (s, 1H), 2.87 (dt, 2H), 2.62 (d, 1H), 2.57 (s, 6H), 2.32 (s, 3H), 1.84 – 1.64 (m, 2H).
564 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 8.20 (d, 1H), 7.56 (dd, 1H), 7.46 (d, 1H), 7.38 (dd, 1H), 7.18 (d, 1H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.96 – 4.80 (m, 2H), 4.48 (d, 1H), 3.12 (t, 1H), 2.92 (d, 1H), 2.80 (s, 1H), 2.57 (s, 3H), 2.42 (s, 1H), 1.83 – 1.66 (m, 2H).
565 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.22 (d, 1H), 8.15 (dd, 1H), 7.81 (dd, 1H), 7.47 (d, 1H), 7.20 (d, 1H), 7.00 (ddd, 2H), 5.06 (s, 2H), 4.47 (dt, 1H), 3.92 (s, 3H), 3.11 (s, 1H), 2.98 – 2.73 (m, 2H), 2.60 (s, 1H), 2.57 (s, 3H), 2.43 (s, 1H), 1.85 – 1.61 (m, 2H).
566 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.45 (dt, 1H), 8.20 (d, 1H), 7.79 (ddd, 1H), 7.53 (dt, 1H), 7.47 (d, 1H), 7.24 (d, 1H), 6.98 (dd, 1H), 5.29 – 5.17 (m, 2H), 3.18 – 3.06 (m, 1H), 2.88 (s, 1H), 2.97 – 2.75 (m, 1H), 2.61 (s, 1H), 2.57 (s, 3H), 2.42 (s, 1H), 1.84 – 1.64 (m, 2H).
567 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.28 (d, 1H), 8.19 (d, 1H), 7.44 (qd, 3H), 7.21 (d, 1H), 6.97 (dd, 1H), 5.10 (s, 2H), 4.91 (t, 1H), 4.48 (d, 1H), 4.07 (dd, 2H), 3.73 (q, 2H), 3.11 (d, 1H), 2.98 – 2.74 (m, 2H), 2.69 – 2.53 (m, 1H), 2.57 (s, 3H), 1.78 (s, 2H), 1.24 (s, 1H).
568 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.58 (d, 1H), 8.19 (d, 1H), 7.77 (td, 1H), 7.63 (dd, 1H), 7.48 (d, 1H), 7.21 (d, 1H), 6.99 (dd, 1H), 5.19 (s, 2H), 4.55 – 4.41 (m, 1H), 3.12 (t, 1H), 2.86 (dt, 2H), 2.57 (s, 4H), 2.47 – 2.39 (m, 1H), 1.82 – 1.74 (m, 1H), 1.71 (qd, 1H).
569 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.68 (s, 1H), 8.21 (d, 1H), 7.45 (dd, 2H), 7.18 (d, 1H), 6.97 (dd, 1H), 6.35 – 6.24 (m, 2H), 4.91 (s, 2H), 4.45 (s, 1H), 3.10 (d, 1H), 2.98 – 2.74 (m, 2H), 2.61 (s, 1H), 2.57 (s, 3H), 1.78 (s, 1H), 1.79 – 1.62 (m, 1H).

570 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.20 (d, 1H), 7.72 (dd, 1H), 7.47 (d, 1H), 7.23 (d, 1H), 7.10 (dd, 1H), 6.99 (dd, 1H), 6.75 (dd, 1H), 5.11 (s, 2H), 3.86 (s, 3H), 3.19 – 3.03 (m, 1H), 2.98 – 2.73 (m, 2H), 2.62 (d, 1H), 2.57 (s, 3H), 2.43 (s, 1H), 1.76 (s, 1H), 1.84 – 1.61 (m, 1H).
571 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.72 – 8.63 (m, 1H), 8.19 (dd, 1H), 7.96 (dt, 1H), 7.64 – 7.53 (m, 2H), 7.48 (dd, 1H), 7.38 – 7.20 (m, 2H), 6.99 (ddd, 1H), 5.13 (s, 2H), 4.43 (s, 2H), 4.11 (d, 1H), 3.12 (s, 1H), 2.88 (dd, 1H), 2.57 (d, 3H), 1.82 – 1.61 (m, 2H).
572 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.26 (d, 1H), 7.62 (d, 1H), 7.40 (d, 1H), 5.38 (s, 2H), 4.48 (dt, 1H), 3.19 – 3.04 (m, 1H), 2.99 – 2.74 (m, 2H), 2.61 (s, 1H), 2.56 (s, 3H), 2.44 (s, 1H), 2.41 (s, 3H), 1.86 – 1.61 (m, 2H).
573 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.33 (d, 1H), 7.09 – 6.95 (m, 2H), 5.33 (s, 2H), 4.47 (d, 1H), 3.11 (s, 1H), 2.98 – 2.73 (m, 2H), 2.59 (s, 3H), 2.43 (d, 1H), 2.42 (s, 3H), 1.72 (ddd, 2H), 1.23 (s, 1H).
574	¹ H NMR (500 MHz, DMSO) δ = 8.21 (dd, 2H), 8.06 (s, 1H), 7.95 (t, 1H), 7.57 (d, 1H), 4.24 (t, 1H), 3.74 (d, 1H), 3.21 – 3.11 (m, 3H), 2.55 (d, 3H), 2.17 (d, 1H), 2.11 – 1.96 (m, 1H), 1.99 (s, 1H), 1.74 (d, 1H), 1.56 (s, 3H), 1.43 (d, 1H), 1.01 (d, 6H), 0.86 (s, 0H).
575 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.78 (t, 1H), 7.46 (d, 2H), 7.40 (d, 1H), 7.16 (s, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 3.56 (dt, 1H), 3.46 (ddd, 1H), 3.23 (t, 1H), 2.60 (s, 3H), 2.42 (s, 3H), 2.30 (s, 6H).
576	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.47 (d, 1H), 7.36 (d, 1H), 7.28 (s, 1H), 7.00 (s, 1H), 6.95 (dd, 1H), 5.33 (s, 2H), 3.40 (d, 2H), 2.61 (s, 3H), 2.42 (s, 3H), 1.16 (s, 6H).
577	¹ H NMR (400 MHz, DMSO) δ = 9.30 (s, 1H), 9.02 (s, 1H), 7.75 (dd, 1H), 7.64 – 7.54 (m, 1H), 7.42 (d, 1H), 7.28 (s, 1H), 7.33 – 7.22 (m, 1H), 5.42 (s, 2H), 4.89 (d, 2H), 4.74 (d, 2H), 2.45 (s, 3H).
578	¹ H NMR (500 MHz, DMSO) δ = 8.70 (s, 1H), 7.56 (d, 1H), 7.49 (d, 1H), 7.23 (d, 2H), 7.19 (d, 1H), 7.02 (dd, 1H), 6.87 (d, 1H), 5.19 (s, 2H), 4.88 (d, 2H), 4.71 (d, 2H), 3.70 (s, 3H), 2.65 (s, 3H).
579	¹ H NMR (400 MHz, DMSO) δ = 8.69 (s, 1H), 7.54 – 7.46 (m, 2H), 7.38 (d, 1H), 7.22 (d, 2H), 7.01 (dd, 1H), 6.38 (d, 1H), 5.21 (s, 2H), 4.88 (d, 2H), 4.68 (d, 2H), 3.86 (s, 3H), 2.67 (s, 3H).
580	¹ H-NMR (400 MHz, DMSO-d ₆): δ 8.67 (s, 1H), 7.70 (s, 1H), 7.51-7.44 (m, 2H), 7.24-7.19 (m, 2H), 6.98 (dd, 1H), 5.34 (s, 2H), 4.87 (d, 2H), 4.68 (d, 2H), 2.65 (s, 3H), 2.63 (s, 3H).
581	¹ H NMR (400 MHz, DMSO) δ = 8.70 (s, 1H), 8.59 (ddd, 1H), 7.85 (td, 1H), 7.57 (dt, 1H), 7.53 – 7.45 (m, 2H), 7.35 (ddd, 1H), 7.21 (d, 2H), 7.02 (dd, 1H), 5.24 (s, 2H), 4.88 (d, 2H), 4.68 (d, 2H), 2.65 (s, 3H).
582	¹ H NMR (400 MHz, DMSO) δ = 8.70 (s, 1H), 7.85 (d, 1H), 7.79 (d, 1H), 7.55 – 7.47 (m, 2H), 7.22 (d, 2H), 7.05 (dd, 1H), 5.50 (s, 2H), 4.88 (d, 2H), 4.69 (d, 2H), 2.66 (s, 3H).
583	¹ H NMR (400 MHz, DMSO) δ = 9.11 – 9.05 (m, 1H), 9.00 (s, 1H), 7.40 (dd, 1H), 7.34 – 7.24 (m, 2H), 7.03 (s, 1H), 5.39 (s, 2H), 4.87 (d, 2H), 4.60 (d, 2H), 2.57 (s, 3H), 2.40 (s, 3H).
584	¹ H NMR (500 MHz, DMSO) δ = 8.74 (s, 1H), 8.67 (dd, 1H), 8.14 (d, 1H), 7.75 – 7.39 (m, 3H), 7.36 – 6.91 (m, 4H), 5.37 (s, 2H), 4.88 (d, 2H), 4.67 (d, 2H), 2.67 (s, 3H).
585	¹ H NMR (500 MHz, DMSO) δ = 11.78 (s, 1H), 8.78 (s, 1H), 7.61 (dd, 1H), 7.51 – 7.43 (m, 2H), 7.39 (dd, 1H), 7.28 (s, 1H), 7.17 (s, 1H), 6.97 (dd, 1H), 6.23 (t, 1H), 4.93 (s, 2H), 4.87 (d, 2H), 4.68 (d, 2H), 2.65 (s, 3H).
586	¹ H NMR (500 MHz, DMSO) δ = 8.70 (s, 1H), 8.16 (dd, 1H), 7.85 (dd, 1H), 7.52 – 7.43 (m, 2H), 7.23 (s, 1H), 7.20 (s, 1H), 7.02 (ddd, 2H), 5.10 (s, 2H), 4.87 (d, 2H), 4.67 (d, 2H), 3.92 (s, 3H), 2.67 (s, 3H).
587	¹ H NMR (400 MHz, DMSO) δ = 9.00 (s, 1H), 8.72 (s, 1H), 7.68 – 7.60 (m, 2H), 7.25 (d, 2H), 5.42 (s, 2H), 4.88 (d, 2H), 4.69 (d, 2H), 2.67 (s, 3H), 2.42 (s, 3H).
588	¹ H NMR (500 MHz, DMSO) δ = 9.00 (s, 1H), 8.78 (s, 1H), 7.29 (d, 1H), 7.22 (s, 1H), 7.05 (dd, 1H), 5.36 (s, 2H), 4.87 (d, 2H), 4.68 (d, 2H), 2.69 (s, 3H), 2.43 (s, 3H).
589	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.49 (d, 1H), 7.44 (s, 2H), 7.13 (d, 1H), 6.97 (dd, 1H), 5.35 (s, 2H), 4.84 (d, 2H), 4.76 (d, 2H), 2.90 (s, 3H), 2.47 (s, 3H), 2.43 (s, 3H).
590 - En 1	¹ H NMR (500 MHz, DMSO) δ = 7.69 (s, 1H), 7.59 (s, 1H), 7.49 (d, 1H), 7.34 (d, 1H), 7.08 (d, 2H), 6.98 (dd, 1H), 5.32 (s, 2H), 4.08 (dd, 1H), 3.83 (d, 1H), 3.65 (d, 1H), 3.43 (td, 1H), 2.63 (d, 6H), 2.34 (d, 1H), 1.95 (td, 1H), 1.76 (d, 1H).
591 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.41 (dd, 1H), 8.24 (s, 1H), 7.81 (dd, 1H), 7.49 (d, 1H), 7.25 (dd, 1H), 7.13 (s, 1H), 7.09 (s, 1H), 7.02 (dd, 1H), 5.16 (s, 2H), 4.18 (d, 1H), 3.94 (d, 1H), 3.90 – 3.79 (m, 2H), 2.62 (s, 3H), 2.53 (s, 3H), 2.41 – 2.28 (m, 2H).
592 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.22 (s, 1H), 7.70 (s, 1H), 7.47 (d, 1H), 7.31 (d, 1H), 7.12 (s, 1H), 7.08 (s, 1H), 5.33 (s, 2H), 4.18 (d, 1H), 3.94 (d, 1H), 3.86 (dd, 2H), 2.62 (d, 6H), 2.36 (hept, 2H).

593 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.48 (d, 1H), 7.33 (d, 1H), 7.14 (s, 1H), 7.08 (s, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 4.19 (d, 1H), 3.94 (d, 1H), 3.85 (dd, 2H), 2.62 (s, 3H), 2.42 (s, 3H), 2.41 – 2.28 (m, 2H).
594 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.54 (d, 1H), 8.24 (s, 1H), 7.77 (dd, 1H), 7.47 (d, 1H), 7.28 (d, 1H), 7.13 (s, 1H), 7.08 (s, 1H), 6.98 (dd, 1H), 5.13 (s, 2H), 4.18 (d, 1H), 3.94 (d, 1H), 3.85 (dd, 2H), 2.62 (s, 3H), 2.47 (s, 3H), 2.41 – 2.28 (m, 2H).
595 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.22 (s, 1H), 7.84 (td, 1H), 7.59 – 7.45 (m, 2H), 7.39 – 7.30 (m, 2H), 7.10 (d, 2H), 7.01 (dd, 1H), 5.22 (s, 2H), 4.19 (d, 1H), 3.93 (d, 1H), 3.89 – 3.79 (m, 2H), 2.61 (s, 3H), 2.42 – 2.26 (m, 2H), 1.25 (dd, 0H).
596 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.26 (s, 1H), 7.58 (dd, 1H), 7.46 (d, 1H), 7.38 (dd, 1H), 7.32 (d, 1H), 7.17 (s, 1H), 7.05 (s, 1H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.91 (s, 2H), 4.20 (d, 1H), 3.93 (d, 1H), 3.84 (t, 2H), 2.61 (s, 3H), 2.37 – 2.31 (m, 1H).
597 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.25 (s, 1H), 8.16 (dd, 1H), 7.83 (dd, 1H), 7.48 (d, 1H), 7.13 (s, 1H), 7.08 (s, 1H), 7.03 (dd, 1H), 6.98 (dd, 1H), 5.08 (s, 2H), 4.18 (d, 1H), 3.93 (d, 1H), 3.93 (s, 3H), 3.90 – 3.78 (m, 2H), 2.62 (s, 3H), 2.38 – 2.27 (m, 2H).
598 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.27 (s, 1H), 7.53 – 7.45 (m, 2H), 7.36 (d, 1H), 7.13 (s, 1H), 7.08 (s, 1H), 7.00 (dd, 1H), 5.19 (s, 2H), 4.20 (d, 1H), 3.94 (d, 1H), 3.85 (dd, 2H), 3.83 (s, 3H), 2.62 (s, 3H), 2.41 – 2.29 (m, 2H).
599	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 7.53 (d, 1H), 7.18 (d, 1H), 7.00 (dd, 1H), 5.37 (s, 2H), 4.98 – 4.92 (m, 2H), 4.91 – 4.85 (m, 2H), 2.93 (s, 3H), 2.54 (s, 3H), 2.43 (s, 3H).
600 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.95 (d, 1H), 7.68 (d, 1H), 7.49 (d, 1H), 7.39 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 5.04 (s, 1H), 4.49 (dt, 1H), 3.72 (d, 2H), 2.63 (d, 6H), 2.42 (s, 3H).
601 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.58 (dt, 1H), 7.94 (d, 1H), 7.84 (td, 1H), 7.67 (d, 1H), 7.57 (d, 1H), 7.49 (d, 1H), 7.40 (d, 1H), 7.35 (ddd, 1H), 7.01 (dd, 1H), 5.20 (s, 2H), 5.03 (t, 1H), 4.48 (dt, 1H), 3.72 (t, 2H), 2.63 (d, 6H).
602	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.93 (t, 1H), 7.48 (d, 1H), 7.30 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.75 (t, 1H), 3.21 (t, 4H), 2.61 (s, 3H), 2.41 (s, 3H), 0.88 (s, 6H).
603	¹ H NMR (400 MHz, DMSO) δ = 8.96 (s, 1H), 7.93 (s, 1H), 7.30 (d, 1H), 7.08 (d, 1H), 5.28 (s, 2H), 4.83 (t, 1H), 3.74 – 3.51 (m, 6H), 2.49 (s, 2H), 2.38 (s, 3H), 2.25 (s, 3H), 2.12 (d, 2H), 1.68 – 1.55 (m, 2H).
604	¹ H NMR (500 MHz, DMSO) δ = 8.16 (s, 1H), 7.45 (d, 1H), 7.39 (s, 1H), 7.28 (d, 1H), 6.95 (dd, 1H), 5.15 (s, 2H), 4.90 (s, 1H), 4.05 (s, 3H), 3.70 (dt, 2H), 3.67 – 3.58 (m, 4H), 2.59 (s, 3H), 2.19 (d, 2H), 1.63 (ddd, 2H).
605	¹ H NMR (500 MHz, DMSO) δ = 7.80 (s, 1H), 7.47 (d, 1H), 7.41 (s, 1H), 7.29 (d, 1H), 6.99 (dd, 1H), 5.30 (s, 2H), 4.93 – 4.87 (m, 1H), 4.06 (s, 3H), 3.66 (dddd, 6H), 2.61 (s, 3H), 2.18 (d, 2H), 1.63 (ddd, 2H).
606	¹ H NMR (400 MHz, DMSO) δ = 8.46 (s, 1H), 7.44 (d, 1H), 7.37 (s, 1H), 7.29 (d, 1H), 6.95 (dd, 1H), 5.07 (s, 2H), 4.88 (t, 1H), 3.86 (s, 3H), 3.74 – 3.63 (m, 4H), 3.67 – 3.58 (m, 2H), 2.59 (s, 3H), 2.19 (d, 2H), 1.63 (ddd, 2H).
607	¹ H NMR (500 MHz, DMSO) δ = 7.64 (s, 1H), 7.45 (d, 1H), 7.40 (s, 1H), 7.27 (d, 1H), 7.00 (d, 1H), 6.96 (dd, 1H), 5.10 (s, 2H), 4.90 (t, 1H), 3.74 – 3.68 (m, 2H), 3.68 – 3.58 (m, 7H), 2.60 (s, 3H), 2.18 (d, 2H), 1.68 – 1.58 (m, 2H).
608	¹ H NMR (400 MHz, DMSO) δ = 7.46 (d, 1H), 7.40 (s, 1H), 7.37 (d, 1H), 7.28 (d, 1H), 6.97 (dd, 1H), 6.37 (d, 1H), 5.18 (s, 2H), 4.90 (t, 1H), 3.85 (s, 3H), 3.76 – 3.56 (m, 6H), 2.60 (s, 3H), 2.18 (d, 2H), 1.70 – 1.57 (m, 2H).
609	¹ H NMR (400 MHz, DMSO) δ = 7.71 (dd, 1H), 7.53 (dd, 1H), 7.49 – 7.38 (m, 2H), 7.21 (d, 1H), 6.94 (dd, 1H), 6.25 (t, 1H), 4.92 (s, 2H), 4.87 (t, 1H), 3.73 – 3.52 (m, 6H), 3.48 (s, 3H), 2.60 (s, 3H), 2.16 (d, 2H), 1.68 – 1.55 (m, 2H).
610	¹ H NMR (400 MHz, DMSO) δ = 7.49 (d, 1H), 7.44 – 7.35 (m, 2H), 7.29 (d, 1H), 7.02 (dd, 1H), 6.47 – 6.38 (m, 2H), 5.14 (s, 2H), 4.90 (t, 1H), 3.75 – 3.55 (m, 6H), 3.49 (s, 3H), 2.61 (s, 3H), 2.18 (d, 2H), 1.63 (ddd, 2H).
611	¹ H NMR (500 MHz, DMSO) δ = 8.41 (dd, 1H), 7.81 (dd, 1H), 7.47 (d, 1H), 7.40 (s, 1H), 7.29 (d, 1H), 7.24 (dd, 1H), 6.99 (dd, 1H), 5.15 (s, 2H), 4.89 (s, 1H), 3.74 – 3.56 (m, 6H), 2.60 (s, 3H), 2.53 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
612	¹ H NMR (400 MHz, DMSO) δ = 8.70 (d, 1H), 7.48 (d, 1H), 7.43 – 7.37 (m, 2H), 7.21 (d, 1H), 7.00 (dd, 1H), 5.19 (s, 2H), 4.87 (t, 1H), 3.73 – 3.61 (m, 4H), 3.56 (td, 2H), 2.61 (d, 6H), 2.15 (d, 2H), 1.62 (ddd, 2H).
613	¹ H NMR (400 MHz, DMSO) δ = 7.68 (s, 1H), 7.45 (d, 1H), 7.40 (s, 1H), 7.24 (d, 1H), 6.94 (dd, 1H), 5.31 (s, 2H), 4.89 (t, 1H), 3.75 – 3.56 (m, 6H), 2.61 (d, 6H), 2.18 (d, 2H), 1.63 (s, 1H).

614	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 7.56 (dd, 1H), 7.45 (d, 1H), 7.42 – 7.34 (m, 2H), 7.22 (d, 1H), 6.94 (dd, 1H), 6.22 (t, 1H), 4.88 (s, 3H), 3.75 – 3.54 (m, 6H), 2.60 (s, 3H), 2.17 (d, 2H), 1.62 (ddd, 2H).
615	¹ H NMR (500 MHz, DMSO) δ = 13.66 (s, 1H), 8.10 (s, 1H), 7.47 – 7.40 (m, 2H), 7.23 (d, 1H), 6.91 (dd, 1H), 5.04 (s, 2H), 4.89 (s, 1H), 3.70 (dt, 2H), 3.67 – 3.57 (m, 4H), 2.60 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
616	¹ H NMR (400 MHz, DMSO-d ₆) δ = 7.82 – 7.83 (m, 1H), 7.46 (d, 1H), 7.38 (s, 1H), 7.26 (d, 1H), 6.95 (dd, 1H), 5.17 (s, 2H), 4.88 (bs, 1H), 3.63 – 3.71 (m, 6H), 2.59 (s, 3H), 2.08 (d, 2H), 1.86 (s, 3H), 1.63 – 1.65 (m, 2H).
617	¹ H NMR (400 MHz, DMSO) δ = 7.48 (d, 1H), 7.40 (s, 1H), 7.32 – 7.25 (m, 2H), 6.99 (dd, 1H), 5.39 (s, 2H), 4.88 (t, 1H), 3.71 (dt, 2H), 3.68 – 3.56 (m, 4H), 2.60 (s, 3H), 2.37 (d, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
618	¹ H NMR (400 MHz, DMSO) δ = 7.46 (d, 1H), 7.38 (s, 1H), 7.25 (d, 1H), 6.96 (dd, 1H), 6.34 (d, 1H), 5.15 (s, 2H), 4.88 (t, 1H), 3.75 – 3.56 (m, 6H), 2.60 (s, 3H), 2.40 (d, 3H), 2.18 (d, 2H), 1.69 – 1.57 (m, 2H).
619	¹ H NMR (400 MHz, DMSO) δ = 8.67 (d, 1H), 8.55 (d, 1H), 7.47 (d, 1H), 7.40 (s, 1H), 7.26 (d, 1H), 6.99 (dd, 1H), 5.23 (s, 2H), 4.89 (s, 1H), 3.74 – 3.54 (m, 7H), 2.59 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
620	¹ H NMR (400 MHz, DMSO) δ = 7.52 – 7.43 (m, 2H), 7.38 (s, 1H), 7.27 (d, 1H), 6.98 (dd, 1H), 5.36 (s, 2H), 4.88 (t, 1H), 3.75 – 3.68 (m, 1H), 3.64 (qd, 5H), 2.59 (s, 3H), 2.44 (d, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
621	¹ H NMR (400 MHz, DMSO-d ₆) δ = 7.74 (d, 1H), 7.62 (d, 1H), 7.45 (b, 1H), 7.38 (s, 1H), 7.27 (d, 1H), 6.98 (dd, 1H), 5.37 (s, 2H), 4.88 (t, 1H), 3.57 – 3.71 (m, 6H), 2.62 (s, 3H), 2.59 (s, 3H), 2.07 (d, 2H), 1.6 – 1.66 (t, 2H).
622	¹ H NMR (500 MHz, DMSO) δ = 8.53 (d, 1H), 7.76 (dd, 1H), 7.45 (d, 1H), 7.39 (s, 1H), 7.31 – 7.23 (m, 2H), 6.95 (dd, 1H), 5.11 (s, 2H), 4.89 (t, 1H), 3.70 (dt, 2H), 3.67 – 3.56 (m, 4H), 2.60 (s, 3H), 2.47 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
623 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.88 (s, 1H), 7.43 – 7.36 (m, 2H), 7.13 (d, 1H), 6.87 (dd, 1H), 5.81 (q, 1H), 4.88 (t, 1H), 3.71 (d, 2H), 3.65 (q, 1H), 3.62 (s, 1H), 3.58 (s, 1H), 2.57 (s, 3H), 2.37 (s, 3H), 2.14 (d, 2H), 1.63 (t, 5H).
624	¹ H NMR (400 MHz, DMSO) δ = 9.22 (dd, 1H), 7.85 (dd, 1H), 7.76 (dd, 1H), 7.48 (d, 1H), 7.39 (s, 1H), 7.29 (d, 1H), 7.01 (dd, 1H), 5.43 (s, 2H), 4.89 (s, 1H), 3.75 – 3.55 (m, 6H), 2.60 (s, 3H), 2.17 (d, 2H), 1.63 (s, 1H).
625	¹ H NMR (400 MHz, DMSO) δ = 8.68 (d, 1H), 8.58 – 8.51 (m, 1H), 7.89 (dt, 1H), 7.50 – 7.37 (m, 3H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.17 (s, 2H), 4.90 (t, 1H), 3.75 – 3.55 (m, 6H), 2.60 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
626	¹ H NMR (400 MHz, DMSO) δ = 8.83 (d, 2H), 7.50 – 7.40 (m, 2H), 7.36 (s, 1H), 7.18 (d, 1H), 6.94 (dd, 1H), 5.29 (s, 2H), 4.86 (t, 1H), 3.73 – 3.51 (m, 6H), 2.57 (s, 3H), 2.14 (d, 2H), 1.62 (ddd, 2H).
627	¹ H NMR (400 MHz, DMSO) δ = 9.11 (d, 1H), 7.99 (d, 1H), 7.46 (d, 1H), 7.40 (s, 1H), 7.26 (d, 1H), 6.96 (dd, 1H), 5.40 (d, 2H), 4.89 (t, 1H), 3.75 – 3.68 (m, 2H), 3.68 – 3.56 (m, 4H), 2.60 (s, 3H), 2.18 (d, 2H), 1.69 – 1.57 (m, 2H).
628	¹ H NMR (500 MHz, DMSO) δ = 11.46 (s, 1H), 7.47 (d, 1H), 7.41 – 7.33 (m, 2H), 7.21 (d, 1H), 6.95 (dd, 1H), 6.36 (d, 1H), 6.21 (dd, 1H), 4.99 (d, 2H), 4.89 (s, 1H), 3.70 (dt, 2H), 3.65 (s, 2H), 3.60 (td, 2H), 2.60 (s, 3H), 2.16 (d, 2H), 1.63 (ddd, 2H).
629	¹ H NMR (400 MHz, DMSO) δ = 8.16 (dd, 1H), 7.46 (d, 1H), 7.38 (s, 1H), 7.22 (d, 1H), 7.05 (dd, 1H), 6.97 (dd, 1H), 6.89 – 6.83 (m, 1H), 5.16 (s, 2H), 4.90 (s, 1H), 3.84 (s, 3H), 3.75 – 3.63 (m, 4H), 3.59 (td, 2H), 2.59 (s, 3H), 2.16 (d, 2H), 1.62 (ddd, 2H).
630	¹ H NMR (400 MHz, DMSO) δ = 11.71 (s, 1H), 7.45 (dd, 2H), 7.40 (s, 1H), 7.22 (d, 1H), 6.95 (dd, 1H), 6.30 (d, 1H), 4.90 (d, 3H), 3.76 – 3.55 (m, 6H), 2.61 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H), 1.23 (s, 0H).
631	¹ H NMR (400 MHz, DMSO) δ = 11.59 (s, 1H), 7.57 – 7.48 (m, 2H), 7.48 – 7.37 (m, 2H), 7.22 (d, 1H), 6.92 (dd, 1H), 6.35 (d, 1H), 4.89 (t, 1H), 4.82 (s, 2H), 3.75 – 3.56 (m, 6H), 2.60 (s, 3H), 2.18 (d, 2H), 1.69 – 1.57 (m, 2H).
632	¹ H NMR (500 MHz, DMSO) δ = 8.26 (d, 1H), 7.80 (dd, 1H), 7.45 (d, 1H), 7.40 (s, 1H), 7.25 (d, 1H), 6.94 (dd, 1H), 6.85 (d, 1H), 5.06 (s, 2H), 4.89 (t, 1H), 3.85 (s, 3H), 3.74 – 3.57 (m, 6H), 2.60 (s, 3H), 2.17 (d, 2H), 1.63 (ddd, 2H).
633	¹ H NMR (400 MHz, DMSO) δ = 8.68 (dd, 1H), 7.95 (t, 1H), 7.62 – 7.55 (m, 2H), 7.47 (d, 1H), 7.41 (s, 1H), 7.36 – 7.26 (m, 2H), 6.98 (dd, 1H), 5.13 (s, 2H), 4.90 (t, 1H), 3.74 – 3.55 (m, 5H), 2.60 (s, 3H), 2.17 (d, 2H), 1.69 – 1.57 (m, 2H).

634	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 7.58 – 7.50 (m, 2H), 7.01 (dd, 1H), 5.33 (s, 2H), 4.26 (s, 2H), 3.75 – 3.63 (m, 2H), 3.58 (dt, 2H), 2.75 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H), 1.65 (d, 3H), 1.53 (d, 2H).
635 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.06 (d, 1H), 7.48 (d, 1H), 7.27 (d, 1H), 7.18 (d, 1H), 7.02 (dd, 1H), 6.86 (d, 1H), 5.13 (s, 2H), 4.36 (ddd, 1H), 3.69 (s, 3H), 3.02 – 2.85 (m, 1H), 2.66 (td, 3H), 2.58 (s, 3H), 2.16 – 2.03 (m, 1H), 1.94 (s, 1H).
636 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.09 (d, 1H), 7.48 (d, 1H), 7.37 (d, 1H), 7.24 (d, 1H), 6.99 (dd, 1H), 6.36 (d, 1H), 5.18 (s, 2H), 3.85 (s, 3H), 2.93 (t, 2H), 2.66 (dt, 2H), 2.58 (s, 3H), 2.09 (q, 1H), 1.91 (d, 1H).
637 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.75 (s, 1H), 8.07 (d, 1H), 7.55 (dd, 1H), 7.47 (d, 1H), 7.37 (dd, 1H), 7.18 (d, 1H), 6.95 (dd, 1H), 6.22 (t, 1H), 4.96 – 4.80 (m, 2H), 4.35 (dd, 1H), 2.93 (s, 2H), 2.92 (d, 1H), 2.67 (q, 2H), 2.57 (s, 3H), 2.41 (s, 1H), 2.13 – 1.98 (m, 1H), 1.90 (d, 1H).
638 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.15 (d, 1H), 7.49 (d, 1H), 7.31 (d, 1H), 7.19 (d, 1H), 7.02 (dd, 1H), 6.86 (d, 1H), 5.14 (s, 2H), 4.62 (dt, 1H), 3.69 (s, 3H), 3.13 – 2.97 (m, 1H), 2.90 (t, 2H), 2.59 (s, 3H).
639 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.19 (d, 1H), 7.49 (d, 1H), 7.37 (d, 1H), 7.27 (d, 1H), 7.00 (dd, 1H), 6.36 (d, 1H), 5.19 (s, 2H), 4.63 (dt, 1H), 3.85 (s, 3H), 3.30 – 3.18 (m, 1H), 3.12 – 2.80 (m, 2H), 2.59 (s, 3H).
640 - En 1	¹ H NMR (500 MHz, DMSO) δ = 11.75 (s, 1H), 8.18 (d, 1H), 7.60 – 7.52 (m, 1H), 7.47 (d, 1H), 7.38 (d, 1H), 7.23 (s, 1H), 6.96 (d, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.62 (s, 1H), 3.58 (s, 1H), 3.03 (s, 1H), 2.88 (s, 2H), 2.59 (s, 3H), 1.24 (s, 0H).
641 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.38 (d, 1H), 7.49 (d, 1H), 7.31 (d, 1H), 7.19 (s, 1H), 7.03 (dd, 1H), 6.86 (s, 1H), 5.15 (s, 2H), 4.86 (dt, 1H), 4.34 (t, 1H), 4.13 (q, 1H), 4.00 – 3.83 (m, 2H), 3.69 (s, 3H), 2.60 (s, 3H).
642 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.41 (d, 1H), 7.50 (d, 1H), 7.37 (d, 1H), 7.27 (d, 1H), 7.01 (dd, 1H), 6.37 (d, 1H), 5.19 (s, 2H), 4.85 (dq, 1H), 4.33 (t, 1H), 4.13 (q, 1H), 3.90 (ddd, 2H), 3.85 (s, 3H), 2.60 (s, 3H).
643 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.39 (d, 1H), 7.69 (s, 1H), 7.49 (d, 1H), 7.24 (d, 1H), 6.98 (dd, 1H), 5.32 (s, 2H), 4.85 (dq, 1H), 4.33 (dd, 1H), 4.13 (q, 1H), 4.01 – 3.79 (m, 2H), 2.61 (d, 6H).
646 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.99 (s, 1H), 8.40 (d, 1H), 7.49 (d, 1H), 7.25 (d, 1H), 6.99 (dd, 1H), 5.32 (s, 2H), 4.85 (dp, 1H), 4.33 (dd, 1H), 4.13 (q, 1H), 3.98 – 3.80 (m, 2H), 2.60 (s, 3H), 2.42 (s, 3H).
647 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.58 (ddd, 1H), 8.39 (d, 1H), 7.84 (td, 1H), 7.60 – 7.44 (m, 2H), 7.35 (ddd, 1H), 7.25 (d, 1H), 7.02 (dd, 1H), 5.21 (s, 2H), 4.84 (dq, 1H), 4.39 – 4.26 (m, 1H), 4.13 (q, 1H), 4.00 – 3.78 (m, 2H), 2.59 (s, 3H).
648 - En 1	¹ H NMR (500 MHz, DMSO) δ = 11.76 (s, 1H), 8.39 (d, 1H), 7.56 (dd, 1H), 7.48 (d, 1H), 7.42 – 7.34 (m, 1H), 7.22 (d, 1H), 6.97 (dd, 1H), 6.22 (t, 1H), 4.90 (s, 2H), 4.96 – 4.77 (m, 1H), 4.33 (t, 1H), 4.12 (q, 1H), 3.98 – 3.80 (m, 2H), 2.59 (s, 3H).
649	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.07 (s, 1H), 7.65 – 7.52 (m, 2H), 7.45 (d, 1H), 7.16 – 7.07 (m, 1H), 6.92 (dd, 1H), 5.35 (s, 2H), 2.63 (s, 3H), 2.46 (s, 2H), 2.42 (s, 3H), 1.50 (s, 6H).
650	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.82 (s, 1H), 7.49 (d, 1H), 7.04 (s, 1H), 6.99 (dd, 1H), 6.96 (s, 1H), 5.32 (s, 2H), 3.80 – 3.70 (m, 2H), 3.64 (td, 2H), 2.64 (s, 3H), 2.41 (s, 3H), 2.13 – 1.94 (m, 4H).
651	¹ H NMR (400 MHz, DMSO) δ = 8.73 (dd, 1H), 8.30 – 8.22 (m, 1H), 7.79 (dd, 1H), 7.70 (s, 1H), 7.48 (d, 1H), 7.28 (d, 1H), 6.98 (dd, 1H), 5.36 – 5.30 (m, 2H), 4.75 (s, 1H), 3.61 (t, 2H), 2.58 (s, 3H), 1.87 (t, 2H), 1.42 (s, 6H).
652	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.69 (s, 1H), 7.45 (d, 1H), 7.28 (d, 1H), 6.93 (dd, 1H), 5.31 (s, 2H), 4.78 (s, 1H), 3.62 (d, 2H), 2.57 (s, 3H), 2.42 (s, 3H), 1.88 (t, 2H), 1.43 (s, 6H).
653 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.53 – 7.43 (m, 3H), 7.20 (d, 1H), 7.00 (dd, 1H), 6.89 (d, 1H), 5.97 (s, 1H), 5.22 – 5.10 (m, 2H), 4.42 (qd, 1H), 4.36 – 4.31 (m, 1H), 4.02 – 3.91 (m, 2H), 3.69 (s, 3H), 3.65 (dd, 1H), 3.59 (t, 1H), 2.63 (s, 3H).
654 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.12 (d, 1H), 7.46 (d, 1H), 7.30 (d, 1H), 7.18 (d, 1H), 7.00 (dd, 1H), 6.86 (d, 1H), 5.37 – 5.32 (m, 1H), 5.15 (s, 2H), 4.25 (ddt, 2H), 4.02 (dd, 1H), 3.94 (dd, 1H), 3.69 (s, 3H), 3.71 – 3.63 (m, 1H), 3.56 (dd, 1H), 2.56 (s, 3H).
655 - En 1	¹ H NMR (400 MHz, DMSO) δ = 7.49 (d, 2H), 7.38 (dd, 2H), 7.00 (dd, 1H), 6.39 (d, 1H), 5.61 (d, 1H), 5.18 (s, 2H), 4.41 (qd, 1H), 4.35 – 4.26 (m, 1H), 4.02 – 3.90 (m, 2H), 3.85 (s, 3H), 3.64 (dd, 1H), 3.59 (t, 1H), 2.64 (s, 3H).
656 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.14 (d, 1H), 7.47 (d, 1H), 7.37 (d, 1H), 7.25 (d, 1H), 6.98 (dd, 1H), 6.37 (d, 1H), 5.31 (d, 1H), 5.19 (s, 2H), 4.24 (s, 1H), 4.02 (dd, 1H), 3.92 (dd, 1H), 3.66 (dd, 1H), 3.56 (dd, 1H), 2.56 (s, 3H).

657 - En 1	¹ H NMR (400 MHz, DMSO) δ = 11.25 (d, 1H), 8.75 (d, 2H), 8.47 (s, 1H), 8.28 (d, 1H), 7.99 (d, 1H), 7.80 (dd, 1H), 7.63 (d, 1H), 7.27 (dd, 1H), 5.36 (s, 2H), 2.96 (d, 2H), 2.72 (d, 1H), 2.38 – 2.27 (m, 2H), 1.93 (s, 1H), 1.61 (d, 1H), 1.24 (s, 1H).
658	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.68 (s, 1H), 8.39 (s, 1H), 7.97 (d, 1H), 7.57 (d, 1H), 7.24 – 7.14 (m, 1H), 5.35 (s, 2H), 4.77 (s, 1H), 3.76 – 3.54 (m, 6H), 2.45 (s, 3H), 2.08 (d, 2H), 1.71 – 1.58 (m, 2H).
659	¹ H NMR (400 MHz, DMSO) δ = 8.72 (dd, 1H), 8.23 (dd, 1H), 7.77 (dd, 1H), 7.50 (d, 1H), 6.99 (dd, 1H), 6.90 (d, 1H), 5.32 (s, 2H), 4.75 (s, 1H), 4.27 – 4.17 (m, 1H), 3.43 (s, 3H), 2.40 (s, 3H), 2.11 (s, 3H), 1.98 (s, 2H), 1.59 (s, 1H), 1.47 (s, 1H).
660	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 7.50 – 7.42 (m, 1H), 6.99 – 6.90 (m, 2H), 5.31 (s, 2H), 4.75 (s, 1H), 4.24 (s, 1H), 3.46 (s, 4H), 2.40 (d, 6H), 2.14 (h, 2H), 2.00 (s, 2H), 1.60 (s, 1H), 1.50 (s, 1H).
661 - En 1	¹ H NMR (400 MHz, DMSO) δ = 8.98 (s, 1H), 8.01 (t, 1H), 7.82 (d, 1H), 7.50 (d, 1H), 7.44 (d, 1H), 6.99 (dd, 1H), 5.33 (d, 2H), 4.69 – 4.59 (m, 1H), 3.29 – 3.21 (m, 1H), 3.15 – 3.06 (m, 1H), 2.66 (s, 3H), 2.42 (s, 3H), 2.04 – 1.90 (m, 2H), 1.84 – 1.69 (m, 2H), 1.52 (q, 1H), 1.25 (q, 1H).
662	¹ H NMR (500 MHz, DMSO) δ = 8.70 (s, 1H), 8.55 (d, 1H), 7.90 (d, 1H), 7.63 (d, 1H), 7.49 (d, 2H), 7.43 (dd, 2H), 7.19 (s, 1H), 7.00 (dd, 1H), 5.18 (s, 2H), 5.03 (t, 1H), 4.48 (dd, 1H), 3.74 (dt, 2H), 2.64 (s, 3H).
663	¹ H NMR (500 MHz, DMSO) δ = 8.23 – 8.12 (m, 2H), 7.81 (dd, 1H), 7.48 (d, 1H), 7.23 (d, 1H), 7.00 (ddd, 2H), 5.08 (s, 2H), 4.61 (dt, 1H), 3.93 (s, 3H), 3.26 (dd, 1H), 3.00 (dt, 1H), 2.85 (dd, 1H), 2.59 (s, 3H).
664	¹ H NMR (400 MHz, DMSO) δ = 8.73 (dd, 1H), 8.43 (d, 1H), 8.26 (d, 1H), 7.79 (dd, 1H), 7.52 (d, 1H), 7.25 (d, 1H), 7.02 (dd, 1H), 5.33 (s, 2H), 4.85 (dt, 1H), 4.32 (t, 1H), 4.13 (q, 1H), 3.98 – 3.77 (m, 2H), 2.60 (s, 3H).
665	¹ H NMR (500 MHz, DMSO) δ = 8.41 (d, 1H), 8.16 (dd, 1H), 7.81 (dd, 1H), 7.49 (d, 1H), 7.24 (d, 1H), 7.01 (ddd, 2H), 5.08 (s, 2H), 4.85 (dp, 1H), 4.32 (dd, 1H), 4.13 (q, 1H), 3.93 (s, 3H), 3.97 – 3.79 (m, 2H), 2.60 (s, 3H).
666	¹ H NMR (400 MHz, DMSO) δ = 8.99 (s, 1H), 8.57 (t, 1H), 7.50 (d, 1H), 7.29 (d, 1H), 7.00 (dd, 1H), 5.33 (s, 2H), 4.19 – 4.03 (m, 2H), 2.61 (s, 3H), 2.42 (s, 3H).
668	¹ H NMR (400 MHz, DMSO) δ = 7.66 (d, 1H), 7.57 (bs, 1H), 7.51 (d, 1H), 7.45 (d, 2H), 7.18 (bs, 1H), 7.02 (dd, 1H), 5.16 (s, 2H), 5.01 (t, 1H), 4.48 – 4.46 (m, 1H), 3.88 (s, 3H), 3.76 – 3.73 (m, 2H), 2.64 (s, 3H).
670	¹ H NMR (400 MHz, DMSO) δ = 7.65 (d, 1H), 7.62 (s, 1H), 7.55 (d, 2H), 7.18 (bs, 1H), 7.01 – 6.96 (m, 1H), 5.17 (s, 2H), 5.02 (t, 1H), 4.69 – 4.63 (m, 1H), 4.52 – 4.40 (m, 1H), 3.77 – 3.73 (m, 2H), 2.64 (s, 3H), 1.40 (d, 6H).
672	¹ H NMR (400 MHz, DMSO) δ = 7.65 (d, 1H), 7.62 (s, 1H), 7.55 (d, 2H), 7.18 (bs, 1H), 7.01 – 6.96 (m, 1H), 5.17 (s, 2H), 5.02 (t, 1H), 4.69 – 4.63 (m, 1H), 4.52 – 4.40 (m, 1H), 3.77 – 3.73 (m, 2H), 2.64 (s, 3H), 1.40 (d, 6H).
674	¹ H NMR (500 MHz, DMSO) δ = 7.63 (d, 1H), 7.52 – 7.48 (m, 2H), 7.42 (d, 1H), 7.19 (bs, 1H), 6.99 (dd, 1H), 6.51 (s, 1H), 5.25 (s, 2H), 5.03 (t, 1H), 4.50 – 4.45 (m, 1H), 3.76 – 3.73 (m, 2H), 2.63 (s, 3H), 2.23 (s, 3H).
676	¹ H NMR (500 MHz, DMSO) δ = 7.61 (d, 1H), 7.52 – 7.40 (m, 4H), 7.19 (s, 1H), 7.00 – 6.94 (m, 1H), 6.37 (d, 1H), 5.20 (m, 2H), 5.02 (t, 1H), 4.65 – 4.58 (m, 1H), 4.52 – 4.44 (m, 2H), 3.80 – 3.70 (m, 2H), 2.64 (s, 3H), 1.40 (d, 6H).
678	¹ H NMR (500 MHz, DMSO) δ = 7.62 (d, 1H), 7.50 – 7.46 (m, 2H), 7.40 (d, 1H), 7.18 (s, 1H), 6.96 (dd, 1H), 5.07 (s, 2H), 5.01 (t, 1H), 4.50 – 4.45 (m, 1H), 3.79 – 3.70 (m, 2H), 2.64 (s, 3H), 2.36 (s, 3H), 2.09 (s, 3H).
680	¹ H NMR (400 MHz, DMSO) δ = 8.28 (s, 1H), 7.62 (d, 1H), 7.49 – 7.46 (m, 2H), 7.41 (d, 1H), 7.18 (s, 1H), 6.97 (dd, 1H), 5.15 (s, 2H), 5.01 (t, 1H), 4.49 – 4.45 (m, 1H), 3.76 – 3.72 (m, 2H), 2.64 (s, 3H), 2.16 (s, 3H).
682	¹ H NMR (500 MHz, DMSO) δ = 7.76 (s, 1H), 7.61 (d, 1H), 7.50 – 7.47 (m, 2H), 7.42 (d, 1H), 7.19 (s, 1H), 6.98 (dd, 1H), 5.33 (s, 2H), 5.02 (t, 1H), 4.51 – 4.45 (m, 1H), 3.79 – 3.70 (m, 2H), 3.29 – 3.21 (m, 1H), 2.63 (s, 3H), 1.31 (d, 6H).
683	¹ H NMR (500 MHz, DMSO) δ = 8.48 (s, 1H), 7.68 (s, 1H), 7.47 (d, 1H), 7.22 (d, 1H), 6.96 (dd, 1H), 6.34 (t, 1H), 5.32 (s, 2H), 2.63 (s, 3H), 2.58 (s, 3H), 2.49 – 2.39 (m, 2H), 2.37 – 2.28 (m, 2H), 2.05 – 1.97 (m, 1H), 1.90 – 1.80 (m, 1H).
684	¹ H NMR (500 MHz, DMSO) δ = 7.62 (d, 1H), 7.54 – 7.46 (m, 3H), 7.42 (d, 1H), 7.19 (s, 1H), 7.01 (dd, 1H), 5.38 (s, 2H), 5.01 (t, 1H), 4.50 – 4.45 (m, 1H), 3.78 – 3.70 (m, 2H), 2.64 (s, 3H), 2.44 (s, 3H).

685	¹ H NMR (400 MHz, DMSO-d ₆): δ 7.88 (bs, 1H), 7.52 - 7.36 (m, 4H), 7.15 (bs, 1H), 6.94 - 6.90 (m, 1H), 5.44 (s, 1H), 5.07 - 5.01 (m, 2H), 4.40 - 4.35 (m, 1H), 4.17 - 4.12 (m, 1H), 2.65 (s, 3H), 1.15 (d, 3H).
686	¹ H NMR (500 MHz, DMSO): δ 7.65 (d, 1H), 7.47 (d, 1H), 7.40 (d, 1H), 6.96 (dd, 1H), 6.33 (d, 1H), 5.01 (s, 2H), 4.48 (t, 1H), 3.82 (s, 3H), 3.77 - 3.73 (m, 2H), 2.63 (s, 3H).
688	¹ H NMR (400 MHz, DMSO): δ 7.62 (d, 1H), 7.57 (d, 1H), 7.50 - 7.49 (m, 2H), 7.42 (d, 1H), 7.19 (bs, 1H), 6.99 - 6.96 (dd, 1H), 6.53 (d, 1H), 5.25 (s, 2H), 5.19 - 5.12 (m, 2H), 5.02 (bs, 1H), 4.50 - 4.46 (m, 1H), 3.74 (d, 2H), 2.64 (s, 2H).
690	¹ H NMR (500 MHz, DMSO): δ 7.63 (d, 1H), 7.51 - 7.43 (m, 3H), 7.40 (d, 1H), 7.20 (bs, 1H), 6.98 (dd, 1H), 6.41 (s, 1H), 5.19 (s, 2H), 5.02 (t, 1H), 4.51 - 4.45 (m, 1H), 4.01 (d, 2H), 3.77 - 3.72 (m, 2H), 2.64 (s, 3H), 1.30 - 1.25 (m, 1H), 0.50 - 0.45 (m, 2H), 0.38 - 0.33 (m, 2H).
692	¹ H NMR (500 MHz, DMSO): δ 8.10 (s, 1H), 7.62 (d, 1H), 7.50 (s, 1H), 7.47 (d, 1H), 7.39 (d, 1H), 7.21 (s, 1H), 6.92 (dd, 1H), 5.05 - 5.00 (m, 3H), 4.51 - 4.47 (m, 1H), 3.91 (s, 3H), 3.78 - 3.73 (m, 2H), 2.63 (s, 3H).
694	¹ H NMR (500 MHz, DMSO): δ 9.24 (s, 1H), 7.67 (d, 1H), 7.52 - 7.41 (m, 3H), 7.17 (s, 1H), 7.02 (dd, 1H), 5.53 (s, 2H), 5.01 (s, 1H), 4.49 - 4.45 (m, 1H), 3.77 - 3.72 (m, 2H), 2.64 (s, 3H).
695	¹ H NMR (500 MHz, DMSO): δ 7.85 (d, 1H), 7.78 (d, 1H), 7.64 (d, 1H), 7.53 - 7.43 (m, 3H), 7.19 (bs, 1H), 7.05 - 7.02 (dd, 1H), 5.46 (s, 2H), 5.01 (t, 1H), 4.50 - 4.45 (m, 1H), 3.76 - 3.73 (m, 2H), 2.64 (s, 3H).
696	¹ H-NMR (500 MHz, DMSO): δ 8.58 (d, 1H), 7.80 - 7.65 (m, 1H), 7.67 - 7.62 (m, 1H), 7.50 - 7.43 (m, 1H), 7.39 (d, 1H), 7.17 (s, 1H), 7.01 (dd, 1H), 5.19 (s, 2H), 5.09 - 5.06 (m, 1H), 4.39 - 4.34 (m, 1H), 4.16 - 4.11 (m, 1H), 2.64 (s, 3H), 1.13 (d, 3H).
697	¹ H NMR (500 MHz, DMSO): δ 9.11 (s, 1H), 8.02 (s, 1H), 7.62 (d, 1H), 7.51 - 7.47 (m, 2H), 7.43 (d, 1H), 7.20 (bs, 1H), 6.99 (dd, 1H), 5.42 (s, 2H), 5.02 (t, 1H), 4.50 - 4.46 (m, 1H), 3.77 - 3.72 (m, 2H), 2.63 (s, 3H).
698	¹ H NMR (400 MHz, DMSO): δ 7.81 (s, 1H), 7.59 (d, 1H), 7.54 (bs, 2H), 7.46 (d, 1H), 7.39 (d, 1H), 7.20 (bs, 1H), 6.92 (dd, 1H), 5.04 (bs, 1H), 4.97 (s, 2H), 4.52 - 4.45 (m, 1H), 3.81 (s, 3H), 3.77 - 3.73 (m, 2H), 2.63 (s, 3H).
700	¹ H NMR (500 MHz, DMSO): δ 8.41 (d, 1H), 7.65-7.58 (m, 2H), 7.49 - 7.40 (m, 4H), 7.18 (s, 1H), 6.98 (dd, 1H), 5.15 (s, 2H), 5.01 (t, 1H), 4.49 - 4.45 (m, 1H), 3.76 - 3.73 (m, 2H), 2.63 (s, 3H), 2.30 (s, 3H).
702	¹ H NMR (500 MHz, DMSO): δ 8.38 (dd, 1H), 7.79 (dd, 1H), 7.64 (d, 1H), 7.52 - 7.46 (d, 3H), 7.19 - 7.13 (m, 2H), 7.02 (dd, 1H), 5.28 (s, 2H), 5.03 (t, 1H), 4.50 - 4.61 (m, 1H), 3.76 - 3.73 (m, 2H), 2.64 (s, 3H), 2.28 - 2.22 (m, 1H), 1.02 - 0.95 (m, 4H).
704	¹ H NMR (500 MHz, DMSO): δ 8.37 (d, 1H), 7.65 (d, 1H), 7.48 - 7.41 (m, 4H), 7.31 - 7.28 (m, 1H), 7.18 (bs, 1H), 7.00 (dd, 1H), 5.32 (s, 1H), 5.07 (bs, 1H), 4.47 (d, 1H), 3.76 (bs, 2H), 2.66 (s, 3H), 2.15 (t, 1H), 0.96 (d, 2H), 0.74 (d, 2H).
705	¹ H NMR (500 MHz, DMSO): δ 8.36 (d, 1H), 7.47 - 7.38 (m, 3H), 7.32 - 7.25 (m, 2H), 7.0 - 6.90 (m, 1H), 5.32 (s, 2H), 4.92 (bs, 1H), 3.73 - 3.59 (m, 6H), 2.58 (s, 3H), 2.20 - 2.10 (m, 3H), 1.68 - 1.58 (m, 2H), 1.00 - 0.96 (m, 2 H), 0.72 - 0.70 (m, 2H).
706	¹ H NMR (500 MHz, DMSO): δ 8.10 - 8.07 (m, 1H), 7.64 - 7.57 (m, 2H), 7.50 - 7.47 (m, 2H), 7.42 (d, 1H), 7.19 (s, 1H), 6.98 (dd, 1H), 6.69 - 6.67 (m, 1H), 5.01 (t, 1H), 4.94 (s, 2H), 4.50 - 4.45 (m, 1H), 4.07 (t, 4H), 3.77 - 3.73 (m, 2H), 2.64 (s, 3H), 2.26 - 2.18 (m, 2H).
708	¹ H NMR (500 MHz, DMSO): δ 8.80 (s, 2H), 7.64 (d, 1H), 7.51 - 7.47 (d, 2H), 7.43 (d, 1H), 7.19 (bs, 1H), 7.01 (dd, 1H), 5.20 (s, 2H), 5.03 (t, 1H), 4.49 - 4.46 (m, 1H), 3.78 - 3.71 (m, 2H), 2.64 (s, 3H), 2.62 (s, 3H).
710	¹ H NMR (400 MHz, DMSO): δ 8.18 (dd, 1H), 7.82 (dd, 1H), 7.61 (d, 1H), 7.47 (d, 2H), 7.38 (d, 1H), 7.16 (bs, 1H), 7.07 - 7.02 (m, 1H), 6.97 - 6.92 (m, 1H), 4.99 (t, 3H), 4.51 - 4.44 (m, 1H), 4.36 - 4.31 (m, 1H), 3.74 (t, 2H), 2.64 (s, 3H), 0.76 - 0.62 (m, 4H).
711	¹ H NMR (400 MHz, DMSO): δ 8.17 (dd, 1H), 7.80 (dd, 1H), 7.45 (d, 2H), 7.37 (bs, 1H), 7.20 (d, 1H), 7.07-7.02 (m, 1H), 6.94 (dd, 1H), 5.00 (s, 2H), 4.85 (s, 1H), 3.72 - 3.56 (m, 6H), 2.59 (s, 3H), 2.16 (d, 2H), 1.68 - 1.58 (m, 2H), 0.78 - 0.64 (m, 4H).
712	¹ H NMR (500 MHz, DMSO): δ 8.83 (d, 2H), 7.60 (d, 1H), 7.48 - 7.46 (m, 3H), 7.38 (d, 1H), 7.17 (bs, 1H), 6.96 (dd, 1H), 5.28 (s, 2H), 5.00 (t, 1H), 4.48 - 4.44 (m, 1H), 3.74 - 3.72 (m, 2H), 2.63 (s, 3H).
714	¹ H NMR (500 MHz, DMSO): δ 8.84 (d, 1H), 8.67 (d, 1H), 8.63 (d, 1H), 7.61 (d, 1H), 7.50 (d, 1H), 7.47 - 7.44 (m, 2H), 7.15 (bs, 1H), 7.04 (dd, 1H), 5.28 (s, 2H), 4.99 (t, 1H), 4.49 - 4.46 (m, 1H), 3.76 - 3.72 (m, 2H), 2.64 (s, 3H).
715	¹ H NMR (500 MHz, DMSO): δ 8.15 (dd, 1H), 7.86 - 7.81 (m, 1H), 7.63 (d, 1H), 7.50 - 7.45 (m, 2H), 7.40 (d, 1H), 7.18 (s, 1H), 7.05 - 6.95 (m, 2H), 5.07 (s, 2H), 5.00 (t, 1H), 4.50 - 4.46 (m, 1H), 3.92 (s, 3H), 3.76 - 3.71 (m, 2H), 2.64 (s, 3H).

716	¹ H NMR (500 MHz, DMSO): δ 8.58 (dd, 2H), 7.62 (d, 1H), 7.50 - 7.47 (m, 4H), 7.41 (d, 1H), 7.19 (s, 1H), 7.00 (dd, 1H), 5.21 (s, 2H), 5.02 (t, 1H), 4.49 - 4.45 (m, 1H), 3.75 - 3.74 (m, 2H), 2.63 (s, 3H).
717	¹ H NMR (500 MHz, DMSO): δ 9.87 (bs, 1H), 9.31 (bs, 1H), 8.74 (d, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 7.61 - 7.57 (m, 1H), 7.50 - 7.22 (m, 3H), 7.02 - 6.97 (m, 1H), 5.35 (s, 2H), 4.88 - 4.80 (m, 1H), 3.87 - 3.79 (m, 2H), 3.36 - 3.30 (m, 1H), 3.26 - 3.15 (m, 1H), 2.63 (s, 3H), 2.10 - 2.00 (m, 2H).
718	¹ H NMR (500 MHz, DMSO): δ 8.59 - 8.57 (m, 1H), 7.83 (td, 1H), 7.56 (d, 1H), 7.50 (d, 1H), 7.45 - 7.42 (m, 2H), 7.40 - 7.33 (m, 2H), 7.17 (s, 1H), 7.02 (dd, 1H), 5.19 (s, 2H), 5.06 (d, 1H), 4.36 (dd, 1H), 4.18 - 4.10 (m, 1H), 2.64 (s, 3H), 1.13 (d, 3H).
719 - En 1	¹ H NMR (400 MHz, DMSO): δ 8.57 (dd, 1H), 7.83 (t, 1H), 7.57 - 7.47 (m, 4H), 7.35 (t, 1H), 7.27 (d, 1H), 7.00 (dd, 1H), 5.24 (s, 1H), 5.19 (s, 1H), 3.74 - 3.62 (m, 2H), 3.31 (s, 1H), 3.11 (d, 1H), 2.59 (s, 3H), 2.21 - 2.15 (m, 2H), 1.83 - 1.74 (m, 2H).
720 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.17 (dd, 1H), 7.86 - 7.82 (m, 1H), 7.64 (s, 1H), 7.50 - 7.42 (m, 3H), 7.28 (s, 1H), 7.05 - 7.01 (m, 1H), 6.97 (dd, 1H), 5.13 - 5.05 (m, 3H), 4.00 - 3.92 (m, 4H), 3.78 - 3.72 (m, 1H), 2.65 (s, 3H), 1.52 (s, 3H).
721	¹ H NMR (500 MHz, DMSO): δ 8.98 (s, 1H), 8.49 (s, 1H), 7.47 (d, 1H), 7.23 (d, 1H), 6.96 (dd, 1H), 6.34 (t, 1H), 5.32 (s, 2H), 2.58 (s, 3H), 2.47 - 2.41 (m, 5H), 2.39 - 2.30 (m, 2H), 2.05 - 1.95 (m, 1H), 1.90 - 1.82 (m, 1H).
722 - En 1	¹ H NMR (500 MHz, DMSO): δ 7.63 (s, 1H), 7.49 (d, 1H), 7.48 - 7.43 (m, 2H), 7.30 (s, 1H), 7.18 (s, 1H), 6.97 (dd, 1H), 5.14 - 5.10 (m, 3H), 4.00 - 3.93 (m, 1H), 3.80 - 3.73 (m, 1H), 2.65 (s, 3H), 2.49 (s, 3H), 1.53
723 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.98 (s, 1H), 8.29 (d, 1H), 7.48 (d, 1H), 7.22 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.73 - 4.62 (m, 1H), 4.00 - 3.88 (m, 2H), 3.75 - 3.59 (m, 2H), 2.58 (s, 3H), 2.41 (s, 3H), 1.95 - 1.86 (m, 2H).
724 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.28 (d, 1H), 7.68 (s, 1H), 7.47 (d, 1H), 7.21 (d, 1H), 6.97 (dd, 1H), 5.31 (s, 2H), 4.75 - 4.62 (m, 1H), 4.00 - 3.88 (m, 2H), 3.74 - 3.58 (m, 2H), 2.63 (s, 3H), 2.57 (s, 3H), 1.95 - 1.88 (m, 2H).
725 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.23 (s, 1H), 7.47 (d, 1H), 7.32 (d, 1H), 7.16 - 7.06 (m, 3H), 6.97 (dd, 1H), 5.13 (s, 2H), 4.18 (d, 1H), 3.94 (d, 1H), 3.85 (t, 2H), 2.61 (s, 3H), 2.41 (s, 3H), 2.38-2.31 (m, 2H).
726 - En 1	¹ H NMR (500 MHz, DMSO) δ = 8.20 (d, 1H), 7.70 (s, 1H), 7.59 (bs, 1H), 7.49 - 7.46 (m, 2H), 7.35 (bs, 1H), 6.95 (dd, 1H), 5.34 - 5.28 (m, 2H), 4.97 - 4.93 (m, 1H), 3.74 - 3.63 (m, 2H), 3.07 (s, 3H), 2.63 (s, 3H), 2.62 (s, 3H).
727 - En 1	¹ H-NMR (500 MHz, DMSO): δ 8.26 (d, 1H), 7.70 (s, 1H), 7.47 (d, 1H), 7.35 (d, 1H), 6.95 (dd, 1H), 5.33 (s, 2H), 4.78 - 4.74 (m, 1H), 4.17 (s, 1H), 3.44 - 3.40 (m, 1H), 3.30 - 3.27 (m, 1H), 3.17 - 3.12 (m, 2H), 2.63 (s, 3H), 2.60 (s, 3H), 2.49 - 2.46 (s, 1H), 2.27 - 2.23 (m, 1H).
727 - En 3	¹ H-NMR (400 MHz, DMSO): δ 8.26 (d, 1H), 7.69 (s, 1H), 7.47 (d, 1H), 7.30 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.70 - 4.64 (m, 1H), 4.07 (s, 1H), 3.45 - 3.40 (m, 1H), 3.30 - 3.27 (m, 1H), 3.18 - 3.10 (m, 2H), 2.63 (s, 3H), 2.59 (s, 3H), 2.46 - 2.41 (m, 1H), 2.33 - 2.26 (m, 1H).
727 - En 4	¹ H-NMR (400 MHz, DMSO): δ 8.26 (d, 1H), 7.69 (s, 1H), 7.47 (d, 1H), 7.30 (d, 1H), 6.95 (dd, 1H), 5.32 (s, 2H), 4.70 - 4.66 (m, 1H), 4.07 (s, 1H), 3.45 - 3.40 (m, 1H), 3.30 - 3.26 (m, 1H), 3.15 - 3.10 (m, 2H), 2.63 (s, 3H), 2.59 (s, 3H), 2.46 - 2.41 (m, 1H), 2.33 - 2.27 (m, 1H).
728 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.98 (s, 1H), 7.55 (s, 1H), 7.44 (d, 1H), 7.26 - 7.20 (m, 1H), 6.93 (dd, 1H), 5.30 (s, 2H), 5.12 - 4.93 (m, 1H), 3.70 - 3.62 (m, 3H), 3.02 - 2.75 (m, 3H), 2.59 - 2.52 (m, 4H), 2.49 (s, 3H), 2.10 - 2.01 (m, 1H), 1.84 - 1.77 (m, 1H).
729 - En 1	¹ H NMR (500 MHz, DMSO): δ 8.99 (s, 1H), 8.47 (s, 1H), 8.06 (d, 1H), 7.97 (s, 1H), 7.73 (s, 1H), 7.46 (d, 1H), 7.36 (s, 1H), 7.27 (d, 1H), 6.97 (dd, 1H), 5.34 - 5.28 (s, 2H), 4.97 - 4.90 (m, 1H), 4.68 - 4.57 (m, 2H), 2.52 (s, 3H), 2.43 (s, 3H).
730 - En 1	¹ H NMR (400 MHz, DMSO): δ 8.08 (s, 1H), 7.78 (s, 1H), 7.51 (s, 1H), 7.45 (d, 1H), 7.23 (d, 1H), 6.91 (dd, 1H), 5.04 (s, 3H), 3.65 - 3.55 (m, 2H), 3.24 - 3.16 (m, 2H), 2.58 (s, 3H), 2.48 - 2.38 (m, 2H).
731 - En 1	¹ H NMR (400 MHz, DMSO): δ 8.12 (s, 1H), 7.58 (bs, 1H), 7.52 (s, 1H), 7.46 (d, 1H), 7.25 (d, 1H), 6.92 (dd, 1H), 5.05 (s, 2H), 3.73 (d, 1H), 3.63 (d, 1H), 3.29 - 3.24 (m, 1H), 3.15 - 3.10 (d, 1H), 2.59 (s, 3H), 2.27 - 2.14 (m, 2H), 1.87 - 1.75 (m, 2H).
732 - En 1	¹ H NMR (400 MHz, DMSO): δ 7.59 (brs, 1H), 7.51 - 7.47 (m, 2H), 7.37 (d, 1H), 7.31 (d, 1H), 7.00 (dd, 1H), 6.39 (d, 1H), 5.23 (brs, 1H), 5.18 (s, 2H), 3.85 (s, 3H), 3.75 - 3.72 (m, 1H), 3.65 - 3.62 (m, 1H), 3.28 - 3.25 (m, 1H), 3.15 - 3.12 (m, 1H), 2.60 (s, 3H), 2.23 - 2.2.17 (m, 2H), 1.85 - 1.73 (m, 2H).
733 - En 1	¹ H NMR (400 MHz, DMSO): δ 7.79 (brs, 1H), 7.51 - 7.47 (m, 2H), 7.37 (d, 1H), 7.29 (d, 1H), 7.00 (dd, 1H), 6.39 (d, 1H), 5.22 (brs, 1H), 5.18 (s, 2H), 3.85 (s, 3H), 3.62 - 3.60 (m, 2H), 3.21 - 3.19 (m, 2H), 2.59 (s, 3H), 2.49 - 2.39 (m, 2H).
734 - En 1	¹ H NMR (400 MHz, DMSO): δ 9.23 - 9.20 (m, 1H), 7.89 - 7.86 (m, 1H), 7.78 - 7.74 (m, 2H), 7.52 - 7.48 (m, 2H), 7.30 (d, 1H), 7.04 (dd, 1H), 5.42 (s, 2H), 5.25 (brs, 1H), 3.65 - 3.55 (m, 2H), 3.29 - 3.25 (m,

	1H), 3.24 - 3.17 (m, 1H), 2.59 (s, 3H), 2.49 - 2.39 (m, 2H).
735 – En 1	1H NMR (400 MHz, DMSO): δ 8.60 - 7.57 (m, 1H), 7.79 - 7.72 (m, 2H), 7.67 - 7.62 (m, 1H), 7.50 - 7.44 (m, 2H), 7.28 - 7.23 (m, 1H), 7.00 (dd, 1H), 5.25 - 5.16 (m, 3H), 3.64 - 3.55 (m, 2H), 3.30 - 3.26 (m, 1H), 3.25 - 3.16 (m, 1H), 2.58 (s, 3H), 2.46 - 2.38 (m, 2H).
736 – En 1	1H NMR (400 MHz, DMSO): δ 8.67 (d, 1H), 8.13 (d, 1H), 7.78 (brs, 1H), 7.66 - 7.61 (m, 1H), 7.54 - 7.46 (m, 2H), 7.30 - 6.96 (m, 3H), 5.34 (s, 2H), 5.21 (brs, 1H), 3.64 - 3.55 (m, 2H), 3.21 - 3.15 (m, 2H), 2.62 (s, 3H), 2.45 - 2.36 (m, 2H).
737 – En 1	1H NMR (400 MHz, DMSO): δ 8.66 (d, 1H), 8.13 (d, 1H), 7.66 - 7.46 (m, 4H), 7.31 - 6.96 (m, 3H), 5.34 (s, 2H), 5.23 (brs, 1H), 3.75 - 3.70 (m, 1H), 3.65 - 3.60 (m, 1H), 3.25 - 3.20 (m, 1H), 3.18 - 3.10 (m, 1H), 2.60 (s, 3H), 2.25 - 2.12 (m, 2H), 1.90 - 1.70 (m, 2H).
738 – En 1	1H-NMR (400 MHz, DMSO): δ 8.58 (d, 1H), 7.84 (td, 1H), 7.63 (s, 1H), 7.58 (d, 1H), 7.51 - 7.46 (m, 2H), 7.43 (s, 1H), 7.36 - 7.33 (m, 1H), 7.29 (s, 1H), 7.02 (dd, 1H), 5.20 (s, 2H), 5.12 (t, 1H), 3.98 - 3.95 (m, 1H), 3.78 - 3.74 (m, 1H), 2.65 (s, 3H), 1.52 (s, 3H).
739 – En 1	1H-NMR (400 MHz, DMSO): δ 8.58 (d, 1H), 7.80 - 7.75 (m, 1H), 7.67 - 7.63 (m, 2H), 7.51 - 7.47 (m, 2H), 7.43 (s, 1H), 7.29 (s, 1H), 7.00 (dd, 1H), 5.19 (s, 2H), 5.12 (s, 1H), 3.96 (d, 1H), 3.76 (d, 1H), 2.65 (s, 3H), 1.52 (s, 3H).
740 – En 1	1HNMR (500 MHz, DMSO): δ 8.25 (s, 1H), 7.53 - 7.45 (m, 2H), 7.34 (d, 1H), 7.13(bs, 1H), 7.08 (bs, 1H), 7.00 (dd, 1H), 6.50 - 6.26 (m, 2H), 5.24 (s, 2H), 4.72 - 4.63 (m, 2H), 4.18 (d, 1H), 3.94 (d, 1H), 3.89 - 3.83 (m, 2H), 2.62 (s, 3H), 2.40 - 2.35 (m, 2H).
741	1H NMR (500 MHz, DMSO): δ 8.59 (d, 1H), 7.80 - 7.76 (m, 1H), 7.67 - 7.62 (m, 2H), 7.50 - 7.47 (m, 2H), 7.43 (d, 1H), 7.20 (bs, 1H), 7.00 (dd, 1H), 5.20 (s, 2H), 5.03 (t, 1H), 4.49 - 4.45 (m, 1H), 3.76 - 3.73 (m, 2H), 2.63 (s, 3H).
742	1H NMR (500 MHz, DMSO): δ 9.00 (s, 1H), 8.35 (d, 1H), 7.73 (d, 1H), 7.54 - 7.31 (m, 3H), 7.26 - 7.21 (m, 2H), 5.36 (s, 2H), 5.05 (t, 1H), 4.53 - 4.47 (m, 1H), 3.80 - 3.73 (m, 2H), 2.43 (s, 3H).
743	1H NMR (500 MHz, DMSO): δ 8.56 (d, 1H), 8.35 (d, 1H), 7.80 (d, 1H), 7.73 (d, 1H), 7.53 - 7.28 (m, 3H), 7.28 (d, 1H), 7.24 - 7.22 (m, 2H), 5.17 (s, 2H), 5.08 (bs, 1H), 3.77 (bs, 2H), 2.47 (s, 3H).
744	1H NMR (500 MHz, DMSO): δ 8.59 (d, 1H), 8.35 (bs, 1H), 7.86 (t, 1H), 7.73 (d, 1H), 7.68 - 7.03 (m, 7H), 5.24 (s, 2H), 5.10 (bs, 1H), 4.49 (bs, 1H), 3.81 - 3.75 (m, 2H).
745	1H NMR (500 MHz, DMSO): δ 8.32 (d, 1H), 7.75 - 7.70 (m, 2H), 7.55 - 7.32 (m, 3H), 7.24 - 7.21 (m, 2H), 5.37 (s, 2H), 5.07 (t, 2H), 4.53 - 4.49 (m, 1H), 3.80 - 3.74 (m, 2H), 2.63 (s, 3H).
746	1HNMR (500 MHz, DMSO): δ 8.31 (d, 1H), 7.73 (d, 1H), 7.56 - 7.30 (m, 3H), 7.21 (d, 3H), 5.18 (s, 2H), 5.07 (s, 1H), 4.55 - 4.45 (m, 1H), 3.77 (bs, 2H), 2.41 (s, 3H).
747	1H NMR (500 MHz, DMSO): δ 8.58 (s, 1H), 7.86 - 7.81 (m, 1H), 7.61 - 7.56 (m, 2H), 7.50 (s, 1H), 7.44 - 7.41 (m, 2H), 7.36 - 7.34 (m, 1H), 7.20 (s, 1H), 6.98 (dd, 1H), 5.19 (s, 2H), 5.04 (t, 1H), 4.51 - 4.47 (m, 1H), 3.80 - 3.71 (m, 2H), 2.77 - 2.70 (m, 1H), 1.16 - 1.07 (m, 4H).
748	1H NMR (500 MHz, DMSO): δ 8.98 (s, 1H), 7.60 (d, 1H), 7.49 (s, 1H), 7.44 - 7.40 (m, 2H), 7.19 (s, 1H), 6.95 (dd, 1H), 5.31 (s, 2H), 5.03 (t, 1H), 4.52 - 4.46 (m, 1H), 3.80 - 3.71 (m, 2H), 2.76 - 2.70 (m, 1H), 2.41 (s, 3H), 1.16 - 1.06 (m, 4H).
749	1HNMR (500 MHz, DMSO): δ 7.71 (s, 1H), 7.59 (d, 1H), 7.52 (s, 1H), 7.43 - 7.40 (m, 2H), 7.22 (s, 1H), 6.94 (dd, 1H), 5.32 (s, 2H), 5.05 (t, 1H), 4.51 - 4.46 (m, 1H), 3.82 - 3.70 (m, 2H), 2.78 - 2.69 (m, 1H), 2.62 (s, 3H), 1.16 - 1.05 (m, 4H).
750	1HNMR (500 MHz, DMSO): δ 8.54 (d, 1H), 7.78 (dd, 1H), 7.59 (d, 1H), 7.51 (s, 1H), 7.44 - 7.40 (m, 2H), 7.27 (d, 1H), 7.21 (s, 1H), 6.94 (dd, 1H), 5.12 (s, 2H), 5.04 (t, 1H), 4.51 - 4.47 (m, 1H), 3.80 - 3.72 (m, 2H), 2.76 - 2.71 (m, 1H), 2.46 (s, 3H), 1.15 - 1.07 (m, 4H).
751	1HNMR (500 MHz, DMSO): δ 7.59 (d, 1H), 7.51 (bs, 1H), 7.43 - 7.41 (m, 2H), 7.20 - 7.18 (m, 2H), 6.96 - 6.92 (dd, 1H), 5.12 (s, 1H), 5.04 (t, 1H), 4.52 - 4.48 (m, 2H), 3.81 - 3.72 (m, 2H), 2.77 - 2.73 (m, 1H), 2.41 (s, 3H), 1.14 - 1.09 (m, 4H).

[0507] In all above cases the analytical LCMS and ¹H NMR data collected for **En2** matched the data for **En1**.

[0508] Chiral analytical data

Chiral SFC analysis						
Code	Column Name	co-solvent	co-solvent %	Flow [g/min]	RT [min]	Purity [%]
cpd 103 - En 1	(1)	MeOH	40	4	3.23	99.0
cpd 103 - En 2	(1)	MeOH	40	4	1.32	100.0

cpd 105 - En 1	(2)	0.5%DEA in MeOH	25	3	3.76	99.5
cpd 105 - En 2	(2)	0.5%DEA in MeOH	25	3	2.49	99.1
cpd 106 - En 1	(3)	MeOH	35	3	7.81	99.2
cpd 106 - En 2	(3)	MeOH	35	3	3.75	99.6
cpd 110 - En 1	(4)	MeOH	40	3	2.74	99.9
cpd 110 - En 2	(4)	MeOH	40	3	1.66	99.9
cpd 111 - En 1	(5)	MeOH	40	3	2.85	99.8
cpd 111 - En 2	(5)	MeOH	40	3	1.16	99.9
cpd 112 - En 1	(5)	0.5%DEA in MeOH	40	3	1.35	95.2
cpd 112 - En 2	(5)	0.5%DEA in MeOH	40	3	2.03	99.1
cpd 113 - En 1	(6)	0.5%DEA in EtOH	20	3	4.59	99.9
cpd 113 - En 2	(6)	0.5%DEA in EtOH	20	3	3.34	99.8
cpd 115 - En 1	(6)	0.5%DEA in MeOH	40	3	6.14	99.6
cpd 115 - En 2	(6)	0.5%DEA in MeOH	40	3	3.98	99.7
cpd 116 - En 1	(4)	MeOH	20	3	3.58	99.1
cpd 116 - En 2	(4)	MeOH	20	3	3.07	99.3
cpd 118 - En 1	(7)	MeOH	15	3	3.90	99.9
cpd 118 - En 2	(7)	MeOH	15	3	2.50	99.9
cpd 120 - En 1	(6)	MeOH	40	3	6.10	99.5
cpd 120 - En 2	(6)	MeOH	40	3	4.52	99.9
cpd 121 - En 1	(5)	IPA	20	3	11.20	96.9
cpd 121 - En 2	(5)	IPA	20	3	9.36	99.7
cpd 123 - En 1	(4)	MeOH	30	3	1.61	99.9
cpd 123 - En 2	(4)	MeOH	30	3	2.22	99.7
cpd 124 - En 1	(8)	MeOH	25	3	5.77	99.9
cpd 124 - En 2	(8)	MeOH	25	3	4.48	99.9
cpd 125 - En 1	(6)	0.5%DEA in MeOH	30	3	3.48	99.5
cpd 125 - En 2	(6)	0.5%DEA in MeOH	30	3	2.59	99.6
cpd 126 - En 1	(9)	IPA	30	3	3.57	95.1
cpd 126 - En 2	(9)	IPA	30	3	2.69	98.7
cpd 130 - En 1	(4)	MeOH	30	3	1.85	99.9
cpd 130 - En 2	(4)	MeOH	30	3	1.29	99.9
cpd 131 - En 1	(7)	MeOH	10	3	3.04	99.0
cpd 131 - En 2	(7)	MeOH	10	3	2.43	98.0
cpd 132 - En 1	(1)	MeOH	30	3	4.50	99.3
cpd 132 - En 2	(1)	MeOH	30	3	2.98	99.7
cpd 134 - En 1	(4)	MeOH	25	3	3.20	99.2
cpd 134 - En 2	(4)	MeOH	25	3	1.48	99.5
cpd 135 - En 1	(1)	MeOH	25	3	2.19	99.8
cpd 135 - En 2	(1)	MeOH	25	3	3.33	99.9
cpd 141 - En 1	(6)	MeOH	15	3	4.48	99.8
cpd 141 - En 2	(6)	MeOH	15	3	5.61	99.9

cpd 147 - Dia 1 - En 1	(9)	IPA	25	3	3.24	99.6
cpd 147 - Dia 1 - En 2	(9)	IPA	25	3	6.21	98.3
cpd 148 - En 1	(10)	MeOH	30	3	5.02	99.3
cpd 148 - En 2	(10)	MeOH	30	3	4.22	99.8
cpd 151 - En 1	(3)	MeOH	30	3	6.04	98.5
cpd 151 - En 2	(3)	MeOH	30	3	9.85	97.9
cpd 155 - En 1	(11)	MeOH	10	3	8.77	95.3
cpd 155 - En 2	(11)	MeOH	10	3	9.41	100.0
cpd 157 - En 1	(2)	MeOH	10	3	8.08	99.7
cpd 157 - En 2	(2)	MeOH	10	3	5.55	98.9
cpd 159 - En 1	(1)	MeOH	30	3	3.21	99.9
cpd 159 - En 2	(1)	MeOH	30	3	4.08	99.8
cpd 160 - En 1	(9)	MeOH	40	4	6.91	99.9
cpd 160 - En 2	(9)	MeOH	40	4	9.94	99.6
cpd 162 - Dia 1 - En1	(5)	MeOH	40	3	2.01	99.7
cpd 162 - Dia 1 - En2	(5)	MeOH	40	3	2.53	99.5
cpd 163 - En 1	(3)	MeOH	35	3	5.40	96.0
cpd 163 - En 2	(3)	MeOH	35	3	3.30	98.3
cpd 164 - En 1	(9)	MeOH	40	3	5.39	99.0
cpd 164 - En 2	(9)	MeOH	40	3	8.72	97.6
cpd 165 - En 1	(6)	0.5%DEA in MeOH	30	3	6.35	96.4
cpd 165 - En 2	(6)	0.5%DEA in MeOH	30	3	4.51	97.4
cpd 169 - En 1	(7)	MeOH	20	3	3.68	94.7
cpd 169 - En 2	(7)	MeOH	20	3	3.10	99.6
cpd 172 - En 1	(11)	MeOH	10	3	13.12	97.6
cpd 172 - En 2	(11)	MeOH	10	3	16.13	99.9
cpd 176 - En 1	(6)	0.5%DEA in EtOH	20	3	2.69	99.6
cpd 176 - En 2	(6)	0.5%DEA in EtOH	20	3	3.87	99.5
cpd 179 - En 1	(6)	0.5%DEA in EtOH	30	3	5.15	98.8
cpd 179 - En 2	(6)	0.5%DEA in EtOH	30	3	3.42	99.3
cpd 180 - En 1	(12)	MeOH	40	3	4.23	99.0
cpd 180 - En 2	(12)	MeOH	40	3	6.03	97.7
cpd 183 - En 1	(6)	0.5%DEA in EtOH	20	3	6.70	99.3
cpd 183 - En 2	(6)	0.5%DEA in EtOH	20	3	3.73	97.1
cpd 184 - En 1	(6)	0.5%DEA in MeOH	30	3	5.84	96.7
cpd 184 - En 2	(6)	0.5%DEA in MeOH	30	3	3.89	99.9
cpd 191 - En 1	(4)	MeOH	40	3	2.24	99.8
cpd 191 - En 2	(4)	MeOH	40	3	0.83	99.9
cpd 195 - En 1	(6)	0.5%DEA in MeOH	30	3	1.79	99.6
cpd 195 - En 2	(6)	0.5%DEA in MeOH	30	3	1.54	99.8
cpd 196 - En 1	(9)	0.5%DEA in MeOH	40	3	1.81	95.6

cpd 196 - En 2	(9)	0.5%DEA in MeOH	40	3	1.47	99.9
cpd 198 - En 1	(4)	0.5%DEA in MeOH	40	3	2.58	99.7
cpd 198 - En 2	(4)	0.5%DEA in MeOH	40	3	2.00	99.9
cpd 199 - En 1	(5)	MeOH	20	3	2.27	99.9
cpd 199 - En 2	(5)	MeOH	20	3	1.80	99.4
cpd 205 - En 1	(7)	MeOH	20	3	3.59	99.7
cpd 205 - En 2	(7)	MeOH	20	3	2.17	99.7
cpd 207 - En 1	(5)	0.5%DEA in MeOH	30	3	2.55	97.2
cpd 207 - En 2	(5)	0.5%DEA in MeOH	30	3	1.92	98.1
Cpd 270 - En 1	(8)	30mM Ammonia in MeOH	25	3	10.80	91.0
Cpd 270 - En 2	(8)	30mM Ammonia in MeOH	25	3	7.55	99.5
Cpd 313 - En 1	(6)	0.5%DEA in MeOH	30	3	7.02	99.3
Cpd 313 - En 2	(6)	0.5%DEA in MeOH	30	3	3.69	99.2
Cpd 315 - En 1	(9)	IPA	40	3	4.60	99.6
Cpd 315 - En 2	(9)	IPA	40	3	3.62	99.9
Cpd 316 - En 1	(6)	MeOH	40	3	1.22	97.6
Cpd 316 - En 2	(6)	MeOH	40	3	1.48	95.6
Cpd 317 - En 1	(13)	MeOH	40	3	5.18	99.8
Cpd 317 - En 2	(13)	MeOH	40	3	3.11	99.9
Cpd 326 - En 1	(3)	MeOH	40	3	7.76	100.0
Cpd 326 - En 2	(3)	MeOH	40	3	9.84	99.6
Cpd 332 - En 1	(5)	MeOH	30	3	2.82	100.0
Cpd 332 - En 2	(5)	MeOH	30	3	3.66	99.6
Cpd 333 - En 1	(11)	MeOH	40	3	2.32	100.0
Cpd 333 - En 2	(11)	MeOH	40	3	3.30	98.2
Cpd 336 - En 1	(1)	MeOH	40	3	2.88	99.4
Cpd 336 - En 2	(1)	MeOH	40	3	4.59	98.7
Cpd 342 - En 1	(6)	MeOH	40	3	5.69	99.8
Cpd 342 - En 2	(6)	MeOH	40	3	2.70	99.9
Cpd 348 - En 1	(9)	MeOH	40	3	5.84	96.7
Cpd 348 - En 2	(9)	MeOH	40	3	3.57	99.2
Cpd 349 - En 1	(9)	MeOH	40	3	3.63	96.9
Cpd 349 - En 2	(9)	MeOH	40	3	2.99	99.2
Cpd 350 - En 1	(9)	MeOH	40	3	4.43	97.6
Cpd 350 - En 2	(9)	MeOH	40	3	3.44	99.2
Cpd 355 - En 1	(5)	MeOH	30	3	3.58	99.8
Cpd 355 - En 2	(5)	MeOH	30	3	4.65	99.0
Cpd 356 - En 1	(11)	MeOH	40	3	3.30	99.9
Cpd 356 - En 2	(11)	MeOH	40	3	4.70	96.8
Cpd 360 - En 1	(11)	MeOH	40	4	12.59	99.2
Cpd 360 - En 2	(11)	MeOH	40	4	9.56	100.0
Cpd 365 - En 1	(4)	MeOH	40	3	3.18	99.9

Cpd 365 - En 2	(4)	MeOH	40	3	4.57	99.8
Cpd 386 - En 1	(4)	0.5%DEA in MeOH	40	3	4.48	99.9
Cpd 386 - En 2	(4)	0.5%DEA in MeOH	40	3	7.10	99.9
Cpd 387 - En 1	(3)	MeOH	50	4	4.32	99.2
Cpd 387 - En 2	(3)	MeOH	50	4	9.59	99.7
Cpd 388 - En 1	(1)	MeOH	40	3	2.04	100.0
Cpd 388 - En 2	(1)	MeOH	40	3	2.86	99.9
Cpd 389 - En 1	(3)	MeOH	40	4	6.07	99.6
Cpd 389 - En 2	(3)	MeOH	40	4	9.29	99.8
Cpd 395 - Dia 1	(4)	IPA	20	3	5.94	96.5
Cpd 395 - Dia 2	(4)	IPA	20	3	4.25	99.5
Cpd 396 - En 1	(1)	0.5%DEA in MeOH	40	3	1.86	92.2
Cpd 396 - En 2	(3)	MeOH	40	3	5.59	96.3
Cpd 397 - En 1	(1)	0.5%DEA in MeOH	40	3	2.79	97.4
Cpd 397 - En 2	(4)	0.5%DEA in MeOH	30	3	3.77	97.6
Cpd 401 - En 1	(13)	0.5%DEA in MeOH	40	3	2.90	99.9
Cpd 401 - En 2	(13)	0.5%DEA in MeOH	40	3	2.19	99.7
Cpd 402 - En 1	(2)	MeOH	25	3	5.92	99.8
Cpd 403 - En 1	(9)	0.5%DEA in MeOH	40	3	7.35	100.0
Cpd 403 - En 2	(9)	0.5%DEA in MeOH	40	3	5.07	100.0
Cpd 404 - En 1	(9)	MeOH	35	3	12.13	96.1
Cpd 404 - En 2	(9)	MeOH	35	3	9.74	99.8
Cpd 406 - En 1	(4)	EtOH	40	3	5.69	99.7
Cpd 406 - En 2	(4)	EtOH	40	3	7.65	99.1
Cpd 407 - En 1	(3)	MeOH	40	4	7.98	99.8
Cpd 407 - En 2	(3)	MeOH	40	4	13.25	99.6
Cpd 408 - En 1	(3)	MeOH	50	4	11.11	99.1
Cpd 408 - En 2	(3)	MeOH	50	4	6.04	99.9
Cpd 409 - En 1	(9)	MeOH	40	3	6.82	99.9
Cpd 409 - En 2	(9)	MeOH	40	3	4.46	100.0
Cpd 410 - En 1	(4)	MeOH	40	3	3.93	99.9
Cpd 410 - En 2	(4)	MeOH	40	3	1.65	99.7
Cpd 411 - En 1	(4)	MeOH	40	3	6.88	96.5
Cpd 411 - En 2	(4)	MeOH	40	3	2.97	98.2
Cpd 412 - En 1	(4)	IPA	25	3	3.30	98.8
Cpd 412 - En 2	(4)	IPA	25	3	2.48	99.3
Cpd 413 - En 1	(6)	0.5%DEA in MeOH	40	3	2.56	99.5
Cpd 413 - En 2	(6)	0.5%DEA in MeOH	40	3	3.51	95.1
Cpd 432 - En 1	(7)	MeOH	40	3	1.86	99.1
Cpd 432 - En 2	(7)	MeOH	40	3	3.67	99.9
Cpd 433 - En 1	(1)	MeOH	30	3	5.13	99.9
Cpd 433 - En 2	(1)	MeOH	30	3	2.46	99.4
Cpd 434 - En 1	(8)	MeOH	40	3	7.31	100.0

Cpd 434 - En 2	(8)	MeOH	40	3	2.97	100.0
Cpd 435 - En 1	(9)	0.5%DEA in MeOH	40	3	3.14	99.9
Cpd 435 - En 2	(9)	0.5%DEA in MeOH	40	3	6.33	99.9
Cpd 436 - En 1	(9)	MeOH	40	3	10.57	99.9
Cpd 436 - En 2	(9)	MeOH	40	3	5.48	99.9
Cpd 437 - En 1	(5)	0.5%DEA in MeOH	40	3	1.84	99.7
Cpd 437 - En 2	(5)	0.5%DEA in MeOH	40	3	5.23	99.8
Cpd 445 - En 1	(9)	0.5%DEA in MeOH	40	3	5.65	98.7
Cpd 445 - En 2	(9)	0.5%DEA in MeOH	40	3	9.32	98.2
Cpd 446 - En 1	(4)	MeOH	40	3	3.08	99.3
Cpd 446 - En 2	(4)	MeOH	40	3	2.08	99.7
Cpd 447 - En 1	(4)	MeOH	35	3	6.58	99.9
Cpd 447 - En 2	(4)	MeOH	35	3	2.35	99.7
Cpd 448 - En 1	(9)	MeOH	30	3	3.26	98.9
Cpd 448 - En 2	(9)	MeOH	30	3	4.80	99.1
Cpd 449 - En 1	(9)	0.5%DEA in MeOH	40	3	4.71	99.9
Cpd 449 - En 2	(9)	0.5%DEA in MeOH	40	3	8.69	99.5
Cpd 450 - En 1	(5)	0.5%DEA in MeOH	30	3	4.32	99.9
Cpd 450 - En 2	(5)	0.5%DEA in MeOH	30	3	6.95	99.6
Cpd 451 - En 1	(9)	0.5%DEA in MeOH	40	3	3.49	99.9
Cpd 451 - En 2	(9)	0.5%DEA in MeOH	40	3	5.14	99.9
Cpd 452 - En 1	(4)	MeOH	40	3	4.12	97.3
Cpd 452 - En 2	(4)	MeOH	40	3	3.42	99.2
Cpd 455 - En 1	(9)	MeOH	40	3	3.10	99.9
Cpd 455 - En 2	(9)	MeOH	40	3	4.74	99.8
Cpd 456 - En 1	(4)	MeOH	35	3	3.92	99.5
Cpd 456 - En 2	(4)	MeOH	35	3	2.54	99.9
Cpd 457 - En 1	(5)	MeOH	40	3	2.05	99.9
Cpd 457 - En 2	(5)	MeOH	40	3	3.79	99.0
Cpd 458 - En 1	(9)	MeOH	40	3	2.84	99.5
Cpd 458 - En 2	(9)	MeOH	40	3	4.36	97.3
Cpd 459 - En 1	(9)	0.5%DEA in MeOH	40	4	9.06	98.8
Cpd 459 - En 2	(9)	0.5%DEA in MeOH	40	4	6.34	94.1
Cpd 460 - En 1	(4)	MeOH	35	3	4.26	100.0
Cpd 460 - En 2	(4)	MeOH	35	3	2.18	100.0
Cpd 461 - En 1	(4)	MeOH	40	3	2.58	99.8
Cpd 461 - En 2	(4)	MeOH	40	3	4.69	98.4
Cpd 462 - En 1	(1)	0.5%IPAmine in IPA	40	3	1.71	99.9
Cpd 462 - En 2	(1)	0.5%IPAmine in IPA	40	3	2.23	98.8
Cpd 463 - En 1	(14)	EtOH	30	3	5.45	99.4
Cpd 463 - En 2	(14)	EtOH	30	3	4.01	96.6
Cpd 464 - En 1	(4)	MeOH	30	3	6.03	99.1
Cpd 464 - En 2	(4)	MeOH	30	3	5.62	95.4

Cpd 465 - En 1	(4)	MeOH	30	3	2.84	99.5
Cpd 465 - En 2	(4)	MeOH	30	3	4.27	99.2
Cpd 466 - En 1	(15)	0.5%IPAmine in IPA	30	3	3.47	98.9
Cpd 466 - En 2	(15)	0.5%IPAmine in IPA	30	3	2.58	99.1
Cpd 467 - En 1	(3)	MeOH	40	4	3.40	99.9
Cpd 467 - En 2	(3)	MeOH	40	4	5.24	99.7
Cpd 468 - En 1	(8)	MeOH	40	4	13.80	99.8
Cpd 468 - En 2	(8)	MeOH	40	4	17.00	97.3
Cpd 469 - En 1	(4)	MeOH	40	3	3.03	99.7
Cpd 469 - En 2	(4)	MeOH	40	3	2.04	97.5
Cpd 487 - En 1	(6)	MeOH	40	3	7.18	99.9
Cpd 487 - En 2	(6)	MeOH	40	3	12.10	99.6
Cpd 488 - En 1	(4)	MeOH	20	3	5.99	99.9
Cpd 488 - En 2	(4)	MeOH	20	3	8.52	97.9
Cpd 489 - En 1	(6)	MeOH	30	3	1.82	99.3
Cpd 489 - En 2	(6)	MeOH	30	3	2.58	100.0
Cpd 491 - En 1	(4)	IPA	30	3	1.66	99.5
Cpd 491 - En 2	(4)	IPA	30	3	2.73	99.7
Cpd 510 - En 1	(3)	EtOH	40	4	6.45	100.0
Cpd 510 - En 2	(3)	EtOH	40	4	13.34	99.9
Cpd 511 - En 1	(5)	MeOH	35	3	3.15	99.9
Cpd 511 - En 2	(5)	MeOH	35	3	4.04	99.8
Cpd 512 - En 1	(5)	MeOH	30	3	7.00	99.9
Cpd 512 - En 2	(5)	MeOH	30	3	9.01	99.8
Cpd 513 - En 1	(13)	MeOH	30	3	2.86	99.8
Cpd 513 - En 2	(13)	MeOH	30	3	3.54	99.3
Cpd 514 - En 1	(13)	MeOH	35	3	5.70	99.7
Cpd 514 - En 2	(13)	MeOH	35	3	7.10	99.3
Cpd 515 - En 1	(11)	MeOH	35	3	6.52	99.8
Cpd 515 - En 2	(11)	MeOH	35	3	10.07	97.9
Cpd 516 - En 1	(13)	0.5%DEA in MeOH	35	3	2.25	99.8
Cpd 516 - En 2	(13)	0.5%DEA in MeOH	35	3	2.62	98.3
Cpd 517 - En 1	(3)	MeOH	50	4	18.69	99.9
Cpd 518 - En 1	(11)	MeOH	50	4	5.46	99.9
Cpd 518 - En 2	(11)	MeOH	50	4	8.69	97.9
Cpd 519 - En 1	(11)	MeOH	40	3	8.75	99.1
Cpd 519 - En 2	(11)	MeOH	40	3	14.26	97.8
Cpd 520 - En 1	(11)	MeOH	50	4	6.38	99.1
Cpd 520 - En 2	(11)	MeOH	50	4	10.10	95.3
Cpd 521 - En 1	(9)	0.5%DEA in MeOH	40	3	5.78	97.7
Cpd 521 - En 2	(9)	0.5%DEA in MeOH	40	3	6.56	96.7
Cpd 522 - En 1	(13)	MeOH	30	3	2.53	99.7
Cpd 522 - En 2	(13)	MeOH	30	3	3.00	98.3

Cpd 530 - En 1	(4)	0.5%DEA in MeOH	40	3	1.36	99.7
Cpd 530 - En 2	(4)	0.5%DEA in MeOH	40	3	3.41	99.4
Cpd 531 - En 1	(2)	MeOH	35	3	2.28	99.9
Cpd 531 - En 2	(2)	MeOH	35	3	3.15	99.9
Cpd 532 - En 1	(2)	MeOH	25	3	4.46	99.7
Cpd 532 - En 2	(2)	MeOH	25	3	6.30	97.1
Cpd 533 - En 1	(16)	MeOH	35	3	4.06	99.7
Cpd 533 - En 2	(16)	MeOH	35	3	5.13	99.5
Cpd 534 - En 1	(4)	MeOH	40	3	4.12	99.9
Cpd 534 - En 2	(4)	MeOH	40	3	2.95	99.5
Cpd 535 - En 1	(16)	0.5%DEA in MeOH	40	4	4.12	97.2
Cpd 535 - En 2	(16)	0.5%DEA in MeOH	40	4	3.49	98.8
Cpd 536 - En 1	(1)	MeOH	30	3	2.43	99.3
Cpd 536 - En 2	(1)	MeOH	30	3	3.49	99.9
Cpd 538 - En 1	(5)	MeOH	30	3	1.68	99.5
Cpd 539 - En 1	(5)	0.5%DEA in MeOH	20	3	1.45	99.8
Cpd 539 - En 2	(5)	0.5%DEA in MeOH	20	3	2.08	99.8
Cpd 540 - En 1	(6)	0.5%DEA in EtOH	40	3	8.33	97.2
Cpd 540 - En 2	(6)	0.5%DEA in EtOH	40	3	7.01	98.9
Cpd 541 - En 1	(6)	0.5%DEA in EtOH	40	3	5.65	99.1
Cpd 541 - En 2	(6)	0.5%DEA in EtOH	40	3	4.02	98.6
Cpd 542 - En 1	(8)	0.5%DEA in MeOH	40	4	9.68	98.4
Cpd 542 - En 2	(8)	0.5%DEA in MeOH	40	4	12.98	97.0
Cpd 543 - En 1	(4)	EtOH	40	3	4.58	99.2
Cpd 543 - En 2	(4)	EtOH	40	3	2.34	98.8
Cpd 544 - En 1	(7)	0.5%DEA in MeOH	30	3	1.72	99.4
Cpd 544 - En 2	(7)	0.5%DEA in MeOH	30	3	2.43	98.7
Cpd 545 - En 1	(4)	0.5%DEA in MeOH	40	3	2.65	97.7
Cpd 545 - En 2	(4)	0.5%DEA in MeOH	40	3	3.57	95.0
Cpd 547 - En 1	(4)	EtOH	40	3	7.20	99.8
Cpd 547 - En 2	(4)	EtOH	40	3	2.19	99.4
Cpd 548 - En 1	(5)	MeOH	40	3	1.59	99.9
Cpd 548 - En 2	(5)	MeOH	40	3	2.44	99.0
Cpd 549 - En 1	(7)	MeOH	30	3	1.46	99.9
Cpd 549 - En 2	(7)	MeOH	30	3	2.18	99.7
Cpd 550 - En 1	(4)	0.5%DEA in MeOH	25	3	4.63	95.6
Cpd 550 - En 2	(4)	0.5%DEA in MeOH	25	3	3.28	99.5
Cpd 551 - En 1	(2)	MeOH	25	3	2.69	99.2
Cpd 551 - En 2	(2)	MeOH	25	3	4.40	98.4
Cpd 552 - En 1	(5)	MeOH	30	3	2.27	99.5
Cpd 552 - En 2	(5)	MeOH	30	3	2.96	99.6
Cpd 553 - En 1	(7)	MeOH	25	3	1.40	98.9
Cpd 553 - En 2	(7)	MeOH	25	3	2.03	98.1

Cpd 554 - En 1	(5)	MeOH	30	3	2.51	99.0
Cpd 554 - En 2	(5)	MeOH	30	3	3.10	99.8
Cpd 555 - En 1	(7)	IPA	40	3	1.13	99.9
Cpd 555 - En 2	(7)	IPA	40	3	1.92	99.4
Cpd 556 - En 1	(5)	0.5%DEA in MeOH	30	3	3.91	97.8
Cpd 556 - En 2	(5)	0.5%DEA in MeOH	30	3	4.83	98.8
Cpd 557 - En 1	(17)	MeOH	40	4	6.63	99.2
Cpd 557 - En 2	(17)	MeOH	40	4	9.10	98.3
Cpd 558 - En 1	(16)	MeOH	30	3	6.15	98.8
Cpd 558 - En 2	(16)	MeOH	30	3	7.89	99.4
Cpd 559 - En 1	(4)	0.5%DEA in MeOH	40	3	4.26	97.3
Cpd 559 - En 2	(4)	0.5%DEA in MeOH	40	3	2.54	97.7
Cpd 561 - En 1	(7)	MeOH	40	3	1.23	98.8
Cpd 561 - En 2	(7)	MeOH	40	3	1.63	99.6
Cpd 562 - En 1	(5)	MeOH	40	3	2.14	99.6
Cpd 562 - En 2	(5)	MeOH	40	3	3.30	97.1
Cpd 563 - En 1	(8)	MeOH	40	4	11.84	99.6
Cpd 563 - En 2	(8)	MeOH	40	4	5.84	99.9
Cpd 564 - En 1	(2)	MeOH	25	3	4.83	99.3
Cpd 564 - En 2	(2)	MeOH	25	3	8.28	97.3
Cpd 566 - En 1	(2)	MeOH	30	3	2.60	99.4
Cpd 566 - En 2	(2)	MeOH	30	3	3.85	97.0
Cpd 567 - En 1	(5)	0.5%DEA in MeOH	30	3	4.17	99.0
Cpd 567 - En 2	(5)	0.5%DEA in MeOH	30	3	5.60	96.2
Cpd 568 - En 1	(6)	0.5%DEA in MeOH	40	3	6.17	99.9
Cpd 568 - En 2	(6)	0.5%DEA in MeOH	40	3	11.11	99.8
Cpd 569 - En 1	(3)	0.5%DEA in MeOH	40	4	11.89	97.8
Cpd 569 - En 2	(3)	0.5%DEA in MeOH	40	4	7.67	96.2
Cpd 570 - En 1	(6)	0.5%DEA in EtOH	30	3	4.64	96.6
Cpd 570 - En 2	(6)	0.5%DEA in EtOH	30	3	3.96	97.2
Cpd 571 - En 1	(4)	0.5%DEA in MeOH	40	3	7.15	99.8
Cpd 571 - En 2	(4)	0.5%DEA in MeOH	40	3	3.90	99.2
Cpd 572 - En 1	(6)	MeOH	40	3	4.63	99.4
Cpd 572 - En 2	(6)	MeOH	40	3	2.94	100.0
Cpd 573 - En 1	(6)	0.5%DEA in MeOH	40	3	3.87	93.9
Cpd 573 - En 2	(6)	0.5%DEA in MeOH	40	3	2.76	97.1
Cpd 575 - En 1	(13)	0.5%DEA in MeOH	20	3	6.59	99.5
Cpd 575 - En 2	(13)	0.5%DEA in MeOH	20	3	7.57	99.6
Cpd 590 - En 1	(4)	IPA	35	3	4.05	96.6
Cpd 590 - En 2	(4)	IPA	35	3	2.96	99.4
Cpd 591 - En 1	(17)	MeOH	40	3	4.20	99.9
Cpd 591 - En 2	(17)	MeOH	40	3	6.10	99.6
Cpd 592 - En 1	(3)	MeOH	50	4	9.41	98.7

Cpd 592 - En 2	(3)	MeOH	50	4	4.05	99.2
Cpd 593 - En 1	(3)	MeOH	30	3	13.39	99.6
Cpd 593 - En 2	(3)	MeOH	30	3	10.89	99.9
Cpd 594 - En 1	(4)	MeOH	40	3	12.23	99.8
Cpd 594 - En 2	(4)	MeOH	40	3	5.43	99.4
Cpd 595 - En 1	(4)	MeOH	40	3	4.72	100.0
Cpd 595 - En 2	(4)	MeOH	40	3	7.39	99.8
Cpd 597 - En 1	(17)	MeOH	40	4	8.05	99.8
Cpd 597 - En 2	(17)	MeOH	40	4	4.95	99.9
Cpd 598 - En 1	(3)	MeOH	30	3	7.79	99.7
Cpd 598 - En 2	(3)	MeOH	30	3	10.31	98.2
Cpd 600 - En 1	(4)	MeOH	40	3	4.15	96.5
Cpd 600 - En 2	(4)	MeOH	40	3	2.49	98.8
Cpd 601 - En 1	(9)	MeOH	40	3	3.22	99.7
Cpd 601 - En 2	(9)	MeOH	40	3	4.69	99.3
Cpd 623 - En 1	(12)	MeOH	20	3	5.96	99.7
Cpd 623 - En 2	(12)	MeOH	20	3	9.51	99.2
Cpd 635 - En 1	(5)	0.5%DEA in MeOH	20	3	3.51	98.9
Cpd 635 - En 2	(5)	0.5%DEA in MeOH	20	3	2.24	99.0
Cpd 636 - En 1	(10)	MeOH	40	4	2.78	98.4
Cpd 636 - En 2	(10)	MeOH	40	4	4.44	97.7
Cpd 637 - En 1	(1)	MeOH	40	3	2.71	98.8
Cpd 637 - En 2	(1)	MeOH	40	3	3.93	99.9
Cpd 638 - En 1	(9)	0.5%DEA in MeOH	40	3	2.17	99.9
Cpd 638 - En 2	(9)	0.5%DEA in MeOH	40	3	1.70	99.8
Cpd 639 - En 1	(6)	0.5%DEA in MeOH	40	3	4.09	97.8
Cpd 639 - En 2	(6)	0.5%DEA in MeOH	40	3	2.82	99.7
Cpd 640 - En 1	(4)	MeOH	40	3	8.41	98.4
Cpd 640 - En 2	(4)	MeOH	40	3	3.13	99.4
Cpd 641 - En 1	(4)	EtOH	40	3	2.13	99.3
Cpd 641 - En 2	(4)	EtOH	40	3	3.53	99.4
Cpd 642 - En 1	(9)	MeOH	15	3	3.43	99.9
Cpd 642 - En 2	(9)	MeOH	15	3	4.41	98.9
Cpd 643 - En 1	(9)	MeOH	30	3	3.59	99.9
Cpd 643 - En 2	(9)	MeOH	30	3	2.52	100.0
Cpd 646 - En 1	(8)	MeOH	45	3	5.57	99.9
Cpd 646 - En 2	(8)	MeOH	45	3	7.23	99.4
Cpd 647 - En 1	(6)	MeOH	40	3	3.26	99.4
Cpd 647 - En 2	(6)	MeOH	40	3	4.85	100.0
Cpd 648 - En 1	(6)	EtOH	40	3	2.04	98.6
Cpd 648 - En 2	(6)	EtOH	40	3	3.16	97.1
Cpd 653 - En 1	(9)	MeOH	4	3	3.26	99.1
Cpd 653 - En 2	(9)	MeOH	4	3	2.60	99.3

Cpd 654 - En 1	(9)	MeOH	4	3	3.00	99.4
Cpd 654 - En 2	(9)	MeOH	4	3	2.47	99.4
Cpd 655 - En 1	(6)	MeOH	40	3	4.72	98.4
Cpd 655 - En 2	(6)	MeOH	40	3	7.67	97.1
Cpd 656 - En 1	(9)	MeOH	35	3	3.11	99.6
Cpd 656 - En 2	(9)	MeOH	35	3	2.48	99.9
Cpd 657 - En 1	(9)	MeOH	25	3	15.35	99.3
Cpd 657 - En 2	(9)	MeOH	25	3	11.72	99.1
Cpd 661 - En 1	(3)	MeOH	40	4	9.70	98.6
Cpd 661 - En 2	(3)	MeOH	40	4	6.77	99.7
Cpd 719 - En 1	(15)	MeOH	40	3	4.31	99.91
Cpd 719 - En 2	(15)	MeOH	40	3	5.49	99.79
Cpd 720 - En 1	(3)	0.5%DEA in EtOH	40	3	2.19	98.40
Cpd 720 - En 2	(3)	0.5%DEA in EtOH	40	3	2.70	96.48
Cpd 723 - En 1	(7)	MeOH	20	3	1.94	99.52
Cpd 723 - En 2	(7)	MeOH	20	3	3.21	98.87
Cpd 724 - En 1	(7)	MeOH	15	3	2.51	99.76
Cpd 724 - En 2	(7)	MeOH	15	3	5.19	99.54
Cpd 725 - En 1	(4)	MeOH	40	3	2.33	99.90
Cpd 725 - En 2	(4)	MeOH	40	3	3.78	99.18
Cpd 726 - En 1	(3)	MeOH	50	4	7.04	99.74
Cpd 726 - En 2	(3)	MeOH	50	4	13.63	99.03
Cpd 727 - En 1	(9)	0.5%DEA in MeOH	40	3	7.45	99.88
Cpd 727 - En 2	(9)	0.5%DEA in MeOH	40	3	9.55	99.41
Cpd 727 - En 3	(9)	MeOH	40	3	7.24	99.95
Cpd 727 - En 4	(9)	MeOH	40	3	8.81	98.96
Cpd 728 - En 1	(6)	0.5%DEA in MeOH	40	3	2.68	98.62
Cpd 728 - En 2	(6)	0.5%DEA in MeOH	40	3	4.26	91.00
Cpd 730 - En 1	(4)	MeOH	35	3	2.38	99.98
Cpd 730 - En 2	(4)	MeOH	35	3	4.47	99.89
Cpd 731 - En 1	(4)	MeOH	35	3	2.91	99.73
Cpd 731 - En 2	(4)	MeOH	35	3	7.73	99.87
Cpd 732 - En 1	(11)	MeOH	40	3	6.38	99.59
Cpd 732 - En 2	(11)	MeOH	40	3	11.44	99.00
Cpd 733 - En 1	(11)	MeOH	35	3	6.49	99.96
Cpd 733 - En 2	(11)	MeOH	35	3	9.83	96.78
Cpd 734 - En 1	(4)	0.5%IPAmine in IPA	40	3	1.80	99.73
Cpd 734 - En 2	(4)	0.5%IPAmine in IPA	40	3	3.15	99.10
Cpd 735 - En 1	(11)	MeOH	40	3	5.11	99.88
Cpd 735 - En 2	(11)	MeOH	40	3	7.47	96.72
Cpd 736 - En 1	(11)	MeOH	40	3	3.76	99.15
Cpd 736 - En 2	(11)	MeOH	40	3	5.26	97.35
Cpd 737 - En 1	(5)	MeOH	30	3	4.52	95.25

Cpd 737 – En 2	(5)	MeOH	30	3	6.07	95.40
Cpd 738 – En 1	(4)	EtOH	40	3	4.42	98.28
Cpd 738 – En 2	(4)	EtOH	40	3	6.48	97.26
Cpd 739 – En 1	(4)	MeOH	40	3	4.49	98.44
Cpd 739 – En 2	(4)	MeOH	40	3	5.55	94.15
Cpd 740 – En 1	(11)	MeOH	35	3	2.83	99.41
Cpd 740 – En 2	(11)	MeOH	35	3	3.47	96.41

- CHIRALCEL OZ-3 (4.6*150mm)3 μ m = (1); CHIRACEL OD-H (250mm x 4.6), 5 μ m = (2); CHIRALPAK AD-H(4.6x250mm),5 μ m = (3); CHIRALPAK AD-3 (4.6*150mm)3 μ m = (4); CHIRALCEL OX-3 (4.6*150mm)3 μ m = (5); Chiralpak IG-3 (4.6x150mm),3 μ m = (6); CHIRALCEL OD-3(4.6*150mm)3 μ m = (7); CHIRALPAK IG-3(4.6*250mm)5 μ m = (8); CHIRALPAK IC-3 (4.6*150mm)3 μ m = (9); Lux Cellulose-2 (4.6x250)mm, 5 μ m = (10);
- 5 CHIRALPAK IE-3(4.6*150mm)3 μ m = (11); Lux-Amylose-2 (4.6x250)mm, 5 μ m = (12); (R,R) WHELK-01(4.6*150mm)3.5 μ m = (13); CHIRLPAK AD-H(4.6*150mm)3 μ m = (14); Lux Cellulose-2 (4.6x150mm)3 μ m = (15); CHIRALCEL OX-H(4.6*250)mm, 5 μ m = (16); CHIRALPAK IF-3 (4.6*150 mm), 3 μ m = (17)

Chiral HPLC analysis						
Cpd	Column Name	Phase A/B	Ratio A/B	Flow [mL/min]	RT [min]	Purity [%]
Cpd 729 - En 1	CHIRALCEL ODH(250x4.6mm):5 μ	n-Hex / EtOH	3 / 7	1	5.44	96.50
Cpd 729 - En 2	CHIRALCEL ODH(250x4.6mm):5 μ	n-Hex / EtOH	3 / 7	1	9.58	99.89

[0509] Part B

10 Monitoring the TRPM3 ion channel driven Ca²⁺ uptake.

[0510] In order to monitor the inhibition of the mouse TRPM3 α 2 (mTRPM3) ion channel by the compounds of the invention, a cellular system making use of an mTRPM3 α 2 or hTRPM3 overexpressing cell line (flip-in HEK293) was used. The TRPM3 channel was stimulated/opened with Pregnenolone sulfate (PS) (50 μ M) which results in Ca²⁺ influx.

- 15 [0511] For mTRPM3, the intracellular Ca²⁺ was measured with a Calcium responsive dye, Fluor-4 AM ester (Invitrogen). Cells were cultured until a confluence of 80-90%, washed with Versene (Invitrogen) and detached from the surface by a short incubation with 0.05% Trypsin (Invitrogen). The trypsination process was stopped by the addition of complete cell culture medium (DMEM, glutamax, 10%FCS, NEAA, Pen-Strep). Cells were collected and resuspended in Krebs buffer without Calcium at RT.

- 20 [0512] Prior the cell seeding ($\pm$ 2000 cells/well into a black, 384 well plate (Greiner)) the diluted compound was added in the assay plate, together with the PS dissolved in Krebs buffer containing Calcium. This resulted in a 2.4mM Ca²⁺ assay solution. Directly after cell addition the plates were read on an Envision fluorescence reader (Perkin Elmer) by an Excitation of 485nm and emission at 535nm.

- 25 [0513] Channel inhibition was calculated compared to a non-PS stimulated control versus a condition stimulated with PS (50 μ M) with vehicle. The ability of the compounds of the invention to inhibit this activity was determined as: Percentage inhibition = $[1 - ((\text{RFU determined for sample with test compound present} - \text{RFU determined for sample with positive control inhibitor}) / (\text{RFU determined in the presence of vehicle} - \text{RFU determined for sample with positive control inhibitor}))] * 100$.

- [0514] The activities of the Example compounds **cpd 001-199** tested are depicted in the table below. The activity
- 30 ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: "A": IC₅₀ <1 μ M; "B": 1 μ M $\leq$ IC₅₀

≤20 μM and “C” : IC₅₀ > 20 μM.

cpd	IC ₅₀
001	B
002	C
003	C
004	C
005	B
006	B
007	B
008	C
009	B
010	B
011	B
012	B
013	B
014	B
015	C
016	C
017	C
018	B
019	C
020	B
021	B
022	A
023	B
024	A
025	A
026	A
027	A
028	A
029	A
030	A
031	B
032	B
033	C
034	B

035	A
036	A
037	B
038	A
039	B
040	C
041	A
042	A
043	A
044	B
045	B
046	A
047	A
048	A
049	A
050	A
051	A
052	B
053	B
054	A
055	C
056	A
057	C
058	A
059	B
060	B
061	C
062	A
063	A
064	A
065	B
066	B
067	A
068	A
069	B

070	A
071	A
072	A
073	B
074	A
075	C
076	B
077	C
078	B
079	B
080	B
081	B
082	B
083	B
084	B
085	B
086	B
087	B
088	B
089	B
090	B
091	B
092	B
093	B
094	B
095	B
096	B
097	B
098	B
099	B
100	B
101	B
102	B
103 - En 1	A
103 - En 2	A

104	A
105 - En 1	A
105 - En 2	A
106 - En 1	A
106 - En 2	A
107	A
108	A
109	A
110 - En 1	A
110 - En 2	A
111 - En 1	A
111 - En 2	A
112 - En 1	A
112 - En 2	A
114	A
115 - En 1	A
115 - En 2	A
116 - En 1	A
116 - En 2	A
117	A
118 - En 1	A
118 - En 2	A
119	A
120 - En 1	A
120 - En 2	A
121 - En 1	A
121 - En 2	A
122	B
123 - En 1	A
123 - En 2	A
124 - En 1	A
124 - En 2	A
125 - En 1	A
125 - En 2	A
126 - En 1	A

126 - En 2	A
127	A
128	A
129	A
130 - En 1	A
130 - En 2	A
131 - En 1	A
131 - En 2	A
132 - En 1	A
132 - En 2	A
133	A
134 - En 1	B
134 - En 2	A
135 - En 1	A
135 - En 2	A
136	A
137	A
138	A
139	A
140	A
141 - En 1	A
141 - En 2	A
142	A
143	A
144	A
145	A
146	A

147 - Dia 1 - En 1	A
147 - Dia 1 - En 2	A
148 - En 1	A
148 - En 2	A
149 - En 1	A
149 - En 2	A
150	A
151 - En 1	A
151 - En 2	A
152	A
153	A
154	A
155 - En 1	A
155 - En 2	A
156	A
157 - En 1	A
157 - En 2	A
158	A
159 - En 1	A
159 - En 2	A
160 - En 1	A
160 - En 2	A
161	A
cpd 162 - Dia 1 - En2	A

cpd 162 - Dia 1 - En1	A
163 - En 1	A
163 - En 2	A
164 - En 1	A
164 - En 2	A
165 - En 1	A
165 - En 2	B
166	A
167	A
168	A
169 - En 1	A
169 - En 2	A
170	A
171	A
172 - En 1	A
172 - En 2	A
173	A
174	A
175	A
176 - En 1	B
176 - En 2	A
177	A
178	B
179 - En 1	B
179 - En 2	C
180 - En 1	B
180 - En 2	B

181	B
182	A
183 - En 1	B
183 - En 2	C
184 - En 1	B
184 - En 2	C
185	B
186	B
187	B
188	B
189	B
190	B
191 - En 1	C
191 - En 2	C
192	C
193	C
194	C
195 - En 1	C
195 - En 2	C
196 - En 1	C
196 - En 2	B
197	B
198 - En 1	B
198 - En 2	B
199 - En 1	A
199 - En 2	A

- [0515] The activities of the Example compounds (cpds 200-299) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: “A”: IC₅₀ <1 μM; “B”: 1 μM ≤ IC₅₀ ≤ 20 μM and “C”: IC₅₀ > 20 μM.

cpd	IC ₅₀
200	A
201	B
202	B

cpd	IC ₅₀
282	A
283	A
284	A

203	A
204	A
205 - En 1	B
205 - En 2	A
206	A
207 - En 1	A
207 - En 2	A
232	A
270 - En 1	C
270 - En 2	C
271	A
272	A
273	A
274	A
275	A
276	A
277	B
278	A
279	A
280	A
281	A

285	A
286	A
287	A
288	A
289	A
290	A
291	A
292	A
293	A
294	A
295	A
296	A
297	A
298	A
299	A

[0516] The activities of the Example compounds (**cpds. 300-399**) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: "A": IC₅₀ <1 μM; "B": 1 μM ≤ IC₅₀ ≤20 μM and "C": IC₅₀ > 20 μM.

5

cpd	IC ₅₀
300	A
301	A
302	A
303	A
304	A
305	A
306	A
307	B
308	B
309	B
310 - En 1	A

cpd	IC ₅₀
328	A
329	B
330	A
331	B
332 - En 1	A
332 - En 2	A
333 - En 1	A
333 - En 2	A
334	A
335 - En 1	A
335 - En 2	A

cpd	IC ₅₀
352	A
355 - En 1	A
355 - En 2	A
356 - En 1	A
356 - En 2	A
357	A
358	C
359	A
360 - En 1	A
360 - En 2	A
361	A

cpd	IC ₅₀
384	A
385	A
386 - En 1	A
386 - En 2	B
387 - En 1	A
387 - En 2	A
388 - En 1	A
388 - En 2	B
389 - En 1	A
389 - En 2	A
390	A

310 - En 2	A
311	A
312	B
313 - En 1	A
313 - En 2	B
314	A
315 - En 1	A
315 - En 2	A
316 - En 1	A
316 - En 2	A
317 - En 1	A
317 - En 2	A
318	A
319	A
320	A
321	A
322	A
323	A
324	A
325	B
326 - En 1	A
326 - En 2	B
327	B

336 - En 1	A
336 - En 2	A
337	A
338 - En 1	A
338 - En 2	A
339	A
340 - En 1	A
340 - En 2	A
341	A
342 - En 1	A
342 - En 2	A
343	A
344	A
345	A
346	A
347	A
348 - En 1	A
348 - En 2	A
349 - En 1	A
349 - En 2	A
350 - En 1	A
350 - En 2	A
351	B

362	A
363	A
364	A
365 - En 1	C
365 - En 2	C
366	B
367	A
368	B
369	B
370	A
371	A
372	A
373	A
374	A
375	A
376	A
377	A
378	A
379	A
380	A
381	A
382	A
383	A

391	A
392	A
393	A
394	A
395 - Dia 1	A
395 - Dia 2	A
396 - En 1	A
396 - En 2	A
397 - En 1	A
397 - En 2	A
398	A
399	A

[0517] The activities of the Example compounds (**cpds. 400-499**) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: “A”: IC₅₀ <1 μM; “B”: 1 μM ≤ IC₅₀ ≤20 μM and “C”: IC₅₀ > 20 μM.

5

cpd	IC ₅₀
400	A
401 - En 1	A
401 - En 2	B
402 - En 1	B
403 - En 1	B
403 - En 2	C
404 - En 1	B
404 - En 2	B
405	C

cpd	IC ₅₀
429	A
430	A
431	A
432 - En 1	B
432 - En 2	A
433 - En 1	A
433 - En 2	A
434 - En 1	A
434 - En 2	A

cpd	IC ₅₀
455 - En 2	A
456 - En 1	A
456 - En 2	A
457 - En 1	A
457 - En 2	A
458 - En 1	A
458 - En 2	A
459 - En 1	A
459 - En 2	A

cpd	IC ₅₀
482	A
483	A
484	A
485	A
486	A
487 - En 1	B
487 - En 2	B
488 - En 1	A
488 - En 2	B

406 - En 1	A	435 - En 1	A	460 - En 1	A	489 - En 1	A
406 - En 2	A	435 - En 2	A	460 - En 2	A	489 - En 2	A
407 - En 1	A	436 - En 1	A	461 - En 1	A	490 - En 1	A
407 - En 2	B	436 - En 2	A	461 - En 2	A	490 - En 2	A
408 - En 1	A	437 - En 1	A	462 - En 1	A	491 - En 1	A
408 - En 2	A	437 - En 2	A	462 - En 2	A	491 - En 2	A
409 - En 1	A	438	A	463 - En 1	A	492	A
409 - En 2	A	439	A	463 - En 2	A	493	A
410 - En 1	A	440	A	464 - En 1	A	494	A
410 - En 2	B	441	A	464 - En 2	A	495	A
411 - En 1	A	442	A	465 - En 1	A	496	A
411 - En 2	A	443	A	465 - En 2	A	497	A
412 - En 1	A	444	A	466 - En 1	A	498	A
412 - En 2	A	445 - En 1	A	466 - En 2	A	499	A
413 - En 1	A	445 - En 2	B	467 - En 1	A		
413 - En 2	A	446 - En 1	A	467 - En 2	A		
414	A	446 - En 2	B	468 - En 1	A		
415	A	447 - En 1	A	468 - En 2	A		
416	A	447 - En 2	A	469 - En 1	A		
417	A	448 - En 1	A	469 - En 2	A		
418	A	448 - En 1	A	470	A		
419	A	449 - En 1	A	471	A		
420	A	449 - En 2	A	472	A		
421	A	450 - En 1	A	473	A		
422	A	450 - En 2	A	474	A		
423	A	451 - En 1	A	475	A		
424	A	451 - En 2	B	476	A		
425	A	452 - En 1	A	477	A		
426	A	452 - En 2	A	478	A		
427	A	453 - En 1	A	479	B		
428	A	453 - En 2	A	480	A		
429	A	454	A	481	A		

[0518] The activities of the Example compounds (**cpds. 500-599**) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: “A”: IC₅₀ <1 μM; “B” : 1 μM ≤ IC₅₀ ≤20 μM and “C” : IC₅₀ > 20 μM.

5

cpd	IC₅₀	cpd	IC₅₀	cpd	IC₅₀	cpd	IC₅₀
------------	------------------------	------------	------------------------	------------	------------------------	------------	------------------------

500	A
501	A
502	A
503	A
504	A
505	A
506	A
507	B
508	A
509	A
510 - En 1	A
510 - En 2	A
511 - En 1	A
511 - En 2	B
512 - En 1	A
512 - En 2	A
513 - En 1	A
513 - En 2	A
514 - En 1	A
514 - En 2	A
515 - En 1	A
515 - En 1	B
516 - En 1	A
516 - En 2	A
517 - En 1	A
517 - En 2	A
518 - En 1	A
518 - En 2	A
519 - En 1	A
519 - En 2	A
520 - En 1	A
520 - En 2	A
521 - En 1	A
521 - En 2	B
522 - En 1	A
522 - En 2	A
523	B

528	A
529	A
530 - En 1	B
530 - En 2	A
531 - En 1	A
531 - En 2	A
532 - En 1	A
532 - En 2	A
533 - En 1	A
533 - En 2	A
534 - En 1	A
534 - En 2	A
535 - En 1	A
535 - En 2	A
536 - En 1	A
536 - En 2	A
537	A
538 - En 1	B
539 - En 1	B
539 - En 2	A
540 - En 1	B
540 - En 2	C
541 - En 1	B
541 - En 2	C
542 - En 1	B
542 - En 2	C
543 - En 1	A
543 - En 2	A
544 - En 1	B
544 - En 2	B
545 - En 1	B
545 - En 2	B
546 - En 1	A
547 - En 1	A
547 - En 2	A
548 - En 1	B
548 - En 2	C

551 - En 1	A
551 - En 2	B
552 - En 1	A
552 - En 2	B
553 - En 1	A
553 - En 2	B
554 - En 1	A
554 - En 2	C
555 - En 1	A
555 - En 2	B
556 - En 1	B
556 - En 2	C
557 - En 1	A
557 - En 2	A
558 - En 1	A
558 - En 2	A
559 - En 1	B
559 - En 2	C
560 - En 1	A
560 - En 2	A
561 - En 1	A
561 - En 2	A
562 - En 1	A
562 - En 2	A
563 - En 1	A
563 - En 2	A
564 - En 1	A
564 - En 2	A
565 - En 1	A
565 - En 2	A
566 - En 1	A
566 - En 2	B
567 - En 1	C
567 - En 2	C
568 - En 1	A
568 - En 2	B
569 - En 1	B

571 - En 2	B
572 - En 1	A
572 - En 2	A
573 - En 1	A
573 - En 2	B
574	A
575 - En 1	A
575 - En 1	A
576	A
577	A
578	B
579	A
580	A
581	A
582	A
583	A
584	A
585	A
586	A
587	A
588	A
589	B
590 - En 1	A
590 - En 2	A
591 - En 1	A
591 - En 2	A
592 - En 1	A
592 - En 2	A
593 - En 1	A
593 - En 2	A
594 - En 1	A
594 - En 2	A
595 - En 1	A
595 - En 2	A
596 - En 1	A
596 - En 2	A
597 - En 1	A

524	A
525	A
526	A
527	A

549 - En 1	A
549 - En 2	B
550 - En 1	B
550 - En 2	B

569 - En 2	C
570 - En 1	A
570 - En 2	B
571 - En 1	B

597 - En 2	A
598 - En 1	A
598 - En 2	A
599	B

[0519] The activities of the Example compounds (**cpds. 600-666**) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: "A": IC₅₀ <1 μM; "B": 1 μM ≤ IC₅₀ ≤ 20 μM and "C": IC₅₀ > 20 μM.

5

cpd	IC ₅₀
600 - En 1	A
600 - En 2	A
601 - En 1	A
601 - En 2	A
602	A
603	B
604	C
605	C
606	B
607	B
608	A
609	B
610	B
611	A
612	B
613	A
614	A
615	A
616	B
617	B
618	A
619	B
620	A

cpd	IC ₅₀
621	C
622	B
623 - En 1	A
623 - En 2	A
624	A
625	A
626	B
627	A
628	B
629	A
630	C
631	C
632	B
633	B
634	A
635 - En 1	A
635 - En 2	B
636 - En 1	A
636 - En 2	A
637 - En 1	A
637 - En 2	A
638 - En 1	A
638 - En 2	B

cpd	IC ₅₀
639 - En 1	A
639 - En 2	A
640 - En 1	A
640 - En 2	A
641 - En 1	B
641 - En 2	B
642 - En 1	A
642 - En 2	A
643 - En 1	A
643 - En 2	A
646 - En 1	A
646 - En 2	A
647 - En 1	A
647 - En 2	A
648 - En 1	A
648 - En 2	A
649	A
650	A
651	A
652	A
653 - En 1	B
654 - En 1	B
653 - En 2	B

cpd	IC ₅₀
654 - En 2	B
655 - En 1	A
655 - En 2	A
656 - En 1	B
656 - En 2	B
657 - En 1	C
657 - En 1	C
658	C
659	B
660	C
661 - En 1	A
661 - En 2	A
662	A
663	A
664	A
665	A
666	A


[0520] The activities of the Example compounds (**cpds. 667-751**) tested are depicted in the table below. The activity ranges A, B and C refer to IC₅₀ values in the Fluo-4 AM assay as follows: "A": IC₅₀ <1 μM; "B": 1 μM ≤ IC₅₀ ≤ 20 μM and "C": IC₅₀ > 20 μM.

10

cpd	IC50	cpd	IC50	cpd	IC50
667		705	B	730 - En 2	A
668	A	706	A	731 - En 1	A
669		707		731 - En 2	A
670	A	708	A	732 - En 1	A
671		709		732 - En 2	A
672	A	710	A	733 - En 1	A
673		711	A	733 - En 2	A
674	A	712	A	734 - En 1	A
675		713		734 - En 2	B
676	A	714	A	735 - En 1	A
677		715	A	735 - En 2	A
678	A	716	A	736 - En 1	A
679		717	A	736 - En 2	A
680	A	718	A	737 - En 1	A
681		719 - En 1	A	737 - En 2	A
682	A	719 - En 2	A	738 - En 1	A
683	A	720 - En 1	A	738 - En 2	A
684	A	720 - En 2	A	739 - En 1	A
685	A	721	A	739 - En 2	A
686	A	722 - En 1	A	740 - En 1	A
687		722 - En 2	A	740 - En 2	A
688	A	723 - En 1	A	741	A
689		723 - En 2	A	742	A
690	A	724 - En 1	A	743	A
691		724 - En 2	B	744	A
692	A	725 - En 1	A	745	A
693		725 - En 2	A	746	A
694	A	726 - En 1	A	747	A
695	A	726 - En 2	A	748	A
696	A	727 - En 1	B	749	A
697	A	727 - En 2	B	750	A
698	A	727 - En 3	B	751	A
699		727 - En 4	B		
700	A	728 - En 1	B		
701		728 - En 2	A		
702	A	729 - En 1	A		
703		729 - En 2	A		
704	A	730 - En 1	A		

CLAIMS

1. A compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof



(I)

wherein

R¹ represents -F, -Cl, -Br, -I, -CN, -**R^W**, -**OR^W**, -OC(=O)**R^W**, -**NR^WR^X**, -**NR^WC(=O)R^X**, -**SR^W**, -S(=O)**R^W**, -S(=O)₂**R^W**, -C(=O)**R^W**, -C(=O)**OR^W**, or -C(=O)**NR^WR^X**;

Q represents -**NR³R⁴**;

R³ represents -OH or -**R^Y**;

R⁴ represents -**R^Y** or -S(=O)₂**R^Y**;

or **R³** and **R⁴** together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

T represents -O- and **U** represents -**CR⁵R^{5*}**-; or **T** represents -**CR⁵R^{5*}**- and **U** represents -O-;

R⁵ and **R^{5*}** independently of one another represent -**R^Y**;

R⁶, **R⁷** and **R⁸** independently of one another represent -F, -Cl, -Br, -I, -CN, -NO₂, -SF₅, -**R^W**, -**OR^W**, -OC(=O)**R^W**, -**NR^WR^X**, -**NR^WC(=O)R^X**, -**SR^W**, -S(=O)**R^W**, -S(=O)₂**R^W**, -C(=O)**R^W**, -C(=O)**OR^W**, or -C(=O)**NR^WR^X**;

V represents 3-14-membered heterocycloalkyl, saturated or unsaturated; or 5-14-membered heteroaryl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO₂, =O, =S, -SF₅, -**R^Y**, -**OR^Y**, -OC(=O)**R^Y**, -**NR^YR^Z**, -**NR^YC(=O)R^Z**, -**SR^Y**, -S(=O)**R^Y**, -S(=O)₂**R^Y**, -C(=O)**R^Y**, -C(=O)**OR^Y**, or -C(=O)**NR^YR^Z**;

wherein

R^W and **R^X** independently of one another in each case independently represent

-H;

-C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

5 **R^Y** and **R^Z** independently of one another in each case independently represent

-H;

-C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

-C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

10 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;

15 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or


5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;


or **R^Y** and **R^Z** together form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

25 and wherein "mono- or polysubstituted" in each case independently means substituted with one or more substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -C₁₋₆-alkyl, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFCl₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-O-CF₃, -C₁₋₆-alkylene-O-CF₂H, -C₁₋₆-alkylene-O-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃, -C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C₁₋₆-alkylene-C(=O)-OH, -C(=O)-OC₁₋₆-alkyl, -C₁₋₆-alkylene-C(=O)-OC₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)-NH₂, -C₁₋₆-alkylene-C(=O)-NH₂, -C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-C(=O)-NH(C₁₋₆-alkyl), -C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-C(=O)-N(C₁₋₆-alkyl)₂, -C(=O)-NH(OH), -C₁₋₆-alkylene-C(=O)-NH(OH), -OH, -C₁₋₆-alkylene-OH, =O, -OCF₃, -OCF₂H, -OCFH₂, -OCF₂Cl, -OCFCl₂, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-O-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-NH₂, -O-C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -O-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-C₁₋₆-alkyl, -O-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C(=O)-O-C₁₋₆-alkyl, -O-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-C(=O)-NH(C₁₋₆-alkyl), -O-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-C(=O)-N(C₁₋₆-alkyl)₂, -O-S(=O)₂-NH₂, -C₁₋₆-alkylene-O-S(=O)₂-NH₂, -O-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-O-S(=O)₂-NH(C₁₋₆-alkyl), -O-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-O-S(=O)₂-N(C₁₋₆-alkyl)₂, -NH₂, -NO, -NO₂, -C₁₋₆-alkylene-NH₂, -NH(C₁₋₆-alkyl), -N(3-14-membered cycloalkyl)(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C₁₋₆-alkylene-

OH, -N(H)-C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -NH-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-C₁₋₆-alkyl, -NH-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-C(=O)-O-C₁₋₆-alkyl, -NH-C(=O)-NH₂, -C₁₋₆-alkylene-NH-C(=O)-NH₂, -NH-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-NH-C(=O)-NH(C₁₋₆-alkyl), -NH-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-C(=O)-N(C₁₋₆-alkyl)₂, -N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-C(=O)-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH₂, -N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C(=O)-N(C₁₋₆-alkyl)₂, -NH-S(=O)₂OH, -C₁₋₆-alkylene-NH-S(=O)₂OH, -NH-S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-S(=O)₂-C₁₋₆-alkyl, -NH-S(=O)₂-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH-S(=O)₂-O-C₁₋₆-alkyl, -NH-S(=O)₂-NH₂, -C₁₋₆-alkylene-NH-S(=O)₂-NH₂, -NH-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-NH-S(=O)₂-NH(C₁₋₆-alkyl), -NH-S(=O)₂N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH-S(=O)₂N(C₁₋₆-alkyl)₂, -N(C₁₋₆-alkyl)-S(=O)₂-OH, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-OH, -N(C₁₋₆-alkyl)-S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-S(=O)₂-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)-S(=O)₂-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-NH₂, -N(C₁₋₆-alkyl)-S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-NH(C₁₋₆-alkyl), -N(C₁₋₆-alkyl)-S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-S(=O)₂-N(C₁₋₆-alkyl)₂, -SH, =S, -SF₅, -SCF₃, -SCF₂H, -SCFH₂, -S-C₁₋₆-alkyl, -C₁₋₆-alkylene-S-C₁₋₆-alkyl, -S(=O)-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)-C₁₋₆-alkyl, -S(=O)₂-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)₂-C₁₋₆-alkyl, -S(=O)₂-OH, -C₁₋₆-alkylene-S(=O)₂-OH, -S(=O)₂-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-S(=O)₂-O-C₁₋₆-alkyl, -S(=O)₂-NH₂, -C₁₋₆-alkylene-S(=O)₂-NH₂, -S(=O)₂-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-S(=O)₂-NH(C₁₋₆-alkyl), -S(=O)₂-N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-S(=O)₂-N(C₁₋₆-alkyl)₂, 3-14-membered cycloalkyl, -C₁₋₆-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -C₁₋₆-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -C₁₋₆-alkylene-phenyl, 5 to 14-membered heteroaryl, -C₁₋₆-alkylene-(5 to 14-membered heteroaryl), -O-(3-14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3-14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)₂-(3-14-membered cycloalkyl), -S(=O)₂-(3 to 14-membered heterocycloalkyl), -S(=O)₂-phenyl, -S(=O)₂-(5 to 14-membered heteroaryl);

with the proviso that the following compounds and their salts are excluded





2. A compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof, as defined in claim 1, wherein R^3 represents -H.
3. A compound of formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and/or polymorph thereof, as defined in claims 1 and 2, wherein R^1 represents $-CH_2F$, $-CHF_2$, or $-CF_3$.
4. The compound according to any one of claims 1 to 3, wherein T represents -O- and U represents $-CR^5R^{5*}$.
5. The compound according to any one of claims 1 to 4, wherein V represents (i) 5-14-membered heteroaryl selected from benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -CN, -OH, =O, $-C_{1-6}$ -alkyl, $-CHF_2$, $-CF_3$, $-C_{1-6}$ -alkylene- NH_2 , $-C_{1-6}$ -alkylene- $NHC(=O)O-C_{1-6}$ -alkyl, $-C_{1-6}$ -alkylene-OH, $-C_{1-6}$ -alkylene- CHF_2 , $-C_{1-6}$ -alkylene- CF_3 , $-C_{1-6}$ -alkylene-cyclopropyl, -cyclopropyl, -O-cyclopropyl, $-C_{1-6}$ -alkylene- $NHC(=O)O-C_{1-6}$ -alkyl, $-C(=O)O-C_{1-6}$ -alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-OC_{1-6}$ -alkyl, $-OCF_3$, $-O-C_{1-6}$ -alkylene- $N(C_{1-6}\text{-alkyl})_2$, $-S(=O)_2-C_{1-6}$ -alkyl, -azetidine, $-C_{1-6}$ -alkylene-O-tetrahydropyran, or -piperazine substituted with $-C_{1-6}$ -alkyl; particularly in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -CN, -OH, =O, $-C_{1-6}$ -alkyl, $-CHF_2$, $-CF_3$, $-C_{1-6}$ -alkylene- NH_2 , $-C_{1-6}$ -alkylene- $NHC(=O)O-C_{1-6}$ -alkyl, $-C_{1-6}$ -alkylene-OH, $-C_{1-6}$ -alkylene- $NHC(=O)O-$

C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -OCF₃, -O-C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -S(=O)₂-C₁₋₆-alkyl, -azetidine, -C₁₋₆-alkylene-O-tetrahydropyran, or -piperazine substituted with -C₁₋₆-alkyl; or represents (ii) -oxetanyl, unsubstituted, mono- or polysubstituted.

- 5 6. The compound according to any one of claims 1 to 5, wherein **R**¹ represents -H, -F, -Cl, -Br, -I, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFC₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃, -C(=O)C₁₋₆-alkyl, -C(=O)OC₁₋₆-alkyl, -C(=O)NH₂, -C(=O)NHC₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -S(=O)-C₁₋₆-alkyl, -S(=O)₂-C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -cyclopropyl unsubstituted, cyclobutyl unsubstituted, cyclopentyl unsubstituted or cyclohexyl unsubstituted.
- 10 7. The compound according to any one of claims 1 and claims 3 to 6, wherein **R**³ represents -H, -OH, -C₁₋₆-alkyl, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH(C₁₋₆-alkyl), -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -CF₃, -CF₂H, -CFH₂, -CF₂Cl, -CFC₂, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-CF₂H, -C₁₋₆-alkylene-CFH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, or -C₁₋₆-alkylene-N(C₁₋₆-alkyl)-C₁₋₆-alkylene-CF₃.
- 15 8. The compound according to any one of claims 1 to 7, wherein **R**⁴ represents
- 20 -H;
-S(=O)₂C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or polysubstituted with -F;
-S(=O)₂(3-14-membered cycloalkyl), saturated, unsubstituted;
-C₁₋₆-alkyl, saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -OH, =O, -OC₁₋₆-alkyl, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkyl, -C(=O)NH₂, -C(=O)-NH-C₁₋₃-alkyl, -C(=O)N(C₁₋₃-alkyl)₂, -phenyl unsubstituted;
- 25 3-14-membered cycloalkyl or -C₁₋₆-alkylene-(3-14-membered cycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-NH-C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-NHC(=O)O-C₁₋₆-alkyl, -OH, -OC₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -NHC(=O)O-C₁₋₆-alkyl;
- 30 3-14-membered heterocycloalkyl or -C₁₋₆-alkylene-(3-14-membered heterocycloalkyl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydropyrrolo[1,2-a]pyrazin, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolizine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxothiacyclohexane, in each case unsubstituted, mono- or polysubstituted
- 35 with substituents independently of one another selected from the group consisting of -F, -OH, =O, -C₁₋₆-
- 40

- alkyl, -C₁₋₆-alkylene-CF₃, -C₁₋₆-alkylene-OH, -C₁₋₆-alkylene-O-C₁₋₆-alkyl, -NH₂, -N(C₁₋₆-alkyl)₂, -C₁₋₆-alkylene-NH₂, -C₁₋₆-alkylene-N(C₁₋₆-alkyl)₂, -C(=O)-C₁₋₆-alkyl, -C(=O)OH, -C(=O)O-C₁₋₆-alkyl, -C(=O)O-C₁₋₆-alkylene-CF₃, -C(=O)NH₂, -C(=O)NH(C₁₋₆-alkyl), -S(=O)₂C₁₋₆-alkyl, oxetanyl, pyrimidinyl, -C₁₋₆-alkylene-phenyl;
- 5 -phenyl unsubstituted;
- 5-14-membered heteroaryl or -C₁₋₆-alkylene-(5-14-membered heteroaryl), wherein -C₁₋₆-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, monosubstituted or disubstituted with
- 10 substituents independently of one another selected from the group consisting of -C₁₋₆-alkyl, -OH.
9. The compound according to any one of claims 1 and claims 2 to 6 wherein **R**³ and **R**⁴ together form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected
- 15 from the group consisting of -F, -C₁₋₆-alkyl, -NH₂, -NHCH₃, -N(CH₃)₂, -C(=O)NH-C₁₋₆-alkyl, -C(=O)N(C₁₋₆-alkyl)₂, -C(=O)O-C₁₋₆-alkyl, -NHC(=O)O-C₁₋₆-alkyl, -pyridyl unsubstituted, and 1,2,4-oxadiazole unsubstituted or monosubstituted with -C₁₋₆-alkyl.
10. The compound according to any one of claims 1 to 9, wherein **R**⁵ and **R**^{5'} independently of one another
- 20 represent
- H;
- C₁-C₆-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- C₁-C₆-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
- 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said
- 25 3-14-membered cycloalkyl is optionally connected through -C₁-C₆-alkylene- or -C₁-C₆-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.
11. The compound according to any one of claims 1 to 10, wherein **R**⁶, **R**⁷ and **R**⁸ independently of one another
- represent
- 30 -H, -F, -Cl, -Br, -I, -OH, -SH, -SF₅, -CN, -NO₂, -C(=O)OH, -NH₂,
- C₁₋₆-alkyl, -CF₃, -CHF₂, -CH₂F,
- O-C₁₋₆-alkyl, -OCF₃, -OCHF₂, -OCH₂F,
- NHC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
- selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
- 35 -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
- N(C₁₋₆-alkyl)₂ unsubstituted or substituted with one or more substituents independently of one another
- selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,
- NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
- C(=O)OC₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another
- 40 selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅,

- NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂;
 -OC(=O)C₁₋₆-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂; or
- 5 -C₁₋₆-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, SF₅, -NO₂, -C(=O)OH, -NH₂, and -C(=O)NH₂.
12. The compound according to any one of claims 1 to 11, which is selected from the group consisting of
- 10 cpd 001 5-(furan-3-ylmethoxy)-2-methylbenzofuran-3-carboxylic acid
 cpd 002 2-methyl-5-(oxazol-5-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 003 2-methyl-5-(pyrrolidin-3-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 004 2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 005 2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxylic acid
- 15 cpd 006 2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 007 2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 008 2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxylic acid
 cpd 009 2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxylic acid
 cpd 010 2-methyl-5-((1-methyl-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid
- 20 cpd 011 2-methyl-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 012 2-methyl-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 013 2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 014 2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxylic acid
 cpd 015 2-methyl-5-((tetrahydro-2H-pyran-4-yl)methoxy)benzofuran-3-carboxylic acid
- 25 cpd 016 5-((3,5-dimethylisoxazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
 cpd 017 5-(benzo[d]thiazol-2-ylmethoxy)-2-methylbenzofuran-3-carboxylic acid
 cpd 018 2-methyl-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxylic acid
 cpd 019 5-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
 cpd 020 (S)-2-methyl-5-(oxazol-5-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
- 30 cpd 021 (S)-2-methyl-5-(pyridin-4-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
 cpd 022 (S)-2-methyl-5-(pyridin-3-ylmethoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
 cpd 023 (S)-2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
- 35 cpd 024 (S)-2-methyl-N-(pyrrolidin-3-yl)-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
 cpd 025 (S)-2-methyl-N-(pyrrolidin-3-yl)-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
 cpd 026 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
 cpd 027 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
 cpd 028 (S)-2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide

	cpd 029	(S)-2-methyl-5-((6-methylpyridin-2-yl)methoxy)-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 030	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	cpd 031	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxamide
5	cpd 032	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(pyrimidin-5-ylmethoxy)benzofuran-3-carboxamide
	cpd 033	2-methyl-5-((6-methylpyridin-3-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
	cpd 034	2-methyl-5-((4-methylpyridin-3-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
10	cpd 035	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiophen-3-ylmethoxy)benzofuran-3-carboxamide
	cpd 036	2-methyl-N-(2-oxopyrrolidin-3-yl)-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 037	2-methyl-5-((4-methylpyridin-3-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 038	2-methyl-5-((5-methylpyridin-3-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
15	cpd 039	2-methyl-N-(1-methylpiperidin-4-yl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 040	5-((4-methoxypyridin-3-yl)methoxy)-2-methyl-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
	cpd 041	2-methyl-N-(1-methylpiperidin-4-yl)-5-(thiophen-2-ylmethoxy)benzofuran-3-carboxamide
20	cpd 042	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 043	2-methyl-5-((4-methylthiazol-2-yl)methoxy)-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 044	5-((2,6-dimethylpyridin-3-yl)methoxy)-2-methyl-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
25	cpd 045	2-methyl-N-(1-methylpiperidin-4-yl)-5-(1-(pyridin-4-yl)ethoxy)benzofuran-3-carboxamide
	cpd 046	5-((2-methoxypyridin-3-yl)methoxy)-2-methyl-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide
	cpd 047	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
30	cpd 048	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 049	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	cpd 050	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
35	cpd 051	5-((2-methoxypyridin-3-yl)methoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
	cpd 052	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
40	cpd 053	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamide

- cpd 054 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
- cpd 055 (S)-2-methyl-N-(pyrrolidin-3-yl)-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 5 cpd 056 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 057 2-methyl-N-(tetrahydrofuran-3-yl)-5-((4-(trifluoromethyl)thiazol-2-yl)methoxy)benzofuran-3-carboxamide
- cpd 058 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 10 cpd 059 5-(isoquinolin-1-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
- cpd 060 5-(isoquinolin-5-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
- cpd 061 5-(isoquinolin-6-ylmethoxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide
- cpd 062 N-(3,3-difluoropiperidin-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 cpd 063 N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- cpd 064 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 20 cpd 065 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((6-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamide
- cpd 066 2-methyl-N-(2-oxopyrrolidin-3-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 067 5-((2-chloropyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
- 25 cpd 068 5-((4-chloropyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
- cpd 069 2-methyl-N-(1-methylpiperidin-4-yl)-5-((5-(trifluoromethyl)furan-2-yl)methoxy)benzofuran-3-carboxamide
- 30 cpd 070 N-(3,3-difluoropiperidin-4-yl)-5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamide
- cpd 071 N-(3,3-difluoropiperidin-4-yl)-5-((6-(dimethylamino)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- cpd 072 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 35 cpd 073 tert-butyl (S)-3-(2-methyl-5-((5-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamido)-pyrrolidine-1-carboxylate
- cpd 074 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide

	cpd 075	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	cpd 076	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamide
5	cpd 077	tert-butyl (S)-3-(2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 078	tert-butyl 4-(5-((6-(dimethylamino)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate
10	cpd 079	tert-butyl 3-(((3-(ethoxycarbonyl)-2-methylbenzofuran-5-yl)oxy)methyl)pyrrolidine-1-carboxylate
	cpd 080	tert-butyl (R)-3-(2-methyl-5-(oxazol-5-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 081	tert-butyl (R)-3-(2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
15	cpd 082	tert-butyl (R)-3-(2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 083	tert-butyl (R)-3-(2-methyl-5-((1-methyl-1H-pyrazol-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
20	cpd 084	tert-butyl (R)-3-(2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 085	tert-butyl (R)-3-(2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
	cpd 086	tert-butyl (R)-3-(2-methyl-5-((6-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamido)-pyrrolidine-1-carboxylate
25	cpd 087	tert-butyl 3,3-difluoro-4-(2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamido)-piperidine-1-carboxylate
	cpd 088	tert-butyl 3,3-difluoro-4-(2-methyl-5-((3-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 089	tert-butyl 3,3-difluoro-4-(5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate
30	cpd 090	tert-butyl 3,3-difluoro-4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
	cpd 091	tert-butyl 3,3-difluoro-4-(5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate
35	cpd 092	tert-butyl 4-(5-((2-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate
	cpd 093	tert-butyl 4-(5-((4-chloropyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamido)-3,3-difluoropiperidine-1-carboxylate
40	cpd 094	tert-butyl 3,3-difluoro-4-(5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate

- cpd 095 tert-butyl 3,3-difluoro-4-(2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
- cpd 096 tert-butyl 3,3-difluoro-4-(2-methyl-5-((3-(trifluoromethyl)pyridin-2-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
- 5 cpd 097 tert-butyl 3,3-difluoro-4-(2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamido)-piperidine-1-carboxylate
- cpd 098 tert-butyl 3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)piperidine-1-carboxylate
- cpd 099 2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
- 10 cpd 100 5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- cpd 101 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
- cpd 102 2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- cpd 103 N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 cpd 104 N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 105 N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 106 N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 cpd 107 N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 108 N-(1-((dimethylamino)methyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 cpd 109 N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 110 N-(3,3-difluoro-1-methylpiperidin-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 111 N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 30 cpd 112 N-(3,3-difluoropiperidin-4-yl)-4-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- cpd 113 N-(3,3-difluoropiperidin-4-yl)-6-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- 35 cpd 114 N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 115 N-(5,5-difluoropiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 116 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)benzofuran-3-carboxamide
- 40

- cpd 117 N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 118 N-(4,4-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 cpd 119 N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 120 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 121 N-(3-(2-hydroxyethyl)tetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
- 10 cpd 122 7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 123 N-(4,4-difluoro-1-methylpyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 cpd 124 N-(4,4-difluoro-1-methylpyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- cpd 125 N-(5,5-difluoropiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 126 N-(3-(2-hydroxyethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- 20 cpd 127 N-(1-(2-hydroxyethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 128 N-(3-(2-hydroxyethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 cpd 129 N-(3-(2-hydroxyethyl)oxetan-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 130 N-(3,3-difluoro-1-methylpiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- cpd 131 N-(4,4-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- 30 cpd 132 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
- cpd 133 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- 35 cpd 134 N-(4,4-difluoro-1-(2-hydroxyethyl)pyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 135 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- cpd 136 N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 40

- cpd 137 N-(1-(aminomethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 138 2-methyl-N-(1H-pyrazol-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 5 cpd 139 N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 140 N-(1-((dimethylamino)methyl)cyclobutyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 141 N-(5,5-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 10 cpd 142 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 143 2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 15 cpd 144 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1H-pyrazol-3-yl)benzofuran-3-carboxamide
- cpd 145 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(((2,2,2-trifluoroethyl)amino)methyl)cyclobutyl)benzofuran-3-carboxamide
- cpd 146 2-methyl-N-(1-methyl-1H-pyrazol-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 20 cpd 147 N-(4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 148 2-methyl-N-(tetrahydrofuran-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 149 2-methyl-N-(1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 25 cpd 150 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1H-pyrazol-4-yl)benzofuran-3-carboxamide
- cpd 151 N-(4,4-difluoro-1-(2-hydroxyethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 152 2-methyl-N-(1-methyl-1H-pyrazol-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 cpd 153 2-methyl-N-(1-(((2,2,2-trifluoroethyl)amino)methyl)cyclobutyl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 154 2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 35 cpd 155 N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 156 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxaspiro[3.3]heptan-6-yl)benzofuran-3-carboxamide
- cpd 157 N-(4,4-difluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 40

- cpd 158 2-methyl-N-(1H-pyrazol-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 159 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(tetrahydrofuran-3-yl)benzofuran-3-carboxamide
- 5 cpd 160 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
- cpd 161 2-methyl-N-(1-methyl-1H-pyrazol-3-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 162 N-(4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 10 cpd 163 N-(5,5-difluoro-1-methylpiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 164 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- 15 cpd 165 6-chloro-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 166 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzofuran-3-carboxamide
- cpd 167 2-methyl-N-(2-oxaspiro[3.3]heptan-6-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- 20 cpd 168 2-methyl-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 169 N-(1-(2-methoxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
- 25 cpd 170 (3-aminotetrahydrofuran-3-yl)methyl 2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxylate
- cpd 171 2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 172 2,2,2-trifluoroethyl 3,3-difluoro-4-(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
- 30 cpd 173 2-methyl-N-(2-azaspiro[3.3]heptan-6-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 174 6-chloro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 cpd 175 2,2,2-trifluoroethyl (R)-3,3-difluoro-4-(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamido)pyrrolidine-1-carboxylate
- cpd 176 N-(3,3-difluoropiperidin-4-yl)-7-fluoro-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- cpd 177 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40

	cpd 178	(3-amino-1H-pyrazol-1-yl)(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-yl)methanone
	cpd 179	N-(3,3-difluoropiperidin-4-yl)-2,6-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
5	cpd 180	N-(1-(2-hydroxyethyl)-5-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)-benzofuran-3-carboxamide
	cpd 181	(4-amino-1H-pyrazol-1-yl)(2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-yl)methanone
	cpd 182	6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
10	cpd 183	N-(3,3-difluoropiperidin-4-yl)-2,7-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
	cpd 184	7-chloro-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
15	cpd 185	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,6-dimethyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 186	N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,7-dimethyl-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
	cpd 187	7-chloro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
20	cpd 188	7-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 189	N-((3-aminooxetan-3-yl)methyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
25	cpd 190	2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-azaspiro[3.3]heptan-6-yl)benzofuran-3-carboxamide
	cpd 191	4-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
	cpd 192	(3-amino-1H-pyrazol-1-yl)(2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-yl)-methanone
30	cpd 193	4-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	cpd 194	6-cyano-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	cpd 195	6-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
	cpd 196	7-cyano-N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
40	cpd 197	2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide

- cpd 198 2-(difluoromethyl)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((4-methylthiazol-5-yl)-methoxy)benzofuran-3-carboxamide
- cpd 199 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)-methoxy)benzofuran-3-carboxamide
- 5 cpd 200 N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 201 N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 10 cpd 202 N-(3-(hydroxymethyl)azetidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)-benzofuran-3-carboxamide
- cpd 203 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- cpd 204 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)-methoxy)benzofuran-3-carboxamide
- 15 cpd 205 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- cpd 206 5-((2-ethoxypyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- cpd 207 N-(3,3-difluoropiperidin-4-yl)-5-((2-ethoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 208 2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 209 2-methyl-5-((2-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 210 2-methyl-5-((2-methyl-4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 211 2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- 25 Cpd 212 2-methyl-5-((2-methylthiazol-4-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 213 2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 214 2-methyl-5-((4-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 215 2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 216 2-methyl-5-((5-methylthiazol-4-yl)methoxy)benzofuran-3-carboxylic acid
- 30 Cpd 217 2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 218 2-methyl-5-(oxetan-3-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 219 2-methyl-5-(pyrimidin-4-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 220 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 221 5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- 35 Cpd 222 5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 223 5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 224 5-((2,5-dimethylthiazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 225 5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 226 5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- 40 Cpd 227 5-((6-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid

	Cpd 228	5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 229	2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 230	2-(difluoromethyl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 231	2-cyclopropyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
5	Cpd 232	2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 233	4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 234	4-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 235	5-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 236	5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
10	Cpd 237	5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 238	5-((2-cyanopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 239	5-((2-ethoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 240	5-((3-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 241	5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
15	Cpd 242	5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 243	6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 244	6-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
	Cpd 245	7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 246	7-fluoro-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
20	Cpd 247	2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 248	2-methyl-5-(1-(2-(trifluoromethyl)thiazol-5-yl)ethoxy)benzofuran-3-carboxylic acid
	Cpd 249	2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 250	2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 251	2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxylic acid
25	Cpd 252	2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxylic acid
	Cpd 253	2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 254	2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 255	2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 256	2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxylic acid
30	Cpd 257	2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 258	2-methyl-5-((3-methylloxetan-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 259	2-methyl-5-((4-methylloxazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 260	2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 261	2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxylic acid
35	Cpd 262	2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 263	2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 264	2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-carboxylic acid
	Cpd 265	2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
	Cpd 266	5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
40	Cpd 267	5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxylic acid

- Cpd 268 2-methyl-5-(1-(4-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxylic acid
- Cpd 269 5-((2-methoxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 270 (2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carbonyl)serine
- Cpd 271 (R)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-
5 carboxamide
- Cpd 272 (R)-N-(1-amino-3-(methylsulfonyl)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 273 (R)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 274 (R)-N-(1-hydroxy-3-(methylsulfonyl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 275 (R)-N-(1-hydroxy-3-(methylsulfonyl)propan-2-yl)-2-methyl-5-((4-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 276 (R)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-
15 yl)methoxy)benzofuran-3-carboxamide
- Cpd 277 (S)-N-(1-(3,3-difluoropyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-
methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 278 (S)-N-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 279 (S)-N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-
carboxamide
- Cpd 280 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 281 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)thiazol-5-
25 yl)methoxy)benzofuran-3-carboxamide
- Cpd 282 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methyl-4-
(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 283 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methyl-4-
oxazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 284 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyridin-3-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 285 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-4-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 286 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-
35 yl)methoxy)benzofuran-3-carboxamide
- Cpd 287 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylpyridin-3-
yl)methoxy)benzofuran-3-carboxamide
- Cpd 288 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-
yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 289 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylisoxazol-3-

- yl)methoxy)benzofuran-3-carboxamide
- Cpd 290 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylthiazol-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 291 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 292 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(oxetan-3-ylmethoxy)benzofuran-3-carboxamide
- Cpd 293 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
- 10 Cpd 294 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrimidin-4-ylmethoxy)benzofuran-3-carboxamide
- Cpd 295 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 296 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 297 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(dimethylamino)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 298 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 299 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,5-dimethylthiazol-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 300 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-aminopyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 301 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 25 Cpd 302 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 303 (S)-N-(1-amino-3-methoxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 304 (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 305 (S)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 306 (S)-N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 307 (S)-N-(3-hydroxy-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 308 2-(difluoromethyl)-N-(1-(hydroxymethyl)cyclopropyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 309 2-(difluoromethyl)-N-(3-(hydroxymethyl)oxetan-3-yl)-5-((4-methylthiazol-5-

- yl)methoxy)benzofuran-3-carboxamide
- Cpd 310 2-(difluoromethyl)-N-(3,3-difluoropiperidin-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 311 2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 312 2-(difluoromethyl)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 313 2-cyclopropyl-N-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 314 2-cyclopropyl-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 315 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1-(oxazol-2-yl)ethyl)benzofuran-3-carboxamide
- Cpd 316 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(1,1,1-trifluoro-3-hydroxypropan-2-yl)benzofuran-3-carboxamide
- 15 Cpd 317 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(5-oxo-1,4-oxazepan-6-yl)benzofuran-3-carboxamide
- Cpd 318 2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 319 2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 320 2-methyl-N-(1-(methylcarbamoyl)cyclobutyl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 321 2-methyl-N-(2-(methylamino)-2-oxoethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 322 2-methyl-N-(2-(methylsulfonamido)ethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 323 2-methyl-N-(2-(methylsulfonyl)ethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 324 2-methyl-N-(3-(methylcarbamoyl)oxetan-3-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 325 3-(((3-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)methyl)picolinamide
- Cpd 326 4-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 327 4-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 328 4-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 329 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-

- y) methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 330 4-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 5 Cpd 331 5-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 332 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 333 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- 10 Cpd 334 5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 335 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 336 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 337 5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 338 5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 339 5-((2-(difluoromethoxy)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 340 5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 341 5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methylbenzofuran-3-carboxamide
- 25 Cpd 342 5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 343 5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- 30 Cpd 344 5-((2-(dimethylamino)pyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 345 5-((2,4-dimethylthiazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 346 5-((2-aminopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- 35 Cpd 347 5-((2-cyanopyridin-3-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 348 5-((2-ethoxypyridin-3-yl)methoxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- 40 Cpd 349 5-((2-hydroxypyridin-3-yl)methoxy)-N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-

- methybenzofuran-3-carboxamide
- Cpd 350 5-((2-hydroxypyridin-3-yl)methoxy)-N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methybenzofuran-3-carboxamide
- 5 Cpd 351 5-((3-(difluoromethyl)pyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methybenzofuran-3-carboxamide
- Cpd 352 5-((3-fluoropyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methybenzofuran-3-carboxamide
- Cpd 355 5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methybenzofuran-3-carboxamide
- 10 Cpd 356 5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methybenzofuran-3-carboxamide
- Cpd 357 5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methybenzofuran-3-carboxamide
- Cpd 358 5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methybenzofuran-3-carboxamide
- 15 Cpd 359 5-((5-fluoropyridin-2-yl)methoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methybenzofuran-3-carboxamide
- Cpd 360 6-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 361 6-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 362 6-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 363 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methybenzofuran-3-carboxamide
- 25 Cpd 364 6-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methybenzofuran-3-carboxamide
- Cpd 365 7-fluoro-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 366 7-fluoro-N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 367 7-fluoro-N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 368 7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methybenzofuran-3-carboxamide
- 35 Cpd 369 7-fluoro-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methybenzofuran-3-carboxamide
- Cpd 370 N-((1-cyanocyclopropyl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 371 N-((1-cyanocyclopropyl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-

	carboxamide
	Cpd 372 N-((1-fluorocyclopropyl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
5	Cpd 373 N-((1-fluorocyclopropyl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 374 N-((1H-pyrazol-3-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 375 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 376 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 377 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 378 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
15	Cpd 379 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 380 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 381 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 382 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 383 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 384 N-((3-fluorooxetan-3-yl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 385 N-((3-fluorooxetan-3-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 386 N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 387 N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 388 N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 389 N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 390 N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 391 N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-

- yl)methoxy)benzofuran-3-carboxamide
- Cpd 392 N-((3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 393 N-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 394 N-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 395 N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(1-(2-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxamide
- 10 Cpd 396 N-(1-((2-hydroxyethyl)(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 397 N-(1-((2-hydroxyethyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 398 N-(1-((2-hydroxyethyl)amino)-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 399 N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 400 N-(1-((difluoromethoxy)methyl)cyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 401 N-(1-(1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 402 N-(1-(2-(2-hydroxyethoxy)ethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 403 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 404 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 405 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 406 - N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 407 - N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 408 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 35 Cpd 409 N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 410 N-(1-(2-hydroxyethyl)-3-methyl-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 411 N-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-

- yl)methoxy)benzofuran-3-carboxamide
- Cpd 412 N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 413 N-(1-(dimethylamino)-3-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 414 N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 415 N-(1-(hydroxymethyl)cyclobutyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 10 Cpd 416 N-(1-(hydroxymethyl)cyclobutyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 417 N-(1-(hydroxymethyl)cyclobutyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 418 N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 419 N-(1-(hydroxymethyl)cyclopropyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 420 N-(1-(hydroxymethyl)cyclopropyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 421 N-(1-(hydroxymethyl)cyclopropyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 422 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 423 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 424 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 425 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 426 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 427 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
- Cpd 428 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 35 Cpd 429 N-(1,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyrimidin-4-ylmethoxy)benzofuran-3-carboxamide
- Cpd 430 N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 40 Cpd 431 N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-

- methylbenzofuran-3-carboxamide
- Cpd 432 N-(1-amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 433 N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 434 N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 435 N-(1-amino-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 10 Cpd 436 N-(1-amino-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 437 N-(1-amino-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 438 N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 439 N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 440 N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 441 N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
- 20 Cpd 442 N-(1-amino-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 443 N-(1-amino-2-methyl-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 25 Cpd 444 N-(1-amino-2-methyl-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 445 N-(1-amino-3-(cyclopropyl(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 446 N-(1-amino-3-(cyclopropyl(methyl)amino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 447 N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 448 N-(1-amino-3-(difluoromethoxy)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 449 N-(1-amino-3-(dimethylamino)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 450 N-(1-amino-3-(dimethylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 451 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide

- Cpd 452 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 453 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 454 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 455 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 456 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 10 Cpd 457 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 458 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 459 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 460 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 461 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 462 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 463 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 464 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 465 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((1-(2,2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 466 N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 30 Cpd 467 N-(1-amino-3-methoxy-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 468 N-(1-amino-3-methoxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 469 N-(1-amino-4-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 470 N-(1-carbamoyl-3,3-difluorocyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 471 N-(1-carbamoylcyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide

	Cpd 472	N-(1-carbamoylcyclobutyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 473	N-(1-carbamoylcyclobutyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
5	Cpd 474	N-(1-carbamoylcyclobutyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 475	N-(1-carbamoylcyclopropyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 476	N-(1-carbamoylcyclopropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 477	N-(1-carbamoylcyclopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 478	N-(1-carbamoylcyclopropyl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 479	N-(1-carbamoylcyclopropyl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 480	N-(1-carbamoylcyclopropyl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 481	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
20	Cpd 482	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 483	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 484	N-(1-hydroxy-2-methylpropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
25	Cpd 485	N-(1-hydroxy-2-methylpropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 486	N-(1-hydroxy-2-methylpropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
30	Cpd 487	N-(1-hydroxy-3-morpholinopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 488	N-(1-hydroxy-3-morpholinopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 489	N-(1-hydroxypropan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 490	N-(1-hydroxypropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 491	N-(1-hydroxypropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 492	(S)-N-(1-hydroxypropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
40	Cpd 493	(R)-N-(1-hydroxypropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide

- Cpd 494 (S)-N-(1-hydroxypropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 495 (R)-N-(1-hydroxypropan-2-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 5 Cpd 496 (S)-N-(1-hydroxypropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 497 (R)-N-(1-hydroxypropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 498 N-(2,2-difluoroethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 499 N-(2,2-difluoropropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 500 N-(2,2-difluoropropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 501 N-(2-acetamidoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 502 N-(2-amino-1-cyano-2-oxoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 503 N-(2-amino-2-oxoethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 504 N-(2-fluoro-2-methylpropyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 505 N-(2-fluoro-2-methylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 506 N-(2-hydroxy-2-methylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 507 N-(3-(aminomethyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 508 N-(3-(dimethylamino)oxetane-3-carbonyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 509 N-(3-(dimethylcarbamoyl)oxetan-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 510 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 511 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 512 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 513 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 514 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 515 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40

- Cpd 516 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 517 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 518 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 519 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 520 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 10 Cpd 521 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 522 N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 523 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 524 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 525 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 526 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 527 N-(3-(hydroxymethyl)oxetan-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
- 25 Cpd 528 N-(3-(hydroxymethyl)oxetan-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 529 N-(3-(hydroxymethyl)oxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 530 N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 531 N-(3-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 532 N-(3-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 533 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 534 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 535 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 40

- Cpd 536 N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 537 N-(3,3-difluoro-1-(hydroxymethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 538 N-(3,3-difluoropiperidin-4-yl)-2,4-dimethyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 539 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)benzofuran-3-carboxamide
- Cpd 540 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 541 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 542 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 543 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 544 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 545 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 546 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 547 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 548 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 549 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 550 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((3-methyloxetan-3-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 551 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylloxazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 552 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 553 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 554 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 555 N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide

	Cpd 556	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxamide
	Cpd 557	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
	Cpd 558	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-carboxamide
5	Cpd 559	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 560	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 561	N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
	Cpd 562	N-(3,3-difluoropiperidin-4-yl)-4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
10	Cpd 563	N-(3,3-difluoropiperidin-4-yl)-5-((2,4-dimethylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 564	N-(3,3-difluoropiperidin-4-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 565	N-(3,3-difluoropiperidin-4-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
15	Cpd 566	N-(3,3-difluoropiperidin-4-yl)-5-((3-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 567	N-(3,3-difluoropiperidin-4-yl)-5-((5-(2-hydroxyethoxy)pyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
20	Cpd 568	N-(3,3-difluoropiperidin-4-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 569	N-(3,3-difluoropiperidin-4-yl)-5-((6-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 570	N-(3,3-difluoropiperidin-4-yl)-5-((6-methoxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
25	Cpd 571	N-(3,3-difluoropiperidin-4-yl)-5-(imidazo[1,2-a]pyridin-6-ylmethoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 572	N-(3,3-difluoropiperidin-4-yl)-6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 573	N-(3,3-difluoropiperidin-4-yl)-7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 574	N-(3,3-difluoropropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 575	N-(3-amino-2-(dimethylamino)-3-oxopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 576	N-(3-amino-2,2-dimethyl-3-oxopropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 577	N-(3-carbamoyloxetan-3-yl)-2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 578	N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide

- Cpd 579 N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 580 N-(3-carbamoyloxetan-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 581 N-(3-carbamoyloxetan-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 582 N-(3-carbamoyloxetan-3-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 583 N-(3-carbamoyloxetan-3-yl)-4-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 584 N-(3-carbamoyloxetan-3-yl)-5-((2-(difluoromethyl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 10 Cpd 585 N-(3-carbamoyloxetan-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 586 N-(3-carbamoyloxetan-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 587 N-(3-carbamoyloxetan-3-yl)-6-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 588 N-(3-carbamoyloxetan-3-yl)-7-fluoro-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 589 N-(3-carbamoyloxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 590 N-(3-carbamoyltetrahydro-2H-pyran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 591 N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 592 N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 593 N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 594 N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 595 N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 596 N-(3-carbamoyltetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 35 Cpd 597 N-(3-carbamoyltetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 598 N-(3-carbamoyltetrahydrofuran-3-yl)-5-((4-fluoro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 40 Cpd 599 N-(3-cyanooxetan-3-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide

- Cpd 600 N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 601 N-(3-hydroxy-1-(methylamino)-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 5 Cpd 602 N-(3-hydroxy-2,2-dimethylpropyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 603 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2,4-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 604 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 605 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,3-triazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 606 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 607 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-imidazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 608 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 609 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 610 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 611 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 612 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylpyrimidin-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 613 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 614 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 615 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 616 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylloxazol-2-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 617 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 618 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylisoxazol-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 619 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylpyrazin-2-yl)methoxy)benzofuran-3-carboxamide
- 40

- Cpd 620 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 621 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((6-methylpyridazin-3-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 622 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 623 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(1-(4-methylthiazol-5-yl)ethoxy)benzofuran-3-carboxamide
- Cpd 624 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridazin-3-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 625 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 626 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(pyrimidin-2-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 627 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(thiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 628 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-hydroxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 629 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((2-methoxypyridin-4-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 630 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-hydroxypyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 631 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 25 Cpd 632 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((6-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 633 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-(imidazo[1,2-a]pyridin-6-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 634 N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-N,2-dimethyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 635 N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 636 N-(4,4-difluoropiperidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 637 N-(4,4-difluoropiperidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 638 N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 639 N-(4,4-difluoropyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 40

- Cpd 640 N-(4,4-difluoropyrrolidin-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 641 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 642 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 643 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 646 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 10 Cpd 647 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 648 N-(4,4-difluorotetrahydrofuran-3-yl)-5-((2-hydroxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 649 N-(4-amino-2-methyl-4-oxobutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 650 N-(4-carbamoyltetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 651 N-(4-hydroxy-2-methylbutan-2-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 20 Cpd 652 N-(4-hydroxy-2-methylbutan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 653 N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 654 N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-imidazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 655 N-(cis-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 656 N-(trans-4-hydroxytetrahydrofuran-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 657 N3-(3,3-difluoropiperidin-4-yl)-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-2,3-dicarboxamide
- Cpd 658 N3-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-2,3-dicarboxamide
- 35 Cpd 659 N-cyclobutyl-N-(2-hydroxyethyl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 660 N-cyclobutyl-N-(2-hydroxyethyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 661 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2-oxoazepan-3-yl)benzofuran-3-carboxamide
- 40 Cpd 662 N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-3-ylmethoxy)benzofuran-3-

- carboxamide
- Cpd 663 N-(4,4-difluoropyrrolidin-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 5 Cpd 664 N-(4,4-difluorotetrahydrofuran-3-yl)-2-methyl-5-((2-(trifluoromethyl)pyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 665 N-(4,4-difluorotetrahydrofuran-3-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 666 2-methyl-5-((4-methylthiazol-5-yl)methoxy)-N-(2,2,2-trifluoroethyl)benzofuran-3-carboxamide
- 10 Cpd 667 5-((1,4-Dimethyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 668 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((1,4-dimethyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 669 5-((4-Chloro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- 15 Cpd 670 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-chloro-1-methyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 671 5-((4-chloro-1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 672 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((4-chloro-1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 673 2-Methyl-5-((3-methylisoxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 674 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((3-methylisoxazol-5-yl)methyl)benzofuran-3-carboxamide
- Cpd 675 5-((1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 676 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-isopropyl-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 25 Cpd 677 5-((2,4-Dimethyl-oxazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 678 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2,4-dimethyl-oxazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 679 2-Methyl-5-((4-methyl-oxazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- 30 Cpd 680 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-methyl-oxazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 681 5-((2-Isopropylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 682 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-isopropylthiazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 683 N-(1-(Difluoromethyl)cyclobutyl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 35 Cpd 684 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylthiazol-2-yl)methoxy)benzofuran-3-carboxamide
- Cpd 685 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
- 40 Cpd 686 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-3-

- yl)methoxy)benzofuran-3-carboxamide
- Cpd 687 2-Methyl-5-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 688 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 689 5-((1-(Cyclopropylmethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 690 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((1-(cyclopropylmethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 691 2-Methyl-5-((1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxylic acid
- 10 Cpd 692 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 693 2-Methyl-5-((4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 694 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((4-(trifluoromethyl)thiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 15 Cpd 695 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(thiazol-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 696 N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 697 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(thiazol-5-ylmethoxy)benzofuran-3-carboxamide
- 20 Cpd 698 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((1-methyl-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 699 2-Methyl-5-((5-methylpyridin-2-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 700 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((5-methylpyridin-2-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 701 5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- Cpd 702 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-cyclopropylpyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 703 5-((3-Cyclopropylpyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- 30 Cpd 704 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((3-cyclopropylpyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide;
- Cpd 705 5-((3-cyclopropylpyridin-2-yl)methoxy)-N-(4-(hydroxymethyl) tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 706 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-(azetidin-1-yl)pyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 35 Cpd 707 2-Methyl-5-((2-methylpyrimidin-5-yl)methoxy)benzofuran-3-carboxylic acid
- Cpd 708 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-((2-methylpyrimidin-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 709 5-((2-Cyclopropoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxylic acid
- 40 Cpd 710 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-cyclopropoxypyridin-3-yl)methoxy)-2-

		methylbenzofuran-3-carboxamide
	Cpd 711	5-((2-cyclopropoxy)pyridin-3-yl) methoxy)-N-(4-(hydroxymethyl) tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide
5	Cpd 712	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrimidin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 713	2-Methyl-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxylic acid
	Cpd 714	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyrazin-2-ylmethoxy)benzofuran-3-carboxamide
10	Cpd 715	(S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 716	(S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-methyl-5-(pyridin-4-ylmethoxy)benzofuran-3-carboxamide
	Cpd 717	5-((3-(Difluoromethyl)pyridin-2-yl)methoxy)-N-(3,3-difluoropiperidin-4-yl)-2-methylbenzofuran-3-carboxamide
15	Cpd 718	N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
	Cpd 719	N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
20	Cpd 720	N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((2-methoxypyridin-3-yl)methoxy)-2-methylbenzofuran-3-carboxamide
	Cpd 721	N-(1-(Difluoromethyl)cyclobutyl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 722	N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
25	Cpd 723	N-(3,3-difluorotetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 724	N-(3,3-Difluorotetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 725	N-(3-carbamoyltetrahydrofuran-3-yl)-2-methyl-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
30	Cpd 726	N-(1-Amino-3-(methylsulfonyl)-1-oxopropan-2-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 727	N-(1-Imino-1-oxidotetrahydro-1H-116-thiophen-3-yl)-2-methyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
35	Cpd 728	N-(3-(hydroxymethyl)pyrrolidin-3-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
	Cpd 729	N-(1-Amino-1-oxo-3-(1H-1,2,4-triazol-1-yl)propan-2-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
40	Cpd 730	N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide

- Cpd 731 N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy)benzofuran-3-carboxamide
- Cpd 732 N-(3-(Hydroxymethyl)-2-oxopiperidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- 5 Cpd 733 N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-((1-methyl-1H-pyrazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 734 N-(3-(Hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-(pyridazin-3-ylmethoxy)benzofuran-3-carboxamide
- Cpd 735 5-((5-Fluoropyridin-2-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- 10 Cpd 736 5-((2-(Difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide
- Cpd 737 5-((2-(Difluoromethyl)pyridin-3-yl)methoxy)-N-(3-(hydroxymethyl)-2-oxopiperidin-3-yl)-2-methylbenzofuran-3-carboxamide
- 15 Cpd 738 N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-2-methyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 739 N-(1-Amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 740 N-(3-carbamoyltetrahydrofuran-3-yl)-5-((1-(2, 2-difluoroethyl)-1H-pyrazol-5-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- 20 Cpd 741 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((5-fluoropyridin-2-yl)methoxy)-2-methylbenzofuran-3-carboxamide
- Cpd 742 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 25 Cpd 743 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- Cpd 744 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- Cpd 745 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- 30 Cpd 746 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(difluoromethyl)-5-((2-methylloxazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 747 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-(pyridin-2-ylmethoxy)benzofuran-3-carboxamide
- 35 Cpd 748 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 749 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((2-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide
- Cpd 750 (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((6-methylpyridin-3-yl)methoxy)benzofuran-3-carboxamide
- 40

Cpd 751 (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-cyclopropyl-5-((2-methyloxazol-5-yl) methoxy) benzofuran-3-carboxamide
and the physiologically acceptable salts thereof.

- 5 13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12.
14. The compound according to any one of claims 1 to 13 or the pharmaceutical composition according to claim 13, for use in the treatment of pain.
- 10 15. The compound or the pharmaceutical composition for use in the treatment of pain according to claim 14, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain; preferably post-operative pain.